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PROGRAM 
 
 
TUESDAY, August 17—7:30 PM 
 
 
SESSION 1 APOPTOSIS AND AUTOPHAGY 
 
Chairperson: E. White, Rutgers University, New Brunswick, New Jersey 
 
 
KEYNOTE SPEAKER 
 
Joan Brugge 
Harvard Medical School 
 
 
Eileen White. 
Presenter affiliation: Rutgers University, New Brunswick, New Jersey. 
 
  
Cyclopamine and the sonic hedgehog pathway in melanoma 
maintenance and chemoresistance 
Agnieszka Checinska, Fernando García, Keith Ashman, Maria 
Soengas. 
Presenter affiliation: CNIO Spanish National Cancer Research Centre, 
Madrid, Spain. 
 
 
 
 
 
1 
  
Interplay between oncogene-induced DNA damage response and 
heterochromatin in senescence and cancer 
Fabrizio d'Adda di Fagagna. 
Presenter affiliation: IFOM Foundation, Milan, Italy. 
 
 
 
2 
  
The pro-apoptotic function of the retinoblastoma tumor 
suppressor protein 
Alessandra Ianari, Tiziana Natale, Eliezer Calo, Elisabetta Ferretti, 
Edoardo Alesse, Isabella Screpanti, Kevin Haigis, Alberto Gulino, 
Jacqueline Lees. 
Presenter affiliation: MIT, Cambridge, Massachusetts; University of 
Rome, La Sapienza, Rome, Italy. 
 
 
 
 
 
 
3 
  
  vi 
Senescence surveillance suppresses carcinogenesis in the liver 
and involves an adaptive immune response against premalignant 
senescent hepatocytes 
Tae-Won Kang, Tetyana Yevsa, Norman Woller, Lisa Hoenicke, 
Torsten Wuestefeld, Thomas Longerich, Peter Schirmacher, Stefan 
Kubicka, Lars Zender. 
Presenter affiliation: Helmholtz Centre for Infection Research, 
Braunschweig, Germany; Hannover Medical School, Hannover, 
Germany. 
 
 
 
 
 
 
 
 
4 
  
Abrogation of oncogene-induced senescence by PI3K pathway 
activation contributes to human nevus-to-melanoma progression 
Liesbeth Vredeveld, Patricia Possik, Chrysiis Michaloglou, Wolter 
Mooi, Daniel Peeper. 
Presenter affiliation: Netherlands Cancer Institute, Amsterdam, the 
Netherlands. 
 
 
 
 
 
5 
  
  
Cdk2 inhibition delays Myc-driven leukemia in vivo through 
induction of cellular senescence 
Eduar Hejll, Per Hydbring, Kari Högstrand, Alf Grandien, Lars-Gunnar 
Larsson. 
Presenter affiliation: Karolinska Institutet, Stockholm, Sweden. 
 
 
 
 
6 
  
 
 
WEDNESDAY, August 18—9:00 AM 
 
 
SESSION 2 SIGNALING MECHANISMS I 
 
Chairperson: R. Shaw, The Salk Institute for Biological Studies,  
La Jolla, California 
 
Reuben Shaw. 
Presenter affiliation: The Salk Institute for Biological Studies, La Jolla, 
California. 
 
  
Mutant N-RAS activates MAPK and STAT3 from lipid rafts to 
suppress apoptosis—A new paradigm for functional specificity 
within the RAS oncoprotein family 
Kevin Haigis. 
Presenter affiliation: Massachusetts General Hospital, Charlestown, 
Massachusetts; Harvard Medical School, Boston, Massachusetts. 
 
 
 
 
 
7 
  
  vii 
Distinct biological outputs of oncogenic N-Ras and K-Ras 
expression in the hematopoietic compartment 
Jin Xu, Kevin Shannon. 
Presenter affiliation: UCSF, San Francisco, California. 
 
 
 
8 
  
The 8p21.3 lung tumor suppressor DOK2 opposes oncogenic 
EGFR and KRAS 
Alice H. Berger, Alessandro Morotti, Katerina Politi, Justyna A. Janas, 
Masaru Niki, Barry S. Taylor, Cameron Brennan, Roderick T. Bronson, 
Marc Ladanyi, Linda Van Aelst, Harold E. Varmus, Pier Paolo Pandolfi. 
Presenter affiliation: Cancer Genetics Program, BIDMC, Boston, 
Massachusetts; Weill Graduate School, New York New York. 
 
 
 
 
 
 
9 
  
Ras oncogene-induced ROS detoxification promotes 
tumorigenesis 
Gina M. DeNicola, Florian A. Karreth, Cong Wei, Kristopher Frese, 
Dipti Mangal, Aarthi Gopinathan, Kenneth H. Yu, Charles J. Yeo, Eric 
S. Calhoun, Francesca Scrimieri, Jordan M. Winter, Ralph H. Hruban, 
Christine Iacobuzio-Donahue, Scott E. Kern, Ian A. Blair, David A. 
Tuveson. 
Presenter affiliation: Cancer Research UK, Cambridge, United 
Kingdom. 
 
 
 
 
 
 
 
 
10 
  
Tumour suppression by NRBP1 through regulation of the Wnt 
pathway 
Catherine H. Wilson, Gino B. Poulin, Catriona Crombie, Alistair G. 
Rust, Nikki H. March, George Poulogiannis, Mark J. Arends, Andy G. 
Fraser, David J. Adams. 
Presenter affiliation: Wellcome Trust Sanger Institute, Hinxton, United 
Kingdom. 
 
 
 
 
 
 
11 
  
Functional dissection of the Chr. 6q deletion reveals Ephrin 
signaling as a tumor suppressive mechanism in follicular 
lymphoma 
Elisa Oricchio, Gouri Nanjangud, Andrew L. Wolfe, Man Jiang, Wayne 
Tam, Hui Zhaoh, Adriana Heguy, Nickolas Socci, Adam Olshen, Raju 
Chaganti, Hans-Guido Wendel. 
Presenter affiliation: Memorial Sloan Kettering Cancer Center, New 
York, New York. 
 
 
 
 
 
 
 
12 
  
Aberrant expression of NF-κB inducing kinase underlies 
constitutive NF-κB activation in cancer cells 
Yasunori Saitoh, Shin Uota, Vicente Javier Martinez Bruyn, Atae 
Utsunomia, Toshiki Watanabe, Shoji Yamaoka. 
Presenter affiliation: Tokyo Medical and Dental University, Tokyo, 
Japan. 
 
 
 
 
 
13 
  viii 
Telomere-driven tetraploidization and its relevance to cancer 
Teresa Davoli, Eros Lazzerini Denchi, Titia de Lange. 
Presenter affiliation: The Rockefeller University, New York, New York. 
 
 
14 
  
SATB2 augments ΔNp63α in head and neck squamous cell 
carcinoma 
Jacky Chung, Joanne Lau, Lynn Cheng, Ian Grant, Suzanne Kamel-
Reid, Jason Moffat, Michael Ohh, Bayardo Perez-Ordonez, David 
Kaplan, Meredith Irwin. 
Presenter affiliation: University of Toronto, Toronto, Canada; Hospital 
for Sick Children Research Institute, Toronto, Canada. 
 
 
 
 
 
 
15 
 
 
WEDNESDAY, August 18—2:00 PM 
 
 
SESSION 3 POSTER SESSION I 
 
  
Structural rearrangements in genetically engineered mouse 
mammary tumors 
Christiaan Klijn, Ignatio Varela, Phillip J. Stevens, Hanneke van 
Gulden, Eva Schut, Lodewyk Wessels, Jos Jonkers, Andy Futreal, 
Mike R. Stratton, David J. Adams. 
Presenter affiliation: Wellcome Trust Sanger Institute, Hinxton, United 
Kingdom. 
 
 
 
 
 
 
16 
  
Characterization of the jumonji domain containing histone 
demethylase Jmjd2c in normal development and cancer 
Karl Agger, Marianne T. Pedersen, Gitte Andersen, Kristian Helin. 
Presenter affiliation: University of Copenhagen, Copenhagen, 
Denmark. 
 
 
 
 
17 
  
β-catenin activation synergises with ras activation to cause 
bladder cancer formation 
Imran Ahmad, Yan Liu, Makoto Mark Taketo, Xue-Ru Wu, Hing Y. 
Leung, Owen J. Sansom. 
Presenter affiliation: Beatson Institute for Cancer Research, Glasgow, 
United Kingdom. 
 
 
 
 
 
18 
  
SSeCKS/AKAP12 maintains cell cycle checkpoint controls that 
prevent oncogenesis by attenuating PKC activation 
Shin Akakura, Peter Nochajski, Lingqiu Gao, Paula Sotomayor, Sei-ichi 
Matsui, Irwin H. Gelman. 
Presenter affiliation: Roswell Park Cancer Institute, Buffalo, New York. 
 
 
 
 
19 
  
  ix 
CONEXIC—An integrative approach to uncover drivers of cancer 
Uri David Akavia, Oren Litvin, Jessica Kim, Felix Sanchez-Garcia, 
Helen C. Causton, Eyal Mozes, Dylan Kotliar, Yossi Tzur, Levi A. 
Garraway, Dana Pe'er. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
20 
  
The role of the transcription factor NR4A1 in mammary epithelial 
cell adhesion and migration 
Annika N. Alexopoulou, Maria Leao, Munro A. Neville, Parmjit S. Jat. 
Presenter affiliation: Ludwig Institute for Cancer Research, Oxford, 
United Kingdom; University College London, London, United Kingdom. 
 
 
 
 
21 
  
Biomarker identification using kinase substrate identifier 
Protoarray® by Invitrogen® 
Eileen Ambing, Pilgrim Jackson, Dominique Verhelle, Laure Escoubet-
Lozach, Brian Cathers, Steven Sakata, Michael Peña, Afshin 
Mahmoudi, Mahan Abbasian, Philip Chamberlain, Neil Raheja, Tao 
Shi, David Young. 
Presenter affiliation: Celgene, San Diego, California. 
 
 
 
 
 
 
22 
  
Conditional deletion of Drosophila activator de2f1 in postmitotic 
cells 
Aaron M. Ambrus, Richard J. Suckling, Vanya I. Rasheva, Maxim V. 
Frolov. 
Presenter affiliation: University of Illinois at Chicago, Chicago, Illinois. 
 
 
 
 
23 
  
Potential role for RNF8 in breast cancer development 
Iván Anduro-Corona, Patricia Thompson, Julie Buckmeier, Maria E. 
Martinez, Luis E. Gutiérrez-Millán. 
Presenter affiliation: Universidad de Sonora, Hermosillo, Sonora, 
Mexico. 
 
 
 
 
24 
  
Transformation of pancreatic epithelial cells by B-Raf V600E 
Victoria A. Appleman, Brian C. Lewis, David Klimstra. 
Presenter affiliation: University of Massachusetts Medical School, 
Worcester, Massachusetts. 
 
 
 
25 
  
Characterization of an ex vivo primary multicellular renal cell 
culture as a model system for Renal Cell Carcinoma 
tumorigenesis 
Alexandra Arreola, W. Kimryn Rathmell. 
Presenter affiliation: University of North Carolina at Chapel Hill, Chapel 
Hill, North Carolina. 
 
 
 
 
 
26 
  
  x 
Exploiting genetically engineered mice for the assembly of 
prostate cancer interactomes to identify new druggable targets 
for advanced prostate cancer. 
Alvaro Aytes, Antonina Mitrofanova, Carolyn W. Kinkade, Celine 
Lefebvre, Chee W. Chua, Mireia Castillo-Martin, Carlos Cordon-Cardo, 
Edward Gelmann, Michael M. Shen, Andrea Califano, Cory Abate-
Shen. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
 
 
 
27 
  
Genomic amplification of c-MYC locus in cancer—The usual 
suspects and more 
Yuen-Yi Tseng, Anindya Bagchi. 
Presenter affiliation: University of Minnesota, Twin Cities Campus, 
Minneapolis, Minnesota. 
 
 
 
 
28 
  
Spontaneous dominant leukemia (Sdl)—A novel mouse model of 
leukemia 
Bruce N. Bagley, Laura G. Bendzick, Rachael A. Lester, Jon G. 
Marshall, Erin M. Riley, Scott C. Kogan, David A. Largaspada, 
Christina M. Kendziorski, Robert T. Cormier, Lara S. Collier. 
Presenter affiliation: University of Wisconsin - Madison, Madison, 
Wisconsin. 
 
 
 
 
 
 
29 
  
Skp2-Cyclin A interaction is dispensable for normal development 
but essential in pRb loss-induced pituitary tumorigenesis 
Frederick S. Bauzon, Luba Goldin, Keiko Nakayama, Keiich I. 
Nakayama, Liang Zhu. 
Presenter affiliation: Albert Einstein College of Medicine, Bronx, New 
York. 
 
 
 
 
 
30 
  
Electronically identifying and evaluating mouse models of cancer 
using the Mouse Tumor Biology (MTB) database 
Dale A. Begley, Debra M. Krupke, Steven B. Neuhauser, John P. 
Sundberg, Carol J. Bult, Janan T. Eppig. 
Presenter affiliation: The Jackson Laboratory, Bar Harbor, ME,. 
 
 
 
 
31 
  
RNA polymerase II Ser2 CTD phoshorylation in cancer cells and 
its relation to poly (A) site choice 
David Bentley, Nova Fong, Jim Dover, Hyunmin Kim. 
Presenter affiliation: University of Colorado School of Medicine, 
Aurora, Colorado. 
 
 
 
 
32 
  
  xi 
The DNA replication checkpoint promotes E2F-dependent cell-
cycle transcription 
Cosetta Bertoli, Tatyana I. Kalashnikova, Clare H. McGowan, Curt 
Wittenberg, Robertus A. de Bruin. 
Presenter affiliation: MRC UCL, London, United Kingdom. 
 
 
 
 
33 
  
The dynamic role of RBP2 during differentiation 
Michael L. Beshiri, Qin Yang, William G. Kaelin, Jr., Elizaveta V. 
Benevolenskaya. 
Presenter affiliation: University of Illinois Chicago, Chicago, Illinois. 
 
 
 
34 
  
Epigenetically regulated genes in B cell lymphoma 
Nicole Bethge, Guro E. Lind, Hilde Honne, Gunhild Trøen, Erlend B. 
Smeland, May L. Bredahl. 
Presenter affiliation: Institute for Cancer Research, Oslo, Norway. 
 
 
 
35 
  
Stabilization of BCL2L10 (BCLb) by the ubiquitin-associated 
protein UBQLN1 (PLIC1) leads to increased oncogenic potential 
Levi J. Beverly, William W. Lockwood, Harold E. Varmus. 
Presenter affiliation: Memorial Sloan-Kettering Cancer Center, New 
York, New York. 
 
 
 
 
36 
  
Thioctans, first-in-class lipoate derivatives, attack specific cancer 
mitochondrial metabolic processes inducing multiple, redundant 
cell death pathways 
Zuzana Zachar, Shawn Stuart, Sunita Gupta, Katy Howell, James F. 
Marecek, Claudia Moore, King Lee, Robert Rodriguez, Robert Shorr, 
Paul M. Bingham. 
Presenter affiliation: Stony Brook University, Stony Brook, New York. 
 
 
 
 
 
 
37 
  
Autophagy contributes to therapy-induced degradation of the 
PML/RARA oncoprotein 
Paulin Isakson, Magnar Bjørås, Anne Simonsen, Stig Ove Bøe. 
Presenter affiliation: Rikshospitalet, Oslo, Norway. 
 
 
 
38 
  
Key mechanisms underlying the stem cell overpopulation that 
contributes to the initiation and promotion of colon 
tumorigenesis 
Bruce M. Boman, Tao Zhang, Daniel Relles, Jeannie Seu, Koree Ahn, 
Olaf A. Runquist. 
Presenter affiliation: Christiana Care Health System, Newark, 
Delaware. 
 
 
 
 
 
 
39 
  
  xii 
Genetic and epigenetic regulation of breast cancer associated 
genes, including BRCA1 
Juliet D. French, Stacey L. Edwards, Kate Peters, Brooke L. Brewster, 
Ania Wronski, Eugene Wee, Chanel E. Smart, Jodi M. Saunus, Glenn 
Francis, Susan J. Clark, Melissa A. Brown. 
Presenter affiliation: University of Queensland, Brisbane, Australia. 
 
 
 
 
 
40 
  
Wip1 phosphatase at the crossroads of cancer and aging 
Dmitry Bulavin. 
Presenter affiliation: IMCB, Singapore, Singapore. 
 
 
41 
  
p19arf suppresses the promotion of K-ras driven non-small cell 
lung cancer 
Stephanie E. Busch, Karen S. Kelly-Spratt, Kay E. Gurley, Christopher 
J. Kemp. 
Presenter affiliation: Fred Hutchinson Cancer Research Center, 
Seattle, Washington; University of Washington, Seattle, Washington. 
 
 
 
 
 
42 
  
Helicobacter pylori decreases gastric epithelial p27 through 
inhibiting histone acetylation of the p27 promoter 
Sang Won Byun, Su Sun Back, Young Jun Chang, Steven F Moss, 
Sung Soo Kim. 
Presenter affiliation: Uijongbu St Mary's Hospital, The Catholic 
University of Korea, Uijongbu, South Korea. 
 
 
 
 
 
43 
  
Elucidating metabolic signals that control cell growth and 
proliferation 
Ling Cai, Benjamin M. Sutter, Benjamin Tu. 
Presenter affiliation: University of Texas Southwestern Medical Center, 
Dallas, Dallas, Texas. 
 
 
 
 
44 
  
Understanding consequences of K-Ras activation by identifying 
substrates of the kinase ERK2 
Scott M. Carlson, Forest M. White. 
Presenter affiliation: Massachusetts Institute of Technology, 
Cambridge, Massachusetts. 
 
 
 
 
45 
  
Dietary folate deficiency and aging alter the adaptive landscape, 
promoting selection for adaptive oncogenic events 
Matias Casás-Selves, Annya Bilousova, Curtis Henry, Jelena Klawitter, 
Uwe Christians, James DeGregori. 
Presenter affiliation: University of Colorado Anschutz Medical Campus, 
Aurora, Colorado. 
 
 
 
 
 
46 
  
  xiii 
The activity of liver-enriched and growth-suppressive 
transcription factor CREB-H is tightly regulated by N-linked 
glycosylation and ubiquitination 
Chi-Ping Chan, To-Yuen Mak, King-Tung Chin, Irene Oi-Lin Ng, Dong-
Yan Jin. 
Presenter affiliation: The University of Hong Kong, Hong Kong. 
 
 
 
 
 
47 
  
Genetics and mechanisms underlying the role of the familial 
Parkinson’s disease gene PARK2 in human oncogenesis 
Timothy A. Chan, Barry Taylor, Shasha Meng, Veeriah Selvaraju, 
Mellinghoff Ingo, Solit David. 
Presenter affiliation: Memorial Sloan Kettering Cancer Center, New 
York, New York. 
 
 
 
 
 
48 
  
Uncovering genetic determinants of therapeutic resistance in 
preclinical models of glioblastoma multiforme 
Jaime Acquaviva, Haihao Zhu, Steve Woolfenden, Hyun Jung Jun, 
Abraham Boskovitz, Melissa Donovan, Ami Raval, Dorcas Chi, 
Amanda Del Rosario, Hannah Johnson, Forest White, Al Charest. 
Presenter affiliation: Tufts Medical Center, Boston, Massachusetts. 
 
 
 
 
 
49 
  
Colorectal tumor growth need not be driven by rare dysregulated 
stem cells 
Peh Yean Cheah, Yi Hong, Soo Chin Liew, Poh Koon Koh, Kong Weng 
Eu. 
Presenter affiliation: Singapore General Hospital, Singapore; National 
University of Singapore, Singapore. 
 
 
 
 
 
50 
  
Novel siRNAs screened from random siRNA library induce 
leukemia cell differentiation 
Meihong Chen, Cuiqing Fan, Yuan Xiong, Ning Zhu, Zicai Liang, Yan 
Shen. 
Presenter affiliation: Chinese Academy of Medical Sciences, Beijing, 
China; Chinese National Human Genome Center, Beijing, China. 
 
 
 
 
 
51 
  
KSHV induces transcriptional reprogramming of lymphatic 
endothelial cells into an invasive cell type 
Fang Cheng, Simonas Laurinavicius, Nami Sugiyama, Peter Biberfeld, 
Stephen Henderson, Chris Boshoff, Kari Alitalo, Kaisa Lehti, Päivi M. 
Ojala. 
Presenter affiliation: University of Helsinki, Helsinki, Finland. 
 
 
 
 
 
52 
 
 
 
  xiv 
In vivo validation of cancer genes using transposons 
Su Kit Chew, Qin Su, Pentao Liu, P. Andrew Futreal. 
Presenter affiliation: Wellcome Trust Sanger Institute, Hinxton, United 
Kingdom. 
 
 
 
53 
  
Forcing glioblastoma tumor initiating cells to differentiate—
Targeting transcription factors and GTPases using RNAi 
M G. Chheda, Y Chudnovsky, M Bray, S Gopal, R Verhaak, J Lee, S 
Silver, A Carpenter, M Meyerson, H Fine, K Ligon, D Root, I K. 
Mellinghoff, D M. Sabatini, W C. Hahn. 
Presenter affiliation: Broad Institute, Cambridge, Massachusetts; 
Memorial Sloan-Kettering Cancer Center, New York, New York; Dana-
Farber Cancer Institute, Boston, Massachusetts. 
 
 
 
 
 
 
 
54 
  
Contribution of NF-κB to cellular senescence and 
chemoresistance 
Yuchen Chien, Claudio Scuoppo, Xiaowo Wang, Agustin Chicas, Scott 
W. Lowe. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York. 
 
 
 
 
 
55 
  
Incremental genetic perturbations to MCM2-7 expression and 
subcellular distribution reveal exquisite sensitivity of mice to DNA 
replication stress 
Chen-Hua Chuang, Marsha D. Wallace, Chris Abratte, John C. 
Schimenti. 
Presenter affiliation: Cornell University, Ithaca, New York. 
 
 
 
 
 
56 
  
Identification of molecular drivers of human glioblastoma tumor 
initiating cell functions using a large-scale RNAi screen 
Y Chudnovsky, M G. Chheda, J Lee, M A. Theisen, S Gopal, S J. 
Silver, M A. Bray, A E. Carpenter, H A. Fine, K L. Ligon, D E. Root, W 
C. Hahn, D M. Sabatini. 
Presenter affiliation: MIT, Cambridge, Massachusetts; Whitehead 
Institute, Cambridge, Massachusetts; Broad Institute, Cambridge, 
Massachusetts. 
 
 
 
 
 
 
 
57 
  
The first targeted p53 knockout rat model 
Xiaoxia Cui, Aaron McCoy, Diana Ji, Edward J. Weinstein. 
Presenter affiliation: Sigma-Aldrich Corporation, St. Louis, Missouri. 
 
 
58 
  
  xv 
Isoprenylation regulates C17orf37 mediated cancer cell migration 
and metastasis 
Subhamoy Dasgupta, Ian Cushman, Patrick J. Casey, Jamboor K. 
Vishwanatha. 
Presenter affiliation: University of North Texas Health Science Center, 
Fort Worth, Texas. 
 
 
 
 
 
59 
  
In vivo RNAi screening identifies new mediators of p53 
independent tumor suppressive functions of p19Arf in the liver 
Daniel Dauch, Torsten Wüstefeld, Tae-Won Kang, Anja Hohmeier, Lisa 
Hoenicke, Peter Schirmacher, Thomas Longerich, Lars Zender. 
Presenter affiliation: Helmholtz Centre for Infection Research, 
Braunschweig, Germany. 
 
 
 
 
 
60 
  
Functional analysis of the PLU1/JARID1B histone demethylase in 
breast cancer 
Dannielle C. DeWaal, Elizaveta Benevolenskaya. 
Presenter affiliation: University of Illinois at Chicago, Chicago, Illinois. 
 
 
 
61 
  
Growth stimulation and proliferation blockage—Dual effects of 
FGF2/FGFR in Ras-driven mouse malignant cells 
Matheus Henrique S. Dias, Fábio Nakano, Cecília S. Fonseca, Hugo 
A. Armelin. 
Presenter affiliation: Universidade de São Paulo, São Paulo, Brazil; 
Instituto Butantan, São Paulo, Brazil. 
 
 
 
 
 
62 
  
Modeling Bcl-2 and Bcl-xL inhibition in the hematopoietic system 
using transgenic RNA interference 
Megumi Takiguchi, Chloe James, Emma C. Josefsson, Prem K. 
Premsrirut, Scott W. Lowe, Justin R. Hamilton, David C. Huang, 
Benjamin T. Kile, Ross A. Dickins. 
Presenter affiliation: Walter and Eliza Hall Institute, Melbourne, 
Australia. 
 
 
 
 
 
 
63 
  
Insulin receptor pathway hyperactivity in IGF-1R null cells and 
suppression of downstream signaling using the dual IGF-1R/IR 
inhibitor, BMS-754807 
Joseph E. Dinchuk, Carolyn Cao, Fei Huang, Xia Zhou, Marco 
Gottardis, Joan M. Carboni. 
Presenter affiliation: Bristol-Myers Squibb, Princeton, New Jersey. 
 
 
 
 
 
64 
  
  xvi 
Rev3 suppression sensitizes drug resistant lung tumors to 
chemotherapy 
Jason Doles, Trudy G. Oliver, Gerald Hsu, Tyler Jacks, Graham C. 
Walker, Michael T. Hemann. 
Presenter affiliation: Massachusetts Institute of Technology, 
Cambridge, Massachusetts. 
 
 
 
 
 
65 
  
Depletion of APC causes multiple developmental defects and 
disrupts hair follicle homeostasis 
Lukas E. Dow, Prem K. Premsrirut, Johannes Zuber, Scott W. Lowe. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York. 
 
 
 
 
66 
  
Identification of cJun NH2-terminal kinase 2 target molecules 
necessary for Ras transformation of mouse embryonic fibroblasts 
Christina Egebjerg, David Mathiasen, Marja Jäättelä, Tuula Kallunki. 
Presenter affiliation: Danish Cancer Society, Copenhagen, Denmark. 
 
 
 
67 
  
Targeting Mitochondrial Apoptotic Pathways in c-Myc-induced 
Mammary Tumors 
Vilja Eskelinen, Anni I. Nieminen, Yan Yan, Johanna Partanen, Juha 
Klefström. 
Presenter affiliation: University of Helsinki, Helsinki, Finland. 
 
 
 
 
68 
  
Influence of CagA EPIYA motifs variations in Helicobacter pylori 
strains from colombia on IL-8 expression and cell elongation 
Carlos A. Fajardo, Andrés Quiroga, Karen Labrador, Paula N. Acosta, 
María P. Delgado, Carlos Jaramillo, María M. Bravo. 
Presenter affiliation: Grupo de Investigación en Agentes Infecciosos y 
Cáncer, Bogotá, Colombia. 
 
 
 
 
 
69 
  
Regulation of dynamic c-Myc promoter binding and 
transcriptional activity by the peptidyl prolyl isomerase Pin1 
Amy S. Farrell, Colin J. Daniel, Xiaoyan Wang, Xiaoli Zhang, Mahnaz 
Janghorban, Rosalie Sears. 
Presenter affiliation: Oregon Health and Sciences University, Portland, 
Oregon. 
 
 
 
 
 
70 
  
Experimental restoration of tumor suppressor function indentifies 
a context specific sensitivity to p53 in non-small cell lung cancer 
David Feldser, Kamena Kostova, Sarah Taylor, Tyler Jacks. 
Presenter affiliation: MIT, Cambridge, Massachusetts. 
 
 
 
71 
  
  xvii 
Functional identification of optimized RNAi triggers using a 
massively parallel sensor assay 
Christof Fellmann, Johannes Zuber, Katherine McJunkin, Kenneth 
Chang, Stephen J. Elledge, Gregory J. Hannon, Scott W. Lowe. 
Presenter affiliation: Cold Spring Harbor Laboratory and Howard 
Hughes Medical Institute, Cold Spring Harbor, New York; University of 
Zurich, Zurich, Switzerland. 
 
 
 
 
 
 
72 
  
Tuberin regulates mitotic onset through the cellular localization 
of cyclin B1 
Elizabeth Fidalgo da Silva, Shora B. Ansari, Jiamila Maimaiti, Miranda 
Hanna, Elizabeth A. Barnes, Monica Kong-Beltran, Daniel J. 
Donoghue, Lisa A. Porter. 
Presenter affiliation: University of Windsor, Windsor, Canada. 
 
 
 
 
 
73 
  
Characterization of the potential tumour suppressor PRDM5 
Giorgio G. Galli, Kristian H. de Lichtenberg, Cathrine K. Fog, Juri 
Rappsilber, Eric Santoni-Rugiu, Anders H. Lund. 
Presenter affiliation: BRIC, Copenhagen, Denmark. 
 
 
 
74 
  
Cdk7 ablation in vivo abolishes cell cycle proliferation and Cdk 
activity without affecting RNA Pol II dependent global 
transcription. 
Mikel Ganuza, Marta Cañamero, Cristina Saiz-Ladera, Alberto Martín, 
Gonzalo Gómez-López, David G. Pisano, Jesús M. Paramio, David 
Santamaria, Mariano Barbacid. 
Presenter affiliation: Centro Nacional de Investigaciones Oncológicas, 
Madrid, Spain. 
 
 
 
 
 
 
 
75 
  
Regulation of FoxM1 in cancer and its potential as a therapeutic 
target 
Marianna Halasi, Uppoor G. Bhat, Bulbul Pandit, Andrei L. Gartel. 
Presenter affiliation: University of Illinois-Chicago, Chicago, Illinois. 
 
 
 
76 
  
SOS regulation by the membrane-actin linker protein Ezrin 
Katja J. Geissler, Tobias Sperka, Ulrike Merkel, Hongchuan Jin, 
Ingmar Scholl, Ignacio Rubio, Reinhard Seifert, Sebastian Peuker, 
Peter Herrlich, Helen Morrison. 
Presenter affiliation: Leibniz Institute for Age Research, Fritz Lipmann 
Institute (FLI), Jena, Germany. 
 
 
 
 
 
77 
  
Oncogenic function of MDM4 in skin melanoma. 
Agnieszka M. Gembarska, Gertrui Denecker, Ghanem E. Ghanem, 
Jody Haigh, James S. Goydos, Jean-Christophe Marine. 
Presenter affiliation: KULeuven-VIB, Leuven, Belgium. 
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  xviii 
Activation of the HMGA2 pathway and not bi-allelic inactivation of 
the tumor suppressor gene TSC2 is required for tumor formation. 
Jeanine D'Armiento, Patrick Geraghty, Devipriya Sankarasharma, 
Takayuki Shiomi, Kiran Chada. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
79 
  
Evidence for a novel mechanism of lentiviral vector-induced 
tumorigenesis 
Reba Condiotti, Daniel Goldenberg, Temima Schnitzer-Perlman, Wing 
Cheung, Simon Waddington, Suzanne M. Buckley, Matthew Themis, 
Charles Coutelle, Hilla Giladi, Emma Osejindu, Eithan Galun, Michael 
Themis. 
Presenter affiliation: Hadassah-Hebrew University Medical Center, 
Jerusalem, Israel. 
 
 
 
 
 
 
 
80 
  
THE role of ATF2 AND ATF7 in models of hepatocellular 
carcinoma 
Malgorzata Gozdecka, Steve Lyons, Wolfgang Breitwieser, Nic Jones. 
Presenter affiliation: Paterson Institute for Cancer Research, University 
of Manchester, Manchester, United Kingdom. 
 
 
 
 
81 
  
Activated BRAF induces pilocytic astrocytomas in mice 
Jan Gronych, Andrey Korshunov, Josephine Bargeritz, Till Milde, 
Manfred Jugold, Dolores Hambardzumyan, Marc Remke, Christian 
Hartmann, Hendrik Witt, Olaf Witt, Wolfhard Semmler, Eric C. Holland, 
Stefan Pfister, Peter Lichter. 
Presenter affiliation: German Cancer Research Center, Heidelberg, 
Germany. 
 
 
 
 
 
 
82 
  
Cdk4 is a central mediator of centrosome amplification in Her2 
positive breast cancer cells. 
Mary Kathryn Harrison, Xiangbin Zeng, Harold I. Saavedra. 
Presenter affiliation: Emory University, Atlanta, Georgia. 
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Physical and functional mapping of the somatically mutated 
EGFR pathway 
Eric B. Haura, Jiannong Li, Keiryn Bennett, Lanxi Song, Ines Kaupe, 
Florian Grebien, Giulio Superti-Furga. 
Presenter affiliation: H. Lee Moffitt Cancer Center, Tampa, Florida. 
 
 
 
 
84 
  
Characterization of the AP4-regulated transcriptome 
Rene Jackstadt, Peter Jung, Reinhard Hoffmann, Prazeres da Costa 
Olivia, Antje Menssen, Heiko Hermeking. 
Presenter affiliation: Ludwig-Maximilians-University Munich, Munich, 
Germany. 
 
 
 
 
85 
  
  xix 
Sirt1 overexpression improves health and protects from liver 
cancer but does not affect p53-knockout associated 
tumorigenesis 
Daniel Herranz, Manuel Serrano. 
Presenter affiliation: Spanish National Cancer Center (CNIO), Madrid, 
Spain. 
 
 
 
 
 
86 
  
Identification of a novel chemosensitizer by screening small 
compounds against human thymidylate kinase 
Chun-Mei Hu. 
Presenter affiliation: National Yang-Ming University, Taipei, Taiwan. 
 
 
 
87 
  
Identification and investigation of the potential tumor suppressive 
function of alpha b-crystallin (CRYAB) in nasopharyngeal 
carcinoma 
Zhiguang Huang, Maria L. Lung. 
Presenter affiliation: The University of Hong Kong, HKSAR, PRC, 
Hong Kong. 
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Wild type p53 controls cell motility and invasion by dual 
regulation of Met in the ovarian surface epithelium 
Chang-il Hwang, Andres Matoso, Andrea Flesken-Nikitin, Wei Wang, 
Carla Boccaccio, Snorri S. Thorgeirsson, Paolo M. Comoglio, 
Alexander Y. Nikitin. 
Presenter affiliation: Cornell University, Ithaca, New York. 
 
 
 
 
 
89 
  
The inv(16) fusion gene Cbfb-MYH11 has activities independent of 
Cbfb/Runx1 repression that are important for leukemogenesis 
R. Katherine Hyde, Yasuhiko Kamikubo, Lemlem Alemu, Ling Zhao, P. 
Paul Liu. 
Presenter affiliation: NHGRI, National Institutes of Health, Bethesda, 
Maryland. 
 
 
 
 
 
90 
  
Differential impact of DMP1-loss between mouse and human 
breast cancer survival 
Pankaj Taneja, Dejan Maglic, Sinan Zhu, Fumitake Kai, Elizabeth A. 
Fry, Robert D. Kendig, Mark C. Willingham, Kazushi Inoue. 
Presenter affiliation: Wake Forest University Health Sciences, Winston-
Salem, North Carolina. 
 
 
 
 
 
91 
  
Downregulation of the cyclin-like protein Spy1 is an essential 
component of the DNA damage response 
Espanta Jalili, Dorota Lubanska, Sylvie Tremblay, Lisa A. Porter. 
Presenter affiliation: University of Windsor, Windsor, Canada. 
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  xx 
Brca2 deficiency in thymocytes instigates p53-dependent T cell 
loss and immune dysfunction 
Jun-hyeon Jeong, Hae-ock Lee, Pilgu Park, Hyunsook Lee. 
Presenter affiliation: Seoul National University, Seoul, South Korea. 
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A functional genetic approach to anti-cancer drug 
characterization 
Hai Jiang, Justin R. Pritchard, Douglas A. Lauffenburger, Michael T. 
Hemann. 
Presenter affiliation: Massachusetts Institute of Technology, 
Cambridge, Massachusetts. 
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The Cebpb 3’UTR suppresses the Ras-induced cytostatic and 
pro-senescence functions of C/EBPβ by inhibiting its post-
translational activation 
Sandip K. Basu, Radek Malik, Christopher J. Huggins, Sook Lee, 
Thomas Sebastian, Krisada Sakchaisri, Octavio A. Quiñones, W 
Gregory Alvord, Peter F. Johnson. 
Presenter affiliation: National Cancer Institute, Frederick, Maryland. 
 
 
 
 
 
 
95 
  
Loss of Cdk1 in liver cancer 
M. Kasim Diril, V C. Padmakumar, Vincenzo Coppola, Lino Tessarollo, 
Philipp Kaldis. 
Presenter affiliation: Institute of Molecular and Cell Biology (IMCB), 
Singapore, Singapore. 
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Role of the Ras effector Rassf5/Nore1 mediating TNF-α induced 
apoptosis in tumorigenesis 
Soo Im Kang, Jikyoung Park, Myoung Shin Kim, Joseph Avruch, Dae-
Sik Lim, Sean Lee. 
Presenter affiliation: National Institutes of Health, Bethesda, Maryland. 
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Differential requirement of B-Raf and C-Raf in K-RasG12D-mediated 
lung tumorigenesis 
Florian A. Karreth, David A. Tuveson. 
Presenter affiliation: Cancer Research UK, Cambridge, United 
Kingdom. 
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Simvastatin increases expression and activity of human 
equilibrative nucleoside transporter 1 (hENT1) in ovarian cancer 
cells sensitizing to gemcitabine 
Sumie Kato, Andrea Leisewitz, Maria I. Barriga, Jorge Brañes, Gareth 
Owen, Mauricio Cuello. 
Presenter affiliation: Pontificia Universidad Catolica de Chile, Santiago, 
Chile. 
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  xxi 
Microglia—A new weapon against brain tumors? 
Tim S. Kees, Jennifer Lohr, Rodrigo Mora, Christel Herold-Mende, 
Anne Régnier-Vigouroux. 
Presenter affiliation: German Cancer Research Center, Heidelberg, 
Germany. 
 
 
 
 
100 
  
Growth factor independent 1 is required for initiation and 
maintenance of leukemia 
Cyrus Khandanpour, James D. Phelan, Shane R. Horman, Marie-
Claude Gaudreau, Jinfang Zhu, William E. Paul, Leighton H. Grimes, 
Tarik Möröy. 
Presenter affiliation: IRCM, Montreal, Canada; Université de Montréal, 
Montreal, Canada. 
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Functional characterization of novel tumor suppressor gene(s) in 
pancreatic cancer 
Md Khursheed, Dity Sen, Murali D. Bashyam. 
Presenter affiliation: Centre for DNA Fingerprinting and Diagnostics, 
Hyderabad, India. 
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GWAS-identified prostate cancer risk SNP rs10993994 
downregulates expression the putative anti-cancer gene MSMB 
Xing Xu, Hans Lilja, Robert J. Klein. 
Presenter affiliation: Memorial Sloan-Kettering Cancer Center, New 
York, New York. 
 
 
 
 
103 
  
Arf promotes tumorigenesis in the context of combined loss of 
function of p53 and Pten in a mouse model of invasive bladder 
cancer 
Takashi Kobayashi, Anna M. Puzio-Kuter, Mireia Castillo-Martin, 
Carlos Cordon-Cardo, Cory Abate-Shen. 
Presenter affiliation: Columbia University, College of Physicians and 
Surgeons, New York, New York. 
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Genomic scale DNA methylation profiling of prostate cancer 
Yuya Kobayashi, K-T Varley, Zulfiqar G. Gulzar, Devin M. Absher, 
James D. Brooks, Gavin Sherlock, Richard M. Myers. 
Presenter affiliation: Stanford University, Stanford, California. 
 
 
 
105 
  
Analysis of escape from oncogene-induced senescence in 
tumorigenesis 
Shinji Kohsaka, Ken Sasai, Kenta Takahashi, Tsuyoshi Akagi, Mishie 
Tanino, Taichi Kimura, Hiroshi Nishihara, Shinya Tanaka. 
Presenter affiliation: Hokkaido University Laboratory of Cancer 
Research, Sapporo, Japan. 
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  xxii 
The MK5/PRAK kinase and Myc form a negative feedback loop 
that is disrupted during colorectal tumorigenesis 
Theresia R. Kress, Ian G. Cannell, Boudewijn M. Burgering, Martin 
Bushell, Andreas Rosenwald, Martin Eilers. 
Presenter affiliation: University of Wuerzburg, Wuerzburg, Germany. 
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The discovery of novel DNA methylation events as prognostic 
markers in prostate cancer 
Ken Kron, Liyang Liu, Vaijayanti Pethe, Nino Demetrashvili, Michael 
Nesbitt, John Trachtenberg, Hilmi Ozcelik, Neil Fleshner, Laurent 
Briollais, Theo van der Kwast, Bharati Bapat. 
Presenter affiliation: University of Toronto, Toronto, Canada. 
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Small molecule kinase inhibitors provide insight into Mps1 cell 
cycle function 
Nicholas P. Kwiatkowski, Nannette Jelluma, Panagis Filippakopoulos, 
Meera Soundararajan, Michael S. Manak, Mijung Kwon, Hwan Geun 
Choi, Taebo Sim, Quinn L. Deveraux, Sabine Rottmann, David 
Pellman, Jagesh V. Shah, Geert Kops, Stefan Knapp, Nathanael S. 
Gray. 
Presenter affiliation: Dana Farber Cancer Institute, Boston, 
Massachusetts; Harvard Medical School, Boston, Massachusetts. 
 
 
 
 
 
 
 
 
109 
  
A Novel GRK2/HDAC6 interaction modulates cell spreading and 
motility 
Vanesa Lafarga, Ivette Aymerich, Olga Tapia, Federico Mayor, 
Petronila Penela. 
Presenter affiliation: CBMSO, Madrid, Spain. 
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CIP2A downregulation is a novel mechanism for p53-mediated 
tumor suppression 
Anni Laine, Alexandra Zwolinska, Jean-Christophe Marine, Anchit 
Khanna, Jos Jonkers, Veli-Matti Kähäri, Kevin Ryan, Melissa Junttila, 
Christophe Come, Jukka Westermarck. 
Presenter affiliation: University of Turku, Turku, Finland. 
 
 
 
 
 
111 
  
Targeting malignant brain tumors 
Johanna Lammi, Katja Häkkinen, Maija Hyvönen, Ulo Langel, Kirsi 
Vuorinen, Pirjo Laakkonen. 
Presenter affiliation: University of Helsinki, Helsinki, Finland. 
 
 
 
112 
  
Prevention of effective arsenic-induced PML and PML/RARA 
proteolysis by mitotic cell division 
Emma Lång, Amra Grudic, Magnar Bjørås, Stig Ove Bøe. 
Presenter affiliation: Oslo University Hospital, Oslo, Norway. 
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  xxiii 
Sensitive and specific probes for discrimination of the three 
major types of ABC transporters using flow cytometry and 
fluorescence microplate-based cytometry 
Irina V. Lebedeva, Dee Shen, Divina Gatica, Wayne F. Patton. 
Presenter affiliation: ENZO Life Sciences, Farmingdale, New York. 
 
 
 
 
114 
  
14-3-3ε promotes SCFfbx4-mediated cyclin D1 degradation and 
contributes to suppression of tumor growth 
Eric K. Lee, Olena Barbash, J. Alan Diehl. 
Presenter affiliation: Abramson Family Cancer Research Institute, 
Philadelphia, Pennsylvania. 
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Aberrant methylation on CpG island of Dkk3 predicts recurrence 
of cervical cancer. 
Eun-Ju Lee, Jae-Hyung Kim. 
Presenter affiliation: Chung-Ang University School of Medicine, 
Yongsan Hospital, Seoul, South Korea. 
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Cisplatin induces human Equilibrative Nucleoside Transporter 1 
(hENT1) expression and activity and Gemcitabine-induced cell 
death in ovarian cancer cells 
Ingrid P. Parejas, Garcia Natali, Sumie Kato, Bruno Nervi, Mauricio 
Cuello, Andrea V. Leisewitz. 
Presenter affiliation: Pontificia Universidad Catolica de Chile, Santiago, 
Chile. 
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An siRNA screen to identify synthetic lethal interactions with 
oncogenic BRAF 
Christelle Lenain, Celia J. Vogel, Johan H. Kuiken, Roderick L. 
Beijersbergen, Sirith Douma, Daniel S. Peeper. 
Presenter affiliation: Netherlands Cancer Institute, Amsterdam, 
Netherlands. 
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Overexpression and neoplastic transforming activity of 
endogenous BRCA1-IRIS in sporadic, human breast cancer cells 
and cell lines 
Andrew G. Li, Wael M. ElShamy, Zhigang C. Wang, Andrew L. Kung, 
Andrea L. Richardson, David M. Livingston. 
Presenter affiliation: Dana-Farber Cancer Institute and Harvard 
Medical School, Boston, Massachusetts. 
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  xxiv 
Essential kinases for human metastatic cells pertaining to c-Met 
signaling. 
Wenliang Li, Nandita Bhattacharya, Michael Collins, Sabina Signoretti, 
Yanhui Hu, Randolph Watnick, Ed Harlow. 
Presenter affiliation: Harvard Medical School, Boston, Massachusetts. 
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Cdk2 and Cdk4 regulate the switch from proliferation to 
differentiation in neural stem cells. 
Shuhui Lim, Philipp Kaldis. 
Presenter affiliation: Institute of Molecular and Cell Biology (IMCB), 
Singapore, Singapore. 
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Transient exposure of HCT116 to MLN4924 induces re-replication, 
apoptosis and cellular senescence 
jie J. lin, Michael A. Milhollen, Peter G. Smith, Usha Narayanan, 
anindya dutta. 
Presenter affiliation: University of Virginia, Charlottesville, Virginia. 
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EphA2-Vav3-Rac1 signaling mediates migratory and invasive 
behavior of prostate cancer cells 
Kai-Ti Lin, Jianli Gong, Te-Hsuan Jang, Huei-Jane Chen, Lu-Hai 
Wang. 
Presenter affiliation: National Health Research Institute, Miaoli County, 
Taiwan. 
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Activation of CREB by PI3 kinase and p38 MAPK is essential for 
elevated expression of TGFβ2 
Youzhong Wan, Maojing Yang, Sunny Kolattukudy, George R. Stark, 
Tao Lu. 
Presenter affiliation: Cleveland Clinic Foundation, Cleveland, Ohio; 
Case Western Reserve University, Cleveland, Ohio. 
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  xxv 
WEDNESDAY, August 18—7:30 PM 
 
 
SESSION 4 MOUSE MODELS 
 
Chairperson: C. Abate-Shen, Columbia University Medical School,  
New York, New York 
 
  
Preclinical and molecular insights into cancer progression using 
genetically-engineered mouse models of prostate and bladder 
cancer 
Cory Abate-Shen, Alvaro Aytes Meneses, Takashi Kobayashi, Carolyn 
W. Kinkade, Antonina Mitrofanova, Celine Lefebvre, Mireia Castillo-
Martin, Edward Gellman, Carlos Cordon-Cardo, Andrea Califano, 
Michael M. Shen. 
Presenter affiliation: Columbia University College of Physicians & 
Surgeons, Center for Computational Biology and Bioinformatics, New 
York, New York. 
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Selective activation of p53-mediated tumor suppression in high-
grade tumors 
Melissa R. Junttila, Anthony Karnezis, Daniel Garcia, Roderik 
Kortlever, Gerard I. Evan, Carla P. Martins. 
Presenter affiliation: University of California San Francisco, San 
Francisco, California; Cancer Research UK, Cambridge, United 
Kingdom. 
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A rapid and scalable system for modeling lung adenocarcinoma 
using RNAi transgenic mice 
Prem K. Premsrirut, Luke E. Dow, Sang Yong Kim, Matthew Camiolo, 
Colin Malone, Greg J. Hannon, Scott W. Lowe. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York; Stony Brook School of Medicine, Stony Brook, New 
York. 
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Pre-clinical mouse models to investigate the molecular 
mechanisms of small cell lung carcinoma development 
Kwon Park, Julien Sage. 
Presenter affiliation: Stanford University, Stanford, California. 
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  xxvi 
Raptor is required for intestinal regeneration and transformation 
but not intestinal homeostasis 
William Faller, Sorina Radulescu, Owen Sansom. 
Presenter affiliation: Beatson Institute for Cancer Research, Glasgow, 
United Kingdom. 
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Genetic Inducible Mosaic Analysis (GIMA)—A novel genetic 
method for modeling and characterizing sporadic tumorigenesis 
in the mouse 
G. Praveen Raju, Zhimin Lao, Luis Barraza, Brian Bai, Alexandra L. 
Joyner. 
Presenter affiliation: Memorial Sloan-Kettering Cancer Center, New 
York New York; Weill Cornell Medical College, New York New York. 
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C-Raf, a bottleneck for K-Ras oncogenic signaling in non small 
cell lung cancer 
Sarah Francoz, Rafael B. Blasco, Marta Cañamero, Pierre Dubus, 
Manuela Baccarini, Mariano Barbacid. 
Presenter affiliation: CNIO (Centro Nacional de Investigaciones 
Oncológicas), Madrid, Spain. 
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Oncogenic BRafV600E elicits papillary thyroid cancer in the mouse 
Martin McMahon, Anny Shai, Christy Trejo, Victoria Marsh, Elena 
Amendola, Charles Roch-Philippe. 
Presenter affiliation: UCSF Comprehensive Cancer Center, San 
Francisco, California. 
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Genetic mosaic analysis reveals a central role of oligodendrocyte 
precursor cells in gliomagenesis 
Chong Liu, Jonathan C. Sage, Michael R. Miller, Roel G. Verhaak, 
Simon Hippenmeyer, Hannes Vogel, Oded Foreman, Akiko Nishiyama, 
Liqun Luo, Hui Zong. 
Presenter affiliation: University of Oregon, Eugene, Oregon. 
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Mouse models to investigate menopausal influences on epithelial 
ovarian cancer risks 
Ying Wang, Cathy Q. Cai, Toni M. Yeasky, Xiang-xi Xu. 
Presenter affiliation: University of Miami, Miami, Florida. 
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  xxvii 
THURSDAY, August 19—9:00 AM 
 
 
SESSION 5 Rb AND p53 NETWORKS 
 
Chairperson: K. Vousden, Beatson Institute for Cancer Research,  
  Glasgow, United Kingdom 
 
  
Mutant p53 drives an invasive program that involves multiple 
RTKs 
Patricia Muller, Jim C. Norman, Karen H. Vousden. 
Presenter affiliation: The Beatson Institute for Cancer Research, 
Glasgow, United Kingdom. 
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Rb regulates tumor-cell plasticity 
Eliezer Calo, Jose A. Quintero-Estades, Jacqueline A. Lees. 
Presenter affiliation: Koch Institute For Integrative Cancer Research, 
MIT, Cambridge, Massachusetts. 
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Loss of the Drosophila retinoblastoma family protein predisposes 
cells to dedifferentiation 
Brandon N. Nicolay, Maxim V. Frolov. 
Presenter affiliation: University of Illinois at Chicago, Chicago, Illinois. 
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p18Ink4c loss leads to tumor progression within Cyclin D1-driven 
senescent pineal hyperplasia in-vivo irrespective of Cdk2 
downregulation 
Hasan Zalzali, Lina Malaeb, Stephen X. Skapek, Mohammad Harajly, 
Nader Chaar, Raya Saab. 
Presenter affiliation: American University of Beirut, Beirut, Lebanon. 
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Combining ATR suppression with oncogenic Ras expression 
synergistically increases genomic instability, causing synthetic 
lethality or elevated tumorigenesis in a dosage-dependent 
manner 
Oren Gilad, Barzin Y. Nabet, Ryan L. Ragland, David W. Schoppy, 
Kevin D. Smith, Amy C. Durham, Eric J. Brown. 
Presenter affiliation: Abramson Family Cancer Research Institute, 
University of Pennsylvania School of Medicine, Philadelphia, 
Pennsylvania. 
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  xxviii 
Chronic cisplatin treatment promotes enhanced damage repair 
and tumor progression in a mouse model of lung cancer 
Trudy G. Oliver, Kim L. Mercer, Leanne C. Sayles, James R. Burke, 
Diana Mendus, David Mu, Scott Powers, Denise Crowley, Roderick 
Bronson, Charles A. Whittaker, Arjun Bhutkar, Stephen Lippard, 
Katherine Lovejoy, Juergen Thomale, Alejandro Sweet-Cordero, Tyler 
Jacks. 
Presenter affiliation: MIT, Cambridge, Massachusetts. 
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53BP1 inhibits homologous recombination in Brca1-deficient 
cells by blocking resection of DNA breaks 
Samuel F. Bunting, Andre Nussenzweig. 
Presenter affiliation: National Cancer Institute, Bethesda, Maryland. 
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Contrasting physiologic roles for Arf and Ink4a during male germ 
cell development 
Michelle L. Churchman, Adam Gromley, Charles J. Sherr. 
Presenter affiliation: Howard Hughes Medical Institute/St. Jude 
Children’s Research Hospital, Memphis, Tennessee. 
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Tgfβ signaling directly induces Arf promoter remodeling by 
Smad-dependent and –independent mechanisms 
Yanbin Zheng, Yi D. Zhao, Melissa Gibbons, John M. Cunningham, 
Stephen X. Skapek. 
Presenter affiliation: The University of Chicago, Chicago, Illinois. 
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New molecular insights into a key role for TCTP in tumorigenesis 
and tumor reversion 
Robert Amson, Salvatore Pece, Alexandra Lespagnol, Giovanni 
Mazzarol, Sylvie Rodriguez-Ferreira, Daniela Tosoni, Ivan Colaluca, 
Jean-Christophe Marine, Olivier Chaloin, Johan Hoebeke, Pier Paolo 
Di Fiore, Adam Telerman. 
Presenter affiliation: Ecole Normale Supérieure, Cachan, France. 
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  xxix 
THURSDAY, August 19—2:00 PM 
 
 
SESSION 6 POSTER SESSION II 
 
  
Sleeping Beauty insertional mutagenesis reveals multiple 
networks of genes co-operating with Apc-deficiency to drive 
intestinal mutagenesis 
Helen N. March, Alistair G. Rust, Nicholas A. Wright, Jelle ten Hoeve, 
Jeroen de Ridder, Matthew Eldridge, Louise van der Weyden, 
Catherine H. Wilson, Richard Kemp, Anthony Uren, Mark Arends, 
Lodewyk Wessels, David J. Adams, Douglas J. Winton. 
Presenter affiliation: Cancer Research-UK Cambridge Research 
Institute, Cambridge, United Kingdom. 
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Dicer1 is required for Retinoblastoma formation 
Irina Lambertz, David Nittner, Frederic Clermont, Alexander Schramm, 
Pieter Mestdagh, Jo Vadesompele, Johannes Schulte, Mike Dyer, 
Jean-Christophe Marine. 
Presenter affiliation: VIB-KULeuven, Leuven, Belgium. 
 
 
 
 
146 
  
PDE4D and prostate cancer—From mouse genetic screening to 
candidate therapeutics 
Paul C. Marker, Kimberly Hammer. 
Presenter affiliation: University of Wisconsin, Madison, Wisconsin. 
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Podoplanin associates with CD44 to promote directional cell 
migration 
Ester Martin-Villar, Beatriz Fernández-Muñoz, Maddy Parsons, Maria 
M. Yurrita, Gareth E. Jones, Miguel Quintanilla. 
Presenter affiliation: Kings College London, London, United Kingdom. 
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The role of dystroglycan in prostate cancer. 
Grinu Mathew, Andrew Mitchell, Simon S. Cross, Chris Moore, Steve J. 
Winder. 
Presenter affiliation: The University of Sheffield, Sheffield, United 
Kingdom. 
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Synergistic induction of apoptosis by the HDACi, panobinostat, 
combined with rhTRAIL or bortezomib, in multiple myeloma 
Geoff Matthews, Marcus Lefebure, Jake Shortt, Kellie Banks, Kym 
Stanley, David Faulkner, Leif Bergsagel, Marta Chesi, Peter Atadja, 
Ricky Johnstone. 
Presenter affiliation: Peter MacCallum Cancer Institute, Melbourne, 
Australia. 
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  xxx 
MicroRNA–tumor suppressor networks on T-cell lymphoblastic 
leukemia 
Konstantinos J. Mavrakis, Xiaoping Liu, Pieter Van Vlierberghe, 
Andrew Wolfe, Nicholas Socci, Frank Speleman, Hans-Guido Wendel. 
Presenter affiliation: Memorial Sloan-Kettering Cancer Center, New 
York, New York. 
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Inducible, reversible essential gene knockdown by transgenic 
RNA interference 
Katherine McJunkin, Anthony Mazurek, Prem Premsrirut, Johannes 
Zuber, Bruce Stillman, Scott W. Lowe. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York; Watson School of Biological Sciences, Cold Spring 
Harbor, New York. 
 
 
 
 
 
 
152 
  
In vivo RNAi screening in hematopoietic malignancies 
Corbin E. Meacham, Michael T. Hemann. 
Presenter affiliation: MIT, Cambridge, Massachusetts. 
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Understanding the roles of BCCIP in prevention of chromosome 
instability and mitosis 
Sonam Mehrotra, Robin Mathew, Eileen White, Zhiyuan Shen. 
Presenter affiliation: CINJ- UMDNJ, New Brunswick, New Jersey. 
 
 
 
154 
  
LINT, a novel dL(3)mbt (Drosophila Lethal 3 malignant brain 
tumor) complex, with a role in stable repression of germline-
specific genes 
Karin Meier, Florian Finkernagel, Gunther Doehlemann, Alexander 
Brehm. 
Presenter affiliation: Institute of Molecular Biology and Tumor 
Research, Marburg, Germany. 
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Role of YAL066w locus in maintenance of genome stability 
Qingchang Meng, Sharon Plon. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
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Mutual regulation connects c-MYC and SIRT1 
Antje Menssen, Per Hydbring, Karsten Kapelle, Jörg Vervoorts, 
Joachim Diebold, Lars-Gunnar Larsson, Bernhard Lüscher, Heiko 
Hermeking. 
Presenter affiliation: Ludwig-Maximilians University, Munich, Germany. 
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  xxxi 
Exploting the role of PTEN in tumor matinenance using 
conditional RNA interference 
Cornelius Miething, Claudio Scuoppo, Prem Premsrirut, Jim Hicks, 
Scott Lowe. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York. 
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Treatment-induced senescence preserves stem cell properties of 
Eμ-Myc driven lymphomas 
Maja Milanovic, Jan Dörr, Yong Yu, Dido Lenze, Michael Hummel, 
Clemens A. Schmitt. 
Presenter affiliation: Charité, Berlin, Germany. 
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A distinctive DNA damage response in human hematopoietic 
stem cells reveals an apoptosis independent role for p53 in self-
renewal 
Michael Milyavsky, Olga Gan, Magan Trottier, Martin Komosa, Ofer 
Tabach, Faiyaz Notta, Eric Lechman, Karin. Hermans, Kolja Eppert, 
Zhanna Konovalova, Olga Ornatsky, Eytan Domany, Stephen Meyn, 
John Dick. 
Presenter affiliation: Ontario Cancer Institute, Toronto, Canada. 
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Investigating UHRF1 as an oncogene in hepatocellular carcinoma 
Raksha Mudbhary, Liz Loughlin, Vinitha Jacob, Anja Lachenmayer, 
Laia Cabellos, Augusto Villanueva, Josep Llovet, Kirsten C. Sadler. 
Presenter affiliation: Mount Sinai School of Medicine, New York, New 
York. 
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miR99a, a microRNA that is repressed during prostate cancer 
progression, can modulate the cellular response to DNA damage 
by regulating Cdc25a synthesis 
Adam C. Mueller, Dandan Sun, Anindya Dutta. 
Presenter affiliation: University of Virginia, Charlottesville, Virginia. 
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Regulation of cell cycle checkpoint pathways by 14-3-3γ 
Amitabha Mukhopadhyay, Amol Hosing, Sorab Dalal. 
Presenter affiliation: Tata Memorial Centre, ACTREC, New Mumbai, 
India. 
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Targeting drug-induced survival pathways—Rational 
development of combinatorial therapies. 
Taru Muranen, Laura Selfors, Fabiana Morales, Yiling Lu, Sizhen Gao, 
Gordon B. Mills, Joan S. Brugge. 
Presenter affiliation: Harvard Medical School, Boston, Massachusetts. 
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  xxxii 
Functional expression of FRS2/3 in prostate cancer 
Tania M. Murphy, Ajay Joseph, Naveen Kachroo, Satoshi Hori, Steven 
Darby, Anne Warren, Vincent J. Gnanapragasam. 
Presenter affiliation: University of Cambridge, Cambridge, United 
Kingdom. 
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Rac1 drives hyperproliferation following APC loss in the small 
intestine. 
Kevin B. Myant, Owen Sansom. 
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Melanoma progression is invariably associated with the acquisition of 
multiple defects in apoptotic pathways. For example, overexpression of 
anti-apoptotic Bcl-2 family members, dysregulation of caspase inducers, 
and deficiencies in p53-dependent death programs are all common features 
of aggressive melanomas. Anti-melanoma therapeutic strategies often aim 
to overcome these negative apoptotic signals, yet the execution of death 
programs remains slow and inefficient, even when using pleiotropic agents. 
These results suggest the existence of yet unidentified mechanisms of 
melanoma cell survival. Here we present a molecular characterization of 
protective responses that precede and can interfere with the activation of 
apoptotic caspases by anticancer drugs. Electron microscopy analyses of 
melanoma cells revealed the presence of autophagosomes after treatment 
with various chemotherapeutic agents. Multillamelar structures surrounding 
cellular organelles were particularly evident upon treatment with 
cyclopamine, an inhibitor of Smoothened (a central modulator of the Sonic 
Hedgehog pathway). Cyclopamine-induced autophagy was further 
confirmed by the lipidation of LC-3 and the relocalization of this protein to 
autophagosomes. Notably, aberrant phagocytic organelles were sustained 
for a long time (up to 70 h) while cells blocked their proliferative capacity 
but remained viable. In contrast to classical genotoxic-induced stress 
programs, the response to cyclopamine was independent of p53. Instead, we 
found that cyclopamine targets and deregulates lysosomal functions. These 
results were unexpected because the Sonic Hedgehog pathway can control 
the proliferative capacity of a variety of tumor cell types (including 
melanoma), but it was not previously known as an inducer of autophagy. 
Interestingly, forcing autophagy with hypoxia or low serum switched the 
outcome of cyclopamine treatment from a protective response to the 
induction of cell death. These data reveal a novel role of autophagy in the 
control of melanoma cell survival, acting independently of the classical 
tumor suppressor p53. Understanding this previously unexplored autophagy 
pathway may reveal new targets for drug design. 
 2 
INTERPLAY BETWEEN ONCOGENE-INDUCED DNA DAMAGE 
RESPONSE AND HETEROCHROMATIN IN SENESCENCE AND 
CANCER 
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Oncogene-induced cellular senescence is a permanent proliferative arrest 
triggered by exogenous or endogenous stresses. Two major mechanisms 
have been causally implicated in the establishment of the senescence state: 
the activation of the DNA Damage Response (DDR) pathway, which 
enforces a permanent checkpoint, and global induction of heterochromatin 
resulting in the formation of Senescence-Associated Heterochromatic Foci 
(SAHF), which have been proposed to suppress the transcription of genes 
involved in proliferation. If and how they interact is unclear. We have 
recently observed that SAHF are preferentially triggered by oncogene 
activation, in a manner dependent on DNA replication and controlled by 
ATR. ATM or p53 inactivation allows the de-repression of proliferative 
genes and proliferation of oncogene-expressing cells bearing SAHF-like 
structures, thus revealing that SAHF and transcriptional repression can be 
uncoupled. In a wide collection of human cancers the levels of 
heterochromatin markers were found to be higher than in normal tissues and 
this is independent of their proliferative index or cancer stage. 
Pharmacological and genetic perturbation of heterochromatin increases 
DDR signalling specifically in oncogene-expressing cells and leads to 
DDR-dependent apoptosis. In vivo, systemic administration of a histone 
deacetylase inhibitor causes heterochromatin relaxation, increased DDR 
activation, apoptosis and tumor regression. 
We propose that oncogenic stress-induced heterochromatin restrains DDR 
and this may provide the rationale for the use of chromatin modifying 
drugs, including histone deacetylase inhibitors, as cancer therapies guided, 
however, by the study of the status of heterochromatin and DDR 
competence of the tumor. 
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The tumor suppressive properties of the retinoblastoma protein (pRB) rely 
largely on its ability to regulate the E2F transcription factors. The resulting 
pRB-E2F complexes can bind, and actively repress, the promoters of cell 
cycle genes. E2F1, among other E2F family members, also promotes the 
transcription of proapoptotic genes in response to both genotoxic and 
oncogenic stress. Prevailing models suggest that pRB inhibits this apoptosis 
by binding to E2F and inducing cell cycle arrest. However, while there is 
strong evidence that pRB promotes arrest in response to DNA damage, the 
interplay between pRB and E2F1 in proapoptotic gene regulation has not 
been elucidated. We address this question here. Remarkably, we found that 
genotoxic agents caused pRB to associate with E2F1 and the transcriptional 
coactivator P/CAF. The resulting complex formed irrespective of the cell 
cycle phasing and it occupied the transcriptionally active form of 
proapoptotic gene promoters. Moreover, pRB was required for the maximal 
activation of DNA damage-induced apoptosis both in vitro and in vivo. 
Notably, genotoxic stress also caused recruitment of pRB, E2F1 and histone 
deacetylase to the cyclin A2 promoter, coincident with its repression. Thus, 
we conclude DNA damage induces two distinct pRB-containing complexes 
that mediate activation of apoptotic genes or repression of cell cycle genes. 
We also examined the effects of E1A, a potent proapoptotic oncogene that 
is thought to act by sequestering pRB and releasing active E2F. Contrary to 
this model, our data suggest that E1A participates in a multimeric pRB-
E2F1-E1A complex that activates both apoptotic and cell cycle genes. 
Taken together, our data reveal a previously unappreciated, positive role for 
pRB in the apoptotic response to both genotoxic and oncogenic stress. This 
is entirely consistent with pRB’s tumor suppressive functions and opens 
new perspectives for cancer therapies. Altogether these data indicate that 
pRB has the ability to promote not only cell cycle arrest but also apoptosis. 
Our current efforts are now directed at the understanding of the molecular 
mechanisms regulating the formation and the activity of the different pRB-
E2F1 complexes. 
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"SENESCENCE SURVEILLANCE" SUPPRESSES CARCINOGENESIS 
IN THE LIVER AND INVOLVES AN ADAPTIVE IMMUNE 
RESPONSE AGAINST PREMALIGNANT SENESCENT 
HEPATOCYTES 
 
Tae-Won Kang1, Tetyana Yevsa1,2, Norman Woller2, Lisa Hoenicke2, 
Torsten Wuestefeld1,2, Thomas Longerich3, Peter Schirmacher3, Stefan 
Kubicka2, Lars Zender1,2  
 
1Helmholtz Centre for Infection Research, Chronic Infection and Cancer 
group, Braunschweig, 38124, Germany, 2Hannover Medical School, 
Gastroenterology, Hepatology and Endocrinology, Hannover, 30625, 
Germany, 3University Hospital Heidelberg, Institute of Pathology, 
Heidelberg, 69120, Germany 
 
To determine whether immune surveillance of premalignant senescent cells 
plays a significant role in tumor suppression, oncogene induced senescence 
(OIS) was triggered by oncogenic NrasG12V in otherwise normal mouse 
hepatocytes in vivo. Cytokine profiling of mouse livers after senescence 
induction revealed expression of various cytokines known to be involved in 
the senescence associated secretory phenotype (SASP) but also an increased 
expression of cytokines regulating the attraction, activation and 
proliferation of T lymphocytes. In accordance with the observed cytokine 
profiles, using histology and FACS profiling, we found a strong influx of 
innate immune cells (neutrophils, macrophages and NK cells) but also of 
adaptive immune cells (CD4+ and CD8+ lymphocytes and dendritic cells) 
into mouse livers harboring senescent hepatocytes.Time course analyses 
revealed clusters of senescent hepatocytes surrounded by immune cells and 
a decrease in the number of senescent hepatocytes over time, thus 
suggesting an immune-mediated clearance of premalignant senescent 
hepatocytes. Experiments with mice harboring either defects in the innate or 
adative immune system side by side with their syngenic wildtype 
counterparts showed that a defective adaptive immunity abolishes the 
immune clearance of premalignant senescent cells. Interestingly, when these 
mice were followed up long term, defective senescence surveillance 
resulted in murine hepatocellular carcinomas (HCC). To delineate the 
mechanism of immune surveillance of premalignant senescent hepatocytes 
in the liver, we took advantage of immunological assays and also studied 
senescence surveillance in an expanded panel of mice with defined immune 
defects and in mice which were treated with different immune cell depleting 
antibodies. Interestingly, experiments in CD4+ knockout mice showed a 
complete abrogation of senescence surveillance and Elispot assays revealed 
the presence of NrasG12V specific T-lymphocytes in mice where liver 
specific senescence had been triggered by NrasG12V. Taken together, our 
data show that senescence surveillance represents an important extrinsic 
component of the senescence anti-tumor barrier which involves an adaptive 
immune response against premalignant senescent cells. 
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Human melanocytic nevi (moles) are benign neoplasms commonly 
harboring activating mutations in BRAF or NRAS. Although nevi are 
considered to be precursors of melanoma, a highly aggressive type of (skin) 
cancer, little is known about the mechanism underlying progression from 
nevus to melanoma. We and others have previously shown that, although 
initially, activated BRAF and NRAS oncogenes act mitogenically, 
eventually oncogene-induced senescence (OIS) ensues. This has led to the 
hypothesis that abrogation of OIS of nevus cells acts as a rate-limiting event 
in melanomagenesis. Favoring this model, nevi and melanomas are 
commonly, and significantly, histologically associated. Indeed, malignant 
melanoma can emerge within a nevus. 
In addition to the activation of the ERK pathway, other frequent genetic 
events include the loss of the CDKN2A and ARF genes. Although the 
involvement of p16 in melanomagenesis is undisputed, there is little 
evidence to support a non-redundant role for p16 in BRAF(E600)- or 
NRAS(K61)-induced senescence, neither in vitro nor in vivo. Another 
common genetic event in melanoma is the activation of the PI3K pathway, 
which is seen in ~60% of cases. This is achieved by loss of PTEN 
expression, increased AKT3 activity or mutations in PIK3CA. Interestingly, 
some 20% of melanomas show concurrent mutation in BRAF and 
diminished expression of PTEN.  
We have found that in cultured human melanocytes, BRAF(E600)-induced 
senescence is accompanied by suppression of AKT3. Activation of the 
PI3K pathway by ectopic expression of AKT or PIK3CA, or depletion of 
PTEN, abrogates senescence. Correspondingly, in a series of contiguous 
human nevus-melanoma specimens, we observed a decrease in PTEN 
and/or an increase in AKT3 in the melanoma relative to the adjacent nevus 
in >50% of the cases. In several of these, laser microdissection-guided 
genetic analysis revealed identical mutations in BRAF or NRAS in the 
nevus and contiguous melanoma, including a rare double mutation, which is 
in support of a nevus-to-melanoma progression model. These findings 
indicate that PI3K pathway activation serves as a rate-limiting event in 
human melanoma progression, acting at least in part by abrogating OIS. 
This provides an explanation for the frequent co-occurrence of mutations in 
BRAF and the PI3K pathway in melanoma. 
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The Myc oncoprotein is a fundamental component of many crucial cellular 
processes, such as cell cycle progression, cell growth, apoptosis, 
metabolism and it has been widely implicated in many human cancers. In 
non-transformed cells, Myc expression is tightly regulated and excessive 
Myc activation triggers apoptosis as a safe guard mechanism. This anti-
tumorigenic response needs to be overcome in tumors. Myc-driven cell 
proliferation is partly achieved by the induction of cyclins and cyclin-
dependent kinases (Cdks). We have recently found that Myc represses 
oncogene-induced senescence, which is another important barrier of tumor 
development. This Myc function requires Cdk2-mediated phosphorylation 
of Myc at serine 62, as shown by inhibition of Cdk2. To investigate whether 
pharmacological inhibition of Cdk2 delays Myc-driven tumor onset in vivo 
trough senescence, we used a bone marrow transduction/transplantation 
model. Hematopoietic stem cells (HSC) purified from bone marrow cells of 
BALB/c mice were transduced with lentiviral vectors containing Myc and 
Bcl-xl cDNA and then transplanted into lethally irradiated mice. The mice 
developed massive CD11+/Gr+ acute myeloproliferative leukemia after 2-3 
weeks. To investigate the importance of Cdk2 in this process, mice 
transplanted with Myc and Bcl-xl-expressing HSC were treated with the 
Cdk2 inhibitor CVT-2584 or vehicle on a daily basis. Analysis of isolated 
bone marrow, liver and spleen cells of mice by flow cytometry revealed a 
significant decrease of CD11+/Gr+ leukemic cell population in the treated 
mice. To gain insight into the effects behind Cdk2 inhibition and to 
corroborate our previous in vitro studies, cellular senescence was assayed in 
spleen and liver tissues from control and treated mice by immunostaining 
with antibodies directed against trimethylated histone H3 lysine 9 
(H3K9me3). H3K9me3-positive senescence-associated heterochromatinic 
foci were more abundant in all analyzed tissues of the treated mice. Further, 
Cdk2 targeting significantly delayed onset of disease and improved mice 
survival. In summary, the selective inhibition of Cdk2 in vivo delayed 
Myc+BclxL driven leukemia and induced cellular senescence in analyzed 
liver and spleen tissues. Our results provide a new rationale for treatment of 
Myc-driven neoplasia by exploiting Cdk2 inhibition as a strategy to induce 
senescence in such tumor cells. 
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The RAS oncoproteins (N-RAS, H-RAS, K-RAS4A, K-RAS4B) have been 
studied extensively for almost three decades. Although activation of RAS 
represents a key feature of malignant transformation for many cancers, we 
are only now beginning to understand the complex underpinnings of RAS 
biology. And while biochemical studies have failed to identify significant 
differences between members of this enzyme family, genetic and cellular 
studies are beginning to reveal non-overlapping functions for RAS family 
members. For example, we have found that mutationally activated N-RAS 
(G12D) is unique among the family members in its ability to suppress 
stress-induced apoptosis in epithelial cells. To do so, mutant N-RAS must 
simultaneously activate both canonical and non-canonical effectors. Like 
other family members, mutant N-RAS potently activates the MAPK 
pathway, but N-RAS is the only family member that can regulate the 
phosphorylation and transcriptional activity of STAT3. Interestingly, 
activation of both MAPK and STAT3 is mediated by RAF-1 and activated 
RAF-1 phenocopies mutant N-RAS in the suppression of apoptosis. Why is 
N-RAS the only family member that can feed into STAT3? Consistent with 
it being the only RAS protein localized to lipid rafts in its GTP-bound state, 
mutant N-RAS activates both ERK and STAT3 from this membrane 
microdomain. Disruption of lipid rafts completely abrogates the anti-
apoptotic phenotype associated with mutant N-RAS. Our studies provide a 
formal demonstration that sub-cellular localization underlies the functional 
differences between the highly related RAS GTPases. These data also 
establish a new paradigm in RAS biology – that functional differences 
among family members derive from specific engagement of non-canonical 
effector pathways. 
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The three Ras proto-oncogenes encode four Ras isoforms (K-Ras 4a, K-Ras 
4b, N-Ras and H-Ras) that function as signal switch molecules to couple 
extracellular signaling with activation of its effectors. Ras activation is 
crucial for modulating cell fate responses, namely proliferation, 
differentiation and survival. The Ras isoforms are highly conserved, 
diverging only in the last 24 amino acids. This variation in their C-terminal 
“hypervariable” domains leads to differential subcellular localization, which 
may contribute to variable effects on downstream effectors. Although RAS 
mutations occur in ~30% of all human cancers, there is an isoform specific 
mutation spectrum in distinct tumor types. For example, Kras mutations 
predominate solid tumors, while Nras mutations are frequently found in 
myeloid malignancies. Previous studies from our laboratory demonstrated 
that endogenous expression of oncogenic K-RasG12D in hematopoietic cells 
causes an aggressive myeloproliferative disorder, whereas endogenous N-
RasG12D expression causes a diverse spectrum of hematologic cancers with 
much longer latencies. My overall goal is to understand the molecular basis 
of the differential effects of oncogenic N-Ras and K-Ras in leukemogenesis. 
I have pursued this general question through two aims: 
1) To characterize a series of NrasG12D and KrasG12D alleles in which I have 
modified their respective hypervariable regions. I have engineered MSCV 
retroviruses encoding chimeric N-Ras and K-Ras molecules and will assess 
the effects of expressing these proteins on myeloid progenitor growth and 
Ras effector activation; and, 
2) To generate and characterize a new mouse strain that will express an 
oncogenic N-RasG12D chimeric protein that contains the K-Ras 4b domain 
from the endogenous Nras locus. These studies will facilitate biochemical 
and cell biologic studies to understand the mechanism of isoform-specfic 
differences and may suggest new strategies for targeting oncogenic Ras in 
leukemias. 
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DOK family proteins are adaptor proteins that modulate receptor tyrosine 
kinases (RTKs), RAS, and SRC signaling pathways. Our group recently 
identified DOK2 as a human lung tumor suppressor gene that is frequently 
downregulated in human lung adenocarcinoma due to broad-scale genomic 
losses encompassing the DOK2 locus at chromosome 8p21.3. Here we find 
that genomic loss of DOK2 in human lung adenocarcinoma is significantly 
associated with both EGFR and KRAS mutation. These associations are 
found to be functionally relevant, because loss of Dok2 in vivo enhances the 
lung tumorigenesis and lethality caused by doxycycline-induced expression 
of oncogenic EGFR or Kras in the murine lung.  
Dok2 knockout (KO) mice expressing an oncogenic deletion mutant of 
EGFR had significantly more tumors, greater lung mass, and shorter 
survival than Dok2 wild-type (WT) EGFRDEL animals. Knockout of Dok2 
could similarly exacerbate the tumor phenotype induced by lung-specific 
expression of an oncogenic Kras G12D allele. Lungs from KrasG12D animals 
without Dok2 had significantly more tumor nodules and a higher percentage 
of Ki67-positive cells than lungs from Dok2 WT KrasG12D mice. 
Co-immunoprecipitation and immunofluorescence analysis showed that 
EGFR and DOK2 interact and co-localize after EGF stimulation. Under 
these conditions, DOK2 is phosphorylated and bound to downstream 
effector proteins. Whereas DOK2 interacts with wild-type EGFR in an 
EGF-inducible manner, DOK2 is constitutively bound to the L858R mutant 
form of EGFR found in human lung cancer.  
These data identify DOK2 as a negative regulator of lung cancer initiated by 
oncogenic EGFR or KRAS. Furthermore, these findings suggest the 
existence of novel RasGAP-independent functions of DOK2 that are 
involved in suppression of KRASG12D-induced transformation. 
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Reactive oxygen species (ROS) are mutagenic and may thereby promote 
cancer. However, somatic mutations that activate the Nrf2 pathway have 
recently been described in human cancer, suggesting that enhanced ROS 
detoxification may be pro-tumorigenic. Here, we demonstrate that ROS are 
actively suppressed by the oncogene K-Ras to stimulate neoplasia. K-
RasG12D engages an antioxidant program mediated by the transcription 
factor Nrf2 to lower intracellular ROS and confer a more reduced 
intracellular environment. Activation of the Nrf2 antioxidant program is 
evident in primary cells and tissues of mice expressing K-RasG12D, and in 
human pancreatic cancer. Activation of Nrf2 occurs independently of 
mutations in Nrf2 and Keap1 and is instead mediated by the MAP kinase 
Ras effector pathway, which promotes transcriptional upregulation of Nrf2 
through c-Jun. Pharmacological and genetic targeting of the MAPK-Nrf2 
pathway impairs proliferation and tumorigenesis in vivo. Thus, the Nrf2 
antioxidant program represents a previously unappreciated mediator of Ras 
tumorigenesis. Furthermore, Nrf2 is also activated by oncogenic B-Raf and 
c-Myc to lower ROS, and thus our findings may represent a general feature 
of cancers with deregulation of these pathways. These findings warrant a re-
evaluation of the role of ROS in carcinogenesis. 
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Development and tumor suppression are intimately linked and the genes 
that function in these processes are highly conserved throughout evolution. 
Here we describe the identification of NRBP1 as a key regulator of the Wnt 
pathway, intestinal differentiation, and tumor suppression. A kinome-wide 
screen in let60 gain-of-function mutant Ras C. elegans revealed that 
H37N21.1, the worm ortholog of NRBP1, co-operates with mutant Ras to 
promote a multivulval phenotype. Suppression of NRBP1 in mouse 
NIH3T3 cells together with expression of RasV12 resulted in enhanced 
transformation. Likewise human BJ-ET-st p53kd,p16kd cells transfected 
with shRNAs against NRBP1 were transformed, but without activation of 
the Ras pathway suggesting NRBP1 functions downstream or in parallel 
with Ras in transformation. Germline deletion of Nrbp1 in the mouse 
resulted in embryonic lethality, while somatic deletion in all tissues of adult 
mice resulted in profound changes to the proliferation and differentiation of 
intestinal cell lineages with 80% of mice dying within 10 days. Expression 
analysis of intestinal tissues from these mice revealed transcriptional 
activation of Wnt pathway targets. Knockdown of NRBP1 in human HCT-
116 and SW480 cell lines using siRNA confirmed activation of Wnt 
reporters. Mosaic somatic deletion of Nrbp1 in the mouse circumvented the 
lethality and resulted in tumorigenesis, with tumors staining strongly 
positive for Wnt targets such as c-Myc. We reveal that NRBP1 is 
downregulated in a range of human tumors and in lung cancer low NRBP1 
expression is associated with reduced survival. Thus, we have established 
that NRBP1 is a novel tumor suppressor that functions in the Wnt pathway. 
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Follicular lymphoma (FL) is the most common histological type of Non-
Hodgkin’s lymphoma and characterized by the t(14;18)(q32;q21) 
rearrangement and increased expression of the anti-apoptotic Bcl2 protein. 
Lymphomagenesis and ultimate transformation towards aggressive 
lymphoma are driven by additional genetic events. Cytogenetic studies have 
linked deletions of Chr. 6q to progression and reduced survival in one third 
of FL patients. To pinpoint genetic suppressors of FL we conducted a 
targeted shRNA screen based on array-CGH analyses 70 FLs. Here we 
show, that a truncated variant of the Ephrin receptor (EphA7TR) acts as a 
secreted tumor suppressor in vitro and in a murine FL model. EphA7TR is 
targeted by the 6q deletion in ~25% of FL and its promoter is uniformly 
silenced. Strikingly, administration of purified EphA7TR suppresses Src 
and Mapk signaling and produces tumor responses in human lymphomas in 
vivo. Hence, the EphA7TR is a secreted lymphoma suppressor that is 
epigenetically silenced and targeted by the Chr. 6q deletion in FL. 
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The Nuclear factor-B (NF-B) family of transcription factors is known to 
regulate expressions of diverse cellular genes related to immune response, 
cell growth and development. Activation of NF-B is controlled by either 
canonical and/or non-canonical signaling pathways depending on the 
stimuli. NF-B has been reported to be constitutively activated in a variety 
of cancer tissues and cell lines and to associate with the manifestation of 
malignant phenotypes of cancer cells, such as cell cycle deregulation, 
resistance to apoptosis, invasion and metastatsis. However, molecular 
mechanisms of constitutive activation of NF-B in cancer cells are in most 
cases remain to be studied. We previously described that adult T-cell 
leukemia (ATL) cells show constitutive NF-B activation although human 
T-cell leukemia virus type I Tax, a potent viral NF-?B activator, was 
undetectable in these cells. Previous studies demonstrated post-translational 
regulation of NIK in cytokine receptor-mediated signaling and mutations in 
multiple myeloma cells leading to aberrant NIK activation. Stimulation by 
cytokines such as B cell-activating factor or CD40 ligand induced 
degradation of TNF receptor-associated factor 3 (TRAF3), which binds to 
NIK and leads to proteasome-dependent NIK degradation in unstimulated 
cells, thereby stabilizing NIK to trigger the non-canonical pathway. 
Multiple myeloma cells achieve increased autonomy from the bone marrow 
microenvironment by mutations that activate either NF-B pathway. We 
demonstrate here that NIK was overexpressed at the pre-translational level 
in ATL, Hodgkin/Reed-Sternberg, lung cancer and breast cancer cells. NIK 
overexpression was not simply due to amplification of the NIK locus or 
stabilization of the NIK mRNA. Depletion of NIK by RNA interference in 
these cancer cells reduced NF-B-dependent gene expression, DNA-
binding activity of NF-B and the abilities of cancer cells to form colonies 
in soft agar or tumor in NOD/SCID/cnull mice. Our results indicate that 
NIK is responsible for constitutive NF-B activation in a wide range of 
cancer cells, contributing to manifestation of malignant phenotypes and 
suggest that NIK can be an attractive molecular target for cancer therapy. 
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Polyploidy is frequently associated with the early stages of human solid 
tumors and has been proposed as an intermediate step toward aneuploidy in 
cancer. However, a general mechanism for the induction of tetraploidy 
during tumorigenesis is lacking. We recently reported that tetraploidization 
occurs in p53-deficient cells experiencing a prolonged DNA damage signal 
due to persistent telomere dysfunction (Davoli et al., Cell, 2010). Live-cell 
imaging revealed that these cells have an extended G2 phase due to 
ATM/ATR- and Chk1/Chk2-mediated inhibition of Cdk1/CyclinB kinase 
and eventually by-pass mitosis. Despite their lack of mitosis, the cells 
showed APC/Cdh1-dependent degradation of the replication inhibitor 
geminin, followed by accumulation of Cdt1, which is required for the 
licensing of replication origins. Cells then entered a second S phase 
resulting in whole-genome reduplication and tetraploidy. Upon restoration 
of telomere protection, these tetraploid cells resumed cell division cycles 
and proliferated.  
 
We next examined the role of telomere-driven endoreduplication in cellular 
transformation and during natural telomere erosion in human cells. An 
inducible system for the expression of the telomeric protein POT1a was 
used to derive diploid and tetraploid cell populations after telomere-driven 
endoreduplication. As compared to the diploid counterpart, tetraploid cells 
showed higher transformation potential in vitro in soft-agar colony 
formation assay and increased in vivo tumorigenic potential after injection 
in mice. Furthermore, in the context of natural telomere attrition, we found 
that after prolonged replication-dependent telomere shortening (crisis 
stage), p53- and Rb-deficient human fibroblasts show DNA damage 
signaling, extended G2 phase and the ability to undergo endoreduplication-
dependent tetraploidy. Expression of telomerase in these cells silenced the 
DNA damage response and restored mitotic division cycles, indicating that 
in this context endoreudplication is dependent on the presence of short 
dysfunctional telomeres. Altogether, these observations suggest a general 
mechanism for the induction of tetraploidization in the early stages of 
human cancer after excessive telomere shortening and a role of this process 
during tumorigenesis. 
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Head and neck squamous cell carcinoma (HNSCC) is a malignancy of the 
squamous epithelium lining the oro- and nasopharynx. Molecularly, 
ΔNp63α, a truncated and oncogenic form of the p53-family of proteins, is 
highly expressed in the vast majority of HNSCC and promotes cancer cell 
survival by inhibiting TAp73β – a potent, apoptosis-inducing p53-family 
member. HNSCC cancer cells are dependent upon ΔNp63α for survival. In 
addition to having a critical role in the development of HNSCC, ΔNp63α 
function is also important in treatment response of HNSCC. Current anti-
cancer drugs exert their effects by downregulating pro-survival ΔNp63α 
while inducing pro-apoptotic TAp73β. Although overexpression of ΔNp63α 
is frequently observed in HNSCC, these tumors, nonetheless, vary in their 
responsiveness to radiation and chemotherapies. In particular, advanced-
stage HNSCC tumors are highly resistant to current treatments, suggesting 
additional factors exist that influence the function of ΔNp63α and 
chemoresponsiveness. Here, we identify Special AT-rich Binding Protein 2 
(SATB2) as a protein promoting chemoresistance of SCC cells of the head 
and neck. SATB2 forms a stable molecular complex with ΔNp63α and 
augments its DNA-binding capability and, thereby, represses apoptotic gene 
expression. RNAi-mediated knockdown of SATB2 sensitizes HNSCC cells 
towards chemotherapy- as well as radiation-induced apoptosis. 
Interestingly, SATB2 expression was preferentially upregulated in 
advanced HNSCC tumors that are typically unresponsive to chemotherapy. 
Taken together, our results suggest that SATB2 promotes survival of SCC 
cells by modulating the pro-survival function of ΔNp63α. 
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Recently massively parallel sequencing has been used to identify somatic 
mutations and structural rearrangements in human cancer genomes. Here we 
present the paired-end massively parallel sequencing of tumors from 
genetically engineered mouse models of mammary cancer to determine how 
faithfully these models recapitulate the landscape of somatic mutations 
found in human mammary tumors. This analysis involved tumors from 
mouse models of Brca1- and Brca2-associated hereditary breast cancer, a 
model in which Trp53 was deleted in the epithelial compartment of the 
breast, and a mouse model of E-cadherin (Cdh1) mutated lobular breast 
cancer. We show that although Brca1- and Brca2-deficient mouse 
mammary tumors have a defect in the homologous recombination (HR) 
pathway there is no apparent difference in the type or frequency of somatic 
rearrangements found in these cancers when compared to HR-proficient 
cancers, and both HR-deficient and HR-proficient tumors show evidence of 
micro-homology mediated repair and non-homologous end-joining 
processes. Analogous to our recent analysis of human breast cancers mouse 
breast cancers carry expressed in-frame fusion genes, but like human these 
fusion genes do not appear to be recurrent. One mouse tumor was found to 
contain an internal deletion of exons of the Lrp1b gene, which leads to a 
smaller in-frame transcript. We found the human ortholog of this gene 
(LRP1b) also shows internal in-frame deletions in a significant number of 
human cancer cell lines, underscoring the potential of mouse cancer genome 
sequencing for finding human cancer-relevant genes. 
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Tri- and di-methylation of lysine 9 on histone H3 (H3K9) is associated with 
heterochromatin formation and transcriptional repression in a variety of 
species. These methylation marks has been shown to be associated with 
normal as well as oncogene-induced senescence and genomic stability. 
Consistent with a role for these marks in tumor suppression, mice lacking 
one of the key H3K9 tri- and di-methylating enzymes are tumor prone. 
Others and we have recently isolated a gene family, called JMJD2, 
encoding for enzymes that demethylate tri- and di-methylated H3K9. 
Interestingly, we have found that the expression of these genes is highly 
elevated in a subset of human cancers, suggesting that they may contribute 
to tumor formation. Supporting this suggestion is the fact that JMJD2C 
(a.k.a. GASC1) was originally identified as a gene amplified in esophageal 
cancer, and that we have shown that inhibition of GASC1 expression slows 
down growth of tumor cell lines. At the meeting data will be presented 
characterizing the function of Jmjd2c during mouse development and its 
role in transcriptional regulation. 
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Although deregulation of the Wnt signalling pathway has recently been 
implicated in urothelial cell carcinoma (UCC), the functional significance 
of this is unknown. To test the importance of deregulated Wnt signalling in 
bladder tumorigenesis, we have targeted the expression of an activated form 
of β-catenin (β-cateninexon3) to the urothelium of transgenic mice using 
Cre-Lox technology (UroIICRE+ β-catenin exon3/+). Expression of this 
activated form of β-catenin (where β-catenin cannot be phosphorylated, and 
thus degraded) led to the formation of localised hyperproliferative lesions 
by 3 months of age, which did not progress to malignancy over 18 months.  
 
We also expressed oncogenic K-Ras and H-Ras in the urothelium alone, 
and in urothelial cells expressing an activated β-catenin. Although Ras 
activation was not sufficient to drive tumourigenesis, Ras activation 
combined with β-catenin activation in UroIICRE+ β –catenin exon3/exon3 
K-RasG12D/+ and UroIICRE+ β –catenin exon3/exon3 H-Ras mice rapidly 
developed UCC. These tumours had massive upregulation of pERK1/2.  
 
Importantly in human UCC, there was a significant correlation between 
high levels of β-catenin and pERK1/2. Taken together these data 
definitively show that deregulated Wnt signalling plays a critical role in 
driving bladder cancer formation.  
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SSeCKS/AKAP12 (SSeCKS) is a tumor suppressor which regulates cell 
cycle progression by scaffolding key mitogenic signaling molecules such as 
PKA and PKC. SSeCKS is downregulated in many human cancers, and we 
have shown previously that SSeCKS-null mice develop prostatic 
hyperplasia exhibiting the hallmarks of senescence. In order to understand 
the molecular mechanism of SSeCKS-mediated cell proliferation, we have 
isolated SSeCKS-null mouse embryonic fibroblasts (KO-MEFs) and found 
that KO-MEFs exhibit multinucleation and premature senescence. Although 
both p53 and Rb pathways were upregulated upon the loss of SSeCKS, the 
senescence was inhibited by E7 or siRNA-Rb, indicating that the 
senescence in KO-MEFs is Rb-dependent. Since SSeCKS is a scaffolder of 
PKC isozymes, we examined the activity of PKC isozymes. We 
demonstrated that PKCα and δ are activated in KO-MEFs, and the 
senescence is driven by PKC hyperactivation in the absence of SSeCKS 
scaffolding. We provided the evidence that activated PKCα induces p16/Rb 
activation through a MEK-ERK-dependent downregulation of Id1, whereas 
activated PKCδ induces cytokinesis defects through the downregulation of 
the mitotic exit network kinase, Warts/Lats1. In addition, we demonstrated 
that KO-MEFs are prone to be immortalized and the cells have increased 
susceptibility to oncogenic transformation. Our data suggest that SSeCKS 
prevents oncogenic progression by attenuating mitogenic and cytokinetic 
functions of PKC isozymes. In order to address the physiological relevance 
of these findings, we performed carcinogenesis experiment using 
DMBA/TPA skin treatment method. We found that papilloma formation 
occurs earlier and more frequently in KO mice, and in KO mice, there is a 
greater transition to squamous cell carcinoma. We also found induced levels 
of focal adhesion kinase (FAK) in KO epidermal layers, notably because 
FAK is required for carcinogen-induced progression to skin cancer 
malignancy. Altogether, this study envisions major mechanisms by which 
SSeCKS maintains cell cycle checkpoint controls to prevent oncogenesis by 
attenuating PKC activation. 
 20 
CONEXIC: AN INTEGRATIVE APPROACH TO UNCOVER DRIVERS 
OF CANCER 
 
Uri David Akavia*1,2, Oren Litvin*1,2, Jessica Kim3,4, Felix Sanchez-
Garcia1, Helen C Causton1, Eyal Mozes1, Dylan Kotliar1, Yossi Tzur1, Levi 
A Garraway3,4, Dana Pe'er1,2  
 
1Columbia University, Department of Biological Sciences, New York, NY, 
10027, 2Columbia University, Center for Computational Biology and 
Bioinformatics, New York, NY, 10032, 3Harvard Medical School, 
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 
MA, 02115, 4Broad Institute of Harvard and MIT, Cambridge, MA, 02142 
 
*Authors contributed equally 
Systematic characterization of cancer genomes has revealed a staggering 
complexity of aberrations among individuals, such that the functional 
importance and physiological impact of most tumor genetic alterations 
remains poorly defined. A major challenge involves the development of 
analysis methods to uncover biological insights from the data, including the 
identification of the key mutations that drive cancer and how these events 
alter cellular regulation.  
We have developed CONEXIC, a novel Bayesian Network-based 
framework to integrate chromosomal copy number and gene expression 
data to detect driving mutations that promote cancer progression, and to 
model how these alterations perturb normal cell growth/survival. The 
underlying assumption is that significantly recurring copy number change, 
coinciding with its ability to predict expression patterns varying across 
tumors, strengthens the evidence of a gene’s causative role in cancer. This 
method not only pinpoints specific regulators within a large aberrant region, 
but can shed light on the way in which regulation is altered. 
We demonstrated the utility of the CONEXIC framework using a melanoma 
dataset (Lin et al., Cancer Research, 2008) that includes paired 
measurements of gene expression and copy number from 62 samples. Our 
analysis correctly identified known drivers in melanoma (e.g. MITF) and 
connected these to many of their known targets, as well as the biological 
processes they regulate. 
In addition, it predicted multiple tumor dependencies not previously 
implicated in melanoma. Two such dependencies involving TBC1D16 and 
RAB27A were confirmed experimentally. The identity of these drivers 
suggests that abnormal regulation of protein trafficking is important for cell 
survival in melanoma and highlights the importance of protein trafficking in 
this malignancy. Together, these results implicate a new tumorigenic 
process in cancer and demonstrate the ability of integrative Bayesian 
approaches to identify novel drivers with biological, and possibly 
therapeutic, importance in cancer. 
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Breast cancer currently accounts for more than a quarter of all female 
cancers and despite the great progress in treatment observed in the last few 
years, the need for the identification of new gene targets that can be used for 
diagnosis, prognosis and therapy is evident. A previous study identified the 
transcription factor NR4A1 as one of the upregulated genes in primary 
breast cancer compared to normal tissue by microarray analysis and 
sequencing technologies. The purpose of the current study was therefore to 
identify the role of NR4A1 in mammary epithelial cell biology.  
NR4A1 belongs to the family of the NR4A orphan nuclear receptors. It is a 
transcription factor shown to be involved in both apoptosis and cell 
proliferation. The current study as well as several previous ones, have 
shown that NR4A1 is expressed in several types of tumours, including 
breast, while its expression is downregulated in higher grade and metastatic 
tumours.  
To study the role of NR4A1 in mammary epithelial cell biology, normal 
mammary epithelial cells (MCF-10A) were infected with a retroviral 
construct containing the full length NR4A1 cDNA. Ectopic expression of 
NR4A1 led to altered ability of the cells to adhere to the extracellular 
matrix, altered integrin cell surface expression and reduced migration in 
scratch wound and transwell migration assays. The initial activation of the 
Erk1/2 MAPK pathway, which is required for the EGF-mediated migration 
of MCF-10A cells, was found to be identical in the control and NR4A1 
overexpressing cells. However, the levels of active Erk1/2 in response to 
EGF stimulation during migration were found to be downregulated faster in 
the cells ectopically expressing NR4A1.  
The above data highlight for the first time the involvement of the 
transcription factor NR4A1 in mammary epithelial cell adhesion and 
migration. Further studies are underway in order to determine the role of 
NR4A1 in the migration of breast cancer lines and to delineate the pathways 
involved.  
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The Kinase Substrate Identifier (KSI) Protoarray (Invitrogen®) was used to 
identify potential upstream biomarkers for a kinase of interest (which was 
expressed and purified in house). The technology allows rapid screening of 
thousands of target proteins as potential protein kinase substrates. Because 
potential targets are so quickly identified from 9600 purified full-length 
proteins, it is a highly desired technology if it can be validated as a method 
to identify direct kinase biomarkers. Nine substrates of interest were chosen 
from the Protoarray® analysis and were generated to be tested for in vitro 
phosphorylation by the kinase of interest. Mass Spectrometry is used to 
analyze the molecular weight of the substrate with and without incubation 
of the kinase of interest. The phosphorylation state as well as whether these 
substrates are phosphorylated at multiple sites with the addition of the 
kinase of interest are assessed. Limited proteolysis is used to identify the 
phosphorylation sites of the substrate and will be followed up with cell 
culture analysis. 
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Regulation of cell proliferation and differentiation are critically important 
developmental events, which when lost can lead to cancer as well as a 
variety of defects. The importance of the retinoblastoma (pRB) tumor 
suppressor protein pathway is underscored by its deregulation in most types 
of cancer. The pRB pathway regulates cell cycle progression by controlling 
the activities of the E2F transcription factors; downstream targets of pRB. 
Cell cycle regulation although remarkably conserved is markedly simplified 
in Drosophila. Similar to their mammalian counterparts, the products of 
Drosophila E2F genes predominately act as transcriptional activators or 
repressors and can be classified as such. However, unlike the mammalian 
genome, which consists of eight E2F genes, the Drosophila E2F family 
consists of only two members; a single activator (dE2F1), and a single 
repressor (dE2F2). Thus, using Drosophila as a research tool has largely 
eliminated the issues which arise from functional redundancy and 
compensation. E2F transcription factors are best known for controlling 
progression through the cell cycle by regulating the transcription of genes 
important for the G1/S transition. While most E2F research has focused on 
its role in the cell cycle, there is emerging evidence that E2F has functions 
that are distinct from the regulation of cell cycle progression, such as 
differentiation and development. While loss of the repressor, dE2F2, has 
relatively mild phenotypes on its own, loss of the activator, dE2F1, leads to 
a severe reduction in cell proliferation. This precludes recovery of de2f1 
mutant tissue, thus complicating the analysis of de2f1 function in 
postmitotic cells. In order to overcome this problem we have developed a 
new conditional knock-out strategy in Drosophila which allows us to delete 
the de2f1 gene specifically in postmitotic cells. Details of the method and 
results of de2f1 deletion follow. 
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Background. Women of Mexican descent have a higher mortality and 
higher proportion of triple negative or basal-like breast cancers. Basal-like 
breast tumors exhibit similar characteristics to tumors arising in the rare 
carriers of BRCA1 mutation. The molecular nature of this “BRCA-ness” in 
the sporadic disease is unknown. Recently, it was shown that knockdown of 
ring finger 8 (RNF8), an E3 ubiquitin-protein ligase, by siRNA inhibited 
BRCA1 focus formation at double strand break sites suggesting that RNF8 
is an important upstream regulator of BRCA1 function. Methods. We are 
investigating the hypothesis that RFN8 is a tumor suppressor gene and acts 
as a novel regulatory protein of BRCA1 expression in human breast 
cancers. We tested whether breast cancers taken from a population of 
Mexican women enriched for basal-like cancers show altered expression in 
RNF8. We analyzed the effect of RNF8 at the gene expression and protein 
levels in 27 formalin fixed paraffin embedded human breast cancers and 
compared expression to normal breast tissue. Results. RNF8 was found to 
exhibit varied expression at the gene level across human breast cancers. 
Among the 27 tumors, one-third of tumors showed decreased expression of 
RNF8, one-third showed no change and the remaining exhibited increased 
expression including cases with > 5-fold increases in the RFN8 levels 
compared to healthy control tissue. These data suggests that RNF8 is 
differentially altered in human breast cancers. Conclusion. This is the first 
report demonstrating differential expression of RNF8 in a series of human 
breast cancers. Given the potential importance of RNF8 in the integration of 
BRCA1 to DNA damage sites, additional studies are needed to understand 
the relation between RNF8 and BRCA expression and functional 
consequence in human breast cancers.  
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Pancreatic cancer is the 4th leading cause of cancer related death in the 
United States with a median survival time of less than 6 months. Pancreatic 
ductal adenocarcinoma (PDAC) accounts for 85% of all pancreatic cancer, 
and is marked by early and frequent mutation of the K-Ras oncogene, with 
activating K-Ras mutations present in over 90% of PDAC. Activation of K-
Ras has been shown to stimulate multiple signaling pathways, including the 
MEK-Erk and PI3K-Akt signaling cascades, but the role of downstream 
effectors in pancreatic tumor initiation and progression remains unclear. 
Interestingly, one third of K-Ras wild type PDACs harbor activating 
mutations in B-Raf, and K-Ras and B-Raf mutations appear to be mutually 
exclusive. We therefore sought to determine the effect of activated B-Raf 
(B-Raf V600E) on primary pancreatic ductal epithelial cells (PDECs). B-
Raf V600E expressing cells displayed increased proliferation relative to 
GFP expressing cells, as well as increased survival when treated with 
apoptotic stimuli, such as ultraviolet irradiation. This enhanced survival is 
dependent on both the MEK-Erk and PI3K-Akt signaling cascades, as 
inhibition of MEK or PI3K results in decreased survival. Surprisingly, this 
survival is also dependent on IGF-1R, as inhibition of IGF-1R results in a 
loss of survival similar to that of MEK and PI3K inhibition, indicating that 
IGF-1R may be an important mediator of signaling downstream of B-Raf. 
Western blot analysis confirmed that expression of B-Raf V600E results in 
the activation of both the MEK-Erk and PI3K-Akt signaling cascades, as 
shown by phosphorylation of Erk at Thr202 and Akt at Ser473. Finally, we 
found that the expression of B-Raf V600E in cells lacking both the 
Ink4a/Arf and Trp53 tumor suppressors was sufficient for tumor formation 
following orthotopic transplant. In addition, preliminary results suggest that 
IGF-1R inhibition impairs B-Raf-induced tumor formation in this model. 
These studies demonstrate that the expression of mutant B-Raf results in the 
transformation of pancreatic epithelial cells, and indicate that tumor 
formation as a result of B-Raf expression may depend not only on signaling 
through the MEK-Erk signaling cascade but also on signaling through the 
PI3K-Akt signaling cascade and the IGF-1R. 
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Sporadic and germline mutations and/or loss of the von Hippel-Lindau 
(VHL) tumor suppressor gene have been linked to varying levels of risk for 
a highly prevalent malignancy, Renal Cell Carcinoma (RCC). To better 
understand the genetic changes associated with RCC tumor formation, 
primary epithelial kidney cells from newborn conditional Vhl null and Vhl 
G518A mutant genetically engineered mouse lines are undergoing 
investigation. This ex vivo system can provide insight into both the cellular 
characteristics and molecular events that contribute substantially to RCC 
tumor formation. Initial observations of primary neonatal epithelial kidney 
cells cultured under mild hypoxia show that these cells preferentially grow 
in an organized multicellular spherical culture. Current work is aimed at 
identifying the cellular makeup of these spheres and determining any role 
individual cellular components may have in tumorigenesis. Given that VHL 
type 2B missense mutations (of which Arg167Gln, represented by the 
murine G518A mutation, is one hotspot example) confer a high risk for 
RCC, this project also aims to identify a hypoxia inducible factor (HIF) 
gene target profile commensurate with the level of risk for RCC. This will 
be done by comparing levels of gene expression when HIFα subunits are 
differentially regulated based on VHL status as compared to primary kidney 
epithelial cells displaying wild type VHL. This project will identify the most 
at-risk cell population of the kidney and analyze the molecular changes in 
this at-risk cell population that promote tumor growth as well as identify a 
gene target profile for these changes in order to have greater insight into 
RCC tumorigenesis. 
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Men diagnosed with castration-resistant prostate cancer eventually succumb 
to lethality since treatment options are limited. Our laboratory has been 
developing new genetically-engineered mouse models based on inducible 
prostate-specific deletion of Pten alone or together with activation of 
oncogenic Kras. These models recapitulate all stages of prostate 
tumorigenesis, including occurrence of distant metastases, and model the 
concurrent deregulation of the Akt/mTOR and Erk/Map kinase pathways, 
observed in more than 25% of advanced prostate cancers. We have been 
exploiting these models to identify fundamental mechanisms and signaling 
pathways deregulated in prostate cancer progression through the assembly 
of human and mouse prostate cancer interactomes, which are genome-wide 
networks of transcriptional and post-translational interactions. Interactomes 
are predicated on the availability of large gene expression profile (GEP) 
datasets representative of the natural phenotypic variability and genetic 
perturbations of prostate cancer. We are generating GEP using a collection 
of mouse models from our laboratory, as well as from the mouse model 
community. We have validated a strategy based on the perturbation of the 
transcriptome in vivo with a collection of compounds able to generate drug-
specific signatures. Our goal is to identify the key regulatory genes causally 
driving progression to advanced prostate cancer, as well as druggable 
targets, through the comparison of independent mouse and human prostate 
cancer interactomes. Based on our findings that concurrent deregulation of 
the Akt/mTOR and Erk/Map kinase pathways is a driving force for 
castration-resistant prostate cancer, we have been pursuing preclinical 
studies, and have found that combination therapy using Rapamycin, a 
mTOR inhibitor, and PD0325901, a MEK inhibitor, is anti-tumorigenic, 
improves survival, and inhibits metastases in these models. In summary, we 
are undertaking a comprehensive approach to identify new molecular 
pathways and druggable targets for advanced prostate cancer, as well as to 
evaluate these targets in preclinical studies that will ultimately be translated 
to clinical trials. 
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The advances in sequencing technologies in the last decade have provoked 
us to re-examine our understanding of cancer genetics. Of the myriad 
genetic mutations that contribute to tumorigenesis, recurrent copy number 
alterations, mainly deletions and amplifications of large genomic intervals, 
are considered major drivers of the disease. Amplification of human 
chromosome 8q24 has been among the most common mutations in 
epithelial tumors. Interestingly, the well studied oncogene c-MYC maps at 
8q24 and is often included in this amplicon. Overexpression of c-MYC has 
been implicated in several cancers, mainly of hematological origin. 
Curiously, in epithelial cancers, c-MYC is mainly found to be co-amplified 
with the 8q24 amplicon. Patients with 8q24 amplification often have poor 
outcomes. Mouse models for studying the effects of c-myc overexpression 
have been helpful in elucidating the role of c-myc in neoplastic 
transformation. However, these models rarely mirror the aggressive cancer 
often seen in the patients harboring 8q24 amplification. This suggests that 
other genetic elements may be present in the amplicon which contribute to 
the poor prognosis in the patients either independently or in synergy with c-
MYC.  
 
To investigate the true impact of the 8q24 amplification in human epithelial 
cancers, we are developing functional models which harbor similar genetic 
mutations found in human cancers with 8q24 amplification. We focused on 
a core 4.3 Mb region in human 8q24 region which is frequently amplified in 
many carcinomas. In addition to c-MYC, this region contains several genes 
and non coding RNAs that have been implicated in various cancers. The 
synteny of this genetic interval is nearly identical to a 4.5 Mb in mouse 
chromosome 15. Using chromosome engineering technology, we are 
developing functional models harboring amplifications of this genetic 
interval in mouse. By accurately mimicking the true nature of the mutation, 
the carcinomas in these mouse models will give us insights to the molecular 
mechanisms involved in tumorigenesis and subsequent progression of 
cancer in these patients, and will contribute to the development of more 
targeted therapies.  
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Survival rates for T-cell lymphoblastic leukemia have increased 
dramatically in recent years. However, treatment is often highly cytotoxic, 
relapse remains difficult to treat, and prognosis remains poor in adults. 
Identification of novel proto-oncogenes and tumor suppressor genes in 
mouse models of leukemia may provide new drug targets useful in treating 
human disease. A spontaneous mutation arose in our mouse breeding 
colony that results in highly penetrant T-cell leukemia in the mice that 
inherit this mutation, so we named this model Spontaneous dominant 
leukemia (Sdl). Approximately 90% of mice that inherit the mutation 
become moribund between 6 and 14 weeks of age, and peripheral blood 
smears show a large increase in the number of circulating leukocytes at 
necropsy. Positional cloning has mapped the mutation to a 1.6Mb region on 
chromosome 16, but the mutation and affected gene have not yet been 
identified. Microarrays comparing gene expression in the thymus of wild-
type mice at 21 days and Sdl carrier mice at 21 days show a trend toward an 
increase in Notch1 expression and activation of downstream targets in the 
carriers, but the changes were not statistically significant. Comparison of 21 
day wild-type thymus to thymic tumors reveals a significant increase in 
expression of Notch1 and its downstream targets. Preliminary analysis of 
the microarray data failed to produce any candidate genes affected by the 
mutation; however, further analysis is ongoing. We hypothesize that Sdl can 
serve as a preclinical model of human leukemia, and that identification of 
the mutation may reveal a novel proto-oncogene or tumor suppressor gene. 
We further hypothesize studying Sdl will provide insight into normal T-cell 
development and progression to leukemia. Experiments are ongoing to 
determine the clonality and cell type of origin of the disease, as well as flow 
cytometry to assess the immunophenotype of white blood cells in the bone 
marrow and peripheral circulation prior to leukemia development. In 
conclusion, the short disease latency and our ability to determine which 
mice inherit the Sdl mutation make this an ideal model to study leukemia 
initiation and progression. 
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Although Skp2 was best known as the F-box protein in the SCFSkp2 E3 
ubiquitin ligase targeting T187 phosphorylated p27, Skp2 was first 
discovered as a cyclin A binding protein and the Skp2-cyclin A complex is 
abundant in various cancer cells. Our lab has conducted more detailed 
studies of the Skp2-cyclin A interaction (Ji et al. 2006 JBC). We determined 
that amino acid residues 40-60 in the Skp2 N-terminus are required for 
Skp2 binding to cyclin A and a peptide spanning residues 40-60 can 
specifically block Skp2-cyclin A interaction but not p27-cyclin A 
interaction. We further showed that Skp2 binding to cyclin A competed 
cyclin A binding to p27 and, as a consequence, Skp2 protects cyclin A from 
inhibition by p27 and p21. When this 40-60 peptide was delivered into cells 
with a membrane permeable sequence, it could induce apoptosis in various 
cancer cells but not in non-transformed cells, suggesting that the Skp2-
cyclin A interaction is important for survival of tumor cells (Ji et al. 2007 
Mol Can Ther). Following these findings, we have now generated KI mice 
in which the 4 required residues in the 40-60 sequence were mutated to 
alanine, the Skp2AAAA KI mice. We have determined that disrupting the 
Skp2-cyclin A binding does not hinder normal murine development and 
obtained initial results showing that Skp2AAAA KI can block pituitary 
tumorigenesis following Rb1 deletion, providing the first evidence for an 
important tumorigenic role of the Skp2-cyclin A interaction. We are also 
generating mice combining Skp2AAAA KI and p27T187A KI (which 
abolishes Skp2’s function in mediating p27 ubiquitination) to determine 
whether inactivation of these two best-established functions of Skp2 will be 
equivalent to Skp2 KO. Findings from these experiments will be presented 
at the meeting.  
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Cancer is a diverse and complex array of diseases that involves a large 
variety of cell types, genetic lesions and interconnecting molecular 
mechanisms. The use of new molecular techniques and development of 
novel tumor models, commonly mouse models, to investigate cancer has 
generated data at an expanding rate. As more and more of these data are 
published it is becoming increasingly difficult to locate and analyze 
information regarding mechanisms of cancer and identify potential 
therapeutics. The Mouse Tumor Biology (MTB) Database is designed to 
provide researchers with access to and the tools to analyze mouse tumor 
data allowing the identification and evaluation of potential mouse cancer 
models (http://tumor.informatics.jax.org). 
MTB includes data from peer-reviewed literature and health surveillance 
data from production mouse colonies at The Jackson Laboratory (JAX) and 
colonies of aging mice from the Jackson Aging Center. Data from public 
databases, including Pathbase and the SKY/M-FISH & CGH Database, and 
direct submissions from cancer researchers and tumor pathologists are also 
collected. MTB contains data from tumors arising in genetically defined 
mice (inbred, hybrid, mutant and genetically engineered mice), both 
spontaneous and endogenously induced. Data include classification, 
incidence and latency of mouse tumors, pathology reports and images and 
somatic genetic changes in tumors and in the genetic (strain) background. 
Pathology images are submitted by the scientific community, from primary 
literature with permission and from JAX. A web based submission form is 
available. New features in MTB include searching MTB using human gene 
symbols or Entrez Gene IDs, a Mouse Cancer Quantitative Trait Loci 
(QTL) viewer, the ability to customize the Tumor Frequency Grid and the 
inclusion of somatic cytogenetic images. 
MTB uses standard nomenclature, controlled vocabularies and inclusion of 
literature citations to facilitate data searches. MTB is integrated with the 
Mouse Genome Informatics database (MGI, 
http://www.informatics.jax.org) and provides links to other related online 
resources such as the Mouse Phenome Database (MPD, Festing's Listing of 
Inbred Strains of Mice, the JAX® Mice Web Site, and the Mouse Models of 
Human Cancers Consortium's (MMHCC's) Mouse Repository. 
MTB provides a web based, integrated resource for identifying information 
on molecular mechanisms in mouse tumors and existing mouse models of 
cancer and also facilitating the discovery and development of new mouse 
cancer models.  
MTB is supported by NCI grant CA089713. 
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Dynamic phosphorylation of the C-terminal domain (CTD) of RNA pol II 
as it transcribes a gene is thought to direct the traffic of pol II-associated 
proteins including those that perform co-transcriptional pre-mRNA 
processing. The CTD comprises conserved heptad repeats (YS2PTS5PS7). 
Phosphorylation of the heptads on Ser2 residues is maximal at 3' ends of 
genes and this modification is important for recruitment of 
cleavage/polyadenylation factors to the transcription elongation complex. 
Cancer cells make abnormal poly(A) site choices; usually preferring to 
process at ORF-proximal upstream sites resulting in shorter mRNA 3' UTRs 
1-3. As a result normal controls of translation and mRNA stability can be 
corrupted. It is not known if altered poly (A) sites in cancer cells result from 
a co-transcriptional or a post-transcriptional decision. To investigate this 
question, we asked whether abnormal poly (A) site choice in cancer cells is 
associated with altered dynamics of RNA pol II CTD phosphorylation on 
Ser2 residues. If this were the case it would strongly implicate a co-
transcriptional mechanism for abnormal poly (A) site choices in cancer 
cells. To this end we have surveyed genome-wide distributions of Ser2 
phosphorylated RNA pol II by ChIP-seq using a phospho-specific antibody. 
We will report results for a panel of human breast cell lines that differ in 
their tumorigenic potential.  
 
 
1. Singh, P. et al. Cancer Res 69, 9422-30 (2009). 
2. Mayr, C. & Bartel, D.P. Cell 138, 673-84 (2009). 
3. Sandberg, R., Neilson, J.R., Sarma, A., Sharp, P.A. & Burge, C.B. 
Science 320, 1643-7 (2008). 
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The primary regulation of cell proliferation in mammalian cells is imposed 
during the G1-phase of the cell cycle. Activation of G1/S transcription is the 
earliest indicator of cell cycle initiation. G1/S transcriptional regulation 
depends on the E2F family of transcription factors (E2F1-8) and their 
regulators, the tumor suppressor pocket protein family members (pRb, 
p107, p130). The high frequency of genetic alterations in human tumor cells 
that affect proteins involved in E2F-dependent transcriptional regulation 
suggests that inactivation of this pathway may be necessary for tumor 
development. For example inactivation of the pocket proteins are often 
associated with cancer; whereas, unrestrained E2F1 activity has been 
associated with excessive apoptosis. In addition, DNA damage induced 
E2F1 activity is coupled to cell death, through the activation of pro-
apoptotic genes. Therefore, understanding how E2F activity is modulated 
both during the cell cycle and in response to activation of cell cycle 
checkpoints will offer insight into cancer biology and medicine.  
Although the activation of E2F-dependent transcription during the G1 phase 
of the cell cycle has been extensively studied, much less is known about 
inactivation once cells progress into S-phase. Our data suggests that the 
mechanism of transcriptional inactivation likely involves E2F6 binding to 
E2F-dependent promoters during S phase, replacing the activating E2Fs. 
Furthermore, we show that in response to DNA replication stress E2F-
dependent transcription is derepressed, which depends on the DNA 
replication checkpoint protein kinase Chk1. We present evidence that the 
mechanism of this regulation likely involves direct Chk1-dependent 
interference of E2F6-dependent repression of E2F-target genes.  
Our work uncovers a simple but elegant mechanism by which checkpoint 
activation can override the regular periodic transcriptional program by 
directly regulating a transcriptional repressor. As a putative target of cell 
cycle checkpoints that regulate genomic stability, E2F6 is expected to play 
a central role in avoidance of DNA damage and chromosomal aberrations, 
phenomena that directly contribute to the genesis of human cancer. 
Elucidating the mechanisms through which E2F transcription is regulated 
both during the cell cycle and in response to activation of cell cycle 
checkpoints, and the relevance of such regulation, will be the focus of our 
future work. 
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Cellular differentiation is disrupted in cancer, resulting in the appearance of 
poorly differentiated cells. The pRB tumor suppressor protein is inactivated 
in the majority of human cancers and is known to potentiate differentiation. 
pRB cooperates with tissue-specific transcription factors (e.g. MyoD in 
skeletal muscle) to execute a transcriptional program. Rb-/- cells are 
deficient in transcriptional activation and fail to terminally exit the cell 
cycle. A number of transcription factors have been linked to the 
establishment or maintenance of this program, but the precise mechanism is 
unknown. Restoring differentiation or specific elimination of abnormally 
differentiated cells is a challenge in cancer therapy. Here we present data 
where the loss of at least one copy of the gene encoding RBP2 histone 
demethylase restores differentiation potential in cells with inactivated pRB. 
RBP2 catalyzes the removal of methyl groups from lysine 4 in histone 3, 
leading to transcriptional repression. Previously we showed that pRB and 
RBP2 physically interact, and pRB mutants that do not form complexes 
with RBP2 are unable to induce differentiation. Early in differentiation, 
RBP2 works primarily in opposition to pRB by maintaining the 
proliferative state. We have shown by transient RBP2 knockdown in Rb-/- 
cells that lowering RBP2 protein levels increases transcription factor 
activity and gene expression associated with differentiation, and induced 
characteristic morphological changes reminiscent of the effects seen by 
reintroducing pRB. Later during differentiation RBP2 binds to promoters of 
genes targeted by RB and E2F. To further address the epistatic relation 
between RB and RBP2 during differentiation and to eliminate confounding 
effects that may arise due to altered function of low levels of Rbp2 in 
knockdown models we generated knockout mice. We can induce 
differentiation in mouse embryonic fibroblasts (MEFs) down the myogenic 
lineage into myotubes by overexpressing MyoD. We found that loss of 
Rbp2 fully rescues expression of early markers and at least partially rescues 
expression of late markers of differentiation. The tube-shaped morphology 
and multinucleation of differentiating cells is partially rescued. 
Differentiating Rb-/-Rbp2-/- cells are death prone and loss of Rbp2 does not 
rescue the inability of Rb-/- cells to exit the cell cycle, likely due to the 
cooperative effect of pRB and RBP2 on E2F target genes. This is consistent 
with the idea that the capacity of pRB to promote differentiation can be 
genetically separated from its role as a repressor of E2F. Our results suggest 
that RBP2 can be a therapeutic target in cancer since inhibition of RBP2 
may generate death prone progenitors in cells with an inactivated pRB 
pathway. 
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Epigenetic changes have been increasingly recognised as an important 
mechanism for altered gene expression in malignant cells, and they have 
been suggested to be even more common than genetic changes in human 
cancer. Altered DNA methylation patterns may serve as biomarkers for 
cancer detection, assessment of prognosis, and prediction of response to 
therapy. In general, many epigenetic changes occur early in tumor 
development. Thus, they can be of value for early diagnosis and possibly as 
sensitive markers for relapse. Importantly, identification of key molecules 
which are deregulated by methylation in cancer is also of therapeutic 
interest, as methylation is potentially reversible with demethylating agents.  
Our group used in vitro models to detect upregulated genes after an 
epigenetic treatment with 5-aza-2’deoxycytidine and trichostatin A. After 
gene expression analysis using microarray technology and normalization, 
we found 2199 upregulated genes. Since we are interested in potential 
tumor suppressor genes, we compared gene expression profiles from 
patients and healthy donors and were able to exclude 32% of the responding 
genes. Genes showing the highest responses to treatment where then 
examined for CpG islands in their promoter regions, thus further excluding 
some of the genes.  
A methylation specific PCR was performed on the main responding genes, 
revealing that 63% of the tested genes are methylated within the promotor 
region. 21% of the methylated genes were also methylated in healthy 
donors, excluding them from further studies. Using these analyses, we now 
have a list of interesting genes showing cancer-specific hypermethylation 
and these genes will be further validated by methylation-specific PCR in 
lymphoma patients at our hospital. Currently, we are performing real-time 
PCR to investigate whether there is a correlation between promoter 
hypermethylation and gene expression. Preliminary results indicate that 
genes showing promoter hypermethylation are also transcriptionally 
inactivated compared to normal B cells.  
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The processes that regulate apoptosis are universally altered in cancer cells 
and the BCL2-like proteins are critical and direct inhibitors of apoptosis. 
Aberrant expression of BCL2 proteins is a well-known mechanism that can 
block apoptosis and contribute to tumorigenesis. As an example, we have 
previously shown that all six members of the BCL2 family can cooperate 
with MYC in a mouse model of leukemia. The least well-studied BCL2-like 
protein, BCLb (or BCL2L10), has recently been shown to be highly 
expressed in a large proportion of primary human cancer samples by 
immunohistochemistry, and the protein levels inversely correlated with 
prognosis and survival outcome in a number of cancer types. We examined 
the protein and mRNA levels of BCLb in a panel of human cancer cell lines 
and did not observe extensive variation in mRNA that would explain the 
vast differences in protein levels. We therefore set out to determine if we 
could identify interacting factors that affect the post-translational stability of 
the BCLb protein. We identified a protein, Ubiquilin1 (or PLIC1) that 
specifically interacts with BCLb, and not with any of the other five BCL2-
like proteins. PLIC1 expression dramatically stabilizes the steady-state 
levels of the BCLb protein. The presence of PLIC1 leads to the mono-
ubiquitination, on multiple lysine residues, of BCLb. Interestingly, when all 
of the lysine residues of BCLb were mutated to arginines, the BCLb protein 
is also stabilized. Stabilization of BCLb, by either the presence of PLIC1 or 
by mutation of lysine residues, enhanced the ability of BCLb to potentiate 
tumorigenesis, in vivo. These findings suggest that any factor that can affect 
the steady-state protein stability of BCL2 family proteins could potentially 
play a direct role in neoplastic transformation. 
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Tumor cell metabolism is now recognized to present extremely promising 
new opportunities for chemotherapy. While several agents targeting these 
processes have been described, no drug with high clinical efficacy has yet 
emerged. We have developed a first-in-class group of non-redox-active 
lipoate analogs, designated thioctans, allowing a novel attack on tumor 
metabolism. These drugs are in human clinical trials and our pre-clinical 
translational studies (below) indicate that they may have unique promise. 
>Specifically, we have used extensive metabolomics analysis and other 
assays to characterize the effects of thioctans on tumor cell metabolism 
(below). Thioctans show high efficacy and very low toxicity in human 
tumor xenograft models and extraordinarily broad spectrum cancer cell 
killing in cell culture assays, efficiently targeting all tested tumor cells 
independently of type (carcinoma, sarcoma, liquid tumor), tissue of origin, 
or genotype. Our new results indicate that these properties arise from 
thioctan targeting of specific metabolic steps in an unprecedented way. The 
blockage of these specific tumor cell metabolic steps, in turn, commits cells 
to multiple, redundant cell death pathways, including both apoptosis and 
non-apoptotic death. 
 
Central to cancer-specific metabolic properties are the mitochondrial 
enzymes pyruvate dehydrogenase (PDH) and alpha-ketoglutarate 
dehydrogenase (KGDH). PDH and KGDH are two of four enzyme 
complexes using lipoate as a covalent cofactor. Moreover, virtually all 
tumor cell mitochondrial carbon and reducing potential enter through PDH 
and KGDH. Further, the regulatory properties of the PDH complex (and 
probably KGDH) are substantially altered in tumor cells relative to non-
cancerous cells. Finally, PDH and KGDH lipoate residues play a central 
role in regulating these enzymes, in addition to their catalytic functions.  
>Our new results demonstrate that both PDH and KGDH activities are 
powerfully inhibited in tumor cell mitochondria by thioctan treatment, 
apparently reflecting regulatory effects of thioctans. This inhibition is 
highly selective, as other metabolic steps are unaffected by initial thioctan 
treatment, apparently becoming altered only secondarily with the onset of 
thioctan-induced cell death. Assessing clinical efficacy of this new approach 
will be important. 
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Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic 
acid (ATRA) and/or arsenic trioxide (ATO) represents a paradigm in 
targeted cancer therapy as these drugs cause clinical remission by affecting 
the stability of the fusion oncoprotein promyelocytic leukemia 
(PML)/retinoic acid receptor alpha (RARA). Previous studies have 
implicated the ubiquitin-proteasome pathway as the main mechanism 
involved in therapy induced PML/RARA degradation. Here we have 
investigated a role of autophagy, a protein degradation pathway that 
involves proteolysis of intracellular material within lysosomes. We found 
that both ATRA and ATO induce autophagy via the mTOR pathway in 
APL cells and that autophagic degradation contributes significantly both to 
the basal turnover as well as the therapy induced proteolysis of 
PML/RARA. In addition, we observed a correlation between autophagy and 
therapy-induced differentiation of APL cells. Given the central role of the 
PML/RARA oncoprotein in APL pathogenesis, this study highlights an 
important role of autophagy in the development and treatment of this 
disease. 
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Purpose: Since cancer stem cell (SC) overpopulation appears to drive 
tumor growth in the colon (Boman & Huang, JCO 2008), effective or even 
curative treatments will likely require targeting mechanisms that underlie 
SC overpopulation. To identify such mechanisms, the organization and 
distribution of colonocyte cell subpopulations in human crypts were 
investigated as a way to evaluate crypt cell maturation. We hypothesized 
that maturation of these subpopulations becomes dysregulated during colon 
tumorigenesis. Methods: Quantitative immunohistochemical mapping of 
crypt cell populations was done using markers for: SC (ALDH1); cell cycle 
transitioning (DNA-synthesis licensing proteins CDT1/geminin/MCM2); 
cell-cycle arrest (P21); apoptosis (M30/TUNEL). The indices of cell 
subpopulations were then used to evaluate maturation, i.e., transitions 
between cell phenotypes in the crypt – from stem (unlicensed) to 
proliferating (licensed) to terminally-differentiated (cell-cycle arrested) to 
apoptotic cells. Results: In normal colon, the proportion of cells expressing 
licensing proteins was low at crypt bottom (where ALDH+ cells reside), 
high among proliferating cells, and nil in upper crypt (where terminally 
differentiated/apoptotic cells reside). This suggests that SC are not licensed 
for DNA-synthesis (consistent with their relative quiescence) and licensing 
mediates generation of proliferating cells from SC. In pre-malignant crypts, 
the population of licensed cells expanded and distributed further up the 
crypt, while P21+, M30+ & TUNEL+ cell subpopulations in the upper crypt 
contracted. Conclusion: Crypt cell maturation (transitions between cell 
phenotypes) is regulated by DNA-synthesis licensing; dysregulation 
promotes delayed maturation, SC overpopulation, and tumorigenesis. 
Therapeutically targeting licensing mechanisms to accelerate cell 
maturation may reverse SC overpopulation. 
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Aberrant expression of cancer-associated genes contributes to initiation and 
progression of the tumourigenic process. Such changes in gene expression 
result from defects in transcriptional control elements including promoters 
and enhancers and in post-transcriptional control elements including those 
found in the 3’UTR. Epigenetic defects include methylation of 
transcriptional regulatory elements and altered targeting of post-
transcriptional regulatory elements by trans-acting factors including 
microRNAs. Our group has a long-standing interest in elucidating the 
genetic and epigenetic regulation of breast cancer associated genes, 
including BRCA1. Our studies have led to the identification of regulatory 
sequences mapping to promoter, intronic, 3’UTR and extragenic sequences 
of BRCA1, and the promoter of AR and a number of miRNAs, including 
miR-200b. We have also identified proteins and miRNAs that target these 
sequences, including the RNA binding protein HuR which targets the 
BRCA1 3’UTR. We have shown that genetic and epigenetic changes in 
these sequences, some of which are associated with breast cancer, affect 
gene expression and are sometimes associated with altered targeting by 
proteins or miRNAs. We have also identified a number of molecules that 
are differentially expressed in the pre-malignant mammary glands of a 
BRCA1-associated breast cancer mouse model. These include the 
mammary luminal progenitor marker c-kit and a number of miRNAs. 
Current studies involve elucidating the mechanism of this regulation and the 
role of these events in mammary tumourigenesis. 
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The PP2C family serine/threonine phosphatase WIP1 is characterized by 
distinctive oncogenic properties mediated by inhibitory functions on several 
tumor suppressor pathways, including ATM, CHK2, p38MAPK and p53. 
PPM1D, the gene encoding WIP1, is aberrantly amplified in different types 
of human primary cancers, and its deletion in mice results in a profound 
tumor-resistant phenotype. Numerous downstream targets of WIP1 have 
been identified, and genetic studies confirm that some play a part in 
tumorigenesis. Recent evidence highlights a new role for WIP1 in the 
regulation of a cell-autonomous decline in proliferation of certain self-
renewing cell types, including pancreatic beta-cells, with advancing age. 
Furthermore, Wip1 phosphatase modulates lifespan. These emerging 
functions of WIP1 make it a potent therapeutic target against cancer and 
aging. 
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Non-small cell lung cancer (NSCLC) is among the deadliest of human 
cancers. Mutations in the K-ras proto-oncogene are a frequent event in 
NSCLC, but tumor suppression in the lung remains poorly elucidated. 
Oncogenes such as K-ras induce expression of the p19arf tumor suppressor 
gene, which is located along with p16ink4a at the Cdkn2a locus. p19arf 
antagonizes the p53 inhibitor Mdm2, thereby stabilizing p53 activity and 
arresting cell growth. Recent findings suggest that a permanent form of 
growth arrest known as senescence acts as a barrier to tumor growth and 
malignant progression in vivo. This phenomenon, termed oncogene-induced 
senescence, is theorized to occur in response to oncogene-induced DNA 
damage signaling through p53. Activated p53 and additional markers of 
DNA damage signaling and senescence have been observed in a range of 
benign lesions, including lung adenomas. p19arf is required for Ras-induced 
senescence to occur in mouse primary cells, and loss of p19arf has been 
shown to cooperate with oncogenic Ras in skin and liver tumor models. 
Urethane-induced NSCLC tumors in mice frequently harbor K-ras 
mutations, and here we use this model to address the role of p19arf in 
suppressing lung tumorigenesis. By means of immunohistochemistry, we 
revealed high p19arf expression in lung adenomas but limited expression of 
p19arf in malignant adenocarcinomas. Germline p19arf deficiency 
accelerated the growth, but not the initiation, of urethane-induced NSCLC 
tumors. Lung tumor burden in p19arf knockout mice was substantial, with 
tumor diameters ranging up to 14mm by 25 weeks post urethane injection. 
Early findings also suggest that p19arf loss potentiates malignant 
conversion, as adenocarcinomas were more common in p19arf knockout 
mice. Furthermore, p19arf knockout mice experienced significantly 
compromised survival compared to wild-type and untreated controls. This 
enhanced mortality was largely due to the unexpected development of 
hemangiosarcomas in p19arf knockout mice under urethane treatment. This 
tumor type was not observed in wild-type treated mice, nor did it occur 
spontaneously in untreated p19arf knockout mice. These results suggest that 
p19arf participates in oncogene-induced signaling to raise a potent barrier 
against tumor promotion in the lung, and that p19arf may restrain the 
proliferation of endothelial cells in adult mice. Identifying the roles of 
p19arf in tumor suppression is an important step toward the development of 
personalized, targeted therapies for cancer patients. 
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Background/Aim: Chronic H. pylori infection is associated with decreased 
p27 expression in gastric epithelial cells. Low p27 levels cause apoptosis-
resistance in gastric epithelial cells and increased tumor susceptibility in 
murine models. We have previously established apoptosis-resistant gastric 
epithelial cell lines by chronic H. pylori infection in vivo. These cells have 
both low p27 protein and low p27 mRNA levels. Because p27 transcription 
may be regulated epigenetically through histone acetylation from delta-
opioid receptor stimulation, we examined whether low p27 levels in H. 
pylori infection was related to inhibition of histone acetylation of the p27 
promoter by H. pylori. Methods: The level of acetylated histone on the p27 
promoter was measured by ChIP assay in the parental AGS gastric cancer 
cell line, AGS cell line following 6 hour infection with H. pylori, and AGS 
derivatives with low p27 expression that were derived from AGS gastric 
cancer cells by chronic H. pylori coculture followed by dilutional cloning 
(“HS3C cells”). p27 mRNA and protein were measured by real-time PCR 
and western blotting. Results: Low p27 expression in the acutely H. pylori-
infected AGS cells and chronically H. pylori-infected HS3C cells were 
associated with an approximate 20% and 40% respectively decrease in p27 
mRNA expression compared with levels in AGS parental cells, and was 
restored by treatment with the delta-opioid receptor agonist, DPDPE ([D-
Pen2,D-Pen5]-enkephalin) and histone deacetylase inhibitor trichostatin A. 
Low p27 mRNA levels were associated with a 15-60% reduction in p27 
promoter histone H4 acetylation by the chromatin Immunoprecipitation 
(ChIP) assay. The p300, gene specific acetyltransferase, which was 
examined by ChIP was also decreased markedly in the acutely H. pylori-
infected AGS cells and chronically H. pylori-exposed HS3C cells compared 
with parental AGS cells. Conclusion: These results demonstrate that in the 
gastric epithelial cells infected with H. pylori, the decrease in p27 
expression is at least in part due to epigenetic mechanisms involving histone 
acetylation of the p27 promoter. 
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We have established the yeast metabolic cycle as a system to study how cell 
growth and proliferation are coordinated with metabolism and cellular 
metabolic state. During continuous growth in glucose poor medium, yeast 
cells become highly synchronized and undergo robust oscillations of 
oxygen consumption that are coupled to their growth and cell cycle. From 
transcription and metabolite profiling studies of these cycles, we found that 
growth, cell division and quiescence happen at distinct phases of the cycle 
and are accompanied by fluctuations of specific metabolites. Addition of 
carbon sources or certain amino acids can induce cycling cells from the 
quiescent phase to enter growth phase prematurely. We believe these 
metabolites are signaling cells to enter growth by activating conserved 
growth control pathways. We are currently investigating the mechanistic 
basis by which carbon sources and products of glycolytic metabolism (e.g., 
lactate, ethanol) signal entry into growth and the transcription of growth 
genes. We believe our studies will provide significant insights into growth 
control mechanisms as well as the metabolic dysfunctions that contribute to 
cancer. 
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The mitogen-activated protein kinases ERK1 and ERK2 (MAPKs) are 
major targets of oncogenic signaling pathways such as constitutive 
activation of K-RAS, B-RAF or receptor tyrosine kinases. MAPKs regulate 
a wide range of normal and pathogenic processes by phosphorylating 
hundreds of substrate proteins. While many MAPK substrates are known, 
incomplete knowledge of targets is a major hurdle to understanding the 
pathological consequences of constitutive activation. To understand how 
ERK2 regulates normal and pathological phenotypes we aim to identify 
direct ERK2 substrates in non-transformed and cancer cells, and to 
determine how a subset of those substrates influences cell behavior. 
 
We are using analog substrate kinases (AS-kinases) to identify direct 
substrates of ERK2. AS-kinases have an expanded ATP-binding pocket that 
accommodates unnatural ATP analogs not used by endogenous kinases. 
ATP analogs with non-bridging γ-thiol allow AS-kinases to 
thiophosphorylate their substrates, and thiophosphate can then serves as a 
“handle” to isolate substrates for identification by HPLC-MS/MS. In an 
initial experiment we applied AS-ERK2 to lysate from NIH 3T3-L1 pre-
adipocytes, using a matched wild-type ERK2 as the negative control. We 
identified 98 ERK2 substrate sites on 80 proteins. 13 of these proteins are 
known substrates while the remaining 67 appear to be novel 
kinase/substrate interactions. Novel substrates span a wide range of 
biological processes including migration and cytoskeletal organization, 
nuclear transport, RNA splicing, phosphorylation signaling, and 
transcriptional regulation. We used quantitative phospho-proteomics to 
show that splicing factor FOX2 and the RhoGAP ARHGAP10 are 
phosphorylated in response to ERK1/2 activation in living cells. 
 
We are extending this approach by using isotopic labels to compare MAPK 
substrate utilization in models of KRAS-driven colon cancer. We are in the 
process of comparing the colon cancer cell lines DLD1 and HCT116, both 
of which carry activated KRAS, with their isogenic derivatives lacking 
activated KRAS. We aim to identify MAPK targets that are enriched in 
presence of activated KRAS, and to determine whether phosphorylation of 
those targets is required for cancer phenotypes. Large-scale discovery and 
quantitative analysis of MAPK targets allows us to map oncogenic 
signaling in unprecedented detail and will provide a new perspective on the 
mechanisms of common oncogenic mutations. 
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The environment plays a critical role in the development of human disease. 
Various investigators have proposed that low micronutrient intake may 
accelerate cancer and degenerative diseases of aging through still poorly 
understood mechanisms. Strikingly and conversely, excessive micronutrient 
intake has been also linked to overall higher incidence of all cause 
mortality. Folate is a B vitamin important for cellular nucleotide synthesis, 
methylation reactions and protection from oxidative stress. Using 
competitive bone marrow transplantation experiments, our lab has explored 
how altered folate intake affects the fitness of hematopoietic cells. We have 
observed that hematopoietic stem and progenitor cells of mice that have 
been subjected to abnormal folate levels, via high and low folate diets, 
exhibit persistent decreases in fitness compared to cells from normal diet 
controls. We have analyzed B-cell progenitor populations under folate 
deficiency and control diet using microarray and proteomic analyses, as 
well as metabolic assays. Our results support a model whereby low folate 
levels appear to promote mitochondrial decay, decreasing electron transport 
chain protein levels and thus causing an accumulation of NADH and a 
decrease of ATP levels in the cell. Interestingly, we observe similar changes 
in B-progenitors from old mice, consistent with well-described 
mitochondrial defects with aging, which may provide an unappreciated link 
between dietary folate deficiency and aging. 
The Bcr-Abl translocation is associated with chronic myeloid and acute 
lymphoblastic leukemias, but associations of these leukemias and diet are 
virtually unexplored. We further demonstrate that either a low folate diet or 
old age substantially promote leukemogenesis initiated by Bcr-Abl, and that 
Bcr-Abl provides an advantage specifically in B-cell progenitors and 
selectively during either dietary folate deficiency or old age. We 
hypothesize that in folate deficient or aged progenitor cell pools, Bcr-Abl 
provides a selective advantage to B-cell progenitors by driving higher levels 
of glycolysis and thus restoring normal ATP amounts. The consequent 
competitive expansion of Bcr-Abl expressing progenitors, a critical step in 
leukemogenesis, would then provide a sufficient target size for secondary 
oncogenic mutations. Thus, oncogene-driven increases in glycolysis may be 
selected for specifically under contexts (such as dietary folate deficiency or 
aging) associated with impairment of the more efficient method of energy 
production (mitochondrial). 
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CREB-H is a liver-enriched bZIP transcription factor of the CREB3 
subfamily. CREB-H has growth suppressive activity and was 
underexpressed in hepatocellular carcinoma (HCC) cells. CREB-H has also 
been suggested to be involved in acute phase inflammatory response, iron 
metabolism and gluconeogenesis. CREB-H is ambiently bound to the 
endoplasmic reticulum (ER) and its proteolytic activation releases an active 
N-terminal piece that translocates to the nucleus. In this study we showed 
that the activity of CREB-H is tightly regulated by N-linked glycosylation 
and ubiquitination. We found that full-length CREB-H is modified at three 
N-linked glycosylation sites in the C-terminal luminal region. N-linked 
glycosylation of CREB-H was prevented if all three sites were disrupted. 
Both unglycosylated and deglycosylated CREB-H was largely unresponsive 
to simulation of intramembrane proteolysis by brefeldin A or ER-localized 
site 1 protease, remained bound to the ER, and unable to activate 
transcription of target genes such as the gene coding for C-reactive protein. 
On the other hand, we also found that the active form of CREB-H 
designated CREB-HΔTC is a rapidly turned-over protein. Poly-
ubiquitination of CREB-HΔTC occurred in the nucleus and targeted the 
protein to proteosome-dependent degradation, preventing the target genes 
from constitutive activation. Taken together, our findings suggest tight 
regulation of CREB-H activation in hepatocytes by post-translational 
modifications. Our work thus reveals novel regulatory mechanisms in 
CREB-H-dependent transcription which might have implications in 
hepatocarcinogenesis.  
 
The study was supported by grants HKU 7486/06M and HKU 7/CRG/09 
from Hong Kong Research Grants Council. 
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In a search for multisite tumor suppressors, we identified PARK2 as a 
frequently targeted gene on chromosome 6q25.2-q27 in cancer. PARK2 
encodes a gene product with E3 ubiquitin ligase activity. We describe 
inactivating somatic mutations and frequent intragenic deletions of PARK2 
in human malignancies. The PARK2 mutations in cancer occur in the same 
domains, and sometimes, at the same residues as the germline mutations 
causing familial PD. Cancer-specific mutations abrogate the growth 
suppressive effects of PARK2. PARK2 mutations in cancer decrease the 
gene product’s E3 ligase activity, compromising its ability to ubiquitinate 
cyclin E, and resulting in mitotic instability. Cell cycle dysregulation 
following PARK2 inactivation requires cyclin E and synergizes with p53 
loss. These data strongly point to PARK2 as a tumor suppressor on 6q25.2-
q27. PARK2, a gene that causes neuronal dysfunction when mutated in the 
germline, may instead contribute to oncogenesis when altered in non-
neuronal somatic cells. 
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Glioblastoma multiforme (GBM) is the most common and rapidly fatal 
primary brain tumor for which current treatment options provide very 
limited survival benefit. Approximately 50% of GBMs are associated with 
hyper-activation of the epidermal growth factor receptor (EGFR). 
Dysregulated signaling through the EGFR pathway facilitates tumor 
initiation, sustains tumor growth, promotes infiltration of tumor cells into 
surrounding tissue and mediates therapeutic resistance. Aberrant EGFR 
signaling is the result of receptor over-expression which often occurs 
concomitantly with activating mutations and generation of 
autocrine/paracrine signaling loops. To explore the pathobiology of GBM 
tumors, our lab has created transgenic mouse models of human GBM based 
on conditional over-expression of activated EGFR in the brain of adult 
mice. Tumors are initiated in the context of PTEN and/or p16Ink4a/p19Arf 
deficiency, other mutations that are prevalent in human GBM. We show 
here that expression of activated EGFR generates high-grade, malignant 
gliomas with histological and molecular characteristics that resemble 
human GBM. We demonstrate that tumor progression in p16Ink4a/p19Arf 
null mice is exacerbated by loss of PTEN. Interestingly, ex vivo analysis of 
primary tumor cultures revealed that PTEN deficient tumor cells are 
resistant to the EGFR kinase inhibitor, gefitinib. Global phosphoproteome 
analysis showed that activation of signaling proteins in PTEN deficient cells 
may mediate survival and account for the differential response to EGFR 
inhibition between tumors of different genetic backgrounds. These findings 
provide important insight into the manner by which specific gene mutations 
confer drug resistance. It is our hope that the preclinical models of GBM 
described herein will provide a platform to discover mechanisms of drug 
resistance and enable testing of therapeutic strategies aimed at increasing 
sensitivity of GBM tumors to targeted therapeutics. 
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The role of stem cells in solid tumors remains controversial. In colorectal 
cancers (CRC), this is further complicated by the conflicting ‘top-down’ or 
‘bottom-up’ hypothesis of cancer initiation. We profiled the expressions of 
genes from the top and bottom of the colonic crypt in morphologically 
normal-appearing mucosa (M) at least 20 cm away from the tumor and 
contrasted this to that of matched mucosa adjacent to tumor (MT) in 
twenty-three sporadic CRC patients using Affymetrix Human Gene 1.0 ST 
Array system. Four-way analysis of variance (ANOVA) with position (top 
or bottom), gender, distance (M or MT) and scan date as factors was 
performed using intersection of position and distance as linear contrast 
factors at false discovery rate corrections of 0.0001. The final list of eighty 
differentially expressed transcripts was used to perform the principal 
component analysis (PCA) for visualization. In thirteen specimens, the 
genetic distance (as measured by Euclidean algorithm) between the bottom 
fractions of M and MT was smaller than the distance between the top 
fractions of M and MT; while in the rest of the specimens, the reverse was 
observed. The results imply that it is equally likely that sporadic colorectal 
tumorigenesis initiate from ‘top-down’ via dedifferentiated colonocytes or 
‘bottom-up’ via dysregulated intestinal stem cells, suggesting that this is a 
random process and hence need not necessarily be driven by rare 
dysregulated intestinal stem cells. Further, regardless of the initiation site, 
differential expression of forty of these genes persisted till tumor formation, 
suggesting that these are the driver genes for CRC. By Ingenuity® pathway 
analysis, these genes were shown to play significant roles in cellular 
signalling, development, growth and proliferation as well as amino acid and 
lipid metabolism and transport, indicating that driver genes are not limited 
to tumor suppressors or oncogenes but encompass a whole gamut of cellular 
functions. 
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Cancer cells are characterized by abnormal differentiation. Poor 
differentiation generally correlates with high malignant degree and poor 
prognosis. Differentiation therapy is an alternative strategy to control cancer 
by inducing cancer cell differentiation. However, the differentiation 
reagents that can be used in clinical practice at present are limited. We have 
previously reported the construction of a random small interfering RNA 
(siRNA) library. Such library is versatile as it avoids siRNA sequence bias, 
and targets both known and unknown genes. With this random siRNA 
library, here we carried out a high throughput screening on an 
erythroleukemia cell line K-562, in order to find siRNAs that can induce 
leukemia cell differentiation. Two novel siRNAs were screened from the 
random siRNA library and verified to be able to induce K-562 cell toward 
erythroid differentiation: the expression of CD235, ε-globin, γ-globin was 
significantly increased, and the cell proliferation rate was slowed down. 
Non-specific interferon induction was not detected, indicating that the 
siRNA-induced K-562 cell differentiation was due to specific effect. Our 
screening process with random siRNA library provides an alternative 
strategy for search of cancer cell differentiation-inducing reagents. Besides 
siRNA, growing number and various types of small RNAs are found to 
regulate gene expression within cells. In addition to random siRNA library, 
silimilar small RNA libraries can therefore be expected as new resources for 
search of therapeutic reagents. 
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Kaposi’s sarcoma (KS) tumors consist of spindle-shaped endothelial cells 
(ECs) that express markers of lymphatic endothelium, smooth muscle cells, 
macrophages and dendritic cells. Upon infection with KSHV, lymphatic 
ECs (LECs) develop spindle morphology, the hallmark of KS tumor cells, 
but do not show other properties of transformed cells.  
To better mimic the microenvironment of infected cells in vivo, we have 
developed a 3-dimensional (3D) organotypic spheroid outgrowth assay for 
KSHV-infected LECs. Interestingly, our results show that while control 
LEC spheroids sprout very little if at all, the KSHV-LEC spheroids show 
extensive sprouting.  
We have also analyzed the cellular differentiation status of KSHV-LEC and 
control LEC spheroids by confocal microscopy and qRT-PCR using a 
variety of markers for cell differentiation. Our data strongly suggests that 
KSHV induces transcriptional reprogramming of LECs into a mesenchymal 
cell type via a process called endothelial to mesenchymal transition 
(EndMT). We are currently deciphering which cellular pathways are 
activated and involved in the KSHV-induced EndMT by performing a 
global gene expression analysis of LEC and KSHV-LEC spheroids. EndMT 
has recently been recognized as a potential source for cancer associated 
fibroblasts (CAFs). To assess if the KSHV-induced EndMT could act as a 
source for KS-associated CAFs we have looked for the presence of KSHV-
positive mesenchymal cells in a panel of KS biopsies. Intriguingly, cells 
positive for both KSHV LANA and mesenchymal markers such as aSMA 
or vimentin can be readily detected in the majority of the KS biopsies 
analyzed.  
EndMT endows cells with migratory and invasive properties as a result of 
the loss of tight-junctions and by expression of N-cadherin. We have 
analysed the invasive potential of the KSHV-LECs, and the results suggest 
that KSHV-LECs can invade the collagen matrix. Inhibition and siRNA 
knock-down experiments indicate that invasion and spheroid sprouting are 
dependent on specific matrix metalloproteinases. We are currently 
investigating the role of viral genes in the transcriptional reprogramming 
and increased invasion.  
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Large scale genetic screens and cancer genome sequencing strategies have 
given rise to a growing list of candidate genes and mutations involved in 
cancer progression. While most strategies for validating cancer genes are 
constrained by the specificity of the system's cellular, tissue or 
developmental contexts, we have developed a system that samples multiple 
tissue- and developmental-contexts in the whole animal. Transposons are 
used to deliver and ectopically express candidate cancer genes. Animals 
with both transposase and oncogene-containing transposons develop a 
broad tumour spectrum, and recapitulate the spectrum seen in humans. Here 
we present an improved design of the platform and ongoing work in 
validating kinase mutations identified in human cancer genomes. The new 
strategy allows us to efficiently assay the in vivo oncogenic potential of 
multiple candidate mutations in the mouse model. 
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Glioblastomas are either purely astrocytic or have mixed astrocytic and 
oligodendroglial features, suggesting the tumor arises from a glial precursor 
cell capable of generating multiple cell types. Tumor initiating cells (TICs) 
isolated from human glioblastomas have properties similar to normal neural 
stem cells and can, at low titer, fully recapitulate the parent tumors in mice 
[Singh SK, et al. Nature. 2004 Nov 18;432(7015):396-401]. There is 
evidence that TICs maintain the tumor bed and are more resistant to 
chemotherapy and radiation then the more differentiated cells in the tumor. 
In vitro, TICs give rise to cells resembling astrocytes, neurons, and 
oligodendrocytes. We are interested in understanding what governs the 
transition from TICs to a more differentiated state, as well as what genes are 
required to maintain the tumor initiating state. We performed an RNAi 
screen on TICs, targeting 2,368 human GTPases and transcription factors 
using ~11,800 shRNAs. Using high throughput, high-content imaging, we 
identified genes whose depletion shifted cells from a sphere forming 
phenotype, characteristic of TICs, towards a differentiated, flat and 
elongated phenotype, a feature of differentiated cells. Here, we present the 
optimization of our high throughput imaging and analysis techniques and 
the preliminary results of our screen. We found 136 genes whose 
suppression gave a differentiated phenotype. Of those, suppression of 5 
genes significantly decreased relative cell number and/or neurosphere 
formation suggesting a role in cell proliferation. Additionally, of these 136 
strong hits, some are overexpressed in particular GBM subtypes. Lastly, 
suppression of 25 genes increased neurosphere number and relative cell 
number suggesting the genes might suppress proliferation of TICs or their 
daughter cells. Orthotopic xenograft studies are underway to clarify the 
effect of targeting these genes on tumorigenicity. Our aim is to identify new 
therapeutic targets and eventually add differentiation therapy to current 
treatment strategies for GBM. 
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Cellular senescence suppresses cancer by arresting cell proliferation in 
response to potentially oncogenic stimuli. Senescent cells undergo massive 
changes in their secretory profile, referred to as the “senescence-associated 
secretory phenotype” (SASP), which reinforces the arrest program and 
triggers an innate immune response that can signal clearance of senescent 
cells in vivo. Interestingly, many of the SASP factors are known targets of 
the NF-κB transcription factors, which are, paradoxically, often considered 
pro-oncogenic. To explore the function of NF-κB during senescence, we 
applied short hairpin RNA (shRNA) against NF-κB to address its 
contribution. We found NF-κB is activated in senescent cells induced by 
different senescence stimuli, including in response to oncogenic Ras and 
DNA-damaging chemotherapeutic agents. In addition, inhibiting NF-κB 
activation in senescent cells abolishes the transcriptional changes linked to 
the SASP and attenuates the ability of senescent cells to be targeted by 
natural killer (NK) cells in vitro. While inhibiting NF-κB alone is not 
sufficient to bypass cellular senescence, co-inhibition of NF-κB and p53 
prevent the induction of senescence and targeting by NK cells. By using a 
murine lymphoma model driven by Myc and the anti-apoptotic lesion Bcl-2, 
we found that chemotherapy-induced senescence depended on NF-κB, such 
that loss of NF-κB was associated with senescence failure and enhanced 
disease progression. These data together suggest a novel tumor suppressive 
function of NF-κB in senescence that contributes to the outcome of cancer 
therapy. 
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Mutations causing replication stress can lead to genomic instability (GIN). 
In vitro studies have shown that drastic depletion of the MCM2-7 DNA 
replication licensing factors, which form the replicative helicase, can cause 
GIN and cell proliferation defects that are exacerbated under conditions of 
replication stress. To explore the effects of incrementally attenuated 
replication licensing in whole animals, we generated and analyzed the 
phenotypes of mice that were hemizygous for Mcm2, 3, 4, 6, and 7 null 
alleles, combinations thereof, and also in conjunction with the hypomorphic 
Mcm4Chaos3 cancer susceptibility allele. Mcm4Chaos3/Chaos3 embryonic 
fibroblasts have ~40% reduction in all MCM proteins, coincident with 
reduced Mcm2-7 mRNA. Further reductions of Mcm2, 4, 6, or 7 in this 
background caused various phenotypes including synthetic lethality, growth 
retardation, decreased cellular proliferation, and early onset cancer. 
Remarkably, heterozygosity for Mcm3 rescued many of these defects, 
including cancer phenotype. Consistent with a role in MCM nuclear export 
possessed by the yeast Mcm3 ortholog, the phenotypic rescues correlated 
with increased chromatin-bound MCMs, and also higher retention of 
nuclear MCM2 at the early of S phase. The genetic, molecular and 
phenotypic data demonstrate that relatively minor quantitative alterations of 
MCM expression, homeostasis or subcellular distribution, can have diverse 
and serious consequences for health, viability and cancer susceptibility. The 
results support the notion that the normally high levels of MCMs in cells are 
needed not only for activating the basal set of replication origins, but also 
“backup” origins that are recruited in times of replication stress to ensure 
complete replication of the genome. 
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Glioblastoma (GBM) is the most aggressive primary brain tumor, with a 
median survival of only 14.6 months. The aggressiveness and therapeutic 
resistance that characterize GBM are due at least in part to the presence of a 
subpopulation of tumor initiating cells (TICs), a.k.a. cancer stem cells. Like 
neural stem cells, GBM TICs possess extensive self-renewal ability and 
multipotency - the capacity to form neurons, astrocytes, and 
oligodendrocytes under differentiating conditions; they are also highly 
tumorigenic, able to recapitulate the original patient tumor upon intracranial 
injection of very few TICs into immunodeficient mice. TICs may also 
possess enhanced chemotherapy and radiation resistance compared to other 
cancer cells. To develop effective therapies against GBM, it is imperative to 
identify the molecular pathways that allow TICs to self-renew, differentiate, 
and initiate tumor formation. 
 
To systematically investigate these pathways, we have developed and 
carried out a large-scale image-based RNAi screen. In human patient-
derived GBM TICs, we established techniques for high-throughput arrayed 
lentiviral shRNA screening and image analysis, using accepted morphologic 
measures of TIC proliferation, self-renewal, and differentiation. With these 
methods, we screened a library of over 11,000 shRNAs targeting more than 
2300 genes encoding all known human GTPases and DNA-binding factors. 
Statistical analysis yielded a hit rate of approximately 5%, identifying genes 
whose knockdown inhibited TIC self-renewal and proliferation and forced 
terminal differentiation. We have gone on to validate several of these genes 
as true, on-target hits in multiple TIC lines from different patients. The 
validated hits include known drivers of TIC functions, such as the oncogene 
Notch2, as well as several novel candidates of previously unknown 
function. We are currently performing in vitro mechanistic studies and in 
vivo tumorigenesis experiments to further ascertain the roles of these novel 
TIC regulators in stemness and tumorigenesis. 
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The laboratory rat is the preferred model system in many biomedical studies 
for its physiology and larger size, including cancer research, specifically in 
breast, prostate and bone metastasis. However, until recently, the lack of 
genetic manipulation tools for the rat genome made the mouse the 
predominant choice for researchers. The creation of the first knockout rats 
via microinjection of zinc finger nucleases (ZFNs) into single-cell embryos 
was the beginning of a revolution in the rat research world. Being the only 
tool to engineer the rat genome in a targeted fashion, ZFN technology 
allows specific and efficient introduction of desired mutations to the gene of 
interest.  
ZFNs are fusion proteins of a zinc finger protein and the DNA 
endonuclease domain of a type II restriction enzyme, FokI. ZFNs are 
engineered to bind and cleave at specific chromosomal locus to generate 
double strand breaks, repair of which results either insertions/deletions 
(potentially gene knockouts) by the non homologous end joining pathway 
or targeted integration/gene replacement by homologous recombination.  
Using ZFN technology, we created p53 KO rats, carrying deletions in exon 
3, where ZFNs target. Western blotting validated the absence of p53 protein 
in p53-/- animals. The homozygotes have a lifespan of up to four months. 
Currently, we are breeding up the colony for carcinogenicity test with 
heterozygotes. We hope the new model will help shorten the time needed 
for carcinogenicity test for new drugs, as the p53 KO mouse model did. In 
the meantime, we are developing conditional p53 KO rats by inserting loxP 
sites to flank exon 3 so that tissue-specific cre expression can be used to 
induce tumors in predicted pattern. We will report the current progress as 
well as any available pathologic data from deceased homozygous rats.  
 59 
ISOPRENYLATION REGULATES C17ORF37 MEDIATED CANCER 
CELL MIGRATION AND METASTASIS 
 
Subhamoy Dasgupta1, Ian Cushman2, Patrick J Casey2,3, Jamboor K 
Vishwanatha1  
 
1University of North Texas Health Science Center, Institute for Cancer 
Research and Department of Molecular Biology and Immunology, Fort 
Worth, TX, 76107, 2Duke University Medical Center, Pharmacology and 
Cancer Biology, Durham, NC, 27710, 3Duke-NUS Graduate Medical 
School, Program in Cancer and Stem Cell Biology, Singapore, 169547, 
Singapore 
 
Post-translational modification by covalent attachment of isoprenoid lipids 
(prenylation) regulates the functions and biological activities of several 
proteins implicated in the oncogenic transformation and metastatic 
progression of cancer. The largest group of prenylated proteins contains a 
‘CAAX’ motif (C denotes cysteine, A represents aliphatic amino acids, and 
X any amino acid) at the carboxyl terminal which serves as a substrate for a 
series of post-translational modifications that convert these otherwise 
hydrophilic proteins to lipidated proteins, facilitating membrane 
localization. A novel gene named Chromosome 17 open reading frame 37 
(C17orf37) located in the 17q12 amplicon is overexpressed in different 
forms of human cancer. Several studies have reported that a 280 kB 
minimal region of 17q12 that contains ERBB2 and C17orf37 is frequently 
amplified in breast and colon cancer. Although C17orf37 overexpression is 
linked with genomic amplification of ERBB2 locus, abundant expression of 
C17orf37 protein in ERBB2 non-amplified breast and prostate tumors 
suggest C17orf37 has an independent functional promoter. The C17orf37 
gene encodes a 12kD protein which enhances migratory and invasive 
phenotype of cancer cells. This function of C17orf37 is due to its ability to 
act as a membrane-bound signaling molecule modulating the PI-3K/Akt 
pathway, there by transcriptionally upregulating NF-κB downstream target 
genes MMP-9, uPA and VEGF. Via this process, C17orf37 overexpression 
in tumors contributes to the migratory and invasive phenotype, facilitating 
the malignant progression of the disease. Here we show that C17orf37 
contains a functional CAAX motif and is post-translationally modified by 
protein geranylgeranyltransferase-I. Geranylgeranylation of C17orf37 at the 
CAAX motif results in translocation of the protein to the inner leaflet of 
plasma membrane, and enhances migratory phenotype of cells by inducing 
increased filopodia formation and potentiation of directional migration. A 
prenylation-deficient mutant of C17orf37 is functionally inactive and fails 
to trigger dissemination of injected cells in a mouse model of metastasis. 
These findings demonstrate that prenylation is required for the function of 
the C17orf37 protein in cancer cells and imply that the modification may 
functionally regulate metastatic progression of disease. 
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Target cells for transformation in human hepatocellular carcinoma (HCC) 
are either bipotential liver progenitor cells (oval cells in rodents) or 
differentiated hepatocytes, whereas up to 80% of all human HCCs are 
thought to be derived from hepatocytes. We observed striking differences 
between progenitor cell- and hepatocyte derived hepatocellular carcinomas 
in mice: Whereas oncogenic Nras (NrasG12V) efficiently triggers 
hepatocellular carcinomas derived from p53-/- liver progenitor cells, almost 
no tumor growth is observed, when NrasG12V is delivered into p53-/- 
hepatocytes. However, aggressive hepatocellular carcinomas develop after 
short latency, when oncogenic Nras is delivered into p19Arf-/- hepatocytes, 
thus suggesting that p19Arf mediates p53-independent tumor suppressive 
functions in differentiated hepatocytes. To identify mediators of such p53-
independent tumor suppressive functions of p19Arf in the mouse liver, we 
set up an in vivo RNAi screen. As a proof of principle we could show that 
co-delivery of NrasG12V and p19Arf-shRNAs into p53-/- hepatocytes via 
transposable elements was able to phenocopy NrasG12V-driven 
hepatocarcinogenesis in p19Arf-/- livers. To perform the screen, a focused 
shRNAmir library was compiled consisting of shRNAs targeting genes 
differentially expressed in NrasG12V; p53-/- mouse livers compared to 
NrasG12V; p19Arf-/- livers. This focused shRNA library was divided into 
several low complexity pools (n=48) and subjected to an in vivo positive 
selection screen in a p53-/- background (co-delivery with NrasG12V). From 
NrasG12V; p53-/- tumors we identified several shRNAs knocking down 
new candidate genes mediating p53-independent tumor suppressive 
functions of p19Arf in the mouse liver. Functional validation experiments 
using single hairpins have already been completed for several candidates, 
among these are genes involved in the mitotic spindle assembly and the 
spindle checkpoint. shRNA-mediated knockdown of those candidate genes 
allows for Ras driven tumorigenesis in a p53-deficient background. 
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Epigenetic mechanisms are important in determining cell fate, including the 
development and progression of cancer, through the regulation of specific 
transcriptional programmes involved in development, differentiation, and 
normal homeostasis. Recent discovery of histone demethylases expands our 
view of epigenetic mechanisms. For example, trimethylated lysine 4 of 
histone H3 is a robust epigenetic mark enriched near transcription start sites 
of active genes and essential to regulation of multiple cellular processes. 
Regulation of this mark is mediated, in part, by the JARID1 subgroup of 
JmjC proteins which have been discovered to demethylate tri- and 
dimethylated H3K4 residues. We identified RBP2/JARID1A as a critical 
regulator of the switch from cellular proliferation to differentiation; we 
found that RBP2 looses binding to some genes that are activated during 
differentiation and recruited to genes that are repressed during 
differentiation in a Retinoblastoma (pRB)-dependent manner, which is 
consistent with pRB’s positive role in differentiation. RBP2’s closest 
homologue, PLU1/JARID1B, is expressed in most breast cancers, and has 
been implicated in cancer progression. Because of the high homology to 
RBP2, we propose that PLU1 also regulates proliferation and 
differentiation. To study the function of PLU1 in breast cancer, we 
employed siRNA technology to knockdown PLU1 in MCF7 and MDA-
MB-231 breast cancer cell lines. siRNAs to PLU1 in MCF7 cells reduces 
proliferation and anchorage-independent growth in soft agar assays 
compared to control siRNAs. Loss of PLU1 in MDA-MB-231 cells induced 
a prominent morphological change to a more epithelial-like morphology 
(round and flat). Additionally, we developed an inducible knockdown 
system to study the importance of both PLU1 and RBP2 in breast cancer. 
Using a Tet-off inducible system, we knocked-down PLU1, RBP2, and pRB 
in MCF7 and MDA-MB-231 cells. By BrdU incorporation, Ki67 
immunostaining, and colony formation assays in MCF7 cells, we found that 
loss of RBP2 decreases proliferation while loss of RB increases 
proliferation. We also found that, like PLU1 knockdown, loss of RBP2 
decreases anchorage-independent growth, while loss of RB increases 
anchorage-independent growth. Thus, we conclude that both PLU1 and 
RBP2 are critical regulators of proliferation in breast cancer cells, and may 
represent important therapeutic targets. 
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Tyrosine kinase receptors’ signaling has ordinarily been implicated in 
mitotic, pro-surviving and sometimes oncogenic signaling pathways which 
stimulate cell growth and proliferation. However, some groups, including 
ours, have reported that in malignant cells RTK’s signaling can also trigger 
unexpected antiproliferative effects. The Fibroblast Growth Factor 2 
(FGF2) is one these RTK ligands which triggers a dual response in 
malignant cells. We have previously shown that FGF2 through its RTK 
receptor (FGFR) restrains the proliferation of Ras-driven mouse malignant 
cells; here, we aim to elucidate cell and molecular mechanisms underlying 
the antiproliferative stress response triggered by FGF2 on K-Ras-dependent 
Y1D1 mouse malignant adrenocortical cells. Cell cycle flow cytometry 
analyses following DNA content and BrdU pulse-labeling showed that 
FGF2, in spite of stimulating G0>G1>S transition, causes in these 
malignant cells a delay in FCS-stimulated DNA synthesis followed by a 
strong block of the G2/M transition, uncoupling cell growth from cell 
division. Polyploidization, giant cells formation and cell death were also 
late effects of FGF2 treatment. Corroborating these results, 48hs growth 
curves further confirmed that FGF2 stimulates an increase in the average 
cell size without signs of mitosis and/or increase in cell number. 
Furthermore, this antiproliferative picture triggered by FGF2 in Ras-
dependent malignant cells is accompanied by the arising of DNA damage 
response markers, pointing to a mechanistic explanation to this stress 
response triggered by FGF2.  
Thus, altogether these results are showing that FGF2/FGFR signaling can 
uncover a cancer-specific “Achilles’ heel” in the K-Ras-dependent 
malignant phenotype of mouse cells one-time highly resistant to cell death. 
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Bcl-2 family proteins including Bcl-2, Bcl-xL, and Mcl-1 promote cell 
survival during development, however they are often aberrantly 
overexpressed in cancer. The novel therapeutic compound ABT-263 targets 
Bcl-2 and Bcl-xL and has shown single agent efficacy in recent clinical 
trials for chronic lymphocytic leukemia. However to date no specific 
inhibitors of Bcl-2 or Bcl-xL are available, therefore it has been difficult to 
assess the contribution of each protein to tumour maintenance. To address 
this question, we have adapted the tetracycline (tet)-regulated expression 
system to generate transgenic mouse strains allowing inducible expression 
of short hairpin RNAs (shRNAs) targeting Bcl-2 or Bcl-xL in vivo. Using a 
reporter strategy, we find that a transgenic strain expressing the rtTA (tet-
on) transactivator under control of the CMV promoter drives particularly 
efficient tet-regulated expression in the megakaryocyte/platelet lineage. 
Employing this system to induce doxycycline-dependent Bcl-xL shRNA 
expression depletes Bcl-xL in megakaryocytes and triggers severe 
thrombocytopenia, consistent with a known role for Bcl-xL in maintaining 
platelet survival. Shutting off shRNA expression normalizes Bcl-xL levels 
and restores platelet numbers, effects akin to those observed with ABT-263. 
Knockdown of either Bcl-2 or Bcl-xL in adult mice results in mild 
lymphopenia, however reporter analysis suggests that shRNA expression is 
variable in the lymphoid compartment using this transactivator strain. We 
are now optimising this inducible knockdown strategy to more accurately 
model systemic therapeutics targeting Bcl-2, Bcl-xL and other potential drug 
targets in established lymphomas and leukemias. 
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The biology of IGF-1R/IR signaling was studied in normal mouse 
embryonic fibroblasts (MEFs) that were either wildtype (wt), heterozygous 
(het), or null for the IGF-1R. The ability of IGF-1, IGF-II or insulin to 
stimulate serum-starved MEFs was characterized by gene expression 
profiling and biochemical analyses for activation of downstream signals. 
Each genotypic group of MEFs exhibited distinct patterns of expression 
both while resting and in response to stimulation. The insulin receptor (IR) 
pathway in IGF-1R null MEFs was hypersensitive to insulin ligand 
stimulation resulting in greater AKT phosphorylation than in wt or het 
MEFs stimulated with the same ligand. Interestingly, the IR pathway 
hypersensitivity in IGF-1R null MEFs occurred with no observed changes 
in the levels of IR isoforms A or B. A new small molecule IGF-1R inhibitor 
(BMS-754807), having equipotent activity against both IGF-1R and IR, 
proved effective in suppressing both AKT and ERK phosphorylation from 
both the IGF-1R and IR pathways by all 3 ligands tested in wt, het and null 
MEFs. The use of a dual IGF-1R/IR inhibitor addresses concerns about the 
use of growth inhibiting therapies directed against the IGF-1R receptor in 
certain cancers. Lastly, comparison of the anti-proliferative effects (IC50s) 
of various compounds in wt vs. null MEFs demonstrates that genetically 
characterized MEFs provide a simple and inexpensive tool with which to 
define compounds as having mostly on-target or off-target IGF-1R activities 
since off-target compounds affect both wt and null MEFs equally. 
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Platinum-based chemotherapeutic drugs are front-line therapies for the 
treatment of non-small cell lung cancer. However, acquired or intrinsic 
resistance limits the clinical efficacy of these agents. Recent evidence 
suggests that loss of the translesion (TLS) polymerase, Polζ, can sensitize 
tumor cell lines to cisplatin, although the relevance of these findings to the 
treatment of chemoresistant tumors in vivo remains unclear. Here, we 
describe a tumor transplantation approach that enables the rapid 
introduction of defined genetic lesions into a pre-clinical model of lung 
adenocarcinoma. Using this approach, we examined the effect of impaired 
translesion DNA synthesis on cisplatin response in aggressive late-stage 
lung cancers. In the presence of reduced levels of Rev3, an essential 
component of Polζ, tumors exhibited pronounced sensitivity to cisplatin, 
leading to a significant extension in overall survival of treated recipient 
mice. Additionally, treated Polζ-deficient cells exhibited reduced cisplatin-
induced mutation – a process that has been implicated in the induction of 
secondary malignancy following chemotherapy. Taken together, our data 
illustrate the potential of Rev3 inhibition as an adjuvant therapy for the 
treatment of advanced non-small cell lung cancer and highlight the utility of 
rapid transplantation methodologies for evaluating mechanisms of 
chemotherapeutic resistance in pre-clinical settings. 
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The adenomatous polyposis coli (APC) gene is one of the most frequently 
mutated genes in colorectal cancer and is often silenced or mutated in other 
human malignancies. APC is thought to function primarily as a negative 
regulator of β-catenin and canonical Wnt signalling although recently, 
various other direct roles have been described. Mice heterozygous for the 
APC min allele (a nonsense mutation creating a truncated protein) develop 
multiple intestinal polyps by 4-5 months of age due to loss of 
heterozygosity at the wt allele., while APC min/min homozygous mice fail to 
progress beyond E7.5 of embryogenesis. Tissue specific truncation of APC 
using Cre/LoxP strategies have indicated a requirement for APC in the 
development of hair follicles and intestinal and hepatic homeostasis, but 
thus far it has not been possible to study the role of APC in multiple tissues 
during early mammalian development or in adult mice. Here, we have used 
a recombinase-mediated ES cell targeting strategy to derive transgenic 
animals expressing a tet-regulated shRNA targeting APC. Knockdown of 
APC in adult animals induces a rapid expansion of the hair follicles and 
within two weeks, dox-fed mice grow significantly longer hair. 
Paradoxically, long-term APC knockdown causes significant hair loss, 
presumably due to depletion of hair follicle stem cells. Knockdown of APC 
during early post-natal development causes multiple phenotypes including 
craniofacial defects and severe runting, which cannot be reverted following 
re-expression of the endogenous APC protein. We are now developing 
improved tet-transactivator mice to optimise the expression of shAPC in 
diverse tissues and investigating the consequences of chronic vs. transient 
disruptions to the Wnt pathway in normal tissue homeostasis and during 
malignant progression.  
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Mutations that lead to activation of the proto-oncogene Ras are found in 
over 25 % of all human cancers, making it the most frequently activated 
oncogene in cancer. The function of active Ras and the pathways it activates 
have been studied intensively, but how Ras signaling actually mediates the 
transformation of a normal cell into a tumor cell is not fully understood.  
It is well established that the Ras oncogene can activate several signaling 
pathways (ERK, NFκB, Ral/JNK and PI3K/AKT) and that they all can 
contribute to cellular transformation. The aim of this project was to find and 
characterize those downstream target/s of the Ras signaling pathway that 
mediate transformation.  
While analyzing the cJun NH2-Terminal kinase (JNK) isoform specific 
knockout mouse embryonic fibroblasts (MEFs), I observed that the Jnk2 
knockout cells, opposite to the corresponding Jnk1 knockout cells, cannot 
be transformed with oncogenic Ras.  
The best studied JNK target, c-Jun which is a part of the activator protein 1 
(AP-1) transcription factor complex, has previously been shown to be 
crucial for Ras transformation. I showed that JNK2 is not functioning via 
cJun/AP-1 (TRE site), since the extent of c-Jun phosphorylation and the 
activity of the AP-1 transcription factor complex was not impaired in Ras 
expressing Jnk2-/- MEFs. Instead expression of the ATF2 protein, which is 
also an AP-1 component was severely impaired in Jnk2-/- MEFs and 
ectopic expression of ATF2 restored the ability for Ras to transform Jnk2-/- 
MEFs. In addition, transformation was rescued by increasing c-Myc protein 
level via ectopic expression of c-Myc or cancerous inhibitor of protein 
phosphatase 2A (CIP2A) that seems to have oncogenic effect in mediating 
Ras transformation in Jnk2-/- MEFs. ATF2, CIP2A and c-Myc seem to 
cooperate in mediating Ras transformation in JNK2-/- MEFs.  
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Evasion of apoptosis is a hallmark of cancer and a major cause of treatment 
failure. In breast cancer, the expression levels of Bcl-2 and Bcl-xL are 
commonly elevated and deregulation of Bcl-2 or Bcl-xL accelerates mouse 
mammary tumor progression by allowing cells to escape apoptosis. 
Upregulated levels of Bcl-2 and Bcl-xL confer resistance to chemotherapy 
and therefore, these proteins are attractive targets for apoptosis sensitization 
and synthetic lethal strategies. We have previously shown that c-Myc-
induced sensitization of mammary cells to apoptosis is tightly linked to 
conformational activation of Bak. Addition of TRAIL to sensitized cells is 
required for progression of Bak to oligomerization stage followed by 
MOMP and strictly Bak-dependent apoptosis. The data infer that 
pharmaceutical neutralization of Bcl-2/Bcl-xL might specifically promote 
apoptosis in c-Myc-induced mammary tumors expressing active Bak. We 
show that WAP-Myc induced mammary tumorigenesis is tightly associated 
with elevated levels of Bcl-xL but not of Mcl-1. In 3D cultures of WAP-
Myc tumors, the BH3 mimetic small molecule inhibitor ABT-737 strongly 
synergizes with active c-Myc in the induction of apoptosis. Consistently, 
administration of ABT-737 as a single agent to the WAP-Myc mice with 
palpable tumors induced significant reduction in the tumor growth rate, 
which associated with increased levels of apoptosis. Furthermore, treatment 
of ex vivo prostate tumor tissue slices induced sporadic activation of Bak as 
a marker of apoptotic sensitization. Notably, previous studies with 
xenograft-based preclinical models have revealed high Bcl-xL levels and 
low Mcl-1 levels as indicators for good ABT-737 efficacy. The responses 
observed in WAP-Myc model endorse the significance of high Bcl-xl/low 
Mcl-1 as predictors of ABT-737 efficacy. These GEMMs for breast cancer 
may thus serve as tractable model for search of treatment modalities based 
on apoptosis sensitization strategies. 
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Helicobacter pylori is a gram negative bacterium that has been associated 
with the development of gatroduodenal diseases such as chronic gastritis, 
duodenal ulcers and gastric cancer. H pylori CagA protein is translocated 
into gastric epithelial cells where it undergoes phosphorylation by cellular 
kinases on tyrosine residues within EPIYA motifs, present within the C-
terminal region of the protein. Phosphorylated CagA activates important 
cell signaling pathways, inducing the expression of the proinflammatory 
cytokine interleukin-8 (IL-8) and cell elongation (also known as the 
“hummingbird phenotype”). EPIYA motifs in Western H. pylori strains are 
classified as EPIYA-A, EPIYA-B and EPIYA-C, based on the sequence 
flanking the motif. The number of EPIYA motifs can vary from two to six. 
Previous studies have suggested a positive association between the number 
of EPIYA motifs, the number of EPIYA-C motifs and the expression of IL-
8 and “hummingbird phenotype” formation. The aim of this study was to 
evaluate the possible association between the variations in the CagA EPIYA 
motifs in H. pylori isolates from Colombia and the expression of IL-8 and 
cell elongation induction in gastric epithelial cells. 84 H. pylori cagA 
positive strains with different EPIYA motifs patterns, isolated from 
Colombian patients with different gastric pathologies, were evaluated. IL-8 
expression was determined by ELISA after taking supernatants from 
cocultures of AGS epithelial gastric cells with H. pylori. For cell elongation 
quantification, coculture photographs were taken and the proportion of 
“hummingbird” cells (>5µm) was determined. There was no association 
between the number of EPIYA motifs and IL-8 expression, although a 
variable expression of IL-8 was observed. Furthermore, no significant 
differences were found in H. pylori-induced IL-8 expression between 
strains isolated from gastric cancer and strains isolated from other gastric 
pathologies. Similar results were obtained for the “hummingbird 
phenotype” induction, for which no association was found neither to the 
number of EPIYA motifs nor to the pathologies from which strains were 
isolated. These results suggest that other factors (e.g. host or environmental) 
may play a more important role than H. pylori CagA protein EPIYA 
variations in gastric cancer development in Colombia. 
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The c-Myc oncoprotein is a transcription factor that regulates most cellular 
functions by either activating or suppressing downstream target genes. 
While c-Myc levels are generally low in most normal tissues, high levels of 
c-Myc expression occur in a wide variety of human tumors. Control of c-
Myc expression can occur at many levels, including transcription, mRNA 
stability, translation, and protein stability. We and others have characterized 
a complex signaling pathway that helps to control c-Myc protein stability 
and accumulation through the sequential phosphorylation of two highly 
conserved sites, Serine 62 (S62) and Threonine 58 (T58). These 
phosphorylation sites have opposing effects on c-Myc stability, where 
phosphorylation at S62 can stabilize c-Myc and subsequent phosphorylation 
at T58 promotes c-Myc ubiquitin-dependent proteolysis. Pin1 is a peptidyl 
prolyl isomerase that plays an important role in this degradation pathway 
for c-Myc. As the only known phosphorylation-specific prolyl isomerase, 
Pin1 plays a key role in the regulation of protein function by alterations in 
substrate conformation after phosphorylation. Pin1 is known to regulate 
diverse cellular processes, and it has been linked to several diseases, 
including cancer, where it is often overexpressed. Here, we show that Pin1 
positively regulates c-Myc’s transcriptional activity by enhancing the on-
rate for c-Myc promoter binding, resulting in changes in the expression of 
endogenous c-Myc target genes and enhanced c-Myc oncogenic potential. 
Moreover, a positive correlation exists between Pin1 levels and phospho-
Serine62 c-Myc levels in human breast cancer cell lines and patient 
samples. We have found that the Axin1 scaffold protein coordinates a 
destruction complex for c-Myc at target gene promoters containing GSK3β, 
PP2A-B56α, and Pin1. Thus, Pin1 plays a dual role in regulating c-Myc, 
both enhancing its transcriptional activity and stimulating its degradation, 
suggesting a mechanism for coordinating the activation of c-Myc with its 
destruction at the promoters of its target genes. Taken together, this work 
highlights the function of Pin1 in the dynamic regulation of c-Myc activity 
and suggests that Pin1 is a viable therapeutic target in human cancers 
overexpressing c-Myc. 
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Reversing the effects of so-called driver mutations to eradicate cancer rests 
on the premise that activation of oncogenes, or inactivation of tumor-
suppressor genes is required not only for tumor genesis, but also for tumor 
maintenance. Experimental genetic approaches and pharmaceutical 
inhibition of the effects of driver mutations has supported the notion that a 
sustained effect of these mutations is indeed required for the viability of 
tumor cells. In contrast, we present evidence for a context specific 
sensitivity to restoration of p53 gene function in non-small cell lung cancer. 
We show that early stage tumors are apathetic to the restoration of p53 gene 
function, whereas more advanced tumors are sensitive to the anti-tumor 
effects of p53. Moreover, we find that all tumors of advanced stage 
maintain varying proportions of less advanced cells within the tumor mass 
that are also indifferent to p53 restoration. These low-grade tumor cells 
persist despite significant loss of tumor volume after p53 restoration. 
Through histological analysis, we provide evidence that p53 opposes tumor 
progression toward the adenocarcinoma stage but has no effect on tumor 
initiation. Advanced lung tumors in KrasLA2; p53 deficient mice 
characteristically harbor high levels of MAPK signaling, that in some 
instances is likely caused by copy number gains of the chromosomal region 
encompassing Kras. Though the mechanisms of MAPK signal amplification 
are diverse, the increased level of signaling that we observe is universally 
associated with increased expression of the p53-activating tumor suppressor 
Arf. These observations have led to a model where increased MAPK 
signaling drives tumor progression but also leads to activation of p53 
through Arf expression. Thus, when p53 gene function is restored, only Arf 
expressing tumors are capable of activating p53’s tumor suppressive effects. 
These findings suggest that restoration of pathways important in tumor 
progression, as opposed to initiation, may lead to incomplete tumor 
regression due to the heterogeneity of cell populations within a tumor. 
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Short hairpin RNAs (shRNAs) enable regulated silencing of target genes 
through their programming of endogenous RNAi pathways. Although 
widely used to study gene function, the identification of potent shRNAs can 
be tedious, often involving the empirical examination of dozens of shRNAs 
to find one that is effective. To overcome this barrier, we developed a 
functional strategy integrating all aspects of the RNAi process to assess the 
potency of shRNAs in a high-throughput manner. By interrogating a library 
of 20,000 constructs comprising every possible shRNA across 9 
mammalian transcripts, we demonstrate that our assay reliably identifies 
highly potent shRNAs that are predominantly missed by existing prediction 
algorithms. Although potent shRNAs are surprisingly rare, they share strong 
nucleotide biases that provide insights into the mechanistic basis of RNAi. 
Overall, this assay can be used to identify potent shRNAs targeting any 
gene, which will enable the production of validated genome-wide shRNA 
libraries and may facilitate the development of effective RNAi therapeutics. 
More broadly, the “Sensor” assay illustrates a general co-optimization 
strategy in which a library of linked regulators and their binding sites can be 
screened in a multiplexed fashion. 
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Tuberous Sclerosis (TS) is a multi-organ disorder characterized by the 
formation of primarily benign tumours, called hamartomas, which affects 
more than 1 million people worldwide annually. TS is caused by a mutation 
in one of two tumor suppressor genes, TSC1 or TSC2 which encode for the 
protein products Hamartin and Tuberin respectively. This TS Complex 
(TSC) is known to negatively regulate protein translation and cell cycle 
progression through G1/S. Herein we demonstrate that Tuberin binds and 
regulates the G2/M cyclin, Cyclin B1 (CycB1). We have determined that 
this binding region encompasses a mutational hotspot within Tuberin 
implicated in some of the most severe cases of TS. Mimicking a mutation 
frequently found in patients we report a significant acceleration in the 
nuclear movement of CycB1 and enhanced mitotic index. These results 
demonstrate a novel and clinically relevant mechanism by which Tuberin 
may function as a tumor suppressor to prevent premature mitotic onset. 
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PRDM5 belongs to PR-domain family of putative methyltransferases. 
Members of this family are characterized by the presence of a N-terminal 
PR/SET domain, typically involved in methyltransferase activity, and a 
variable number of C-terminal C2H2 zinc fingers domains likely 
responsible for DNA and protein binding.  
PRDM5 has been reported to be a tumour suppressor due to its lowered or 
lost expression in different types of cancer, including breast, ovarian and 
gastric cancer. The transcriptional silencing of PRDM5 is caused by 
promoter hyper-methylation, and is especially frequent among tumours of 
gastrointestinal tract origin (Watanabe et al., Gastroenterology, 2009). 
Furthermore, over-expression of PRDM5 in cancer cells induces cell cycle 
arrest, apoptosis and block of proliferation (Deng et al., Oncogene, 2004), 
sustaining the notion of PRDM5 as a tumor-suppressor. Moreover, in a 
zebrafish model, Prdm5 has been reported to be involved in mesoendoderm 
development and to collaborate with the WNT pathway.  
We have initiated a comprehensive project aiming to mechanistically 
characterize the tumour-suppressive functions of PRDM5 in vivo. Towards 
this, we have generated a PRDM5 knockout mouse model that we are 
currently analyzing for spontaneous and chemically induced tumour 
formation and in crosses with tumour-prone mouse strains.  
Interestingly, our preliminary data from knockout MEFs show that loss of 
Prdm5 results in increased growth and susceptibility to RAS-V12-mediated 
cellular transformation. Moreover, we are evaluating a potential role of 
PRDM5 in WNT pathway activation in terms of target genes modulation.  
To unveil the molecular mechanism of PRDM5, yeast-two-hybrid and 
mass-spec analysis of biochemical protein complex purifications have been 
performed and reveal that PRDM5 participate in large MDa-size complexes 
also encompassing a range of chromatin-modifying proteins. Despite the 
presence of a PR/SET domain we have not been able to detect any intrinsic 
methyltransferase activity of PRDM5, but we have confirmed the 
interaction of PRDM5 with the HMT G9a and HDACs.  
Current efforts focus on a more detailed phenotypic analysis of the Prdm5 
KO mouse strain and on the identification of PRDM5 target genes using a 
combination of expression array analyses and ChIP-seq.  
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The activation of Cdks require two main steps: Cyclin binding and 
phosphorylation of their T-loop. The latter is mediated by CAK (Cdk 
Activating Kinase), a trimeric kinase that includes Cdk7, Cyclin H and 
Mat1. CAK has also been identified as part of the general transcription 
factor TFIIH. Here, CAK is responsible for the phosphorylation of the 
carboxy-terminal domain (CTD) of the large subunit of the RNA 
Polimerase II, a process thought to be essential for the generation of 
mRNAs. We have generated germ line as well as conditional Cdk7 mutant 
mice. Ablation of Cdk7 in the germ line results in early embryonic lethality. 
The elimination of Cdk7 in the epidermis of newborn mice leads to a 
cytologically and architecturally dysplasic skin, characterized by an 
improper differentiation of keratinocytes, as demonstrated by an altered 
cytokeratin pattern. On the other hand, depletion of Cdk7 in adult tissues 
with low proliferation rate, such as brain, cerebellum or liver, did not 
produce any histological alteration. 
In MEFs, the elimination of Cdk7 arrests them in G1 and G2 phases of the 
cell cycle, and when serum starved they are no longer able to exit 
quiescence. We did not observe variation in phosphorylation degree of Ser 
5 in the CTD. Moreover, the mRNA levels of all the housekeeping genes 
that we have analysed, were not modified. Remarkably, we were able to 
restore the proliferation of cells lacking endogenous Cdk7 by expression of 
an exogenous Cdk7 mutant that only shows activity towards Cdks. 
Although less eficiently, proliferation can also be rescued by expression of 
phosphomimetic mutants in Thr of the T-loop of Cdk1 or Cdk2. We can 
conclude that the main role of Cdk7 in cell division can be attributed to Cdk 
activation. 
Since Cdk7 depletion would not affect global gene expression in non-
dividing cells, thereby limiting undesired side effects, it should be 
considered as an interesting druggable target. Inhibition of Cdk7 would 
deprive cancer cells of the Cdk activity required to promote E2F- dependent 
transcription and orderly progression throughtout the cell division process.  
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The oncogenic transcription factor FoxM1 is an attractive therapeutic target in 
the fight against cancer, because it is overexpressed in the majority of human 
tumors, while the tumor suppressor p53 is mutated and inactivated in 50% of 
human tumors. We found that the FoxM1 gene is repressed by p53 and that 
FoxM1 overexpression in cancers can partially be explained by the absence of 
p53 mediated repression. In addition to being upregulated in cancers, we found 
that FoxM1 protein is stabilized by DNA-damage in human cancer cells with 
mutant p53, and FoxM1 inhibits apoptosis induced by radiation or DNA-
damaging agents, making cancer cells resistant to treatment. Knockdown of 
FoxM1 sensitized human cancer cells to radiation or DNA-damaging drugs.  
 
Earlier, we identified the thiazole antibiotics Siomycin A and thiostrepton as 
specific inhibitors of FoxM1 transcriptional activity and expression that induce 
apoptosis in cancer cells. Paradoxically, at the same time Siomycin A and 
thiostrepton stabilized the expression of a variety of proteins, such as p21, Mcl-
1, p53 and hdm-2 and also act as proteasome inhibitors in vitro. In contrast, we 
found that other known thiazole antibiotics neither inhibit FoxM1 activity, nor 
act as proteasome inhibitors and did not induce apoptosis in mammalian cells. 
Moreover, we found that thiostrepton could suppress tumor growth in human 
cancer xenograft models suggesting that it has anticancer activity in vivo. 
Interestingly, thiostrepton synergistically induced apoptosis in human cancer 
cells following combination treatment with another proteasome inhibitor 
bortezomib.  
 
Furthermore, well-known proteasome inhibitors such as MG115, MG132 and 
Velcade also inhibit FoxM1 transcriptional activity and FoxM1 expression. 
Siomycin A/thiostrepton and traditional proteasome inhibitors induced 
apoptosis and suppressed FoxM1 at the same time in human cancer cell lines of 
different origin. Our data indicate that proteasome inhibitors generally inhibit 
FoxM1 expression and this may contribute to their efficacy as anticancer drugs. 
Since proteasome inhibitors stabilize the majority of cellular proteins, we 
hypothesize that they stabilize a negative regulator of FoxM1 that inhibits 
FoxM1 transcriptional activity. Since FoxM1 induces its own expression, then 
by repressing FoxM1 transcriptional activity negative regulator of FoxM1 will 
also inhibit FoxM1 expression. Overall, since FoxM1 plays an important role in 
driving tumorigenesis and may induce resistance to anticancer treatment, it is a 
viable target for cancer therapies. In the end, we propose a strategy to identify 
novel FoxM1 inhibitors compounds that are not proteasome inhibitors. 
This work was supported by NIH grants 1RO1CA1294414 and 
1R21CA134615. 
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Small G proteins of the Ras subfamily control the communication between 
the cellular outside and inside. The level and life time of the GTP-loaded 
active state is mainly regulated by two factors: GTPase activating proteins 
(GAPs) and guanine nucleotide exchange factors (GEFs). Upon receptor 
tyrosine kinase (RTK) activation adaptor proteins recruit the GEF son of 
sevenless (SOS) to the receptor and thereby into the proximity of Ras, 
where SOS can catalyze GTP loading of Ras. 
 
SOS carries an allosteric domain whose interaction with Ras-GDP or Ras-
GTP is required for effective catalytic action on another Ras molecule. This 
allosteric site is, however, blocked by autoinhibitory SOS domains. The in 
vivo trigger that releases SOS autoinhibition is currently only partially 
known. Here we show SOS regulation by the membrane-actin linker protein 
ezrin (or the related proteins radixin and moesin [ERM]). We can 
distinguish two steps: interaction of ezrin with the Dbl homology/pleckstrin 
homology domain of SOS which promotes unfolding of SOS and release 
from autoinhibition; and more efficient presentation of Ras-GDP by ezrin to 
the allosteric site of SOS. Moreover SOS/Ras regulation by ezrin is 
physiologically antagonised by the neurofibromatosis type 2 tumour 
suppressor merlin. Taken together we propose a new level of SOS/Ras 
control involving a family of actin-binding proteins that is relevant in 
human cancer as well as in physiological processes involving Ras. 
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MDM2 and MDM4 are key negative regulators of p53. Aberrant expression 
of either MDM2 or MDM4 is thought to impair p53 tumor suppression 
function and therefore to favor the development of tumors that retain wild-
type p53. 
 
p53 mutations (less than 5%) and MDM2 amplification and/or 
overexpression are rare events in skin melanoma,. We have examined the 
levels of MDM4 expression in a panel of 16 skin melanoma cell lines and 
40 primary melanoma tumors (10 primary lesions, 10 dermal invasive 
tumors, 10 lymph node metastasis and 10 distant metastasis). As expected, 
only 4 primary tumors and 3 melanoma cell lines showed elevated MDM2 
levels. In contrast, MDM4 protein levels were elevated in about 65% of all 
primary tumors and 38% of the melanoma cell lines analyzed. Preliminary 
knock-down experiments indicate that MDM4 prevents induction of p53-
mediated growth arrest and is therefore required for the proliferation of 
these cell lines. 
 
In order to further establish a causative link between MDM4 overexpression 
and melanoma formation in vivo, we sought to develop a Mdm4 melanoma 
mouse model. To this end, a conditional Mdm4 transgenic line has been 
intercrossed with mice expressing the Cre recombinase (Tyr::Cre) and the 
NrasQ61R mutant specifically in melanocytes (Tyr::NrasQ61R). Data from 
these crosses are not yet available, however, we will provide compelling 
evidence that loss of p53 on this specific melanoma background 
(Tyr::NrasQ61R) accelerates tumor formation. 
 
Together these data, yet preliminary, indicate that MDM4 might contribute 
to the development of skin melanoma. Consequently, MDM4 might be a 
potential drug target for the treatment of this disease. 
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Tuberous sclerosis complex (TSC) is regarded as a tumor suppressor gene 
syndrome whereby the classical bi-allelic inactivation of either TSC genes 
(TSC1, hamartin or TSC2, tuberin) is said to activate the mTOR pathway 
and ultimately lead to tumorigenesis. TSC is associated with the widespread 
development of mesenchymal tumor cell types, manifestations such as 
lymphangiomyomatosis (LAM) and renal angiomyolipomas (AML). High 
mobility group A2 (HMGA2) is an architectural transcription factor, that is 
misexpressed in a number of benign mesenchymal tumors and its 
tumorigenic ability in differentiated mesenchymal cells in vivo studies.  
 
Our experiments were directed at the potential genetic interaction between 
the TSC2 and HMGA2 pathways. Similar to humans, Tsc2+/- mice display a 
wide spectrum of tissue tumor cell types in multiple tissues. Our initial, 
correlative studies demonstrated that the HMGA2 pathway was activated in 
100% of human and mouse TSC2 tumor samples. Tumor incidence was 
examined in Tsc2+/– mice following loss of HMGA2. Most dramatically, 
there was a complete absence of mesenchymal tumors in the Tsc2+/–Hmga2-
/- mice that are observed in the liver, lung, eyes and skin of the Tsc2+/– mice. 
Therefore, there is an absolute requirement for HMGA2 activation in 
mesenchymal tumor pathogenesis in the Tsc2+/– mice. In the course of our 
studies, tuberin expression was analyzed and surprisingly, tuberin was 
detected in all of the mouse and human tumor cell types with the exception 
of a subset of kidney tumors that had undergone LOH at the TSC2 locus.  
 
Our results have important ramifications for the prevailing hypothesis in 
TSC and by extension, to other tumor suppressor syndromes. These studies 
demonstrate that haploinsufficiency in a tumor suppressor gene is necessary 
for tumor initiation but bi-allelic inactivation is not required for tumor 
formation. Additional pathways therefore are activated and in TSC, the 
HMGA2 pathway was found to be essential for mesenchymal tumor 
formation. Furthermore, it appears that Knudson’s hypothesis may apply in 
a highly tissue-specific manner such that in TSC, LOH is observed only in 
the kidney. In conclusion, the present study has identified the activation of 
the HMGA2 pathway as an obligate requirement for mesenchymal tumor 
formation and for TSC specifically the HMGA2 pathway provides novel, 
potential drug targets for therapy in the broad spectrum of tumors. 
 80 
EVIDENCE FOR A NOVEL MECHANISM OF LENTIVIRAL VECTOR-
INDUCED TUMORIGENESIS 
 
Reba Condiotti*1, Daniel Goldenberg*1, Temima Schnitzer-Perlman1, Wing 
Cheung2, Simon Waddington2, Suzanne M Buckley3, Matthew Themis4, 
Charles Coutelle5, Hilla Giladi1, Emma Osejindu4, Eithan Galun1, Michael 
Themis4,6 
  
1Hadassah-Hebrew University Medical Center, Goldyne Savad Institute of 
Gene Therapy, Jerusalem , 91120, Israel, 2University College, Institute for 
Women’s Health, London, WC1E 6HX, United Kingdom, 3University 
College Medical School, Department of Haematology, London, NW3 2PF, 
United Kingdom, 4Brunel University, Division of Biosciences, Middlesex, 
UB8 3PH, United Kingdom, 5Imperial College, Gene Therapy Research 
Group, London, SW7 2AZ, United Kingdom, 6Imperial College, National 
Heart and Lung Institute, London, SW7 2AZ, United Kingdom 
 
Safer and more effective lentiviral vectors are presently being used for gene 
delivery in early phase clinical trials. In contrast to leukemias that 
developed following gamma-retroviral transduction, as yet, no adverse 
outcomes have resulted from lentiviral-based therapy. In this study, we 
focused on prenatal liver-directed gene transfer by transducing fetal mice 
with a lentiviral vector derived from feline immunodeficiency virus. This 
procedure resulted in efficient hepatocyte transduction, however, 3/8 
transduced mice each developed two hepatocellular carcinomas. To 
investigate the link between lentiviral transduction and tumor development, 
we mapped viral integration and chromosomal aberration sites and found 
them to be unique in each tumor. Gene expression analysis using 
microarrays did not reveal differential expression of oncogenes or tumor 
suppressor genes in the vicinity of viral integrations; however, 5/6 tumors 
exhibited common activation patterns of genes associated with DNA repair, 
chromosomal instability, oncogenesis, and E2F transcription factors. Thus, 
we propose that lentiviral transduction may induce a global cellular 
mechanism entailing the DNA damage response that leads to upregulation 
of E2F target genes, resulting in oncogene activation and tumor 
development. 
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ATF2 and ATF7 are members of the AP-1 transcription factor family which 
regulate expression of genes involved in stress and DNA damage response. 
In cancer, ATF2 has been reported to be involved in tumour suppressing but 
also in tumour promoting activities. Here we present an analysis of potential 
roles for ATF2/7 in response to oncogenic Ras transformation in a model of 
hepatocellular carcinoma (HCC).  
Using mouse knockouts we have previously established that the two factors 
are essential for the embryonic liver development by engaging in 
antiapoptotic mechanisms to ensure the survival of hepatoblasts. Cultured 
hepatoblasts can be used to study the onset of hepatocellular carcinoma via 
transformation with oncogenes and reintroduction into recipient livers 
through orthotopic transplantation. We found that ATF2/7 double knockout 
hepatoblasts transformed with the H-Ras oncogene (H-RasG12D) produced 
significantly more and larger colonies in vitro. After orthotopic 
transplantation transformed knockout cells developed tumour nodules in 
recipient livers at significantly faster rates and in greater numbers compared 
to cells that were normal for ATF2. In addition, deletion of ATF2 and ATF7 
in cells isolated from established liver tumours also result in accelerated 
growth in graft models.  
Therefore, in contrast to their antiapoptotic activities in primary 
hepatoblasts, our data support a growth suppressing role for ATF2/7 in 
response to oncogenic transformation.  
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Pilocytic astrocytoma (PA) comprises the most common primary brain 
tumor in children and is assigned to grade I according to the WHO. 
Although PA shows a benign biologic behavior, many patients suffer from 
therapy-related neurologic impairment and up to 20% of cases experience 
tumor recurrence. Due to the slow growing nature of PA, post-operative 
radiation and chemotherapy are only moderately effective. 
Recent research has led to the discovery of the activation of mitogen-
activated protein kinase (MAPK) signaling as a general molecular 
pathomechanism in PA and a potential molecular target for therapy. 
Germline NF1 gene mutation is associated with astrocytoma development, 
which leads to aberrant MAPK pathway activation. Intriguingly, also 
sporadic cases of PA show similar MAPK target gene signatures. We and 
others have previously identified duplications or activating mutations 
(V600E) of the proto-oncogene BRAF at 7q34 or fusion genes including the 
BRAF kinase domain as a predominant genetic mechanism leading to 
MAPK pathway activation in more than 50% of PAs.  
However, generation of an appropriate model for PA by using 
xenotransplants or genetically engineered mice has been hampered by the 
low proliferative character of these tumors and a lack of knowledge about 
their molecular etiology. 
To evaluate the oncogenic potential of BRAF, we used the replication 
competent avian leukosis virus with splice acceptor (RCAS)/Tv-a system 
for retroviral gene transfer to introduce different BRAF variants into nestin 
positive cells in the brain of Ntv-a mice. Thereby, we were able to induce 
astrocytic tumors, which closely resemble the histology of human PAs, and 
show a causal role of BRAF activation in the pathogenesis of PA. This 
model now enables us to perform pre-clinical assessment of novel therapy 
approaches. 
 83 
CDK4 IS A CENTRAL MEDIATOR OF CENTROSOME 
AMPLIFICATION IN HER2 POSITIVE BREAST CANCER CELLS. 
 
Mary Kathryn Harrison, Xiangbin Zeng, Harold I Saavedra 
 
Emory University, Radiation Oncology, Atlanta, GA, 30322 
 
Centrosome amplification, the acquisition of three or more centrosomes per 
cell, contributes to carcinogenesis by generating multipolar spindles and 
aneuploidy. Observations in breast tumors show that adenocarcinoma cells 
have a much higher frequency of centrosome defects when compared to 
normal breast tissue. Similar phenotypes are also found in pre-invasive in 
situ ductal carcinoma, suggesting that these aberrations occur early in breast 
carcinogenesis. Identification of the pathways and regulatory molecules 
involved in the generation of centrosome amplification is essential to 
understanding the role of centrosome amplification in breast tumorigenesis. 
Due to the strong association between Her2 over-expression and 
centrosome amplification in human breast cancers, our goal is to identify 
cell and centrosome cycle regulators that are de-regulated by aberrant Her2 
signaling in human and mouse mammary epithelial cells. Her2 signals 
through various pathways, including Ras. Results from our lab show breast 
cancer cells over-expressing Her2, human mammary epithelial cells over-
expressing H-RasG12V, and pre-malignant mouse mammary hyperplasias 
expressing Neu or K-RasG12D harbor centrosome amplification. Genome-
wide and targeted expression screens of human and mouse mammary 
epithelial cells expressing Her2 and Ras, respectively, show up-regulation 
of cyclin D1 and other important centrosome regulatory molecules. 
Abrogation of Cdk4, a catalytic partner of cyclin D1, using siRNA and 
lentiviral shRNA reduced the frequencies of centrosome amplification in 
Ras and Her2+ cells without affecting the cell cycle. In contrast, silencing 
cyclin B2, cyclin E1, or Cdk2 did not affect centrosome profiles. We 
postulate that Cdk4 is an important link between centrosome amplification, 
aneuploidy, and mammary epithelial transformation, as ablation of Cdk4 
not only abrogates centrosome amplification, but also mouse mammary 
tumorigenesis triggered by Neu and H-RasG12V. We want to elucidate the 
mechanism responsible for centrosome amplification in Her2+ breast 
cancers and determine its involvement in breast carcinogenesis. We propose 
that in Her2+ cells, Cdk4 signals centrosome amplification through a 
classical pathway involving hyperphosphorylation of NPM at Thr199, a site 
that negatively regulates centrosome duplication. Our results challenge the 
classical view that Cdk2 is critical to oncogene-triggered centrosome 
amplification. We propose a new paradigm: Oncogenes such as Her2/Ras 
signal centrosome amplification exclusively through Cdk4, while other 
oncogenes, such as E7 or ablated p53 signal centrosome amplification 
through Cdk2 and Cdk2&Cdk4, respectively. 
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We are undertaking a comprehensive characterization of signaling elicited 
by somatically mutated epidermal growth factor receptors (EGFR). These 
mutations occur in nearly ten-percent of lung cancer and predict EGFR 
kinase inhibitor sensitivity. Physical maps of EGFR signaling are being 
created using (i) detailed protein-protein interaction map using tandem 
affinity purification in conjunction LC-MS/MS and (ii) a global 
characterization of tyrosine phosphorylated proteins regulated by EGFR 
using immunoaffinity capture with anti-phosphotyrosine antibodies and LC-
MS/MS. By interrelating protein-protein interactions, phosphotyrosine 
signatures, and data from a RNA interference screen, a map of signaling 
will be constructed to highlight important components vulnerable to attack. 
Using EGFR as a bait, we identified 36 interacting proteins in PC9 lung 
cells including known components such as other Erb members (ErbB2), 
adaptors (Grb2, ShcA), EGFR regulators (MIG6, Sts1, AP2u1), and 
chaperones (HSP90, Cdc37, BIP). We selected an additional 9 proteins for 
additional TAP experiments and produced a protein-protein interaction 
network consisting of 110 putative proteins. We found PI3K subunits in 
complex with ErbB3 but not EGFR nor ErbB2. AP2M1 associated with its 
larger family of AP proteins, EPS15, and proteins involved in cell adhesion 
icluding E-cadherin and catenin-delta. Cdc37 bound multiple kinases, 
including EGFR, ARAF, CDK4, and NFκB members, suggesting chaperone 
requirements of these kinases in partnership with Hsp90 and functional 
importance in these cells. Consistent with this hypothesis, RNAi mediated 
loss of Cdc37 reduced EGFR expression and increased apoptosis in EGFR 
addicted lung cancer cells. Additional selected targets have been 
functionally validated using RNA interference or overexpression studies. 
Overexpression of MIG6 over a one month period resulted in reduced 
EGFR and Erk phosphorylation consistent with its known role as a negative 
regulator of EGFR kinase. Interestingly, cells overexpressing MIG6 
developed gradual resistance to EGFR tyrosine kinase inhibitors and were 
found to have increased Akt phosphorylation. No evidence exists for 
upregulation of another receptor tyrosine kinase as a mechanism of 
increased Akt phosphorylation. These preliminary results suggest that 
kinase addicted cells could adapt to negative regulators of EGFR through 
mechanisms that increase signaling through Akt. Current studies on this 
mechanism are planned and updated work will be presented. 
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Recently, we identified the AP4 gene as a direct target of the c-MYC proto-
oncogene. Similar to c-MYC, AP4 encodes a BR-HLH-LZ transcription 
factor which binds to so-called E-boxes in the vicinity of target genes. 
However, the AP4 binding sites have a different consensus (CAGCTG) 
when compared to the c-MYC E-box (CACGTG). Therefore, AP4 
presumably regulates a different set of genes than c-MYC. We previously 
found that AP4 represses expression of the CDK inhibitor p21 via 4 E-
boxes in the p21 promoter. Interestingly, AP4 is expressed in progenitor 
cells in a number of tissues and human tumors often show high levels of 
AP4 expression. Here we characterized the set of genes directly regulated 
by AP4 in colorectal cancer cells by a combination of microarray and global 
ChIP-Seq analyses. Thereby we found that AP4 induces the expression of 
122 genes and represses 129 genes more than 2 fold. The regulation of 
selected genes by AP4 was confirmed at the mRNA, gDNA and protein 
level, and in vivo by confocal microscopy of intestinal crypts, in which AP4 
is expressed at the base and declines towards the top. The identity of the 
validated AP4 targets indicates that AP4 is a coordinating regulator of cell 
cycle progression and differentiation. Therefore, the AP4-regulated 
transcriptome presumably fulfills important functions during normal and 
tumorigenic processes. 
 86 
SIRT1 OVEREXPRESSION IMPROVES HEALTH AND PROTECTS 
FROM LIVER CANCER BUT DOES NOT AFFECT P53-KNOCKOUT 
ASSOCIATED TUMORIGENESIS 
 
Daniel Herranz, Manuel Serrano  
 
Spanish National Cancer Center (CNIO), Molcular Oncology Program 
(Tumor Suppresion Group), Madrid, 28029, Spain 
 
Sirt1 is the mammalian closest homologue to yeast Sir2, a protein 
deacetylase that has been shown to increase the lifespan of lower organisms 
when overexpressed. Besides, it has been proposed to mediate calorie 
restriction beneficial effects on health, which include lifespan extension and 
cancer protection, although genetic evidence is lacking in mammals. We 
have generated transgenic mice moderately overexpressing Sirt1 under its 
own regulatory elements (Sirt1-tg mice). We have found that Sirt1-tg mice 
do not live longer but preserve a better health at old ages according to a 
variety of physiological indicators. Moreover, Sirt1-tg mice are also 
protected from metabolic syndrome-associated liver cancer1. We present 
evidence indicating that the beneficial effects of Sirt1 are due to its impact 
on metabolism1,2 and genomic integrity1. On the other hand, Sirt1 doesn’t 
affect either 3-methylcolanthrene-induced fibrosarcoma development or 
spontaneous cancer associated to p53-knockout background, being the latter 
a tumorigenesis that is known to be delayed by calorie restriction. Together, 
these results indicate that Sirt1 overexpression improves health and protects 
from certain type of cancers but it does not fully recapitulate calorie 
restriction-associated phenotypes. 
 
 
1Herranz, D. et al., (2010). Sirt1 improves healthy ageing and protects from 
metabolic syndrome-associated cancer. Nat Commun 1:3, doi: 
10.1038/ncomms1001 
 
2Pfluger, P.T*., Herranz, D.*, et al., (2008). Sirt1 protects against high-fat 
diet-induced metabolic damage. Proc Natl Acad Sci U S A 105, 9793-9798.  
*: these authors contributed equally to the work. 
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Thymidylate kinase (TMPK) is an essential enzyme for dTTP formation in 
either de novo or salvage pathways. Our previous study has shown that 
silencing human TMPK by shRNA decreases the cellular level of dTTP and 
sensitizes colon cancer cells to doxorubicin-induceddeath, suggesting that 
agent that blocks TMPK function can be used as a chemotherapysensitizer. 
We then further identified a novel inhibitor of TMPK, designated H9805, 
by a biolueminescence-based screening. H9805 inhibited TMPK enzymatic 
reaction in a dose-dependent manner with Ki of 0.22 ± 0.03 μM. H9805 
treatment decreased the cellular dTTP level and caused a significant 
synergistic effect with doxorubicin in killing a variety of cancer cell lines 
but not normal cell lines. Interestingly, doxorubicin sensitivity was 
increased by H9805 treatment 1.7- and 30-fold in in non-tumorigenic 
H184B5F5/M10 and tumorigenic MDA-MB-231 cells, respectively. When 
profiling the cell cycle of these two cell lines in response to doxorubicin 
treatment, we found that MDA- MB231 cells were accumulated in S and G2 
phase, whereas H184B5F5/M10 cells showed more population in G1 phase. 
The differential checkpoint activation induced by doxorubicin treatment and 
the sustained checkpoint activation for complete DNA repair, may 
determine the chemosensitization effect of H9805. Moreover, animal 
experiments also showed its effectiveness on suppressing tumor growth 
when combined with low dosage of doxorubicin. These data suggest H9805 
compound as a good lead candidate for chemosensitization.  
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Regions of chromosome 11 are frequently lost in many cancers including 
nasopharyngeal carcinoma (NPC). This may reflect the possibility that 
essential tumor suppressor genes are harbored in the lost regions. 
Previously, we have transferred the intact chromosome 11 into the NPC cell 
line HONE1. Functional suppression of tumor formation in nude mice 
suggests intact chromosome 11 is able to suppress tumor growth. 11q13 and 
11q22-23 were identified as tumor suppressive critical regions (CRs). Alpha 
B-crystallin (CRYAB) maps within the 11q22-23 CR and is down-regulated 
in all NPC cell lines and in approximately 47% of NPC tumors via promoter 
hypermethylation and allelic loss. In this study, we provide the functional 
evidence that CRYAB suppresses in vivo tumor formation in nude mice. Re-
expression of CRYAB protein in the stable transfectants affects cell 
adhesion and invasion ability. These results suggest that CRYAB may be a 
potential tumor suppressor gene in NPC and play a role in affecting tumor 
cell adhesion and metastasis. 
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Association of p53 gain of function mutations with poor prognosis has been 
well established for cancers of some systems, such as colorectal and 
hematopoietic. Recently, it has been recognized that such mutations may 
facilitate carcinogenesis by increasing cell motility and invasion. 
Intriguingly, these observations have been difficult to reconcile with the 
poorest prognosis of p53 null mutations reported in some types of cancer, 
including ovarian carcinoma. To evaluate the effects of loss vs. gain of 
function p53 mutations on the ovarian surface epithelium (OSE) we have 
taken an advantage of previously established by us conditional mouse 
model of epithelial ovarian cancer. Cre-loxP-mediated p53 inactivation 
resulted in immediate upregulation of Met receptor tyrosine kinase and led 
to increased cell motility and invasion of the OSE. These effects were 
abrogated by deletion of the Met gene. In addition to previously reported 
Met regulation by p53-transactivated miR-34, we determined that p53 
represses Met expression by inhibiting Sp1 transcription factor binding to 
the proximal region of Met promoter. Notably, while miR-34-mediated 
regulation of Met was inactive in the OSE with both null and missense 
mutations, mutant p53 retained Met promoter suppressive function by 
interacting with Sp1. Accordingly, conditional activation of p53 R172H and 
R270H mutants led to increased OSE motility and invasion, but to a lesser 
degree than p53 null mutation. Taken together, our findings identify Met as 
a critical player in p53-mediated control of motility and invasion and 
provide a mechanistic explanation for less pronounced effect of mutant p53 
on ovarian carcinogenesis. These results indicate that personalized 
therapeutic approaches tailored to p53 mutational status may have uneven 
effect in a cell context -dependent manner. 
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Inv(16) is found in nearly all patients with acute myeloid leukemia (AML) 
subtype M4Eo. Inv(16) results in the fusion of the transcription factor gene 
CBFB, and the MYH11 gene, which encodes Smooth Muscle Myosin Heavy 
Chain. The leukemia fusion gene CBFB-MYH11 is thought to induce 
leukemia by repressing RUNX1 and CBFß. Consistent with this model, 
mice expressing a knocked in Cbfb-MYH11 allele (Cbfb+/MYH11) have a 
similar phenotype as mice nullizygous for either Cbfb (Cbfb-/-) or Runx1 
(Runx1-/-). Embryos of all 3 genotypes have a complete block in definitive 
hematopoiesis. Recently we showed that Cbfb-MYH11 also causes defects 
during the earlier stage of primitive hematopoiesis. Cbfb+/MYH11 embryos 
have a delay in differentiation that is not seen in either Cbfb-/- or Runx1-/- 
indicating that Cbfb-MYH11 has additional activities independent from the 
repression of Cbfb and Runx1. We also showed that these new activities are 
potentially important during leukemogenesis. To determine which domains 
of the fusion protein may be involved in this new activity, we generated 
knock-in mice expressing a mutant Cbfb-MYH11 allele with a deletion of 
the 95 C-terminal amino acids (Cbfb+/MYH11?95). During primitive 
hematopoiesis, we found that Cbfb+/MYH11?95 and CbfbMYH11?95/MYH11?95 mice 
had no or very mild differentiation defects, statistically significantly less 
severe than seen in embryos expressing full-length Cbfb-MYH11. This 
finding indicates that Cbfb-MYH11?95 has lost the Cbfb/Runx1-repression 
independent activities. During definitive hematopoesis, there were no 
observable defects in Cbfb+/MYH11?95 mice, but CbfbMYH11?95/MYH11?95 embryos 
showed a complete block in definitive hematopoiesis implying that Cbfb-
MYH11?95 is capable of repressing Cbfb and Runx1, although less 
efficiently than full-length Cbfb-MYH11. Importantly, Cbfb+/MYH11?95 mice 
did not develop leukemia, even after treatment with the mutagen N-ethyl-N-
nitrosourea, which we’ve shown previously to quickly and efficiently 
induce leukemia in mice expression full length Cbfb-MYH11. Together, 
these results indicate that the 95 C-terminal amino acids of Cbfb-MYH11 
are required for leukemogenesis and that the recently described Cbfb/Runx1 
repression independent activities are important during this process. 
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Dmp1 (cyclin D binding myb-like protein 1; Dmtf1) is a transcription factor 
that causes p19Arf-, p53-dependent cell cycle arrest in response to oncogenic 
Ras and HER2 signaling. HER2/neu is amplified in nearly 30% of human 
breast cancers and is associated with metastatic disease, and thus, with poor 
prognosis of patients. The receptor is activated by overexpression or by 
making heterodimers with other EGFR family proteins. Both the Dmp1 and 
Arf promoters are activated by HER2/neu through the PI3K-Akt-NF-?B 
pathway. Molecular genetic analyses of MMTV-neu mammary tumors 
showed that biallelic Arf deletions, Mdm2 overexpression, or p53 mutations 
were rare. On the other hand, we found that the Dmp1 gene was deleted in 
more than 50% of MMTV-neu tumors, suggesting the critical role of Dmp1-
inactivation in HER2/neu-driven mammary carcinogenesis. Overexpression 
of Tbx2 and Pokemon was also frequent in neu tumors. Tumor-free survival 
of MMTV-neu mice was significantly shortened in both Dmp1+/- and Dmp1-
/- with no significant differences between the two cohorts, suggesting 
haploid-insufficiency of Dmp1 for neu tumor suppression. Tumors from 
Dmp1+/- or Dmp1-/- mice were significantly larger than those from Dmp1+/+ 
mice when weighed 30 days after detection, and showed more invasive 
phenotypes than those from wild-type neu mice. Analysis of 66 pairs of 
human breast cancer samples showed loss of heterozygosity (LOH) of 
hDMP1 in ~50% of breast carcinomas, the frequency of which was even 
higher than LOH of the INK4a/ARF (~20%) or p53 (~30%) locus, or 
amplification of the Hdm2 gene (~10%) with the same samples. LOH of 
hDMP1 was typically found in mutually exclusive fashion from that of the 
INK4a/ARF or the p53 locus. The hDMP1 protein expression was low or 
barely detectable in the nuclei of breast carcinomas that showed LOH for 
hDMP1. LOH of hDMP1 was associated with low Ki67 index and diploid 
karyotype of tumor cells, suggesting favorable prognosis. Consistently, 
breast cancer patients with LOH for hDMP1 showed significantly longer 
relapse-free survival than those without LOH. Thus, loss of DMP1 has 
differential prognostic impact on survival of breast cancer between mice 
and humans, possibly because of the low frequency of the Ink4a/Arf, Mdm2, 
and p53 locus involvement in murine tumors. 
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Maintenance of DNA integrity is essential for the viability of the organism. 
Potentially oncogenic lesions trigger a signalling cascade known as the 
DNA damage response (DDR) which initiates repair of the DNA as well as 
essential cell cycle checkpoints, serving as a safeguard against 
transformation. This research focuses on a cyclin-like protein Spy1 
(Speedy; Spdy1) previously shown to prevent DDR-induced apoptosis 
when ectopically overexpressed and to promote clonal cell growth in cells 
harboring damaged DNA. Spy1 has been found at elevated levels in several 
human cancers including breast and liver. Herein we demonstrate that 
selective degradation of Spy1 is an essential component of the DDR 
signalling cascade occurring in response to both DNA damage as well as 
critically shortened telomeres. Interestingly, our work suggests that 
endogenous expression of Spy1 may play a pivotal mechanism in DDR 
recovery to promote cell cycle re-entry following DNA repair. This work 
suggests a mechanism whereby the cell could adapt to the DDR to promote 
malignant progression. 
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Germline mutation in BRCA2 is linked to the familial breast cancer as well 
as to the progressive bone marrow failure syndrome, Fanconi Anemia. 
Established mouse knock out models to study the function of Brca2 show 
embryonic lethality, but ones with truncating mutation at more C-terminus 
survive to birth and succumb to thymic lymphoma at an early age. To 
overcome early lethality and investigate the function of Brca2, we utilized T 
cell specific conditional Brca2 knock-out mice which develop thymic 
lymphoma at a moderate penetrance. In the conditional knock out mice, we 
found that the number of peripheral T cells, especially naïve pools 
drastically decline with age. The decline was due to the loss of thymic input 
as well as inapt peripheral T cell maintenance. Furthermore, Brca2-deficient 
T cells were highly compromised in cell division and in effector cytokine 
production upon activation. These defects were due to the activation of p53 
pathway, as the Brca2 deficient phenotypes were rescued by p53 
heterozygosity. Altogether, our study faithfully records the molecular 
events occurring in the Brca2-deficient T cells and suggests that mutation in 
Brca2 could lead to the malfunction of T cell populations which will make 
the host more susceptible to cancer. 
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Identifying mechanisms of drug action remains a fundamental impediment 
to the development and effective use of chemotherapeutics. Here, we 
describe an RNA interference (RNAi)-based approach to characterize small 
molecule function in mammalian cells. By examining the response of cells 
expressing a validated set of short hairpin RNAs (shRNAs) to a diverse 
selection of chemotherapeutics, we could generate a functional shRNA 
signature that was able to accurately group drugs into established 
biochemical modes of action. This, in turn, provided a diversely sampled 
reference set for high-resolution prediction of mechanisms of action for 
poorly characterized small molecules. For example, we were able to use this 
approach to classify two ill-defined cytotoxic drugs as inhibitors of 
topoisomerase I and II, respectively. We could further reduce the predictive 
shRNA target set to as few as 8 genes, and by using a newly derived 
probability based nearest neighbors approach, could extend the predictive 
power of this limited shRNA set to characterize additional drug categories. 
Thus, a focused shRNA phenotypic signature can provide a highly sensitive 
and tractable approach for characterizing new anti-cancer drugs. 
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C/EBPβ is an auto-repressed protein that is activated by Ras signaling and 
contributes to oncogene-induced senescence (OIS) in primary fibroblasts. 
We discovered that Ras-induced post-translational activation of C/EBPβ 
(LAP) is suppressed in several immortalized and transformed cell lines by 
the 3’ untranslated region (3’UTR) of its mRNA. The Cebpb 3’UTR 
blocked RasV12-stimulated proliferative arrest by C/EBPβ, as well as DNA 
binding, transactivation, phosphorylation, and homodimerization, without 
significantly affecting C/EBPβ expression. The Cebpa 3’UTR similarly 
suppressed the anti-proliferative activity of C/EBPα and that of C/EBPβ 
when appended to its coding region. An AU-rich element (ARE) and its 
cognate RNA-binding protein, HuR, were required for Cebpb 3’UTR 
inhibition. The 3’UTR also excluded the Cebpb transcript from a 
juxtanuclear region of the cytoplasm in a manner that depended on the ARE 
and HuR, suggesting a functional link between mRNA localization and 
protein activation. Importantly, 3’UTR inhibition was diminished in 
primary fibroblasts, allowing Ras-induced C/EBPβ activation and OIS to 
proceed. C/EBPβ expressed from a coding region construct (C/EBPβCR) 
induced a gene signature in NIH 3T3Ras cells that was biased toward 
inflammatory and anti-proliferative mediators. In contrast, genes activated 
by the 3’UTR-containing construct (C/EBPβUTR) showed associations with 
cancers and the TGFβ pathway. These results suggest that the 3’UTR 
instructs C/EBPβ to activate a pro-oncogenic program in immortalized or 
transformed cells and suppresses its ability to induce genes involved in 
tumor suppression and senescence. In summary, our findings reveal a novel 
regulatory mechanism, termed 3’UTR regulation of protein activity or UPA, 
in which non-coding mRNA sequences control post-translational activation 
of C/EBPβ and may thereby determine its pro- versus anti-oncogenic 
functions. 
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In most tumors, the activity of cyclin-dependent kinases (Cdks) is elevated. 
It is still not clear if this is a cause or consequence of tumorigenesis. We 
have shown in the past that there is significant functional overlap between 
Cdk2, Cdk4, and Cdk1. Because of this, Cdk2-/- mice do not display any 
overt phenotype. Mouse genetics has demonstrated that in Cdk2-/-Cdk4-/- 
double mutants, the transcriptional expression of Cdk1 is repressed because 
of hypophosphorylation of the retinoblastoma protein (Rb). Loss of the 
tumor suppressor p53 induces tumors in mice and we found that 
concomitant loss of Cdk2 does not alleviate tumorigenesis. Even the loss of 
Cdk2 & Cdk4 in a p53 null background does not affect cell transformation 
because the loss of p53 induces the expression of Cdk1 and cyclin B1. All 
these results indicated an essential role for Cdk1 in controlling cell division 
in tumorigenesis. Therefore, we generated mice that do not express Cdk1 in 
hepatocytes. These Cdk1-liver-knockout mice were viable and did not 
display any obvious phenotype. Liver tumors in mice can be induced by tail 
vein injection of activated Ras in combination with silencing of p53. Within 
3-4 months, wild type mice developed massive liver tumors. Currently, we 
are currently testing Cdk1-liver-knockout mice for the development of liver 
tumors induced by activated Ras/shp53. We will report our newest results. 
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Epigenetic silencing of Ras-Association Domain Family (RASSF) genes, 
RASSF1 and RASSF5 (also called NORE1), by CpG hypermethylation is 
found frequently in many cancers. While the physiological roles of RASSF1 
have been studied in some detail, the exact functions of RASSF5 are not 
well understood. 
Here, we show that RASSF5 plays an important role in TNF-α meditated 
apoptosis. Depletion of RASSF5 by siRNA significantly reduced the TNF-α 
mediated apoptosis, most likely through its interaction 
with proapoptotic kinase MST1, a mammalian homolog of Hippo.  
Consistent with this, siRNA knockdown of MST1 also resulted in resistance 
to TNF-α−induced apoptosis. In addition to its interaction with MST1, 
RASSF5 formed complexes with WW45, LATS1, and YAP1, which are 
components of the Hippo signaling pathway. Genetic ablation of Rassf5 in 
mouse embryonic fibroblasts also resulted in resistance to TNF-α induced 
apoptosis. 
Importantly, Rassf5-null mice were significantly more resistant to the TNF-
α induced apoptosis and failed to activate Mst1 in vivo. Furthermore, 
Rassf5-null MEFs underwent spontaneous immortalization 
at earlier passages than the control MEFs and showed increased 
susceptibility to oncogenic transformation by K-RasG12V. Together, our 
results demonstrate a direct role for RASSF5in TNF-α mediated apoptosis 
and further suggest an important role for RASSF5 in tumorigenesis. 
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Mutations in KRAS are frequently occurring genetic lesions in the genesis 
of human pulmonary adenocarcinoma. Despite extensive efforts, therapeutic 
strategies targeting Ras have remained unsuccessful so far; thus, Ras 
effector pathways may present more suitable targets for therapeutic 
intervention. However, which Ras effector pathways are critical for 
tumorigenesis is incompletely understood. Here we show that in a K-
RasG12D mutant mouse model of lung cancer, both B-Raf and C-Raf are 
involved in the regulation of lung tumor development. Genetic deletion of 
C-Raf drastically reduced the number of lung tumors and overall disease 
burden, leading to a significantly extended lifespan of these animals. 
Tumors that developed in these mice showed inefficient recombination of 
the floxed C-Raf allele, indicating that C-Raf is required for tumor 
initiation. B-Raf deficiency did not reduce tumor burden at early time-
points, but decreased MAPK activation, proliferation and tumor size, 
resulting in increased survival of these mice. B-Raf was also found to 
mediate K-RasG12D-induced proliferation in mouse embryonic fibroblasts, 
while C-Raf is critical for survival in response to apoptotic stimuli. Thus, B-
Raf and C-Raf play important but distinct roles in mediating the oncogenic 
effects of K-RasG12D. These results suggest dual targeting of B-Raf and C-
Raf as suitable therapeutic option for the treatment of K-Ras mutant lung 
adenocarcinomas. 
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Ovarian cancer is the most lethal gynecological cancer with less than 40% 
of 5-year overall survival. The major chance of successful therapeutic 
outcome is obtained when optimal debulking and sensitivity to 
chemotherapy are achievable. Recently, retrospective studies have 
supported that those patients who were contemporarily receiving statin 
treatment -when treated for ovarian cancer- had better survival. Statins, 
HMG-CoA reductase inhibitors, are used to decrease cholesterol levels and 
also show pleiotropic effects including antiproliferative and apoptotic 
effects in several epithelial cancers. So far, it is not well known how statins 
can improve chemotherapeutic response and survival. The hENT1 is a 
transporter facilitating the entrance of Gemcitabine into cancer cells. This 
drug is one of the alternatives chosen to treat recurrent ovarian cancer. 
Objectives: Studying the effect of Simvastatin in hENT1 expression, 
transporter activity, and changes in sensitivity to Gemcitabine in ovarian 
cancer cells. Methods: The A2780 ovarian cancer cell line and primary 
tissue cultures established from ascites coming from advanced ovarian 
cancers were both treated with different concentrations of Simvastatin at 
different intervals. Upon Simvastatin incubation, mRNA hENT1 levels 
were determined by RT-PCR and its activity measured ENT-1 transport 
activity assay. Simvastatin effect on Gemcitabine sensitivity was addressed 
using 6h of statin or vehicle preincubation followed by 48h of drug 
exposure. Gemcitabine-mediated cell death was studied by MTS and 
apoptosis confirmed by detection of cleaved form of PARP by WB. Results: 
An increase in mRNA hENT1 levels was observed after 6h of Simvastatin 
treatment both in the A2780 cells as well as in the primary cultures. The 
maximum increase in ENT-1 activity was reached after 24h of Simvastatin 
incubation. A synergistic effect by the combination was observed in MTS 
assays and confirmed by fractional inhibition analysis. An increase in the 
cleaved form of PARP was also observed with this combination compared 
with each reagent used alone. Conclusions: Simvastatin increase hENT1 
expression and activity sensitizing ovarian cancer cells to gemcitabine-
mediated cell death. Changes in activity of certain transporters induced by 
statins could account for better response to chemotherapy in advanced 
ovarian cancer contributing to better survival. (Funded by FONDECYT 
1080163, 1060495 and 11080206)  
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The role of microglia, the resident macrophages of the brain, in brain tumor 
biology is not well understood. Despite their potent capability of killing 
tumor cells, microglia seem to support tumor growth rather than suppress it. 
Clinical data suggest that a higher grade of microglial infiltration into brain 
tumors correlates with worse prognosis. A better understanding of this 
tumor supporting phenotype of microglia and putative ways to stimulate 
microglia to recover anti-tumor properties could pave the way for new 
immunotherapeutical approaches. Here we report for the first time that 
human microglia, isolated from brain tumor specimen, secrete factors that 
support tumor migration in a 3D collagen invasion assay. On the other 
hand, a stimulation of human microglia with the TLR-3 agonist poly(I:C), 
but not with any other TLR agonist, leads to a phenotype that suppresses 
tumor cell growth, as shown by viability assays. Furthermore, this 
stimulation leads to the secretion of factors that exert a cytotoxic and an 
anti-migratory effect on tumor cells, as shown by 2D wound healing and 3D 
collagen invasion assays. In summary, these data show that human 
microglia isolated from tumor tissue have a tumor supporting phenotype 
that can be switched to a tumor killing phenotype by application of a proper 
stimulus. 
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Lymphoma and leukemia represent approximately 8% of cancer incidence 
in North America and Europe. Here we show that the transcriptional 
repressor protein Growth factor independent-1 (Gfi1) plays an important 
role in the initiation, maintenance and progression of lymphoid leukemia 
and lymphoma. Specifically, GFI1 expression is associated with Notch 
signaling in human T-ALL and collaborates with Notch to induce murine 
leukemia. In contrast, constitutive absence or inducible deletion of Gfi1 
significantly delayed or completely prevented the initiation of T-cell 
lymphoma in three independent experimental models, in which T-ALL was 
elicited either by a carcinogen (N-ethyl-N-nitrosourea (ENU)), by a non 
acute transforming retrovirus (MoMuLV) or by expressing a truncated 
Notch transgene (NotchΔCT) mimicking Notch mutations of human T-ALL 
cases. Furthermore, Gfi1 deletion is counter-selected during leukemia 
initiation in these models of T-ALL, when the Gfi1 alleles are conditionally 
deletable. Most striking is that Gfi1 is required for T-ALL maintenance 
such that inducible deletion of Gfi1 leads to tumor regression, which we 
could demonstrate by using ultrasound allowing us to follow growth and 
regression of T-cell lymphoma in mice. A similar observation was made 
using an Eμ-Myc lymphoma mouse model, in which tumors emerge that 
resemble human B-cell lymphoma. Mx-Cre, Eμ-Myc , Gfi1fl/fl mice were 
monitored for B-cell lymphoma development by ultrasound and once the 
lymphoma was detected, the Gfi1 gene was deleted by pIpC and a 
regression of the tumor could be observed by ultrasound. Moreover, we 
attempted to simulate a therapeutic regimen used for human leukemia 
patients in our lymphoma prone mice. We found that the ablation of Gfi1 
enhances the efficacy of a combination therapy including radiation and bone 
marrow transplantation by sensitizing tumor cells to p53-dependent 
apoptosis. This effect can be blocked by Bcl-2 and is very likely due to the 
function of Gfi1 as a repressor of the proapoptotic Bax gene. In conclusion, 
we have gathered data using several different leukemia mouse models that 
suggest that lymphoid leukemia and lymphoma are dependent on Gfi1 for 
survival and that Gfi1 may represent a promising therapeutic target 
structure for new treatments against lymphoid malignancies.* authors 
contributed equally 
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Pancreatic cancer is perhaps the most lethal form of cancer with low 5 year 
survival rate (<5%). Surgery and conventional chemotherapy have not led 
to any improvement in the dismal prognosis necessitating urgent efforts 
towards development of targeted therapy. DNA copy number alterations 
(CNAs) are the hallmark of solid tumors and have been suggested to harbor 
important oncogenes and tumor suppressor genes (TSGs). Previous studies 
from our laboratory and others have led to the identification of localized 
DNA amplifications and deletions from pancreatic cancer genomes and 
studies on a novel localized amplification at 18q11.2 led to the 
identification of GATA6 as a lineage specific oncogene in pancreatic 
cancer. In the current study, we report the identification and characterization 
of two novel TSGs viz. ARID1B and PARD6G located within two 
independent regions viz. 6q25.3 and 18q23 respectively, which are 
frequently deleted in pancreatic cancer.  
ARID1B is a member of the human ATP-dependent SWI/SNF chromatin 
remodeling complex, and PARD6G is a member of the epithelial cell 
polarity complex. ARID1B stable clones were generated in MiaPaCa2 
pancreatic cancer cell line (harboring a homozygous deletion of ARID1B). 
We first analyzed the ability of ARID1B stable clones to exhibit loss of 
contact inhibition and anchorage independence. There was a significant 
reduction in the number and size of colonies in ARID1B stable clones as 
compared to vector stable clones in liquid colony formation and soft agar 
colony formation assays, indicating that expression of ARID1B may reduce 
tumor-related characteristics in pancreatic cancer cell lines. 5-Aza2-
deoxycytidine treatment of pancreatic cancer cell lines SW1990, CFPAC-1 
and Panc10.05 (harboring single copy loss and low level of expression of 
ARID1B) and SW1990 and CFPAC-1 (harboring single copy loss and low 
level of expression of PARD6G), resulted in an increase in transcript level 
of both the genes in a dose dependent manner. A strong hypermethylated 
CpG island in the putative promoter region of ARID1B in CFPAC-1 and a 
partial methylated CpG island in the first intron of PARD6G in CFPAC-1 
and other cell lines were identified, suggesting thereby that ARID1B and 
PARD6G may be transcriptionally repressed through CpG island 
hypermethylation in pancreatic cancer cells. We also identified the correct 
ARID1B transcript isoform expressed in pancreatic cancer. In addition, a 
novel 6bp insertion mutation was identified in the promoter of PARD6G 
gene in CFPAC-1. Further experiments are currently underway to study 
tumor suppressor function of the two genes in relation to pancreatic cancer.  
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Recent genome-wide association studies (GWAS) have identified numerous 
common, inherited single nucleotide polymorphisms (SNPs) that influence 
an individual’s susceptibility to develop cancer. Despite these robust 
findings, no clear mechanism explains how these alleles confer a modest 
change in disease susceptibility. One such SNP, rs10993994, is located in 
the promoter of the gene β-microseminoprotein (MSMB), whose gene 
product (β-MSP) is one of the major secretory products of the prostate and 
which may have anti-tumor properties. We have shown that the risk allele 
(“T”) correlates with decreased levels of β-MSP in both the semen and 
serum of healthy young men. The risk allele at rs10993994 also correlates 
with increased levels of the prostate proteins PSA and hK2, in both younger 
and older men. We now show that the risk allele at rs10993994 is less able 
to drive promoter activity than the wild-type allele. The SNP appears to 
abrogate a CREB binding site, and only the promoter with the wild-type 
allele is sensitive to the action of forskolin. We conclude that the “T” allele 
at rs10993994 confers increased cancer susceptibility by destroying a 
CREB binding site, thereby resulting in decreased production of β-MSP. 
These data suggest that one mechanism by which a SNP can confer a 
modest change in cancer risk is by subtly altering expression levels of a 
gene with tumor suppressive properties. Current experiments are aimed at 
understanding how decreased levels of β-MSP promote tumorigenesis.  
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Although most superficial bladder cancers can be resectable transurethrally 
with an excellent prognosis, clinical outcome becomes much more 
problematic for patients who develop muscle-invasive disease. Indeed, 
invasive bladder cancer is a major clinical challenge since it is often 
associated with regional or distant metastasis, for which there is no effective 
treatment and, even if radical surgery is curative, it involves removal of the 
entire bladder, resulting in poor quality of life caused by urinary tract 
diversion. Clearly, there is a need for the identification of novel prevention 
and treatment paradigms for invasive bladder cancer; however, our limited 
understanding of the molecular mechanisms of bladder tumorigenesis has 
hampered the identification of new targets for therapuetic intervention.  
To investigate mechanisms of bladder tumorigenesis, we have developed a 
genetically-engineered mouse model of invasive bladder cancer based on 
the combinatorial deletion of p53 and Pten in bladder epithelium using an 
adenovirus expressing Cre recombinase (Adeno-Cre) delivered to the 
bladder lumen. p53 and PTEN are frequently inactivated in human bladder 
cancers especially those with poor prognosis. Additionally, carcinoma in-
situ (CIS) is often observed adjacent to invasive tumors in the mouse model. 
Collectively, these and other data indicate that our mouse model accurately 
recapitulates the progressive stages of human invasive bladder cancer. In 
our analyses of cancer mechanisms in these mice, we have found that 
expression of p19Arf is up-regulated in the p53; PTEN deficient mouse 
bladder tumors, which is consistent with the observed up-regulation of 
p14Arf in human invasive bladder cancers. We have found that depletion of 
p19Arf in primary cultures from the p53 and Pten deficient mouse bladder 
tumors resulted in suppression of tumor growth in cell recombination 
model, while overexpression of p14Arf with concomitant p53 and PTEN 
knock-down promoted tumor formation in Arf-null human bladder cancer 
cells. Furthermore, targeted deletion of Arf in the context of p53 and Pten 
deletion suppresses bladder tumor growth and promoted survival in the 
context of the mouse model in vivo. Our findings suggest that Arf has a 
context-dependent tumor-promoting role in bladder tumorigenesis.  
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Prostate cancer is the most common cancer and the second leading cause of 
cancer mortality for men in the United States with 192,280 new cases and 
27,360 deaths in 2009. Aberrant DNA methylation has been implicated in 
playing a role in tumorigenesis and cancer progression in many tissue types. 
In prostate, previous candidate-gene studies showed strikingly tumor-
specific DNA methylation changes at several promoter CpG-islands. In this 
study, we profiled DNA methylation at 27,578 promoter region CpG sites in 
95 prostate cancer samples and 86 healthy prostate samples. Analysis of 
these data suggests a large-scale change in DNA methylation across nearly 
one-third of all the assayed CpG sites. These data, combined with available 
clinical data, revealed novel candidates for diagnostic markers of prostate 
cancer as well as prognostic makers of aggressive tumors. 
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Oncogenic stimuli, such as a constitutively active form of H-Ras (H-
RasV12), induce oncogene-induced senescence (OIS) in normal cells in 
order to protect cells against transformation. In this study, we show that a 
population of the human diploid fibroblasts is resistant to H-Ras-induced 
senescence and escapes OIS defense mechanism. We designated these OIS-
escaped cells as OISECs (oncogene-induced senescence escaped cells) and 
investigated the character of OISECs. OISECs did not exhibit any 
tumorgenic activity in vivo. By re-introduction of H-RasV12, OIS or stress-
induced premature senescence could be induced in OISECs. Further 
introduction of SV40 early region induced transformation of OISECs with 
weak potential of tumorigenisity in vivo. Although frequent aneuploidy was 
observed in H-Ras-transformed fibroblasts, stable ploidy of OISECs may 
contribute to their limited transforming activity. These results suggest that a 
population of the cells can escape from OIS and such cells are ready to 
transformation by additional oncogenic stimulation, however, stable ploidy 
of OISECs or accumulation of DNA damages suppresses their transforming 
activity. 
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Myc oncoproteins are transcription factors that regulate multiple cellular 
functions, including proliferation and apoptosis. A tight control of Myc 
levels is therefore essential for sustaining cellular and organismal 
homeostasis. Mechanisms that stabilize Myc in response to growth factor-
dependent signals, e.g. via the MAPK and PI3K pathways, have been 
identified. However, downregulation of Myc expression in response to 
stress signals allows cells to cease proliferation and escape apoptosis but the 
mechanisms involved in this process are poorly understood.  
To identify novel mechanisms that regulate Myc at a posttranscriptional 
level, we have used immunofluorescence based high-content siRNA 
screening of the human kinome. We identified the MAP kinase activated 
protein kinase MK5 (MAPKAPK5, PRAK) as a negative regulator of Myc 
expression. MK5 regulates translation of Myc, since it is required for 
expression of miR-34b and miR-34c, that bind to the 3'-UTR of MYC. 
Although p53 is a known inducer of the miR-34 family of miRNAs, MK5 
regulates Myc translation in a p53-independent manner. MK5 activates 
miR-34b/c expression via phosphorylation of the transcription factor 
FoxO3a at multiple serine residues, thereby promoting nuclear localisation 
of FoxO3a. It enables FoxO3a to bind to the miR-34b/c promoter, induce 
their expression and arrest proliferation. Conversely, expression of MK5 is 
directly activated by Myc, forming a negative feedback loop. 
Immunohistochemical stainings reveal that MK5 is expressed in normal 
colon mucosa, but downregulated in poorly differentiated colorectal 
adenocarcinomas, reciprocal to the expression profile of Myc. Our data 
identify a novel MK5/FoxO/miR-34/Myc feedback loop that is disrupted 
during colorectal tumorigenesis. 
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Aberrant DNA methylation in gene promoters causes gene silencing and is 
a common event in prostate cancer development and progression. While 
commonly identified methylated genes have been analyzed for their 
potential clinical utility, few studies have attempted a genome-wide 
methylation approach to discover new and possibly improved biomarkers. 
We have investigated the methylation profile of approximately 28,000 CpG 
islands in prostate cancer to uncover methylated DNA loci that can better 
serve as diagnostic and prognostic markers.  
In order to identify DNA methylation changes associated with aggressive 
prostate cancer, we have performed a genome-wide analysis of 39 prostate 
cancers using Agilent human CpG island microarrays. We have verified the 
array methylation profiles using EpiTYPER mass spectrometry analysis and 
have validated candidate genes using quantitative MethyLight technology in 
an independent series of 214 cancers. The resulting methylation profiles 
were compared with clinicopathological paramaters.  
We discovered previously unidentified methylation of HOXD3, TGFβ2, 
HOXD8 and CRIP3 as potential prognostic biomarkers. Within the 
independent cohort, we observed a greater proportion of cases with high 
methylation (HM) in GS 7 versus GS ≤ 6 cancers for HOXD3, HOXD8 and 
CRIP3 (chi-squared p-values = 0.001, 0.032 and <0.001, respectively). 
There were also significant increases in methylation from Gleason pattern 3 
to 4/5 for both HOXD3 and CRIP3 (Mann-Whitney p-values < 0.001). 
Furthermore, a combination of TGFβ2, HOXD8 and CRIP3 HM was 
significant in predicting biochemical recurrence in univariate analysis (p-
value = 0.002) and multivariate analysis (p-value = 0.034). In order to 
determine the consequence of these specific methylation events in prostate 
cancer, we analyzed the expression level of HOXD3 in fresh frozen tumors 
and discovered HOXD3 methylation and overexpression as compared to 
normal tissue. The cause of the paradoxical relationship between 
methylation and overexpression for HOXD3 is currently being explored.  
These results indicate that a panel of novel DNA methylation markers 
including HOXD3, TGFβ2, HOXD8 and CRIP3 distinguish low grade 
prostate cancers from intermediate and high grade ones, and methylation of 
these genes in combination can predict poor clinical outcome.  
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Mps1, a dual-specificity kinase, is required for the proper functioning of the 
spindle assembly checkpoint and the maintenance of chromosomal stability. 
As Mps1 function has been implicated in numerous phases of the cell cycle, 
it is expected the development of a potent, selective small molecule 
inhibitor of Mps1 would greatly facilitate dissection of Mps1-related 
biology. We describe the cellular effects and Mps1 co-crystal structures of 
novel, selective small molecule inhibitors of Mps1. Consistent with RNAi 
studies, chemical inhibition of Mps1 leads to defects in Mad1 and Mad2 
establishment at unattached kinetochores, decreased Aurora B kinase 
activity, premature mitotic exit, and gross aneuploidy, without any evidence 
of centrosome duplication defects. However, in U2OS cells possessing extra 
centrosomes, an abnormality found in some cancers, Mps1 inhibition 
increases the frequency of multipolar mitoses. Lastly, Mps1 inhibitor 
treatment resulted in a decrease in cancer cell viability. 
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Cell migration is a critical step in tumor invasion and metastasis, being the 
mechanisms underlying this process extensively studied with the aim to 
develop proper therapies for treating cancer. Directed cell motility requires 
the coordinate reorganization of both actin cytoskeleton and microtubules 
(MTs) in order to promote membrane protrusions, adhesion turnover and 
traction forces. The regulation of microtubule dynamics by post-
translational modifications of tubulin subunits is crucial for different MT-
based responses. In particular, control of acetylation levels in α-tubulin by 
the class III deacetylase enzyme HDAC6 has a functional impact in cell 
motility and cellular spreading. HDAC6 over-expression enhances invasive 
motility and a wide range of HDAC6 specific inhibitors have being studied 
as potential anticancer-drugs, but how the activity of such tubulin modifier 
is regulated in response to different signaling inputs remains to be 
determined.  
 
We have identified the G protein-coupled receptor kinase GRK2 as a new 
regulator of HDAC6-mediated functions. This serine-threonine kinase is a 
well-known negative modulator of the G protein-coupled receptor (GPCR) 
activity that also interacts with a variety of non-GPCR “transducing” 
proteins, contributing to signal propagation. GRK2 binds to and 
phosphorylates HDAC6 in vitro, increasing its ability to deacetylate α-
tubulin, while the presence of kinase-defective mutants towards HDAC6 
increases the cellular levels of acetylated tubulin in the lamelipodium. 
Accordingly, GRK2 co-localization with HDAC6 is detected at the leading 
edge of migratory cells in wound-healing assays. Moreover, increased 
tubulin acetylation in Hela cells caused by an impaired GRK2-dependent 
phosphorylation of HDAC6 correlates with a higher rate of membrane 
extension during early spreading, a process that is modulated by MT 
dynamics. These results predict that alterations in GRK levels and/or 
activity, as those reported in inflammatory or tumoral contexts may have 
important effects on cell motility by altering the acetylation state of tubulin 
and perhaps of other HDAC6 substrates related to migration.  
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For a long time it has been known that tumor suppressor p53 has an 
important limiting role in cellular transformation. In addition, inactivation 
of p53 is frequently found from different kind of cancer types. Nowadays, 
tumor suppression by reactivation of p53 is in intense focus of drug 
development. In our study, we propose that recently discovered oncogene, 
CIP2A, has a critical role in p53-mediated tumor suppression. 
CIP2A (Cancerous Inhibitor of PP2A) inhibits activity of Protein 
phosphatase 2A in human malignancies. We have demonstrated that CIP2A 
is required for the malignant cellular growth, for in vivo tumor formation 
and that it is overexpressed in common human malignancies, such as breast 
cancer (Junttila et al. 2007, Come et al. 2009, Khanna et al. 2009). 
Importantly, overexpression of CIP2A in human immortalized cells results 
in cellular transformation (Junttila et al. 2007). According to our published 
results high CIP2A mRNA expression is associated with p53 mutation 
status in human breast tumors (Come et al. 2009). In addition, p53 
reactivation negatively regulates CIP2A expression in breast cancer cells. 
Also, we show that CIP2A downregulation is necessary for p53 
reactivation-induced tumor suppression in breast cancer cells in vitro. Data 
about the functional relevance of p53-mediated regulation of CIP2A will be 
presented at the meeting “Mechanisms & Models of Cancer”. Overall, our 
study reveals a novel mechanism for p53-mediated tumor suppression. 
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Gliomas are a class of brain tumors arising from glial cells, especially from 
astrocytes. The mean life expectancy of high-grade glioma patients has 
risen from 12 to only 15 months during the past two decades despite of 
numerous studies on more effective treatments. Therefore it is essential to 
clarify the mechanisms of the growth and invasion of these tumors and to 
develop new treatment strategies. 
Using phage display method, we have identified a peptide (CooP) that 
effectively and selectively homes to the co-opted vessels in murine 
orthotopic glioma models. We have also identified the receptor for CooP 
(CooP-receptor, CooPR) using the yeast two-hybrid screen. We have 
generated a breast cancer (MDA-MB-231) cell line stably expressing  143, 
respectively, 143 vs. 378 mm3 CooPR, and implanted these cells 
subcutaneously to nude mice. Expression of CooPR resulted in accelerated 
tumor growth compared to the parental MDA-MB-231 tumors (603 mm3  
p<0,8; p 0,6 vs. 2,7 % 0,05). Histological analyses of the tumors showed 
that CooPR expression reduced the relative area of blood vessels in tumors 
compared to the parental tumors (1,2 % <0,05). 
Our protein analyses showed upregulation of vasculature-associated 
proteins in the CooPR expressing tumors. These include α smooth muscle 
actin (SMA) and integrin α v (CD51). SMA is expressed in the smooth 
muscle cells and pericytes of the blood vasculature. CD51 links cells to 
neighbouring cells and is highly upregulated in the angiogenic vasculature. 
Its expression has also been linked to the invasiveness in various 
carcinomas, including high-grade gliomas. Expression of both SMA and 
CD51 was associated with the vasculature in the parental MDA-MB-231 
tumors, while in the CooPR expressing tumors also the tumor cells 
expressed them at high levels. Intriguingly, our preliminary data indicate 
that tumors arising from the CooPR expressing cells were more metastatic 
than the parental tumors. We have now created human U87MG glioma cells 
stably expressing CooPR to study the effect of CooPR expression on the 
growth and infiltration of intracranial tumors. 
In order to study the potential of our peptide in targeted drug delivery we 
conjugated the CooP-peptide to a cell-penetrating peptide and 
Chlorambucil. When we used this compound to treat mice with intracranial 
gliomas, we were able to significantly prolong the lifespan of mice 
compared to the control animals treated with only Chlorambucil. 
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The drugs al trans retinoic acid (ATRA) and arsenic trioxide (ATO) are 
being used in the clinic to cure the cancer acute promyelocytic leukemia 
(APL). Both of these components induce complete remission of the disease 
through a mechanism that involves targeted degradation of the APL 
associated fusion oncoprotein PML/RARA. Recent publications have 
revealed that ATO initiates degradation of PML and PML/RARA by 
contacting a zinc-binding motif present within the PML protein. This 
interaction leads to modification of PML by the small ubiquitin-like 
modifier (SUMO) that subsequently causes poly-ubiquitination by the 
ubiquitin ligase RNF4 and degradation by the proteasome. In the present 
study we have used biochemical analysis and live cell imaging of cells 
expressing EYFP-tagged PML to study the fate of PML in ATO-treated 
cells. We find that ATO-induced SUMO conjugates become effectively 
removed from the PML protein by SUMO proteases during entry of cells 
into mitosis. This leads to accumulation of un-degraded PML as stable 
cytoplasmic aggregates that are refractory to further ATO induced 
proteolysis. Consequently, we observe a more effective PML and 
PML/RARA eradication by ATO in cells that are prevented from 
undergoing mitotic cell division. Our data may, in part, explain the synergy 
effect observed between ATO and drugs that cause reduced cell 
proliferation. 
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The phenomenon of multi drug resistance (MDR) of tumor cells is a well 
known problem in oncology. One of the underlying molecular rationales for 
MDR is the up-regulation of a family of MDR transporter proteins that belong 
to the family of ATP binding cassette (ABC) proteins and cause chemotherapy 
resistance in cancer by actively extruding a large variety of therapeutic 
compounds from the malignant cells. The three major multidrug resistance ABC 
proteins are MDR1 (P-glycoprotein, ABCB1), MRP1 (ABCC1) and BCRP 
(ABCG2, MXR).  
Because of a significant role that ABC transporters play in cancer multidrug 
resistance and the body’s protection against xenobiotics, sensitive and specific 
quantitative assays are required for the detection of the activity of these 
proteins. Functional activity of these proteins may not correlate with their 
expression levels detected by classical methods, such as Northern blotting, 
RNA in situ hybridization, RT PCR or immunostaining. Expression levels can 
be below the detection threshold of some techniques, as relatively few active 
transporter molecules can cause major alterations in drug transport.  
To characterize the actual function expression levels of ABC transporters the 
cellular uptake of a number of fluorescent substrates can be measured using 
flow or fluorescence microplate-based cytometry. Typically, live cells are 
loaded with the MDR probe in the presence or absence of inhibitors. Cells with 
increased ABC transporter activity demonstrate lower fluorescence in the 
absence of the specific efflux inhibitors. Increased fluorescent signal in the 
presence of any of the specific inhibitors indicates activity of the corresponding 
transporter protein. Most dyes used as indicators (Rho123, DiOC2(3), Calcein-
AM) have limited applicability as they do not detect the three major types of 
ABC transporters at once. Dyes with broad specificity (such as doxorubicin or 
mitoxantrone) lack sensitivity due to overall dimness and may yield a 
significant percentage of false negative results. We developed two fluorescent 
probes that are substrates for all three common types of ABC transporters and 
can serve as indicators of MDR in flow or fluorescence microplate-based 
cytometry assays using live cells. The probes demonstrate fast internalization, 
favorable uptake/efflux kinetics and high sensitivity of MDR detection. Used in 
combination with general or specific inhibitors of ABC transporters, both dyes 
readily identify functional efflux and can detect small degrees of efflux as well 
as define the type of multidrug resistance. The assay may be applicable to the 
screening of putative modulators of MDR-ABC transporters. The described 
assay workflow facilitates rapid, reproducible, specific and relatively simple 
functional detection of ABC transporter activity, high-volume specimen 
throughput and can readily be implemented on widely available 
instrumentation.  
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Cyclin D1, a bona fide oncogene, is frequently over-expressed in human 
cancer through impaired proteolysis. The SCFFbx4 E3 ligase catalyzes 
ubiquitylation and subsequent degradation of cyclin D1 following the G1/S 
transition. GSK3β contributes directly to this regulation through both 
phosphorylation of cyclin D1 on T286 to generate a phospho-degron and 
through phosphorylation of Fbx4. GSK3β-dependent phosphorylation of 
Fbx4 on S12 increases SCFFbx4 activity by facilitating dimerization. 
Missense mutation of S12 in Fbx4 impairs SCFFbx4 activity; the presence of 
such mutations in human cancer suggest that impaired Fbx4 function 
contributes to tumorigenesis. However, a mechanistic understanding of 
SCFFbx4 activation remains incomplete. We have identified 14-3-3ε as a 
novel regulator of SCFFbx4 dimerization and activity. Phosphorylation of 
S12 creates a 14-3-3ε binding motif in Fbx4. Cancer derived mutations that 
inhibit S12 phosphorylation or target serine 8 directly interfere with 14-3-3ε 
binding and Fbx4 dimerization. Data to be presented demonstrate that 14-3-
3 binding increases Fbx4 dimerization. Inhibition of the Fbx4 S12 kinase 
GSK3B also inhibits 14-3-3ε-Fbx4 binding. The association of Fbx4 with 
14-3-3ε is maximal in the S-phase of the cell cycle, coinciding with the 
peak of GSK3β-dependent Fbx4 phosphorylation and cyclin D1 
degradation. 14-3-3ε enhances SCFFbx4 ubiquitylation of cyclin D1 in vitro 
and in vivo and loss of 14-3-3ε leads to cyclin D1 stabilization. 
Reconstitution of Fbx4 in human esophageal carcinoma cell lines harboring 
inactive Fbx4 leads to the inhibition of cell growth in soft agar, providing 
evidence for the SCFFbx4-cyclin D1 pathway as a potential therapeutic target 
in human cancer. 
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PURPOSE: This study aimed to assess the quantitative methylation levels 
of the promoter region of the Dkk3 gene in human uterine cervical 
carcinoma and determine potential clinical correlations.  
EXPERIMENTAL DESIGN: Sixty-two patients with primary uterine 
cervical carcinoma and 13 patients with uterine leiomyoma, used as normal 
controls were included in this study if frozen tissues were available for 
further investigation. Quantitative metylation levels were evaluated by 
pyrosequencing after bisulfite treatment. Clinical and pathological findings 
were obtained from the medical records. Correlation or t-test statistics were 
used to analyze the relationship between the methylation levels and the 
clinical features. Survival data were estimated using Kaplan-Meier 
estimates and compared with the log-rank test where indicated. Multivariate 
analysis was performed using the Cox-regression method. Classification 
performance, using the adaBoost M1 algorithm in the Weka data mining 
program was used to estimate the recurrence-prediction value.  
RESULTS: Pyrosequencing analysis showed that the methylation level of 
four out of five CpG positions were aberrantly and strongly methylated in 
the cervical carcinoma compared to the normal cervical tissue samples 
(P<0.005). The methylation in positions 1 and 2 were stronger in patients 
with higher serum levels of the SCC tumor marker and larger tumors. The 
patients with a methylation level above 26.28% at position 1 had a lower 
survival rate than the patients with methylation levels at position 1 that were 
below 26.28%. The accuracy of the methylation levels at the five CpG sites 
for the prediction of disease recurrence in patients with cervical cancer was 
estimated to be 78.3%.  
CONCLUSIONS: The results of this study defined a threshold level of 
methylation associated with recurrence-free survival. In addition, the 
findings suggest that the quantitative methylation levels may aid in the 
prediction of disease recurrence in patients with cervical cancer with an 
accuracy of 78.3%.  
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Ovarian cancer (OC) is the leading cause of gynecologic cancer-related 
mortality in the United States. Currently, standard primary therapy for advanced 
disease involves the combination of maximal cytoreductive surgery and 
chemotherapy with Carboplatin plus Paclitaxel or with Carboplatin alone. 
Despite high initial response rates, a large proportion of patients relapse, 
resulting in a therapeutic challenge.  
Gemcitabine (2',2'-difluorodeoxycytidine) is one of the most actively 
investigated drugs in OC. Carboplatin-Gemcitabine doublet is an important 
therapeutic option for patients with both previously treated and untreated OC. 
Many molecular mechanisms have been proposed to be involved in GEM 
sensitivity/resistance including the Equilibrative Nucleoside Transporter-1 
(hENT1). 
Equilibrative Nucleoside Transporters (ENTs) are facilitative nucleoside 
transporters. ENTs play a key role in physiology and pharmacology by the 
modulation of nucleoside concentration and nucleoside analog availability such 
as anticancer and antiviral agents. The observation that hENT1 expression is an 
indication of anti-cancer therapy success makes ENTs an important target for 
study to improve anti-cancer therapy and drug effectiveness, specially the study 
of hENT1 activity and expression regulation. It is currently unknown how 
several parameters or treatments modulate the activity or expression of these 
transporters affecting cell proliferation and most importantly chemotherapy 
success with nucleoside analogs. 
Using ovarian-derived tumor cell lines, A2780 (Cisplatin sensitive) and SKOV3 
(Cisplatin resistant), we investigated the effects of Cisplatin on hENT1 
expression and transport activity. Cisplatin increases hENT1 expression and 
hENT1-dependent nucleoside uptake in both cell lines. Under these conditions 
several kinases were activated such as JNK, ERK and Akt, however only a 
potent PI3K inhibitor, blocked the Cisplatin effects on hENT1 activity and 
expression, strongly suggesting the involvement of PI3K-Akt pathway. On the 
other hand, MTT assays showed an increase in cell death when cells were 
incubated with the combination of Cisplatin and Gemcitabine.  
In summary we show that Cisplatin induces hENT1 expression and transport 
activity in A2780 and SKOV3 cells, probably through the PI3K-Akt pathway 
sensitizing to Gemcitabine-induced cell death.  
 
 
Research funded by FONDECYT 11080206 (AL), 1080163 (MC) and 
11085015 (BN) 
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Activating mutations of the protein kinase BRAF are a major cause of 
melanoma, a disease for which currently available therapeutics show little 
clinical benefit. A large proportion of BRAF mutant melanomas are highly 
dependent on BRAF and the MEK signalling pathway. The novel BRAF 
inhibitor PLX4032 has shown promising results in clinical trials, however, 
there are already indications of serious side effects and drug resistance. An 
alternative to the clinical targeting of mutant BRAF or its downstream 
effectors is to inhibit genes that are essential specifically in the context of 
this mutation. An effective way to screen for such genes is based on the 
principle of synthetic lethality, whereby only a combination of two 
perturbations, but not each individual one, causes loss of fitness. 
We have performed an siRNA screen to identify synthetic lethal partners of 
oncogenic BRAF. We used a genetically defined cell system, which was 
based on immortalized fibroblasts expressing oncogenic BRAFE600. The 
screen was performed in a single well format with the Dharmacon kinome 
library. After hit selection and several rounds of validation, we identified 28 
genes whose knockdown by at least two independent siRNAs selectively 
impaired the proliferation or viability of BRAFE600-expressing cells.  
We subsequently set out to confirm the synthetic lethal relationship using 
shRNA-expressing lentiviral vectors, in the same cell system. We identified 
a number of genes for which at least three non-overlapping shRNAs gave 
rise to toxicity only selectively in the context of oncogenic BRAFE600. For 
two of these genes, we have demonstrated that the ability of the shRNAs to 
diminish cell viability is associated with efficient downregulation of the 
genes they targeted.  
Currently, we are studying the effect of the depletion of these two genes in 
multiple melanoma cell lines, in order to determine whether the requirement 
for these genes is specific to BRAFE600-expressing melanoma cells. 
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BRCA1-IRIS, a 1399 residue product of alternative splicing of the BRCA1 
gene locus, is a proliferation-stimulating, chromatin-associated polypeptide 
when normally expressed. In this context, it interacts with the replication 
initiation regulator, geminin, the outcome of which is facilitated origin 
firing and normal S phase passage timing (ElShamy and Livingston, 2004). 
When BRCA1-IRIS is overexpressed, cells progress too rapidly through S 
phase, and the opposite phenotype develops when it is depleted from cells. 
BRCA1-IRIS does not appear to colocalize in nuclear foci with BRCA1-
p220, the primary DNA damage repair and breast/ovarian cancer 
suppressing product of the gene, and BRCA1-p220 lacks the S phase 
progression function of BRCA1-IRIS. BRCA1-IRIS is also overexpressed 
in multiple, established human breast cancer cell lines (ElShamy and 
Livingston, 2004). Moreover, using qRT-PCR, we have recently detected 
significant overexpression of BRCA1-IRIS mRNA, by comparison with its 
expression in normal mammary tissue, in 28% of 78 sporadic human breast 
cancers. Where tested, the most highly mRNA-overexpressing tumors also 
overexpressed the protein, as detected by Western blotting. When 
ectopically overproduced in primary human mammary epithelial cells, 
BRCA1-IRIS stimulated the RNA and protein expression of two, breast 
cancer-associated proteins, Her2 and cortactin, the former of which is a 
known breast cancer oncoprotein. In this setting, BRCA1-IRIS was detected 
by ChIP at a specific segment of the ErbB2 promoter. Also induced were 
abnormal mammary acinus formation and certain aspects of a neoplastic 
phenotype, including an epithelial to mesenchymal transition, membrane 
invasion, and hypermobility. Specific RNAi-driven depletion of 
endogenous, naturally overexpressed BRCA1-IRIS from certain breast 
cancer cell lines led to decreased expression of Her2 and cortactin and to 
marked suppression of anchorage-independent growth but no major effect 
on colony formation on a plastic surface. Taken together, our results 
indicate that, although it is the product of an established tumor-suppressing 
locus, BRCA1-IRIS is not infrequently overproduced in breast cancers and, 
when sufficiently overproduced, it can function like a transforming protein. 
 
Reference 
ElShamy, W.M., and Livingston, D.M. (2004). Identification of BRCA1-IRIS, a 
BRCA1 locus product. Nat. Cell Biol. 6, 954-967. 
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Kinases play key roles in the regulation of many cellular processes and are 
postulated to participate in the development of metastatic capability. To test 
the role of kinases in tumor progression, we compared matched pairs of 
non-metastatic and metastatic tumor cells, a commonly used model, to 
study the cellular changes that accompany metastasis. As such, we 
performed arrayed shRNA screens to determine how kinase requirements 
for survival and proliferation varied between pairs of non-metastatic and 
metastatic cell lines. These screens revealed patterns of kinase requirements 
among 4 pairs of cell lines. Of particular interest, we identified a set of 
kinases that were essential predominately for metastatic cells, including c-
Met. In vivo metastatic experiments are underway to evaluate which kinases 
can promote metastasis when ectopically expressed in otherwise non-
metastatic cells. Since inhibition of these kinases phenocopied c-Met 
inhibition, we also sought to test if any of these kinases are functionally 
linked to c-Met signaling. Indeed, several of the identified kinases, 
including PRKCZ, became essential when immortalized melanocytes were 
made tumorigenic and metastatic by introduction of activated c-Met. 
Biochemical and genetic rescue experiments are currently ongoing to 
further examine the links between these genes and c-Met. These studies 
offer new insights into the cellular signaling pathways operating in 
metastatic cancer cells and also suggest potential targets to treat metastatic 
cancers. 
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In stem cells, the switch from proliferation to differentiation is a highly 
coordinated event where cell cycle regulators play indispensible roles. Self-
renewing neural stem cells typically remodel their cell cycle structure such 
that the length of G1 is extended as they gradually adopt more committed 
cell fates. Recent studies have assigned novel functions to components of 
the cell cycle machinery in the control of neurogenesis that are independent 
of their role in regulating cell cycle progression. This represents an effective 
way to concurrently initiate multiple processes so as to achieve a common 
desired effect. In view of the importance of Cdk2 and Cdk4 in G1/S 
transition, we sought to determine if they possess additional abilities to 
modify critical components required for stem cell maintenance such that 
when their activities are down-regulated during differentiation, the 
modification, and thus stem cell identity, is gradually lost. Cdk2 and Cdk4 
double knockout neural stem cells were isolated from the telencephalon of 
E13.5 embryos and expanded in vitro as neurospheres. As expected, the 
neurospheres that lack Cdk2 and Cdk4 had a significantly lengthened G1 
phase and differentiated into the neurons and astrocytes without problems. 
However, the DKO were more prone to spontaneous neuronal 
differentiation. More importantly, we found that a transcription factor 
necessary for the maintenance of the undifferentiated state in stem cells was 
directly modified in the absence of Cdk2 and Cdk4. We therefore 
hypothesize that Cdk2 and/or Cdk4 regulate the decision of stem cells to 
self-renew or to differentiate. 
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MLN4924, an anti-cancer drug currently in clinical trials, is effective at 
inhibiting the proliferation of various human cancer cell lines. MLN4924 
inhibits the NEDD8 pathway and consequently increases the abundance of 
substrates of cullin-RING E3 ubiquitin ligases whose activity is dependent 
on NEDD8 modification. Here we show that the stabilization of Cdt1 in S 
phase is the key step in the induction of DNA re-replication by MLN4924. 
Significantly, short-exposure of the human colon cancer HCT116 cells to 
MLN4924 is sufficient to induce DNA re-replication and activate both 
apoptosis and senescence pathways. MLN4924-induced cell senescence is 
inhibited, but not prevented, in cells lacking the tumor suppressor p53 or its 
downstream effecter the CDK inhibitor p21Waf1. Despite this, p53-/- and p21-
/- HCT116 cells are more susceptible to growth inhibition by MLN4924 
than wild-type HCT116 cells, suggesting that apoptosis, and not 
senescence, is more important for decreasing cell numbers by MLN4924 
and showing the utility of the investigational drug on p53- and p53+ cancer 
cells. 
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Vav3 is a Rho GTPase guanine nucleotide exchange factor. Using tissue 
array immunostaining, we found that Vav3 expression was significantly 
increased during the progression of prostate cancer. The purpose of our 
study is to investigate the role of Vav3 in the prostate cancer metastasis. We 
showed that Vav3 expression was increased in androgen independent 
prostate cancer cells (LNCaP C4-2, DU145, and PC3) when compared with 
androgen dependent prostate cancer cells (LNCaP). Cells with increased 
Vav3 expression showed higher migration and invasion ability. 
Overexpression of Vav3 in LNCaP cells increased its migration and 
invasion ability, mainly through Rac1 activation. Vav3 was tyrosine 
phosphorylated upon activation of EphA2 by its cognate ligand, ephrinA1-
Fc, suggesting ephrinA as a potential stimulus for Vav3 activation in 
LNCaP and PC3 cells. Knocking down Vav3 expression in PC3 cells leads 
to decreased Rac1 activity, as well as migration and invasion ability of the 
cells. Furthermore, mRNA levels in some MMPs, especially MMP3, 7, and 
13, were reduced when reducing Vav3 expression in PC3 cells. Overall, our 
data provide evidence suggesting the involvement of Vav3 in migration and 
invasion of prostate cancer cells, via EphA2-Vav3-Rac1 signaling axis. The 
role of Vav3 in metastasis of prostate cancer is being tested in nude mice 
model using orthotropic implantation. 
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TGFβ2 is highly expressed in a variety of different cancer cell lines. Using 
Z12 cells, a mutant of 293 cells with overexpression of TGFβ2, we found 
that the cAMP-responsive element (CRE) sequence in the promoter of the 
TGFβ2 gene is crucial for its increased expression. Furthermore, 
constitutive phosphorylation of cAMP-responsive element binding protein 
(CREB) is increased in these cells. Treating Z12 cells with either the PI3 
kinase inhibitor LY294002 or the p38 MAPK inhibitor SB203580 
significantly inhibited both the phosphorylation of CREB and the 
expression of TGFβ2. In addition, treating Z12 or cancer cell lines with 
either of these two inhibitors significantly decreased their secretion of 
TGFβ2. These data suggest that activated PI3 kinase and p38 MAPK play 
an important role in the high expression of TGFβ2 in cancer cells by 
stimulating the phosphorylation of CREB, which activates the CRE element 
in the promoter of the TGFβ2 gene. We have identified an important link 
between PI3 kinase, p38 MAPK and TGFβ2, providing an additional 
rationale for using inhibitors of these kinases as therapeutic drugs in cancer. 
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Our laboratories have been investigating novel mechanisms of cancer 
progression, as well as new therapeutic approaches for early intervention 
and treatment of advanced disease by integrating analyses of human clinical 
data with molecular and functional studies of genetically engineered mutant 
(GEM) mice. In our analyses of prostate cancer, we have generated GEM 
mice that recapitulate the entire spectrum of disease progression from pre-
invasive lesions, termed PIN, to castration-resistant and metastatic disease, 
which are the lethal forms of prostate cancer. By comparative analyses of 
large-scale gene expression profiling data for mouse and human prostate 
cancer, we have been assembling molecular networks, called interactomes, 
to elucidate conserved cancer pathways and new druggable targets, and we 
have been evaluating the potential therapeutic relevance of these targets by 
pursuing preclinical studies in the GEM mice. For example, we have found 
that combinatorial inhibition of the Akt/mTOR and MAP kinase two 
signaling pathways, which are often co-activated in human prostate cancer, 
inhibits castration resistant prostate tumor growth, improves survival and 
inhibits metastases in preclinical studies in GEM mice. We are now 
translating these findings from GEM mice to human clinical trials.  
In our analyses of bladder cancer, we have generated GEM mice that 
develop pre-invasive phenotypes, termed CIS, which progress to invasive 
bladder cancer. Analyses of these GEM mice have revealed a critical role 
for ARF in bladder tumorigenesis, as well as the therapeutic benefit of 
inhibiting mTOR signaling for both prevention and treatment of invasive 
bladder tumors. In summary, our investigations of prostate and bladder 
cancer in GEM mice have revealed promising new molecular targets and 
new therapuetic approaches for the treatment of human cancer.  
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Inactivation of the p53 pathway is a common feature of human 
tumorigenesis and has fostered the attractive notion that restoring p53 
function in established tumors would constitute an effective and tumor-
specific therapeutic strategy. Indeed, p53 restoration was recently shown to 
trigger dramatic tumor regression in distinct (oncogene overexpresion-
driven) murine tumor models. However, recent data suggest that low-levels 
of oncogenic stress may be sufficient to initiate tumorigenesis but unable to 
induce a p53-mediated response, emphasizing the need for a better 
functional characterization of this potential therapeutic target during tumor 
evolution. To achieve this we carried out a comprehensive analysis of the 
timing and mechanisms of p53 activation during the evolution of non-small 
cell lung carcinoma (NSCLC). NSCLC is the leading cause of cancer-
related death worldwide, with an overall 5-year survival rate of only 10-
15%. Kras activation and p53 mutations are frequently found NSCLC. To 
define the nature and timing of p53 activation during NSCLC evolution we 
crossed the LoxStopLox-KrasG12D (KR) mouse model to our switchable 
p53 knock-in (KI) model and restored p53 function during distinct stages of 
NSCLC development in KR;p53KI/KI animals. Unexpectedly, p53 
restoration failed to induce tumor clearance but effectively targeted high- 
(but not low-) grade lung tumors, leading to a significant decrease in the 
frequency of high-grade lesions. This tumor stage specific activation of p53 
resulted from selective induction of its activator p19ARF in high-grade 
tumors. Furthermore, we show that the p19ARF/p53 axis is activated in 
response to increased oncogenic stress, as malignant progression is 
accompanied by an increase in phosphorylated-ERK levels and Kras copy 
number imbalance. Taken together, our data show that p53 restoration is 
able to cull the most malignant cells within a tumor, but allows for less 
aggressive cell populations driven by low-level oncogenic signals to 
survive. These data have major therapeutic implications as they indicate that 
at least in this tumor type, p53 restoration would be a means of tumor 
containment rather than eradication. The potential mechanisms of p53 
activation in other tumor types will also be discussed. 
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RNA interference is a powerful tool for controlling gene expression in 
mammalian systems; as such, it has become an effective alternative to 
conventional knockout approaches. RNAi has proven to be an efficient 
method to inhibit tumor suppressor gene function and yield insight into the 
important players in cancer biology. Still, the promise of regulatable RNAi 
transgenic mice has yet to be realized because the reproducible generation 
of these animals remains a significant technical limitation. By combining 
optimized fluorescence-coupled mir30-based shRNA technology with high 
efficiency ES cell targeting, we developed a flexible and scalable pipeline 
for the rapid and reliable production of doxycycline-regulated shRNA 
transgenic mice. These RNAi mice contain single copy DOX-regulatable 
shRNAs downstream of the endogenous Collagen Type 1 locus, allowing 
for spatial, temporal and reversible gene expression in mice. Using this 
platform, we generated novel DOX-regulated shRNA transgenic lines 
targeting the bioluminescence reporter Luciferase and endogenous tumor 
suppressor genes, including Trp53, INK4a and ARF, each showing strong 
doxycycline-dependent knockdown of its target protein, without disrupting 
processing of endogenous miRNAs. To study the role of these TSGs in the 
maintenance of KrasG12D driven lung adenocarcinomas, we crossed these to 
produce mice bearing an shRNA, CCSP-rtTA (clara cell specific promoter - 
reverse tet-transactivator), LSL-KrasG12D and LSL-Luciferase alleles. 
However, owing to the slow rate and high expense of producing quadruple 
transgenic mice, we later devised a strategy for “speedy” mouse model 
production. This approach entailed re-derivation of embryonic stem cells 
harboring the relevant alleles and subsequent generation of “mosaic” 
models produced by blastocyst injection. Using these RNAi mouse models, 
we show that INK4a/ARF or Trp53 downregulation by RNAi cooperates 
with KrasG12D to accelerate lung tumorigenesis and recapitulate the 
phenotypes of knockout models. Additionally, we investigate whether 
INK4a/ARF or Trp53 knockdown is required for tumor maintenance. 
Together, this work built a platform that greatly accelerates the rate at 
which one can study genetic interactions and tumor maintenance genes and 
also identify and validate new drug targets in vivo. This approach can be 
applied to build many other complex cancer models and thus may have 
significant implications for guiding future therapies. 
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Small cell lung carcinoma (SCLC) is a neuroendocrine subtype of lung 
cancer with a 5-year survival rate of less than 10%. We have developed 
mouse models for human SCLC based on the observations that the RB and 
p53 tumor suppressor genes are mutated in more than 90% of human SCLC 
tumors and on emerging evidence that loss of p130 function correlates with 
poor prognosis. Rb/p53 and Rb/p53/p130 mutant mouse lung tumors closely 
resemble human SCLC at the cellular and molecular levels, providing in 
vivo models to investigate the mechanisms underlying the development and 
the maintenance of SCLC. 
 
Hedgehog (Hh) signaling plays a key role during normal lung development 
and response to injury but normally has low activity in the adult lung 
epithelium. Preliminary evidence in a small number of human samples and 
tumor cell lines raises the possibility that SCLC tumors may rely on the Hh 
signaling pathway for their growth. However, the significance of these 
observations in vivo has not been tested, and whether Hh signaling plays a 
cell autonomous or a non-cell autonomous role is still controversial. 
 
To investigate a potential functional role for Hh signaling in SCLC in vivo, 
we crossed Rb/p53 and Rb/p53/p130 mutant mice to Ptch1lacZ/+ mice. Using 
this reporter strain and monitoring the activity of target genes of the Hh 
pathway, we found that Hh signaling was active in all the SCLCs that 
developed in these mutant mice. Experiments with cell lines derived from 
mouse tumors also indicated that the activation of Hh signaling in these 
cells was autocrine or juxtacrine. Constitutive activation of the Hh pathway 
using a mutant allele of Smo was sufficient to enhance SCLC development 
in vivo. Conversely, inhibition of the Hh pathway reduced the survival of 
SCLC cells in culture and of primary tumors in vivo, indicating that 
activation of the Hh pathway is also necessary for the expansion of these 
tumor cells. Thus, the Hh pathway is active in SCLC cells and plays an 
intrinsic role in the initiation and the maintenance of SCLC. 
 
These observations in a pre-clinical mouse model identify Hh signaling as a 
therapeutic target against SCLC in patients. 
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The Apc (Adenomatous Polyposis Coli) tumour suppressor gene is mutated 
in approximately 80% of colorectal cancers. Its major tumour suppressor 
function is thought to be through the negative regulation of ß-catenin and 
downstream Wnt target genes such as c-Myc.  
 
We have previously shown that the conditional deletion of Apc within the 
mouse intestine leads to a crypt progenitor-cell like phenotype, with 
intestinal enterocytes proliferating independently of position and failing to 
differentiate or migrate. These phenotypes are all associated with 
deregulated Wnt signalling and can be rescued by deletion of a single Wnt 
target gene c-Myc.  
 
To assess c-Myc regulated Wnt target genes, we have examined the 
transcriptome of double Apc Myc knockouts and find that mTOR 
(mammalian target of rapamycin) appears to be a Wnt/Myc regulated target 
gene. To inhibit mTOR, we have conditionally deleted raptor (required for 
the MTORC1 complex) from the mouse intestine. Surprisingly intestines 
lacking raptor show no problems in homeostasis. However, intestinal 
regeneration is perturbed, a process which we have previously shown to be 
c-Myc dependent. Co-deletion of Apc and Raptor strongly suppresses the 
proliferation of Apc deficient cells and raptor deletion strongly suppresses 
tumorigenesis even in stem cell models of early intestinal cancer. 
Intriguingly, raptor deletion only marginally protected against 
tumorigenesis in models where both Apc and PTEN were deleted. Deletion 
of MTORC2 complex component Rictor had no impact on the phenotypes 
of Apc loss  
 
Taken together this study highlights that MTORC1 is required for the 
proliferation of Apc deficient cells in vivo. In contrast to c-Myc, there are a 
number of inhibitors to MTORC1 which raises the possibility that these 
inhibitors may be able to prevent tumours arising in patients with high 
familial risk of colorectal cancer. 
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Current genetic mouse models of cancer do not accurately model sporadic 
tumors that comprise the vast majority of human cancers. Of crucial 
importance is to understand the role of dysregulated oncogenic pathways in 
individual tumor cells versus neighboring cells within the 
microenvironment, and how this influences tumor behavior from initiation 
to later stages of tumor progression. Furthermore, the molecular 
characterization of cancer cells versus microenvironment, at various tumor 
stages, is likely to reveal insights into cancer biology including the 
identification of putative therapeutic targets. Several critical issues that need 
to be addressed in modeling sporadic cancers using genetically engineered 
mice are: 1) controlling initial mutant cell number, 2) controlling timing of 
induction of mutations, and 3) being able to unambiguously identify mutant 
cells among the surrounding wild type microenvironment. 
We have developed a novel genetic technique termed Genetic Inducible 
Mosaic Analysis (GIMA) to generate mosaic mice in which genes are 
conditionally mutated in single cells at endogenous loci and simultaneously 
marked with GFP under both temporal and cell type-specific control. This 
mosaic technique allows us to analyze and compare GFP+ mutant to GFP- 
wild type cells within a tissue or tumor in vivo. Specifically, we have 
generated a mouse strain (R26-GIMA) that activates an eGFPCre fusion 
protein following Flp-mediated recombination of the ubiquitously expressed 
ROSA26 locus. To test the efficacy of our system, we combined the R26-
GIMA allele with a transgene that broadly expresses an inducible Flp (CAG-
FlpeER) and a floxed reporter allele (R26R-lacZ) to mimic a mutant allele. 
Efficient mosaic marking of cells (GFP+) was achieved within 24 hours of 
tamoxifen (Tm) administration and ~98% of GFP+ cells carried a mutant 
allele (LacZ+) by 72 hours after Tm administration with eventual 100% 
concordance. Furthermore, medulloblastomas were indeed induced using 
CAG-FlpeER and the R26-GIMA alleles to activate the Hedgehog pathway 
in relatively few cells in the cerebellum. Utilizing an optimized Flp (Flpo), 
we have generated Math1-FlpoER and Nestin-FlpoER mice to model 
specific subclasses of sporadic medulloblastoma thought to arise within 
granule cell or ventricular zone progenitor cells, respectively. Our GIMA 
approach allows for unambiguous lineage tracing of mutant cells from 
tumor initiation, thus enabling the isolation of pure populations of cancer 
cells versus tumor microenvironment cells for characterization of changes 
in gene expression and chromosome content at multiple stages of tumor 
progression. These studies lay the foundation for use of our novel GIMA 
approach for modeling and characterizing any sporadic cancer. 
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The K-Ras oncogene is mutated in about 25% of non-small cell lung cancer 
(NSCLC), one of the most common types of human cancer. Although Ras 
proteins are not druggable targets, they are known to signal through a 
cascade of kinases that, in principle, could be targeted with small molecule 
inhibitors. To determine which kinases are critical in mediating K-Ras 
oncogenic signaling in NSCLC, we have crossed our K-Ras+/LSLG12Vgeo 
strain, known to develop lung adenocarcinomas upon Cre-mediated 
recombination of the K-RasLSLG12Vgeo allele, with mice carrying either null 
or conditional mutations for each of the members of the Raf, Mek and Erk 
families of kinases.  
Our results indicate that ablation of individual Mek or Erk kinases did not 
affect K-RasV12-induced lung tumorigenesis. However, combined 
elimination of either both Mek or both Erk in lung tissue, effectively 
impaired development of both adenomas and adenocarcinomas. These 
observations provide genetic evidence that the tumorigenic properties of K-
Ras oncogene are solely mediated by the Mek/Erk kinase pathway, at least 
in lung tissue. Unfortunately, widespread depletion of both Mek or both Erk 
kinases in adult mice induces death of the animals in less than 4 weeks. 
Ablation of B-Raf had neither effect on tumor development nor Erk 
phosphorylation, suggesting that in the absence of B-Raf, c-Raf (and/or A-
Raf) effectively mediated K-Ras oncogenic signaling. Surprisingly, K-
RasV12 induced few adenomas or adenocarcinomas in the absence of c-Raf. 
Indeed, these tumors expressed c-Raf, suggesting inefficient recombination 
of the c-Raflox alleles. These findings indicate that K-Ras oncogenic 
signaling is selectively mediated by c-Raf and that the absence of this 
kinase cannot be compensated by either B-Raf or A-Raf. Importantly, 
widespread depletion of c-Raf did not affect the overall health of the mice, 
suggesting that pharmacological inhibition of this kinase will be well 
tolerated. Therefore c-Raf could be a relevant therapeutic target to treat 
NSCLC induced by K-Ras oncogene. To further validate this concept, we 
are currently utilizing K-Ras+/FSFG12V;c-Raflox/lox mice to determine whether 
ablation of c-Raf (via Cre recombinase) in CT+ and PET+ tumors (induced 
by FLPase mediated recombination at the K-Ras locus) also results in 
efficient tumor inhibition. 
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Mutational activation of BRAF is detected in ~7% of all human 
malignancies but with a particularly high frequency in papillary thyroid 
cancer (~40%). The most common mutation, T1799A, encodes BRAFV600E 
the expression of which leads to sustained activation of the BRAF-MEK-
ERK MAP kinase pathway. To understand the earliest effects of oncogenic 
BRAFV600E we generated BRafCA mice carrying a Cre-activated allele of 
mouse BRaf. BRafCA expresses normal BRaf until recombined by Cre 
recombinase to express BRAFV600E at normal levels of expression under the 
control of the chromosomal promoter.  
 
Using Thyroglobulin::CreERT2 (Thyr::CreER) transgenic mice we initiated 
expression of BRAFV600E in thyrocytes of adult mice. Within 1-2 weeks the 
mice developed a dramatically enlarged, goiterous thyroid that was readily 
detected using ultrasound. Concomitantly, the mice displayed a deficit in 
thyroid hormone production and/or release and a dramatic elevation in the 
levels of Thyroid Stimulating Hormone (TSH). Unlike the situation in lung 
epithelial cells or melanocytes where expression of oncogenic BRAFV600E 
results solely in benign tumors that do not progress to cancer due to 
oncogenic-induced senescence, mice with thyrocyte expression of 
BRAFV600E developed papillary thyroid cancer with 6-9 months without any 
deliberate manipulation of umor suppressor genes. However, we are 
crossing Thyr::CreER; BRafCA mice to mice carrying conditional alleles of 
Trp53, Cdkn2a or Pten to determine how tumor suppressor gene silencing 
influences BRAFV600E-induced thyroid carcinogenesis in the mouse.  
 
Thyr::CreER; BRafCA mice provide a convenient platform for pre-clinical 
evaluation of pharmacological agents that target signal transduction 
pathways in thyroid cancer. Consequently, we treated Thyr::CreER; BRafCA 
mice with either a MEK inhibitor (PD325901) or synthetic thyroid hormone 
or a combination of both. Whereas MEK inhibition had a dramatic effect on 
the size of the mouse thyroid, synthetic thyroid hormones were without 
effect. These data suggest that activated MEK is essential for the effects of 
BRAFV600E in the thyroid but that endocrine stimulation of G protein 
signaling through the TSH receptor is not essential. These data further 
emphasize the utility of BRafCA mice for studying malignancies in which the 
RAF-MEK-ERK MAP kinase pathway is implicated in the initiation, 
progression or maintenance of disease.  
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Pinpointing the identity of tumor propagating cells (TPCs) in gliomas is 
critical for designing targeted therapies. Previous studies have postulated 
the neural stem cell (NSC) nature of TPCs based on their abilities to self-
renew and to differentiate into multiple cell types in cell culture. However, 
the sole dependence of end-point analysis could be misleading since late-
stage tumor cells could acquire aberrant features during malignant 
transformation. An ideal approach to fully understand TPCs would be to 
analyze mutant cells throughout the tumorigenic process, with a greater 
focus on stages prior to the malignant transformation. To overcome the 
difficulty in identifying pre-transformed mutant cells free of identifiable 
pathological features, we used a mouse genetic mosaic model termed 
MADM to generate sporadic GFP-labeled mutant cells in an otherwise 
colorless normal mouse, enabling mutant cell visualization upon their 
generation. By inducing co-LOH of p53 and NF1 from embryonic NSCs, 
MADM model effectively induced glioma formation with almost full 
penetrance within 4-6 months. Genomic fingerprinting confirmed the close 
relevance of this model to the proneural subtype of human GBMs based on 
recent TCGA classification. Taking advantage of the unambiguous GFP 
labeling of mutant cells, we analyzed the extent of cell expansion in each 
and every CNS lineages in 2-month-old mice, prior to any signs of 
malignancy. Surprisingly, although mutations were induced in NSCs, there 
was no detectable over-proliferation of mutant NSCs compared to WT ones. 
Among all neuroglial lineages, the oligodendrocyte precursor cell (OPC) 
lineage was the only one showing drastic over-expansion. Upon tumor 
formation, marker staining and microarray analysis again revealed that 
actively proliferating tumor cells share many OPC features. Interestingly, 
purified OPC-like tumor cells could self-renew in culture, differentiate into 
multiple cell types upon induction, and initiate secondary tumors by 
orthograft assay. In conclusion, MADM enabled us to study TPC identity as 
a developmental process. Our findings suggest that stem cell features of 
TPCs may not necessarily be an indication of their NSC nature, rather these 
features could be acquired by mutant OPCs during malignant 
transformation. 
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Epidemiological data indicates that the risk of ovarian cancer is highest 
among peri- or post- menopausal women, while increased parity and the use 
of oral contraceptive are preventive. These data suggest that reproductive 
factors are associated with the risk of ovarian cancer, however, the 
molecular mechanisms underlying such a link remains obscure. We have 
established ovarian tumor mouse models that incorporate both the impact of 
menopausal physiology and genetic mutations using the germ cell-deficient 
Wv (White spotting variant) mice and targeted mutations of p53 and p27. 
The Wv mice harbor a point mutation at c-Kit, which reduces the tyrosine 
kinase activity to about 1%, resulting in a premature loss of ovarian germ 
cells and follicles. By 8 weeks of age, the ovarian follicles are depleted and 
ovarian surface epithelial cells proliferate and invaginate in the, and by 3 
months of age benign ovarian epithelial tumors replace the entire ovary in 
virtually all the female Wv/Wv mice. Thus, the unique tumor prone 
phenotype in the ovaries of Wv mice may represent an exaggerated model 
of menopausal physiology on ovarian cancer risk. We have refined Wv/Wv 
ovarian tumor model by deleting tumor suppressor genes p53 or p27kip1 in 
ovarian surface epithelial cells. We found that both Wv/Wv:p27+/- and p27 
-/- mice develop neoplastic ovarian epithelial tumors, which consist of 
papillary structures lined by hyperchromatic neoplastic cells. Cytokeratin 8 
staining was positive in the Wv/P27 tumors indicating the epithelial origin 
of these tumors. When p53 was unilaterally deleted in the ovarian surface 
epithelial cells of the Wv/Wv:p53flox/flox mice by Adenoviral cre injection, 
malignant conversion of the tumors developed. Metaplastic differentiation 
and infiltration into the surrounding tissues were seen in the p53 deficient 
Wv tumor lesions. Thus, we conclude that oncogenic mutations can convert 
the benign epithelial lesions presented in follicle-depleted ovaries to 
neoplastic tumors. The results indicate that ovarian aging in 
postmenopausal physiology and oncogenic mutations cooperate in ovarian 
cancer development. 
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The p53 tumour suppressor protein restrains malignant progression through 
a number of mechanisms, and most cancers show loss of the normal 
functions of p53. In many cancers this is due to a mutation in the p53 gene 
that leads to the expression of a mutant p53 protein. These tumour 
associated mutant p53s not only lose wild type p53 activity but can also 
acquire the ability to promote cell motility and migration, and so contribute 
to the development of metastases. We have found that tumour associated 
mutant p53s can promote invasion and loss of directionality when cells 
migrate in vitro. These activities are independent of the loss of wild type 
p53 function, and reflect activation of integrin and EGFR trafficking that 
depends on Rab-coupling protein (RCP) and which results in constitutive 
activation of EGFR/integrin signalling. Simultaneous loss of p53 and p63 
recapitulates the phenotype of mutant p53, suggesting that this function of 
mutant p53 reflects, at least in part, the inhibition of the p53 family member 
p63. Using both stably expressing mutant p53 cells and cells that 
endogenously express mutant p53, we also observed a potent induction of 
mutant p53-dependent invasion of cells towards HGF, the ligand of the c-
MET receptor. As with EGFR dependent invasion, c-MET dependent 
invasion requires engagement of α5β1 integrin and RCP, and correlates 
with inhibition of p63. HGF is also known as scatter factor and causes 
dispersion of colony forming cell lines by weakening cell-cell interactions 
via c-MET signalling. We have been able to show a role for mutant p53 in 
driving the dispersion of cells and a relocalization and/or loss of specific 
cell-cell junction proteins. Interestingly, a c-MET inhibitor could abrogate 
these effects of mutant p53. Together these data suggest that mutant p53 can 
drive a complex invasive program that involves multiple RTKs and open 
the possibility that blocking α5β1 integrin and/or the RTKs will have 
therapeutic benefit in mutant p53 expressing cancers. 
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Mutation of the RB-1 tumor suppressor occurs in one third of all human 
tumors and is particularly associated with retinoblastoma and osteosarcoma. 
We have modeled osteosarcoma in the mouse using a targeted conditional 
approach in which Rb and/or p53 are deleted in pre-osteoblasts. We find 
that Rb loss synergizes strongly with p53-inactivation: it greatly accelerates 
tumor development and it expands the tumor spectrum from osteosarcoma 
in the p53 single mutants to multiple soft tissue sarcomas in the Rb;p53 
DKO. This led us to hypothesize that Rb loss promotes cellular plasticity. 
Thus, to directly address the influence of Rb status in mesenchymal 
tumorigenesis we used inducible systems to control pRb’s expression. Our 
data show that toggling between Rb loss or Rb re-activation is sufficient to 
switch the fate commitment of osteosarcoma tumor cells in vitro through 
direct regulation of master regulators of mesenchymal differentiation. In 
addition, we find that reactivation of Rb in tumors generated from Rb;p53 
DKO cells is sufficient to halt tumor progression in vivo. Taken together, 
our data suggest that Rb loss promotes tumorigenesis, at least in part, by 
modulating the differentiation potential of committed pre-osteoblasts. 
 137 
LOSS OF THE DROSOPHILA RETINOBLASTOMA FAMILY PROTEIN 
PREDISPOSES CELLS TO DEDIFFERENTIATION 
 
Brandon N Nicolay, Maxim V Frolov  
 
University of Illinois at Chicago, Biochemistry and Molecular Genetics, 
Chicago, IL, 60607 
 
Functional inactivation of the Retinoblastoma (pRB) pathway is an early 
and obligatory event in tumorigenesis. This is widely attributed to the need 
of tumor cells to bypass the ability of pRB to promote cell cycle exit. While 
support of this is well documented, pRB is involved in other cellular 
processes that are less understood. Here we demonstrate that independently 
of cell cycle exit control, pRB, in cooperation with the Hippo tumor 
suppressor pathway, functions to maintain the terminally differentiated 
state. Using the Drosophila eye as a model of tumorigenesis, we found that 
mutations in the Hippo signaling pathway, wts or hpo, trigger widespread 
dedifferentiation of rbf mutant cells. Initially rbf wts or rbf hpo double 
mutant photoreceptors are morphologically indistinguishable from their 
wild type counterparts as they properly differentiate, express mature 
neuronal markers, and develop axonal projections. However, double mutant 
cells stochastically lose their neuronal identity as they undergo 
dedifferentiation and become uncommitted eye specific cells. Surprisingly, 
this dedifferentiation is fully independent of cell cycle exit defects and 
occurs even when inappropriate proliferation is blocked by a de2f1 
mutation. The implication of these findings is that pRB functions to 
maintain an irreversible state of terminal differentiation. Thus, our results 
reveal the novel involvement of the pRB pathway in postmitotic cells and 
suggest that terminally differentiated Rb mutant cells are intrinsically prone 
to dedifferentiation, can be converted to progenitor cells, and thus 
contribute to cancer advancement. 
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Cellular senescence is a tumor suppressor mechanism that is activated in 
response to oncogenic signals and other tumor-promoting insults. Tumor 
progression in premalignant senescent lesions is thought to arise when cells 
either primarily bypass, or secondarily revert from, cellular senescence. 
Progression from a premalignant, senescent lesion to an invasive tumor is 
presumed to occur in certain human cancers, since senescent lesions are 
found in proximity to malignant lesions in mouse models and human pre-
invasive lesions, such as nevi, lung adenomas, or colorectal adenomas. 
We now show evidence in-vivo that tumors can evolve within premalignant 
senescent lesions using a mouse model of Cyclin D1-driven pineoblastoma. 
While absence of p53 leads to primary evasion of senescence, loss of the 
Cdk-inhibitor p18Ink4c leads to tumor progression within a premalignant, 
largely senescent lesion. Although Cdk4-dependent Rb phosphorylation 
was decreased suggesting compensation for p18Ink4c in the senescent cells, 
tumor progression occurred in all Cyclin D1, p18-/- mice by 7 months of 
age. P15Ink4b was not expressed in Cyclin D1, p18-/- tumors, making this a 
possible mechanism for escape from senescence.  
Notably, Cyclin D1,p18-/- tumors, which differed from Cyclin D1, p53-/- 
tumors in that they were preceded by a senescent state, also differed on a 
molecular level. Specifically, decreased expression of Cdk2 correlated with 
p53-dependent senescence and was abrogated in the absence of p53. On the 
contrary, Cdk2 downregulation still occurred in the absence of p18Ink4c as 
the cells senesced, and low levels did not prevent tumor progression. These 
findings suggest that prospects for use of Cdk2-inhibitors as senescence-
promoting therapy may depend on the molecular characteristics of the 
tumor, and the mechanism by which bypass of senescence occurs.  
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Previous studies indicate that oncogenic stress activates the ATR-Chk1 
pathway. Here, we demonstrate that ATR-Chk1 pathway engagement is 
essential for limiting genomic instability following oncogenic Ras 
transformation. ATR pathway inhibition in combination with oncogenic Ras 
expression synergistically increased genomic instability, as quantified by 
chromatid breaks, sister chromatid exchanges and H2AX phosphorylation. 
This level of instability was significantly greater than that observed 
following ATR suppression in untransformed control cells. In addition, 
consistent with a deficiency in long-term genome maintenance, 
hypomorphic ATR pathway reduction to 10-25% of normal levels was 
synthetic lethal with oncogenic Ras expression in cultured cells. Notably, 
elevated genomic instability and synthetic lethality following suppression of 
ATR were not due to accelerated cycling rates in Ras-transformed cells, 
indicating that these synergistic effects were generated on a per-cell-cycle 
basis. In contrast to the synthetic lethal effects of hypomorphic ATR 
suppression, subtle reduction of ATR expression (haploinsufficiency) in 
combination with endogenous levels of K-RasG12D expression elevated the 
incidence of lung adenocarcinoma, spindle cell sarcoma and thymic 
lymphoma in p53 heterozygous mice. K-RasG12D-induced tumorigenesis in 
ATR+/-p53+/- mice was associated with intrachromosomal deletions and loss 
of wild-type p53. These findings indicate that synergistic increases in 
genomic instability following ATR reduction in oncogenic Ras-transformed 
cells can produce two distinct biological outcomes: synthetic lethality upon 
significant suppression of ATR expression and tumor promotion in the 
context of ATR haploinsufficiency. The roles of the ATR pathway as a 
barrier to malignant progression and as a potential target for cancer 
treatment will be discussed. 
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Chemotherapy resistance is a major obstacle in cancer treatment, yet the 
mechanisms of response to specific therapies have been largely unexplored 
in vivo. By employing genetic, genomic, and imaging approaches, we have 
examined the dynamics of response to a mainstay chemotherapeutic, 
cisplatin, in multiple mouse models of human non-small cell lung cancer 
(NSCLC). We show that lung tumors initially respond to cisplatin by 
sensing DNA damage, undergoing cell cycle arrest and inducing 
apoptosis—leading to a significant reduction in tumor burden. Importantly, 
we demonstrate that this response does not depend on the tumor suppressor 
p53 or its transcriptional target p21. Prolonged cisplatin treatment promotes 
the emergence of resistant tumors with enhanced repair capacity that are 
cross-resistant to platinum analogs, exhibit advanced histopathology, and 
possess an increased frequency of genomic alterations. Cisplatin-resistant 
tumors express elevated levels of multiple DNA damage repair and cell 
cycle arrest-related genes, including p53-inducible protein with a death 
domain (Pidd). We demonstrate a novel role for PIDD as a regulator of 
chemotherapy response in human lung tumor cells. Preliminary data suggest 
that PIDD-induced chemo-resistance is due to its ability to promote cell 
cycle arrest. Our current focus is aimed at elucidating the signaling 
mechanisms that dictate this response.  
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Defective DNA repair by homologous recombination (HR) is thought to be 
a major contributor to tumorigenesis in individuals carrying Brca1 
mutations. Here, we show that DNA breaks in Brca1-deficient cells are 
aberrantly joined into complex chromosome rearrangements by a process 
dependent on the nonhomologous end-joining (NHEJ) factors 53BP1 and 
DNA ligase 4. Loss of 53BP1 alleviates hypersensitivity of Brca1 mutant 
cells to PARP inhibition and restores error-free repair by HR. 
Mechanistically, 53BP1 deletion promotes ATM-dependent processing of 
broken DNA ends to produce recombinogenic single-stranded DNA 
competent for HR. In contrast, Lig4 deficiency does not rescue the HR 
defect in Brca1 mutant cells but prevents the joining of chromatid breaks 
into chromosome rearrangements. Our results illustrate that HR and NHEJ 
compete to process DNA breaks that arise during DNA replication and that 
shifting the balance between these pathways can be exploited to selectively 
protect or kill cells harboring Brca1 mutations. 
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When induced by sustained and elevated levels of mitogenic signals, 
production of the p19Arf tumor suppressor inhibits the Mdm2 E3 ubiquitin 
ligase to activate p53 in response to oncogenic stress. Although the 
accepted paradigm for Arf action involves p53 engagement, p19Arf interacts 
with protein targets other than Mdm2 and can play p53-independent roles in 
tumor suppression. For example, by inhibiting the Senp3 SUMO2/3 
protease, p19Arf can induce the sumoylation of many proteins, including 
nucleophosmin (NPM, B23), Miz1, and others to affect cellular processes 
such as ribosomal biogenesis and RNA transcription in a p53-independent 
manner. 
 
Arf is transiently expressed in mitotically dividing spermatogonia, but its 
expression is extinguished in the primary meiotic spermatocytes that arise 
from them. Lineage tracing experiments using an Arf-Cre “knock-in” 
mouse crossed to Rosa26 indicator strains that express LacZ or YFP in 
response to Cre recombinase demonstrated that expression of p19Arf in 
spermatogonia neither prevents their mitotic division nor their ability to 
generate meiotic spermatocytes and, ultimately, mature sperm. In direct 
contrast, Arf inactivation in spermatogonia results in p53-dependent 
apoptosis of meiotic spermatocytes, thereby contributing to significantly 
reduced spermatogenesis throughout the life of Arf-null mice. Analysis of 
ArfCre/Flox mice revealed that the defect in spermatogenesis is germ cell-
autonomous. The spermatocytes of Arf-null animals exhibit decreased levels 
of SUMO2/3-conjugates accompanied by increased γH2AX and TUNEL 
staining. Together, these findings indicate that transient p19Arf expression, 
which is normally restricted to spermatogonial progenitors, triggers a 
salutary program that protects their meiotic progeny from unrepaired DNA 
damage and p53-mediated apoptosis. Surprisingly, Ink4a inactivation leads 
to an increased number of spermatocytes and output of mature sperm. The 
effects of Arf inactivation are therefore offset in double knock-out Ink4a-
Arf-null mice, which exhibit normal testis weights and sperm counts. These 
findings are without precedent in defining in vivo roles for Ink4a and Arf 
proteins in regulating normal tissue homeostasis outside the context of 
classical tumor suppression. 
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The Arf tumor suppressor gene product, p19Arf, is induced in response to 
oncogenic signals to block cancer development and progression. We 
previously showed that Arf expression is diminished in the absence of 
Tgfβ2 at several sites in the developing mouse. We used complementary in 
vivo and cell culture models to further explore the relationship between 
Tgfβ and Arf and to define the molecular mechanisms by which the latter is 
induced. First, we show that conditional inactivation of Arf in cells arising 
from a Wnt1-expressing lineage leads to pericyte hyperplasia around 
vessels in the primary vitreous. Conditional inactivaton of TbrII in this 
same lineage leads to a similar phenotype, suggesting that both Tgfβ 
receptor II and p19Arf act in the same cell to prevent proliferation of 
pericytes in the developing eye. To further demonstrate that Tgfβ resides 
upstream of Arf, we showed that its capacity to arrest cell proliferation in 
vivo depended on p19Arf. Tgfβ1, 2, and 3 (but not the BMP-2, another 
member of the Tgfβ superfamily) induced p19Arf expression in wild type 
mouse embryo fibroblasts (MEFs), and they enhanced Arf promoter activity 
in Arf lacZ/lacZ MEFs. Chemical inhibitors of Smad-dependent and -
independent pathways showed that SB431542, a Tgfβ type I receptor 
inhibitor, and SB203580, a p38 MAPK inhibitor, impeded Tgfβ2 induction 
of Arf. Genetic studies confirmed the findings: transient knock-down of p38 
MAPK, Smad2 or Smad3 blunted Tgfβ2 effects, as did Cre recombinase-
treatment of Tbr II flox/flox MEFs to delete Tgfβ receptor II. Chromatin 
immunoprecipitation revealed that Tgfβ rapidly induced Smad2/3 binding 
and histone H3 acetylation at genomic DNA proximal to Arf exon 1β. This 
was followed by increased RNA Polymerase II binding and progressively 
increased primary Arf transcripts from 24 through 72 hours, indicating that 
the induction was due to increased transcription. In summary, our results 
reveal the signal transduction cascade and molecular events at the Arf 
promoter that underlie its transcriptional induction by Tgfβ. 
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We and others have provided evidence that aggressive tumors can quit their 
malignant state through a process called tumor reversion (1). By comparing 
the gene expression profiles of these revertant cells to their parental tumor 
cells, Translationally Controlled Tumor Protein (TCTP) was identified as 
the most significantly down-regulated gene in the revertant cells. This gene 
is conserved in all species examined and functions as a pro-survival factor. 
Here we show that TCTP and p53 are mutually repressive. Whereas p53 
down-regulates TCTP at the transcriptional level, TCTP promotes MDM2-
mediated degradation of p53 by competing with NUMB. This inhibition, of 
NUMB by TCTP, most likely affects the composition of the 
p53/MDM2/NUMB tri-complex (2). To assess the clinical relevance of our 
findings, we screened a cohort of 516 breast cancers for TCTP expression 
by immunohistochemistry. High TCTP expression is significantly 
associated with poorly differentiated, aggressive G3 tumors as opposed to 
low (G1) and intermediate (G2) grade tumors. High TCTP levels inversely 
correlate with a defective p53 status. Importantly, the elevated expression of 
TCTP also predicts poor prognosis in breast cancer patients (p<0.0005). 
TCTP is also highly expressed in normal mammary stem cells as opposed to 
differentiating progenitors, suggesting a role for TCTP in the maintenance 
of an undifferentiated state, a function that might be relevant to the 
pathogenesis of poorly differentiated tumors. This observation is consistent 
with a previously recognized role for TCTP in stemness via its ability to 
regulate the expression of oct4 and nanog. In conclusion, these results 
provide further support of a role for TCTP in tumorigenesis and new 
insights into its molecular mechanisms of action. The elevated expression of 
TCTP in stem cells and G3 tumors will be discussed in the framework of 
disease specificity, tumor progression and reversion.  
 
1. Telerman A, Amson R. Nat Rev Cancer. 2009 Mar;9(3):206-16.  
2. Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, 
Viale G, Pece S, Di Fiore PP. Nature. 2008 Jan 3;451(7174):76-80 
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The stepwise model of Vogelstein and Fearon represents the paradigm for 
colorectal cancer progression. However, recent studies have indicated that 
the molecular events involved are far more complex and suggest that a large 
repertoire of genes may contribute to intestinal mutagenesis (Wood et al., 
Science 318, 1108-13 (2007)). To identify alternative candidate genes and 
pathways implicated in the development of colon cancer we have performed 
a comprehensive forward genetic screen using insertional mutagenesis in 
mice carrying conditional (Apcfloxed) and constitutive (ApcMin) mutations of 
Apc, representing models of sporadic colorectal cancer and familial 
adenomatous polyposis coli (FAP) respectively. We harvested 446 lesions 
for splinkerette-PCR and 454 sequencing, and parallel histopathological 
analysis. Using a Gaussian kernel convolution algorithm optimized over 
two scale spaces of 30kb and 120kb we identified 997 common insertion 
sites (CIS), equating to 958 potential cancer driver genes. This was 
compared to results generated by Monte Carlo simulations, a second 
statistical framework, to produce a concordance between the two methods 
of 75%. From cross-species oncogenomics 318 of these genes are also 
mutated in human colorectal carcinogenesis including 37 Wnt targets, of 
which 20 were found to be modifiers of Wnt signaling. Furthermore, 290 
genes were identified in 148 significant canonical pathways using Ingenuity 
Pathway Analysis. Some 97 genes in 38 groupings co-occur with higher 
than predicted frequency in mini-networks. We also identified genes 
specifically associated with a subset of tumors showing aberrant Paneth cell 
differentiation, a hallmark of deregulated Wnt signaling, and genes 
associated with germline versus sporadic loss of Apc. In summary, this 
study expands the potential gene signature for colorectal cancer. 
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A large body of evidence indicates that alterations in the expression of 
miRNAs contribute to cancer pathologies. DICER1, which encodes an 
enzyme playing a critical role in miRNA biogenesis, is the target of 
mutations or haploid deletions in human cancers. Surprisingly, however, 
homozygous deletions or loss-of-function mutations in DICER1 are not 
found in human tumors.  
Consistent with these observations, we have recently shown that Dicer1 
functions as a haploinsufficient tumor suppressor in a preclinical mouse 
model of retinoblastoma. We now show that complete ablation of Dicer1 in 
retinal progenitor cells prevents the formation of retinoblastoma in mice 
that harbour inactivating mutations targeting both the Rb and p53 tumor 
suppressor pathways. Importantly, loss of Dicer1 in retinal progenitor cells 
does not affect survival (nor retinogenesis) in the absence of Rb; instead, it 
induces their apoptotic death upon concomitant inactivation of p53. miRNA 
profiling of Rb/p53-deficient mouse tumors, as well as human 
retinoblastoma samples, identified specific microRNAs as key pro-
oncogenic agents in retinoblastoma. High-resolution Array-CGH revealed 
that focal amplification of or a gain of the genomic region where these 
microRNAs reside occurs in a subset of human retinoblastoma. Functional 
inactivation of these miRNAs resulted in the death of human retinoblastoma 
cell lines. 
Our data therefore identify Dicer1 as the first synthetic lethal partner of 
tumor suppressor p53 and specific microRNAs as key therapeutics targets 
for the treatment of retinoblastoma. 
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We have been conducting a two-species screen for prostate cancer 
oncogenes that are suitable for use as new prostate cancer drug targets. The 
initial screen utilized transposon-based somatic mutagenesis in mice to 
induce prostate tumors and molecularly tag candidate oncogenes. This 
approach identified several candidate prostate cancer genes including 
known oncogenes such as Nras and Braf as well as new candidate 
oncogenes including Pde4d. A secondary screen used human prostate tissue 
microarrays (TMAs) to validate the relevance of new candidate oncogenes 
for understanding human prostate cancer. Automated quantitative analysis 
of PDE4D protein expression on the human TMAs confirmed its over-
expression in human prostate cancer patients. The Pde4d mRNA is 
alternatively spliced to encode a family of related PDE4D enzymes. These 
enzymes share a common catalytic domain that gives all of the enzymes 
cAMP-specific 3',5'-cyclic phosphodiesterase activity. Protein domains 
outside the catalytic domain allow for differential protein regulation and 
sub-cellular localization of different PDE4D isoforms. Several small 
molecules have been identified that are highly selective inhibitors of 
PDE4D activity including cilomilast and NVP-ABE171. Testing of these 
small molecules has shown that they inhibit the growth of prostate cancer 
cell lines in vitro, and growth-inhibition was associated with down-
regulation of hedgehog pathway signaling. Daily oral administration of 
PDE4D inhibitors also dramatically inhibited the growth of prostate cancer 
xenografts with no adverse affects on the xenograft hosts. These data 
indicate that PDE4D inhibitors are exciting new candidate drugs for 
prostate cancer. 
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Podoplanin is a transmembrane glycoprotein up-regulated in human 
carcinomas. Its expression in tumour cells is linked to increased cell 
migration and invasiveness. Since podoplanin has no obvious enzymatic 
motif within its structure, the identification of podoplanin-binding proteins 
is crucial to fully understand its specific role in cancer. We report that 
CD44, the major hyaluronan (HA) receptor, is a novel partner for 
podoplanin. Expression of the CD44 standard isoform (CD44s) is co-
ordinately up-regulated together with that of podoplanin during progression 
to highly aggressive spindle cell carcinomas in a mouse skin model of 
carcinogenesis, and during epithelial-mesenchymal transition (EMT). 
Furthermore, podoplanin binds to CD44s at cell surface protrusions in 
migrating cells and CD44 is required for podoplanin-enhanced cell 
migration and directionality in epithelial cells. Our results suggest a role for 
CD44-podoplanin interaction in driving tumour cell migration during 
malignancy.  
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Cell adhesion to the basement membrane is critical in rendering cell 
functionality, polarity and tissue specificity. Dystroglycan (DG) is a 
versatile signal transducing molecule that links cellular cytoskeleton to the 
basement membrane; it is postranslationally processed into two subunits 
termed as α-DG and β-DG. In majority of human cancers there is loss or 
weak expression of β-DG. Prostate cancer is now the most common cancer 
in men in the UK. It accounts for 24 out of every 100 cancers diagnosed in 
men. The loss of β-DG is associated with progression of prostate cancer 
(Cross et al., 2008). However, the mechanisms that regulate the 
functionality of β-DG in prostate cancer have not been thoroughly 
investigated. In the present study, we investigated the role of β-DG in the 
progression of prostate cancer using benign and malignant prostate cell 
lines. We have demonstrated using various antibodies a change in the sub-
cellular localization of β-DG. β-DG is localized to the cell periphery and 
cell-cell junctions when probed with an antibody recognizing the c-terminus 
of β-DG, but was detected exclusively in the nucleus on probing with an 
antibody that recognizes phosphorylated (pY892) DG. Post-translational 
modification of β-DG is postulated to be involved in the sub-fragmentation 
of β-DG. On transient over expression in cancer cell lines the cytoplasmic 
domain of β-DG fused to GFP (cβ-DG-GFP) is localized to the nucleus 
while the construct with a mutated nuclear localization domain (cβ-DG Δ 
NLS-GFP) was targeted to the cytoplasm. Prostate cancer cells respond to 
androgen stimulus mediated by intracellular androgen receptor (AR). As 
expected AR protein was detected in the nuclear fraction of cells treated 
with dihydrotestosterone. Interestingly β-DG was also detected in the 
nuclear fraction. A microarray analysis comparing prostate cell lines 
transfected with the cβ-DG-GFP and cβ-DG Δ NLS-GFP constructs will be 
performed to study the significance of β-DG processing in cancer. Using 
immunoprecipitation experiments we are currently investigating the 
probable interaction between AR and the nuclear localization of β-DG. We 
have also developed a 3D culture model of benign and malignant human 
prostate cells; this will be a useful tool to evaluate the contribution of β-DG 
towards maintaining prostate tissue polarity. Our results suggest key 
mechanisms involving the regulation of β-DG in prostate cancer cells. 
 
Reference:  
Cross, S. S., et al., 2008. Expression of beta-dystroglycan is reduced or 
absent in many human carcinomas. Histopathology. 53, 561-6. 
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The HDACi panobinostat belongs to a class of chemotherapeutics with 
demonstrated anticancer activities in laboratory studies and within the 
clinic. Here we investigated the ability of panobinostat to induce apoptosis 
in human multiple myeloma (MM) cell lines, alone and in combination with 
agents that target the extrinsic apoptosis pathway (TRAIL) or proteosome 
inhibition (bortezomib). We have employed the Vk*MYC model of MM to 
determine the effects of panobinostat and combination therapies in an in 
vivo setting. Human MM cell lines were treated with panobinostat, TRAIL 
or bortezomib alone or in combination. Cell viability and cell cycle were 
assessed by FACS. Histone acetylation was assessed by western blot. 
C57BL/6 mice bearing transplanted Vk*MYC MM were treated with 
panobinostat (25mg/kg, d1-4; 15mg/kg 5d/wk, 3wk), MD5-1 (mouse α-
DR5 Ab, 50ug/mouse, d1, 4, 8, 12), bortezomib (0.5mg/kg, every 4d) or 
vehicle (D5W ± UC81B9). Combination therapies were panobinostat 
(10mg/kg) + MD5-1 or bortezomib. M-protein was assessed weekly in all 
mice. Treatment of MM cell lines with panobinostat resulted in time- and 
dose-dependent induction of apoptosis with G1/G2-M phase arrest and 
histone H3 acetylation. Combined panobinostat with TRAIL or bortezomib 
synergised to mediate robust and rapid apoptosis in the human MM cells. 
Serum M-protein in mice with Vk*MYC MM cells was significantly 
reduced after treatment with panobinostat, but not MD5-1 or bortezomib, 
alone compared with control mice (p<0.01). Overall, panobinostat induced 
a significant survival advantage compared with vehicle (median=36.5 vs. 16 
d). Combinations of panobinostat with bortezomib synergised to reduce M-
protein levels to a greater extent than either agent alone. Combination 
therapies with MD5-1 are ongoing. These results suggest that panobinostat 
has single agent activity against MM cells in vitro and provides significant 
benefit to mice with syngeneic MM tumours. Moreover, therapies 
consisting of HDACi with TRAIL or bortezomib may provide a rational 
approach to the treatment of MM. Future studies will investigate the 
molecular events underpinning the effects mediated by combined 
panobinostat with MD5-1 or bortezomib in the Vk*MYC MM model. 
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MicroRNAs have emerged as important new cancer genes and individual 
microRNAs have been shown to behave as oncogenes or tumors 
suppressors in many hematological cancers. However, a comprehensive 
analysis of the contribution of several microRNAs in one cancer has been 
lacking. Here we combine an analysis of microRNA expression changes in 
T-ALL with an unbiased microRNA library screen to systematically 
identify microRNA activities that contribute to T-ALL. Following 
validation in a murine T-ALL model and in xenografted human T-ALL, we 
confirm several known oncogenic (e.g. miR-19) and tumor suppressive (e.g. 
miR-451) microRNAs along with new candidates. Strikingly, it emerges 
that these microRNAs act on overlapping sets of tumor suppressor genes 
including Ikaros, Pten, Phf6, and Bim. Hence, a systematic analysis of 
microRNA functions in one cancer reveals a surprisingly clear pattern of the 
microRNA-tumor suppressor interactions involved in T-cell leukemia. 
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RNA interference (RNAi) technology enables systematic loss-of-function 
genetics in mammalian systems. Previous work from our laboratory has 
shown that regulated expression of transgenic shRNAs targeting tumor 
suppressor genes can recapitulate null phenotypes in adult mice. To 
determine whether the same technology could be applied to study essential 
genes, we aimed to inducibly and reversibly target cell proliferation. 
Initially, an in vitro screen with an shRNA library targeting known and 
putative DNA replication factors was conducted to identify gene targets 
whose loss inhibited cell proliferation. Multiple shRNAs against 
Replication protein A3 (Rpa3) were identified. We then targeted embryonic 
stem (ES) cells with an inducible Rpa3 shRNA cassette at the collagen A1 
locus. Doxycycline-driven shRNA expression inhibited cell proliferation in 
ES cells and mouse embryonic fibroblasts derived from transgenic animals. 
 
When Rpa3 shRNA expression was induced in adult mice, they quickly lost 
weight and became moribund within two weeks. Histological analysis 
revealed a complete destruction of the intestinal epithelium upon Rpa3 
knockdown. Other highly proliferative organs were also atrophied, 
especially the spleen. Proliferating cells were absent in the liver and 
kidneys, which maintained normal architecture but were reduced in size. 
Remarkably, if shRNA expression was extinguished even after dramatic 
weight loss, transgenic mice could regain weight and survive. Thus, we can 
model a transient blockade in cell proliferation that mimics the effects of 
conventional chemotherapy. Looking ahead, the ability to target anti-
proliferative genes in our system will be an important tool to model 
inhibition of rational cancer drug targets. In general, inducible, reversible 
essential gene inactivation in adult mice brings mammalian genetics a step 
closer to other model organisms where temperature-sensitive mutations are 
used to study lethal phenotypes. 
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Mouse models have dramatically improved our understanding of cancer 
development and tumor biology. However, these models have shown 
limited efficacy as tractable systems for unbiased genetic experimentation. 
We have previously adapted a transplantable mouse model of Burkitt’s 
lymphoma to in vivo screening applications, and have now extended this 
technology to investigate modulators of central nervous system metastasis 
in hematopoietic malignancies. Metastasis to the brain represents a 
significant clinical challenge in certain leukemias and lymphomas. Patients 
who relapse in the CNS have an extremely poor prognosis, and there are 
very few stratifiers to effectively identify patients who are at high risk for 
CNS involvement. To look for novel determinants of leukemia cell 
metastasis to the CNS, we performed an RNAi-based screen in a mouse 
model of acute lymphoblastic leukemia (ALL). This screen has yielded a 
number of genes, including the pro-inflammatory cytokine IL-1β, that are 
important modulators of CNS infiltration. Together, these screens have 
identified critical determinants of tumor cell behavior in vivo, highlighting 
the utility of performing shRNA screens within a relevant physiological 
context. 
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Polyploidy and aneuploidy are major sources of chromosome instability 
frequently observed in cancer cells. Published studies from the Shen 
laboratory have shown, that severe knock down, BRCA2 and CDKN1A 
(Cip/p21) Interacting Protein (BCCIP) results in reduced homologous 
recombination (HR) mediated DNA repair, polyploidy, aneuploidy, 
formation of multiple spindles and abnormal centrosome amplification 
during mitosis. In addition, down regulation of BCCIP exhibits an increase 
in the percentage of cells joined by intercellular bridges, suggesting mitotic 
and/or cytokinesis defect. Although these data clearly suggest that BCCIP 
plays a role in preventing in chromosome instability and mitotic errors, the 
mechanisms by which BCCIP regulates these processes have not been 
determined.  
In this study, we used serial time lapse microscopy followed by frame by 
frame analysis of BCCIP deficient HT1080 cells. We found that BCCIP 
deficient cells take a significantly longer time to complete mitosis than 
BCCIP proficient cells (p=0.001). This suggests that mitosis may be 
extended in BCCIP knockdown cells. In addition to the extended mitosis in 
BCCIP knockdown cells, it was also observed that some BCCIP 
knockdown cells initiated mitosis but aborted prior to the formation of a 
visible cytoplasm bridge at cytokinesis, suggesting a possibility of 
endomitosis. In some instances the cells aborted mitosis and re-entered 
interphase, to undergo asymmetric division and produced three daughter 
cells. Further analyses by using BCCIP deficient HT1080 stable cell lines 
expressing GFP tagged H2B, revealed that BCCIP deficient cells also 
required more time for chromosome segregation as well as exhibited defects 
in metaphase plate formation. Approximately 50% of BCCIP deficient cells 
showed delay in completion of chromosome segregation, compared to 
control cells.  
BCCIP has been known to function in the regulation of homologous 
recombination (HR) mediated DNA repair as well as regulation of BRCA2 
function. Our new data suggest that the functions of BCCIP in HR may be 
necessary in preventing chromosome damage such as caused by replication 
stress, which may subsequently affect mitosis. However, the novel BCCIP 
functions during G2/M checkpoint and/or mitosis as well as cytokinesis 
may further contribute to prevention of mitotic errors and chromosome 
instability. 
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The MBT (Malignant Brain Tumor) domain is a “chromatin reader”, a 
module that specifically recognizes mono- and di-methylated lysines within 
histone tails and has been suggested to compact nucleosomes to form higher 
order chromatin structures. Interestingly, MBT domain containing proteins 
were previously shown to have critical functions in developmental 
processes, maintenance of transcriptional repression and tumor suppression. 
Data from both Drosophila melanogaster and human suggest that MBT 
domain proteins are part of multisubunit protein complexes. In human, the 
functional analysis of MBT proteins is complicated by the existence of at 
least eight closely related paralogues. In contrast, Drosophila possesses 
three MBT proteins and therefore is a helpful model organism to better 
understand and unravel the functional roles of MBT proteins. Besides 
dL(3)mbt (Drosophila Lethal 3 malignant brain tumor), the founding 
member of the family of MBT domain proteins, there are the two Polycomb 
group proteins, called Scm and Sfmbt. The latter two act in concert with 
transcriptional repressor complexes, to counteract Trx proteins and stably 
repress hox gene expression. While the polycomb group proteins are rather 
extensively studied, little is known about the molecular functions of 
dL(3)mbt. Previous studies found dL(3)mbt to be a substoichiometric 
subunit of the Myb-MuvB/dREAM complex and in this context to be 
involved in the repression of a certain subset of dE2F-regulated genes. 
Moreover, in vitro studies have implicated dL(3)mbt in the process of 
chromatin maturation.  
Using anti-Flag affinity purification and subsequent peptide mass 
fingerprinting, we biochemically isolated and identified LINT (L(3)mbt 
interacting), a novel complex containing dL(3)mbt, the uncharacterized 
protein dLint-1 (exhibiting a PHD finger like domain), histone demethylase 
and histone deacetylase activity. Microarray expression analysis upon 
dL(3)mbt or dLint-1 knockdown in Kc cells revealed that LINT is critical 
for the maintenance of stable repression of genes with testis- or ovary-
specific expression patterns. Further investigation by chromatin 
immunoprecipitation (ChIP) demonstrates that LINT binds directly to 
promoter regions of target genes, which display reduced nucleosome 
occupancy. The loss of LINT from the promoter upon dL(3)mbt 
knockdown, which in turn leads to the derepression of target genes, is 
accompanied by changes in specific histone modifications. Current 
experiments aim to gain deeper insight into the mechanism of gene 
repression by the novel dL(3)mbt containing LINT complex.  
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The results of a recent genetic screen to identify dosage-sensitive 
Saccharomyces cerevisiae genes affecting chromosome stability revealed 
that heterozygous deletion of YAL066w results in a highly reproducible 
100 fold increase in spontaneous chromosome instability. The putative ORF 
of YAL066w encodes a 102 amino acid peptide but the protein product of 
this gene has never been detected. Moreover, most transcriptome studies 
failed to demonstrate a polyadenylated transcript derived from this locus. 
We thus reasoned that YAL066w might encode a non-coding RNA. To 
support this hypothesis, we generated several nonsense mutations in 
YAL066w and determined the chromosome instability rate of the resulting 
strains. While c.77T>A, c.131T>A, c.246T>A nonsense mutations have no 
effect on genome stability, c.186C>G heterozygous mutation strain shows 
increased genome instability although a C>T change at the same base has 
no phenotype. This result demonstrates that nonsense mutations of 
YAL066w, unlike typical protein coding genes, have very low effect on 
YAL066w gene function, indicating it is possible that YAL066w might 
encode a non-coding RNA (ncRNA) which functions in maintaining 
chromosome stability. However, both reverse transcriptase-PCR and primer 
extension experiments optimized for short RNA transcripts have failed to 
detect transcripts from this locus. Further investigation of whether non-
coding RNA transcripts are encoded in YAL066w locus or if inter-
chromosomal and/or intra-chromosomal interactions with YAL066w might 
account for the possible mediation of chromosome instability are underway. 
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SIRT1 is an NAD+-dependent deacetylase which inhibits pro-apoptotic 
factors including p53. Here we show that activation of the c-MYC 
oncogene mediates an increase in SIRT1 protein level and activity, which is 
necessary for suppression of apoptosis and senescence in human cells 
immortalized by c-MYC. A previously unknown c-MYC target gene 
facilitated the c-MYC induced SIRT1 activation. Additionally, c-MYC 
sequestered the SIRT1-inhibitor DBC1 (deleted in breast cancer 1) from 
SIRT1. Inactivation of SIRT1 by RNA interference, chemical inhibitors or 
ectopic expression of DBC1 sensitized c-MYC-expressing cells to 
apoptosis. Furthermore, SIRT1 interacted with, and deacetylated c-MYC 
resulting in increased c-MYC transcriptional activity. Collectively, the 
mutual regulation of c-MYC and SIRT1 constitutes a positive feedback 
loop that promotes cell proliferation and survival. Deregulation of this 
circuitry presumably contributes to cancer but may also provide an 
attractive target for therapy. 
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The PI3K-Akt-mTOR (PAmT) pathway is mutationally activated in a broad 
range of human cancers and is the target of various drugs in clinical trials. 
The PTEN gene encodes a lipid phosphatase that acts as a negative 
regulator of the PAmT pathway, and is lost or inactivated in many tumor 
types. To genetically dissect the importance of the PAmT pathway in tumor 
maintenance, we generated a transgenic RNAi-based mouse model that 
allows conditional PTEN inactivation in a time- and tissue-specific manner. 
We have targeted the 3´UTR of the col1A1 locus in ES cells with an 
expression cassette consisting of the tet-responsive TRE-promoter followed 
by EGFP and a PTEN shRNA embedded into the miR30 backbone. This 
system enables single-copy tet-regulated expression of the PTEN shRNA 
which can be easily tracked by EGFP monitoring. To explore the effects of 
PTEN knockdown in the lymphoid system, we crossed PTEN shRNA 
transgenic mice to a lymphoid-specific transactivator mouse line. These 
mice initially showed increased numbers of CD4/CD8 double-positive (DP) 
T-cells, and subsequently developed T-cell lymphoma/T-ALL at a similar 
latency to PTEN KO animals. The diseased mice presented with an 
enlarged thymus, spleen and peripheral lymph nodes, consisting of EGFP+, 
CD4/CD8 DP T-cells, which also infiltrated other organs like liver and 
kidney. Western blot of tumor tissues demonstrated knockdown of PTEN to 
almost undetectable levels, and CGH analysis revealed recurrent genetic 
abnormalities, including those involving c-myc. To study the effects of 
PTEN reactivation in these tumors, we serially transplanted malignant cells 
and treated part of the mice with doxycycline (dox). Suppression of the 
PTEN shRNA by dox reactivated PTEN expression and led to a substantial 
survival advantage, although all mice eventually succumbed to cancer. 
Thus, PTEN restoration appears to delay, but not abolish, tumor 
progression. The biological and molecular basis for these observations are 
currently under investigation. Understanding how tumor cells respond to 
genetic inhibition of the PAmT pathway may help guide the clinical use of 
small molecules that inhibit its components. 
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A connection between “stemness” and senescence has been recently 
suggested, where senescence-relevant pathways limit the efficacy of 
reprogramming somatic cells to pluripotency. Senescence and “stemness” 
thus use the same regulatory networks, but in opposite ways, mutually 
controlling each other. Viewing “stemness” as the critical capacity 
determining long-term faith of cancer cells, we studied the interference of 
the senescence machinery with stem cell characteristics. 
We analysed the expression of stem cell-associated gene sets in untreated 
vs. adriamycin-exposed, therapy-induced senescent (TIS) Eµ-myc 
lymphomas (apoptosis-protected by Bcl2 overexpression). The 
clonogenicity and proliferative capacity of cells were tested upon disrupting 
senescence by acute deactivation of senescence-specific regulators.  
Results show that TIS in Eµ-Myc lymphoma cells leads to significant 
changes in the expression of two alternative stem cell-defining genetic 
signatures, the embryonic stem cell-like (ESCL) and an adult tissue stem 
cell (ATSC) signature. The ESCL signature, indicative of aggressive tumor 
behavior, was reduced in TIS. However, the ATSC profile was highly 
upregulated, along with several transcripts associated with invasive 
neoplastic features, like Twist1/2, Snail1/2, Cdh2 or Mmp2. Even with 
ESCL profile reduced in senescent cells, the levels of reprogramming 
factors such as Klf4 and Sox2 remain high. Upon releasing the senescence 
barrier by disabling downstream senescence-specific pathways, cells 
resumed to proliferate with increased clonogenic potential and reverted to 
the initial ESCL profile. A similar oscillation between two stemness-
maintaining profiles is observed in hematopoietic stem cells alternating 
between proliferation and quiescence. Analogous to quiescence as an 
acknowledged stemness-preserving condition, our results indicate that cells 
in a formally terminal cell-cycle arrest preserve or even enrich the 
components of a self-renewal machinery.  
These results argue for a bi-directional relation between senescence and 
“stemness” rather than a mere mutual-restraining. While leading to a robust 
cell-cycle arrest, induction of TIS simultaneously promotes aggressive 
cancer features, like self-renewal, invasion and motility, suggesting that 
neoplastic properties are kept in check by similar molecular events as 
cellular senescence. Disrupting this broadly operating failsafe mechanism, 
for instance by inactivating mutations, will unleash a spectrum of 
detrimental growth capabilities. 
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Highly regenerative tissues such as blood must possess effective DNA 
damage responses (DDR) that balance long-term regeneration with 
protection from leukemogenesis. Hematopoietic stem cells (HSC) sustain 
life-long blood production, yet their response to DNA damage remains 
largely unexplored. We report that human HSC exhibit delayed DNA 
double strand break rejoining, persistent γH2AX foci, and enhanced p53 
and ASPP1-dependent apoptosis following γ-radiation compared to 
progenitors. p53 inactivation or Bcl-2 overexpression reduced radiation-
induced apoptosis and preserved in vivo repopulating HSC function. 
Despite similar protection from irradiation-induced apoptosis, only Bcl-2 
overexpressing HSC showed higher self-renewal capacity, establishing that 
intact p53 positively regulates self-renewal independently from apoptosis. 
The reduced self-renewal of HSC with inactivated p53 was associated with 
increased spontaneous γH2AX foci in secondary transplants of HSC. Our 
data reveal distinct physiological functions of p53 that together ensure 
optimal HSC function: apoptosis regulation and prevention of γH2AX foci 
accumulation upon HSC self-renewal. 
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Background: The cell cycle regulator UHRF1 mediates gene silencing by 
epigenetic mechanisms, including DNA methylation. UHRF1 is over expressed 
in many human cancers and its depletion from cancer cells leads to apoptosis or 
sensitization to DNA damage. In zebrafish, uhrf1 is essential for hepatocyte 
proliferation during liver development and liver regeneration following injury. 
Therefore, increased expression of UHRF1 may cause aberrant cell 
proliferation.  
 
Aim: To test the hypothesis that UHRF1 participates in hepatocellular 
carcinoma (HCC) we are (i) investigating UHRF1 expression in human HCC 
patients and (ii) examining the effects of liver-specific UHRF1 over expression 
in transgenic zebrafish. 
 
Methods & Results: UHRF1 mRNA expression was examined in tumor 
samples from 78 patients with hepatitis C. There is a significant positive 
correlation of UHRF1 expression with disease progression. While UHRF1 
expression was not significantly changed in dysplastic nodules, there was 5-fold 
upregulation in early HCC and 22-fold upregulation in very advanced HCC. 
UHRF1 protein expression mirrors this pattern. Additionally, the HCC samples 
with the highest UHRF1 levels fall into a subclass of tumors characterized by 
increased proliferation and chromosomal instability. To explore the role of 
UHRF1 as a candidate oncogene in vivo, we created transgenic zebrafish which 
over express human UHRF1 in hepatocytes (Tg(fabp10: UHRF1-GFP)). Over 
expression of an oncogene in non-transformed cells can induce cellular 
senescence, resulting in negative selection of oncogene expressing cells. We 
found that cells over expressing UHRF1 in the developing liver are out 
competed by non-expressing cells. In addition, when UHRF1 is highly 
expressed in all hepatocytes in stable Tg(fabp10: UHRF1-GFP) fish, although 
embryogenesis appears normal, these fish had a mean survival of less than one 
month. Preliminary histological analysis of the livers from Tg(fabp10: UHRF1-
GFP) fish reveal nuclear crowding, degeneration of hepatocytes, nuclear atypia, 
and destruction of the hepatic architecture.  
 
Conclusions: Tumors from patients with advanced HCC demonstrate 
significantly higher expression of UHRF1 mRNA and protein. Forced high 
expression of UHRF1 in the zebrafish liver of Tg(fabp10: UHRF1-GFP) fish 
resulted in decreased competitive advantage of over expressing cells and 
reduced survival along with abnormal livers of stable transgenics. Ongoing 
work is focused on delineating the precise cellular abnormalities that occur in 
hepatocytes that over express UHRF1. 
 162 
MIR99A, A MICRORNA THAT IS REPRESSED DURING PROSTATE 
CANCER PROGRESSION, CAN MODULATE THE CELLULAR 
RESPONSE TO DNA DAMAGE BY REGULATING CDC25A 
SYNTHESIS. 
 
Adam C Mueller, Dandan Sun, Anindya Dutta  
 
University of Virginia, Biochemistry and Molecular Genetics, 
Charlottesville, VA, 22908 
 
Exposure of cancer cells to ionizing radiation or DNA damaging 
chemotherapy activates checkpoint mechanisms where Cdc25a is degraded 
following phosphorylation by Chk1, which leads to an increase in 
phosphorylation of CDK2 tyrosine-15 by Wee1 kinase and a corresponding 
decrease in DNA synthesis. In a screen for microRNAs that are decreased 
during prostate cancer progression, we found miR99a to be significantly 
downregulated during progression. Additionally, expression of miR99a was 
lower in breast cancer cell lines that had acquired mutations in p53. Cdc25a 
was predicted as a target of miR99a by multiple algorithms. The main 
function reported for Cdc25a is that its degradation following DNA damage 
inhibits S-phase progression as part of the cell’s adaptive response. When 
an exogenous mimetic of miR99a was introduced into C4-2 prostate cancer 
cells, Cdc25a transcript shifted from being predominantly associated with 
polyribosomes to monoribosomes, indicating an inhibition of its translation. 
In the presence of exogenous miR99a, Cdc25a levels declined in C4-2 cells 
following DNA damage by ionizing radiation. Additionally, exogenous 
miR99a expression suppressed DNA synthesis following irradiation of 
prostate cancer cell lines. These data suggest that miR99a is important for 
the cellular response to DNA damage by regulating the rate of Cdc25a 
synthesis, which becomes apparent following the destabilization of Cdc25a 
protein post-irradiation. Loss of miR99a during prostate cancer progression 
or in breast cancer cells mutated in p53 thus decreases the cellular response 
to DNA damage. The results imply that progression associate changes in 
microRNAs could make cancers less sensitive to chemo- or radiotherapy. 
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Background:  
14-3-3 proteins are phospho-serine/phospho-threonine binding proteins that 
interact with a diverse array of binding partners and regulate the core 
phospho-regulatory signaling pathways of eukaryotic cells. 14-3-3 binds to 
the ligands containing mainly two different phosphorylated consensus 
motifs known as mode-I [RSXpSXP] or mode-II [RX(Y/F)XpSXP]. We 
have shown that two of the 14-3-3 isoforms, 14-3-3ε and 14-3-3γ, form a 
specific complex with the mitotic phosphatase cdc25C, and inhibit its 
function in vivo.  
 
Materials and Methods:  
To understand the role of 14-3-3ε and 14-3-3γ in cell cycle checkpoint 
function and cellular transformation, levels of these two isoforms have been 
down regulated by vector driven sh-RNA and lentiviral vectors. 14-3-3γ 
knockdown clones show abrogation of G2/M checkpoint function which 
could be restored by the sh-RNA-resistant-14-3-3γ. Down regulation of 14-
3-3γ also shows higher rate of premature chromatin condensation, higher 
mitotic index and higher frequency of multi-centriole formation during 
mitosis. To study the role of 14-3-3γ further, a novel proteomic screen was 
designed to identify specific binding partners for 14-3-3γ. Ligands for 14-3-
3γ were identified by comparing the phosphorylation level of the binding 
partners from knockdown and vector-control cells. GST-pulldown, western 
blot, MALDI-TOF and immuno-precipitation analyses were performed to 
identify and validate the binding partners. Using this screening module, 
several ligands for 14-3-3γ such as IRS1, c-Cbl, Kinesin1 (KIF5B), KLC-2, 
hsp7C, Zinc finger protein 224, GCP2 have been identified. Binding 
partners identified so far indicate the involvement of 14-3-3γ in insulin 
signal transduction pathway and regulation of centrosome duplication.  
 
Results and Conclusions:  
In brief, the work done so far shows that 14-3-3γ is required to maintain (i) 
the incomplete S phase and (ii) G2/M checkpoint function. Ligands of 14-3-
3γ obtained from this screen help to understand the role of 14-3-3γ in 
cellular transformation via insulin signal transduction pathways and 
regulation of centrosome duplication. It has been demonstrated by other 
studies that deregulation of 14-3-3γ is associated with colorectal,lung and 
breast cancer. Therefore understanding the role of 14-3-3γ in cell cycle 
checkpoint function and cellular transformation will be important for future 
therapeutic applications.  
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Alterations in the PI3-kinase pathway are common in breast, endometrial, 
and ovarian cancer and are thought to serve as major drivers of proliferation 
and survival. Multiple compounds targeting PI3-kinase pathway have been 
generated. We have examined the sensitivity of ovarian tumor cell lines to 
PI3K/mTOR inhibitors in 3D tumor spheroid assays. Interestingly, tumor 
cells that are not attached to matrix are generally highly sensitive to NVP-
BEZ235, whereas those in contact with matrix are highly resistant. In order 
to understand the mechanism of this resistance and to identify candidate 
targets to abrogate the matrix resistance, we performed reverse phase 
protein array of cells treated with NVP-BEZ235. While NVP-BEZ235 
inhibited known downstream targets of PI3K/mTOR, there was significant 
upregulation of multiple proteins known to regulate cell survival including 
IGF1R, pEGFR, p90RSK and Bcl-2. This response raised the question 
whether combined inhibition of PI3K/mTOR and any of the induced 
proteins would increase cell death in the matrix-attached cells. Interestingly, 
inhibition of Bcl-2 by ABT737 caused widespread apoptosis in the 3D 
structures, but only in combination with NVP-BEZ235. In addition, matrix-
resistance was abrogated by combined treatment with NVP-BEZ235 and 
inhibition of EGFR or knockdown of p90RSK or IGF1R.  
 
These results indicate that inhibition of PI3K/mTOR leads to induction of 
protective compensating pathways and that suppression of these pathways 
can significantly enhance sensitivity to PI3K/mTOR targeted therapies. In 
addition, these studies suggest a rational approach to the development of 
combination therapies -- that is, through identification of drug-induced 
survival pathways and targeting these pathways in combination. Our current 
efforts center on investigating the mechanisms of PI3K/mTOR inhibition 
resistance, and identification of other therapeutically relevant drug 
combinations.  
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Enhanced FGF signaling pathway is commonly implicated in the initiation 
and progression of prostate cancer. FGF receptor substrates such as FRS2 
and FRS3 are known key adaptor proteins that interact with the FGF 
receptor to mediate FGF-FGFR downstream signalling. In this study, we set 
out to investigate the functional expression of FRS2 and FRS3 in prostate 
cancer. 
 
The expression levels of FRS2 and FRS3 were characterised by real-time 
PCR and western blotting in a number of prostate cancer cell lines. Laser 
capture microdissection techniques were used in clinical samples obtained 
from prostate gland biopsies to differentiate specimens according to 
Gleason grade (3, 4 or 5). Protein expression was studied by 
immunohistochemistry in a large tissue microarray (TMA). An in vitro 
model was designed to assess the functional effect of FRS2 and FRS3 
manipulation in prostate cancer.  
 
Heterogeneous FRS2 and FRS3 expression was noted in both malignant and 
benign cells in vitro and in our clinical samples. Interestingly, we observed 
a preferential over-expression of FRS3 compared to FRS2 in a subset of 
high grade cancers. To further examine the functional effect of an increased 
FRS3 expression, stable FRS3 over-expressing DU145 prostate cancer cell 
lines were produced. We found that FRS3 over-expression results in an 
enhanced colony formation (p=0.001), cell proliferation (p=0.005) and 
migration (p<0.05) compared to control vector cells. Furthermore, over-
expression of FRS3 was able to compensate for targeted knockdown of 
FRS2. We next tested the therapeutic principle of targeting FRS molecules 
in prostate cancer cells using dual silencing of FRS2 and FRS3. In these 
experiments co-suppression of FRS2/3 resulted in a significant inhibition of 
pERK activation and a concomitant reduction in cell proliferation (p<0.05), 
migration and invasion (p<0.05) regardless of the ligand stimulus. Finally, 
synchronous knockdown of FRS2/3 with concomitant exposure to cytotoxic 
irradiation resulted in a significant reduction in cell survival compared to 
cytotoxic irradiation alone (p<0.05).  
 
Our results confirm the functional redundancy of the FRS adaptor proteins 
in FGF mediated growth factor signalling pathway in prostate cancer. 
Furthermore, our results suggest a potentially important role for the FRS3 
homologue in a subset of aggressive prostate cancers. Thus strategic 
inhibition of FRS2/3 may be a useful therapeutic target to disrupt global 
aberrant FGF signalling in prostate cancer. 
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Inactivation of the gene encoding the adenomatous polyposis coli (APC) 
tumour suppressor protein is recognized as the key early event in the 
development of colorectal cancers. APC loss leads to nuclear localization of 
beta-catenin and constitutive activity of the beta-catenin-Tcf4 transcription 
complex. Direct targets of this complex include the c-Myc proto-oncogene 
and cyclin D2. Acute loss of APC in the small intestine leads to 
hyperproliferation within the intestinal crypt, increased levels of apoptosis, 
and perturbed differentiation and migration. Recent work has shown that 
co-deletion of c-Myc rescues these abnormalities indicating that c-Myc is a 
key mediator of the phenotypic effects of APC loss (Sansom et al., 2007).  
 
Microarray analysis from mice deficient for APC or both APC and c-Myc 
identified the guanine nucleotide exchange factor T-cell lymphoma invasion 
and metastasis 1 (TIAM1) as a potential c-Myc target gene (Sansom et al., 
2007). TIAM1 activates small rho GTPase proteins such as Rac1, Cdc42 
and RhoA. Rho GTPases control a variety of cellular processes including 
cell migration, differentiation and cell-cycle progression. In this study we 
identify a requirement for Rac1 in promoting crypt hyperproliferation 
following deletion of APC. We find that following APC loss in the small 
intestine TIAM1 is upregulated and this coincides with an increase in levels 
of GTP bound active Rac. Furthermore, co-deletion of Rac1 and APC 
strongly perturbes the hyperproliferation phenotype associated with APC 
loss. This correlates with a decrease in the activity of several cyclin proteins 
indicating that Rac1 may be required for efficient G1/S phase cell cycle 
progression in vivo. We also find that the TIAM-Rac inhibitor NSC23766 
strongly attenuates the hyperproliferative phenotype associated with APC 
loss. These data indicate that TIAM1-Rac1 operate downstream of c-Myc, 
are required for hyperproliferation following loss of APC and that Rac 
maybe a useful therapeutic target in colorectal cancer. Future work will 
attempt to determine the mechanisms by which Rac1 drives APC loss 
induced hyperproliferation and whether its inhibition can perturb growth of 
APC deficient tumours.  
 167 
THE ONCOPROTEIN GLI1 INDUCES A PROGRAM OF REGRESSION 
THAT CONFERS A BASAL-LIKE AND ANDROGEN-INDEPENDENT 
PHENOTYPE UPON LNCAP PROSTATE CANCER CELLS 
 
Sandeep K Nadendla1, Matt Ward1, Lisa J Harper1, David M Prowse2, 
Karwam A Moutasim3, Gareth J Thomas3, Mahmoud Naase4, Lucy R 
Ghali4, Michael P Philpott1, Graham W Neill1  
 
1Barts and The London School of Medicine and Dentistry (QMUL), The 
Blizard Institute, London, E1 2AT, United Kingdom, 2Barts and The 
London School of Medicine and Dentistry (QMUL), Institute of Cancer, 
London, EC1M 6BQ, United Kingdom, 3University of Southampton Shool 
of Medicine, Cancer Sciences Division, Southampton, S016 6YD, United 
Kingdom, 4Middlesex University, Biomedical Sciences, London, NW4 
4BT, United Kingdom 
 
The GLI transcription factors have been implicated in the development and 
progression of prostate cancer although the mechanism(s) by which this 
occurs and how this may relate to androgen receptor (AR) function remains 
unclear. We observed that GLI1 mRNA expression and GLI reporter 
activity were both higher in normal (PNT-2) and tumourigenic (DU145 and 
PC-3) androgen-independent cells compared to androgen-dependent LNCaP 
cancer cells. We, therefore, investigated the hypothesis that: ‘GLI1 confers 
androgen-independence upon epithelial prostate cells’. Ectopic GLI1 
induced a dramatic change in LNCaP cell morphology that correlated with 
increased expression of the basal/stem-like markers CD44, β1-integrin, 
ΔNp63 and Bmi-1, as well as decreased expression of the luminal markers 
AR and PSA. Accordingly, LNCaP-GLI1 cells were viable in the presence 
of the AR inhibitor bicalutamide. Global gene expression profiling revealed 
that LNCaP-GLI1 cells are more similar to DU145 and PC-3 cells than to 
LNCaP cells and identified an EMT signature (low E-cadherin, high 
vimentin) that was verified at the protein level. Indeed, LNCaP-GLI1 cells 
were highly invasive through a Matrigel substrate and they also had a 
higher proliferative potential when seeded at a low density. Intriguingly, 
however, unlike LNCaP cells neither LN-GLI1 nor DU145 cells formed 
colonies in soft agar or prostaspheres in suspension indicating that tumours 
may arise from luminal-like cells. In summary, these data provide further 
evidence that GLI1 promotes prostate tumour cell migration and, more 
significantly, that it may help confer resistance to androgen ablation therapy 
through the induction of a basal-like phenotype which is characteristic of 
some advanced tumours.  
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Infiltration of myeloid-derived inflammatory cells to tumors is associated with 
tumor progression because different types of myeloid cells can suppress the 
anti-tumor immune response and produce factors that promote tumor growth, 
angiogenesis, or metastatic spread. 
 
Chemotherapeutic drugs, such as doxorubicin, frequently suppress immune 
cells, particularly myeloid cells, in the bone marrow; yet, their effects on 
myeloid cells within tumors are relatively unknown. We hypothesized that in 
tumors, chemotherapy alters the balance between different types of myeloid-
derived immune cells, thereby changing the tumor microenvironment. 
 
Using the polyoma middle T antigen (PyMT) mouse model of breast cancer, we 
identified changes in myeloid cell populations following doxorubicin treatment. 
To directly visualize the effects of chemotherapeutic treatment on tumor-
infiltrating myeloid cells, intravital imaging was performed. PyMT mice were 
cross bred with those expressing enhanced cyan fluorescent protein (ECFP) in 
cancer cells and enhanced green fluorescent protein (EGFP) in the myeloid cell 
population. This enabled us to use spinning disk confocal microscopy to follow 
individual cells in tumors of live mice for up 40 hours. Intravital microscopy 
showed that myeloid cells were recruited to areas with cancer cells that were 
killed by doxorubicin. Immunohistochemistry identified the major infiltrating 
myeloid cell population as neutrophils/immature monocytes. Cytokine profiling 
by antibody arrays showed an upregulation of the chemokines CCL2 and 
CCL12 following doxorubicin treatment, suggesting a role for these molecules 
in the recruitment of the neutrophils/immature monocytes. Ongoing studies 
include flow cytometric analyses of changes in immune cell populations within 
the tumor following chemotherapy, and dual treatments of doxorubicin and 
CCL2/CCL12 antagonists to determine the importance of these chemokines in 
myeloid cell recruitment and host response to chemotherapy. 
 
In conclusion, after treatment with the chemotherapeutic drug doxorubicin, the 
balance between different tumor infiltrating myeloid cells are pushed towards 
neutrophils and immature monocytes due to increased recruitment of these cells 
to the treated tumor. Given the many different roles of different myeloid cells 
on tumor progression, these findings may have clinical implication. 
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Cbl family E3 ubiquitin ligases are negative regulators of tyrosine kinase 
signaling. Recent work has revealed a critical role of Cbl in the maintenance 
of hematopoietic stem cell (HSC) homeostasis and mutations in CBL have 
been identified in myeloid malignancies. Here we show that, in contrast to 
Cbl- or Cbl-b- single-deficient mice, concurrent loss of Cbl and Cbl-b in 
HSC compartment leads to an early-onset lethal myeloproliferative disease 
in mice. Importantly, expression of mutant Cbl was not required for 
pathogenesis. Cbl, Cbl-b double-deficient bone marrow cells are 
hypersensitive to cytokines, and show altered biochemical response to 
thrombopoietin. Thus, Cbl and Cbl-b play redundant but essential roles in 
HSC regulation whose breakdown leads to a hematological malignancy that 
phenocopies crucial aspects of mutant Cbl-driven human myeloid 
malignancies. 
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The cyclin D-cdk4/6 complex has two distinct functions. Its catalytic role 
involves its ability to act as serine/threonine kinase, responsible for 
phosphorylation of substrates required for cell cycle transitions, while its 
sequestration function involves its ability to act as a reservoir for p27Kip1. 
This association sequesters p27 from cyclin E-cdk2 complexes, allowing 
them to remain active. We exploited the ability of TGF-β to induce 
p15Ink4b in order to ascertain whether the catalytic and sequestration roles 
of cdk4 and cdk6 were required equally during proliferation. p15 binding 
destroys the cyclin D/cdk4 complex, negating both the catalytic and 
sequestration functions and results in G1 arrest. Expression of wild type, 
catalytically inactive or p15-resistant cdk4 or cdk6 mutants rendered 
Mv1Lu cells resistant to TGF-β-mediated growth arrest. Cells expressing a 
catalytically inactive, p15-resistant double cdk6, but not cdk4, mutant were 
also resistant to TGF-β-mediated arrest, proliferating in the absence of all 
cdk4/6 kinase activity. Expression of this cdk6 mutant acted as a sink for 
p27, allowing cdk2 to remain active, and suggested that the sequestration 
function was sufficient in continuously proliferating cells. Interestingly, the 
homologous cdk4 mutant was unable to overcome TGF-β-mediated arrest. 
When contact arrested cells were released from quiescence in the presence 
of exogenous cdk4, the G0-G1 transition was accelerated in a kinase-
dependent manner. In contrast, overexpression of both catalytic and non-
catalytic cdk6 alleles accelerated G0 exit, suggesting that cdk6 may play a 
different role in the G0-G1 transition. Gel filtration analysis of cdk4 and 
cdk6 pools in proliferating and arrested cells revealed the presence of a 
previously unidentified cyclin D-cdk6 dimer. Phosphoamino acid analysis 
demonstrated that cdk4 and cdk6 were differentially modified in 
proliferating cells. Taken together, the gel filtration data and phosphoamino 
acid data may explain the differential activity of these kinases to promote 
proliferation of cells both in cycle and upon reentry from the quiescent 
state. 
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High mobility group box 1 (HMGB1) is a small DNA-binding protein with 
roles in DNA repair and transcription. It is thought to bind DNA through its 
HMG-box motifs without sequence specificity and aid in distorting the 
DNA structure to allow access for other proteins. In addition to functions in 
the nucleus, HMGB1 acts as a cytokine when released from cells. 
Extracellular HMGB1 binds to the Receptor for Advanced Glycation End 
Products (RAGE) or TLR2/4 and causes downstream p42/44 MAP kinase 
and NFκB pathway activation. HMGB1 is overexpressed in various cancers 
and is correlated with poor prognosis, higher tumor grade and metastasis. 
Although many correlations between HMGB1 expression and cancer exist, 
its specific functions are unclear. We have used a stable lentiviral 
knockdown system in MDA-MB-231 breast cancer cells to further study the 
role of HMGB1 expression in cancer. HMGB1 depletion causes a change in 
cell morphology, decreases cell scattering and reduces F-actin foci in vitro. 
In a xenograft model HMGB1 knockdown tumors grow at a significantly 
slower rate than control tumors and show reduced angiogenesis and 
increased necrosis. Despite decreased growth in vivo, there is no difference 
in doubling time in vitro. Knockdown cells also produce about 50% fewer 
metastases in a colonization/metastasis assay in mice. HMGB1 depletion 
does not reduce p42/44 MAPK pathway activity, likely due to preexisting 
activating mutations in this pathway in MDA-MB-231 cells. Using a 
microarray, we have found 44 genes significantly down-regulated by 
HMGB1 shRNA and 167 genes that are up-regulated. Notably, HMGB1 
knockdown decreases pro-angiogenic VEGF expression and increases the 
anti-angiogenic semaphorins expression, consistent with our observations of 
decreased angiogenesis in the absence of HMGB1. The metastasis-related 
protein CD24 is also down-regulated with HMGB1 knockdown. CD24 is a 
ligand for the endothelial cell surface protein P-selectin and can promote 
tumor cell adhesion and metastasis, which is in line with our finding that 
HMGB1 is required for colonization of tumor cells from the circulatory 
system. We have used our HMGB1-dependent gene signature and 
compared it to primary tumor array data. A set of 18 genes, including the 
semaphorins, is significantly correlated with HMGB1 expression in primary 
breast tumors, suggesting HMGB1 regulates a specific gene expression 
program in breast cancer.  
This work shows a role for HMGB1 in tumor growth, angiogenesis and 
metastasis that are independent of MAPK pathway activation and defines a 
set of genes that are regulated by HMGB1 expression.  
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Mutations in the human homologue of the Drosophila Patched1 (Ptc1) gene 
are responsible for basal cell nevus (BCN) syndrome, and are commonly 
found in sporadic basal cell carcinoma (BCC), medulloblastoma (MB) and 
rhabdomyosarcoma (RMS). MBs are highly malignant tumors originating in 
the cerebellum and represent the most common pediatric brain neoplasia. 
RMSs are tumors of the striated skeletal muscle and are the most common 
pediatric soft-tissue sarcoma. Mice heterozygous for an inactivating 
mutation in Ptc1 (Ptc1+/-) spontaneously develop MB and RMS, and 
develop BCC following radiation exposure. The susceptibility of Ptc1+/- to 
MB or RMS is highly dependent on the genetic background of the mice. 
C57BL/6 (B6) Ptc1+/- mice are susceptible to MB while BALB/c (BALB) 
Ptc1+/- mice are susceptible to RMS.  
We are using Sleeping Beauty (SB), a member of the Tc1/mariner 
superfamily of transposable elements isolated from salmon fish genome, for 
our forward genetic screen to discover cancer genes. This is a bipartite 
system that consists of an inducible SB transposase gene under the control 
of Cre-recombinase and multiple copies of a mutagenic SB transposon that 
is engineered to either deregulate the expression of proto-oncogenes or 
inactivate the expression of tumor suppressor genes. To sensitize the system 
for MB and RMS, we combined the SB mutagenesis system with the Ptc1 
mutation. We find that SB decreases the latency for the development of MB 
and RMS, increases the penetrance of the disease and the incidence of RMS 
in Ptc1+/- mice that is of a predominately B6 background. We are currently 
in the process of cloning SB integration sites to identify genes/pathways 
critical for the initiation and propagation of MB and RMS. By combining 
the SB mutagenesis system with Ptc1 mutation, we have a powerful new 
model for dissecting the cancer genome of MB and RMS. 
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G protein-coupled receptor kinase 2 (GRK2) plays a central role in the 
regulation of G-protein-coupled receptors (GPCR) by triggering receptor 
desensitization and GPCR internalization. However, this protein is also able 
to phosphorylate non-GPCR substrates and associate with a variety of 
signaling molecules, thus emerging as a relevant node in signaling pathways 
with unforeseen influences in basic cellular processes such as cell cycle 
progression or cell motility. Consistently, the expression and function of 
GRK2 is tightly regulated and its protein levels are often altered in 
pathological conditions such as inflammatory diseases and certain tumors. 
Related to this, our group has shown that GRK2 is rapidly degraded by the 
proteasome pathway in a c-Src and MAPK phosphorylation-dependent 
manner and that Mdm2, an E3-ubiquitin ligase involved in tumorigenesis, 
plays a key role in its ubiquitination and turnover. Upon GPCR challenge, 
the adaptor proteins β-arrestins facilitates the Mdm2 and GRK2 association, 
while over-stimulation of the PI3K/Akt axis prevents the Mdm2-mediated 
degradation of GRK2 and leads to its accumulation in several transformed 
cell lines, contributing to alter their migratory properties and proliferation. 
Interestingly, changes in the expression level of β- arrestins and in their 
scaffolding ability have also been described in different tumor cells and 
signaling contexts what could affect the stability of GRK2. Therefore, we 
have addressed the impact of β-arrestins as Mdm2 co-factors in the 
modulation of GRK2 turnover in response to different challenges. Our 
results indicate that in the absence of GPCR activation, β-arrestins do not 
perform an adaptor role for GRK2/Mdm2 association, but rather compete 
with GRK2 for direct Mdm2 binding. On the other hand, β-arrestin 
modifications as those promoted by receptor tyrosine kinase activation 
interfere with the GPCR-triggered recruitment of c-Src and MAPK required 
for phosphorylation of GRK2, thus favoring kinase stabilization. Our data 
suggest that disruption of the scaffolding functions of β-arrestins in Mdm2-
dependent GRK2 degradation, kinase levels may lead to kinase 
upregulation and contribute to tumorigenesis in particular settings. 
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Traditional chemotherapy of hematologic malignancies is increasingly 
being supplemented with the use of monoclonal antibodies that target 
specific epitopes on cancer cells.  
Here we generated a platform to model chemo-immune treatment of human 
B-cell malignancies, using the humanized mouse model. Human 
hematopoietic stem cells (HSCs) were isolated from cord blood, expanded 
in vitro, and transduced with a lentivirus in which the B-cell-specific human 
CD19 promoter controls the expression of cMyc and Bcl-2. Ex vivo 
infected HSCs were injected into sublethally irradiated NOD-SCID-IL2Rγ-/- 
(NSG) mice. Two months following this reconstitution, mice develop an 
acute lymphoblastic leukemia, where malignant human pro-B cells infiltrate 
numerous host organs and lead to rapid weight loss, neurological symptoms 
and eventual death. Transplanting leukemic cells into non-irradiated 
(secondary) NSG mice induced a phenotypically identical disease. 
Notably, leukemic cells express CD52, the epitope targeted by the 
monoclonal antibody Alemtuzumab. Secondary NSG mice were 
transplanted with human pro-B ALL; 2-3 weeks later they were treated with 
1-3 i.v. injections of Alemtuzumab. Treated mice showed a significant 
decrease in leukemic cell frequency in the spleen, liver, and peripheral 
blood, but not in the bone marrow or the brain. Killing of leukemic cells 
required Alemtuzumab to possess an intact Fc region, but was independent 
of complement fixation. Depleting macrophages in vivo prior to 
Alemtuzumab treatment abrogated the therapeutic response, strongly 
suggesting that macrophages mediate the anti-leukemic effect of 
Alemtuzumab, by binding and destroying antibody-coated leukemic cells. 
In order to overcome resistance to Alemtuzumab in the bone marrow, we 
initiated leukemia treatment using Cyclophosphamide, mimicking 
chemoimmunotherapy in clinical practice. Combining Cyclophosphamide 
with Alemtuzumab led to a nearly complete clearance of human leukemic 
cells from both the brain and the bone marrow. 
Here we introduce a humanized mouse model of pro-B ALL, where 
leukemic cells arise de novo from lentivirus-infected human HSCs. This 
model provides the opportunity to test in vivo the efficacy of human-
specific monoclonal antibodies against human leukemia cells. Using this 
model we elucidated the mechanism of its action and developed a 
successful synergistic chemo-immune therapy. Future experiments will 
address mechanisms of treatment resistance in the bone marrow using in 
vivo RNAi-screening technology. 
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The retinoblastoma protein (pRB) is thought to act as a tumor suppressor 
mostly through its ability to restrain cell division. Here we report a 
previously unappreciated role for pRB in epithelial cell migration. We have 
discovered that Rb null chimeric embryos have impaired eyelid closure, a 
defect commonly associated with mutations in genes affecting cell motility. 
Indeed, by generating Rb null keratinocytes, we have found that Rb mutant 
cells show reduced migratory capacity, both as single cells and wounded 
monolayers. This defect is further highlighted by the inability of Rb-
deficient skin to effectively repair wounds. What is the basis of this altered 
motility in Rb deficient epithelial cells? Our data suggest that deregulation 
of the EGF signaling pathway is the underlying cause of the tissue closure 
defects in Rb mutant mice and of the altered motility in Rb deficient 
epithelial cells. These findings open the door to the possibility that the 
mechanisms by which Rb acts as a tumor suppressor may extend to 
processes beyond the cell cycle. As cell migration represents a fundamental 
facet of tumorigenesis, the discovery that Rb appears to play a role in 
coordinating cell dissemination may offer new insight into its role in cancer. 
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Germ-line mutations that inactivate BRCA2 predispose to early-onset 
cancer. In previous studies, BRCA2 was shown to control the HR 
(homologous recombination) through regulating Rad51 oligomerization. 
The partaking in the HR makes BRCA2 absolutely required for error-free 
DNA repair, but other functions of BRCA2 are largely unknown. Recently, 
we have found that the C-terminus of BRCA2 (B2-9 fragment) interacts 
with a spindle assembly checkpoint protein, BubR1. This suggests for a role 
of BRCA2 in the regulation of accurate chromosome segregation. 
Moreover, the B2-9 fragment contains a motif that is required for Rad51 
oligomerization. Thus, we suspected that ectopic expression of B2-9 
fragment may induce an unbalanced HR and spindle assembly checkpoint 
function. Therefore, we generated a transgenic mouse ubiquitously 
expressing the C-terminus of Brca2. Indeed, the embryonic fiblroblasts 
from the B2-9 transgenic mice showed defects in both spindle assembly 
checkpoint and DNA damage response, suggestive of functional disruption 
of BRCA2. Furthermore, these mice developed various type of tumor 
including skin squamous cell carcinoma, adenocarcinoma, teratoma-like 
mass and leukemia at 71~109 weeks after birth. Taken together, our study 
reveals the dual function of Brca2 C-terminus in regulating HR and the 
mitotic checkpoint.  
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MicroRNAs are critical regulators that influence numerous cellular and 
developmental processes through their ability to control gene expression. 
Nearly one thousand human and more than 600 mouse microRNA 
sequences have been described, many of which are mis-regulated in 
diseases, including cancer. Despite much investigation, their roles and 
targets are largely unknown. Generation of animal models in which 
microRNA levels can be regulated in vivo will significantly expedite our 
understanding of microRNA biology. We therefore have launched an effort 
to generate a collection of ES cells expressing tet-regulatable microRNAs 
and sensors using an established Flp/Frt recombinase-mediated cassette 
exchange system that utilizes our own custom-designed Flp-in targeting 
vector. All mouse microRNAs known to date, and their corresponding 
sensors (microRNA complementary sites) have been inserted downstream 
of GFP in the “tet-on”-Flp-in targeting vectors, which allows for regulatable 
expression of microRNAs and sensors in ES cells. The microRNAs will be 
expressed in two different contexts; 1) in its natural context and 2) 
embedded in the miR30 backbone. The latter is potentially advantageous in 
that it bypasses the natural inhibitory pathways of microRNA biogenesis. 
These ES cell lines can be used to generate transgenic mice expressing 
regulatable microRNAs and sensors to study the role of microRNAs in 
cancer. This collection of ES cell lines will be made available to the 
community via the NCI Mouse Models of Human Cancer Consortium 
mouse repository. We anticipate that this resource will serve as a powerful 
tool for the research community at large.  
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Cellular organization into epithelial architecture maintains structural 
integrity and homeostasis by suppressing cell proliferation and apoptosis. 
We have previously shown that differentiated epithelial organization of 
MCF10A 3D acini blocks the ability of c-Myc to re-initiate cell cycle 
progression and induce transformation. This epithelial architecture imposed 
restraint to the oncogenic c-Myc is dismantled upon silencing of LKB1, the 
mammalian homologue of polarity protein PAR4 (Partanen et al., PNAS 
2007). Here we have explored the role of LKB1 in formation and 
maintenance of epithelial architecture in vivo using mice, in which Lkb1 
alleles can be conditionally deleted in the luminal epithelial cells of 
mammary gland. We show that loss of Lkb1 induces gross alterations in the 
epithelial architecture of 3D structures and in the mammary gland, 
manifested by loss of cell polarity, defects in the basement membrane 
structure and spontaneous hyperbranching. Loss-of Lkb1, when combined 
with mammary specific overexpression of c-Myc, led to dramatic 
acceleration of c-Myc induced mammary tumorigenesis. These mice exhibit 
increased tumor multiplicity and volume, and in addition the tumors show 
histopathological features distinct from Myc-induced mammary tumors. 
Furthermore, the cooperation of Lkb1 loss and c-Myc activation resulted in 
strikingly transformed 3D acini, which allows studies on molecular 
mechanisms underlying the synergy. In conclusion, our data show evidence 
that Lkb1 has a crucial role in formation of epithelial architecture and 
apicobasal polarity and that loss of Lkb1 significantly cooperates with 
activated c-Myc oncogene in tumorigenesis. 
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Deletions in the short arm of human chromosome 1 (1p36) are frequently 
observed in a variety of human cancers. Our laboratory identified 
Chromodomain Helicase DNA-binding domain 5 (CHD5) as a novel tumor 
suppressor mapping to 1p36. Recent studies show that CHD5 is 
hypermethylated or mutated in several forms of human cancer. As a 
member of the CHD family of SWI/SNF-like ATP dependent-chromatin 
remodeling proteins, CHD5 has been proposed to regulate chromatin 
dynamics.  
 
Eukaryotic transcription is dynamically regulated by different 
posttranslational modifications of histone tails, which are identified by 
distinct sets of protein complexes. Here we show that Chd5 recognizes 
unmethylated H3K4 through its predicted tandem plant homeodomains 
(PHDs). We identified specific amino acids within this domain that are 
essential for mediating H3K4me0 binding. Mutation of these residues 
abolishes Chd5 function. Overexpressing or reducing the level of Chd5 
identifies its role in both activating and repressing target gene expression. 
Mutations in PHD fingers that abrogate H3 binding fail to modulate Chd5-
target gene expression. These findings reveal a critical role of histone 
interaction by the tandem PHD modules in mediating Chd5’s cellular 
function. This study further expands our view on CHD5’s tumor 
suppressive mechanism that may help to design novel anti-cancer strategies. 
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Kaposi`s sarcoma herpesvirus (KSHV) is a human tumor virus and the 
causative agent of three human malignancies: Kaposi sarcoma (KS), 
primary effusion lymphoma (PEL), and multicentric Castleman’s disease. 
KSHV latent protein v-cyclin is a cellular cyclin D2 homolog reported to 
promote G1-S transition in the cell cycle, induce DNA damage and have 
oncogenic potential. To assess the oncogenic potential of v-cyclin in vivo 
we have targeted v-cyclin expression to the B and T lymphocyte 
compartments using the Eμ-promoter/enhancer. Expression of v-cyclin in 
the CD1/ICR genetic background leads to markedly accelerated 
tumorigenesis, as the mice develop undifferentiated T-cell lymphomas even 
as early as 1 month of age with a disease penetrance over 90%. The onset of 
tumorigenesis is p53-independent, as the mice retain wildtype TP53 and 
INK4a. Intriguingly, the pre-tumorigenic thymi and spleens had a decreased 
cellularity in the v-cyclin transgenic mice, although the number of 
proliferating cells was similar or even higher as in the non-transgenic 
littermates, and apoptosis was not increased. Preliminary studies on the 
differentiation status of the T lymphocytes suggest alterations in the v-
cyclin transgenic mice over the non-transgenic littermates. We are currently 
addressing the mechanisms and pathways leading to this high-penetrance 
tumorigenesis and altered differentiation of the T lymphocytes by genome-
wide gene expression analysis combined with functional assays. 
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During cancer progression epigenetic events, like alteration of histone 
modification markers, co-exist with genetic events and affect cell properties line 
cell migration and invasion. We analysed the role of global histone 
modifications, how this modifications may be affected by pathways activated by 
oncogenes and their association with epithelial plasticity.  
We generated oncogene-transformed colon cell lines by RASV12, BRAFV600E 
oncoproteins. Notably, the phenotype of the H-RASV12 oncoprotein-
transformed cells (Caco-H) is associated with Epithelial-Mesenchymal 
Transition (EMT) characteristics (3). We have shown that E-cadherin is 
regulated by TAF12 transcription factors (4).  
A global histone modification analysis revealed a general de-regulation of 
histone modification markers, in particular H3K27me3 by H-RAS. The 
dependence of histone modification marker by MER-ERK signalling pathways 
(5). Variations of methyl- and acetyl-transferase enzymes as EZH2, JMJD3, 
PCAF GNC5 and HDACs are associated with appearance of aggressive tumour 
properties. Evidence will be presented for the role of particular histone methyl- 
and acetyltransferases in cell processes associated to Epithelial-Mesenchymal 
Transition (EMT) . In order to elucidate the mechanisms, ChIP analysis has 
been used to identify their target genes in EMT. Interestingly, Cyclin D1 and E-
cadherin genes demonstrate inverse histone repression patterns on their 
promoter, associated to their inverse expression levels.  
This study provides details on a) Cyclin D1 and E-cadherin promoters are 
regulated by histone modifications in a RAS-dependent manner. b) EMT 
associated E-cadherin expression correlates with existence of H3 histone 
methylation markers on the promoter c) global histone modification changes 
and/or their histone modifiers can be proven reliable tumour markers.  
 
(1) Oikonomou E., Makrodouli E., Evagelidou, M., Joyce T., Probert, L. and Pintzas 
A. (2009). Neoplasia 11, 1116-1131 .  
(2) Roberts, M., Drosopoulos, K., Vasileiou, G., Stricker, M., Taoufik E., Maercker, 
C., Guialis, A., Alexis, MN. and Pintzas, A. (2006). Int. J. Cancer 118, 616–627.  
(3) Joyce, T., Cantarella, D., Isella, C., Medico, E. and Pintzas A. (2009). Clin Exp 
Metastasis 26, 569–587 .  
(4) Voulgari, A., Voskou, S., Tora, L., Davidson, I. Sasazuki T., Shirasawa, S., and 
Pintzas, A. (2008). Mol. Cancer Res. 6, 1071-108  
(5) Mazón Peláez, I., Kalogeropoulou, M., Voulgari, A., Pankotai, T., Boros, I., and 
Pintzas, A. (2010). Int. J. Biochem. Cell Biol. 42, 911–920  
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During colorectal cancer progression BRAF and KRAS oncogenes are often 
mutated in about 15% and 35% respectively, but the two mutants rarely coexist 
in the same tumour. Unlike BRAF and KRAS, mutations in RHO genes are 
extremely rare in tumours, but they contribute with distinct roles in invasion and 
metastasis. The aim of this study is to compare and define the effect of 
BRAFV600E, KRASG12V and HRASG12V oncoproteins in cell migration and 
invasion pathways mediated by specific members of the Rho GTPase family. 
For that, RAS and BRAF oncogenes were either stably transfected or silenced 
in colon cancer cells (1, 2, 3) and analysis of Rho GTPase pathways was 
performed.  
Evidence presented here indicate that BRAFV600E provides colon cancer cells 
with high migration and invasion properties in vitro, through activation of 
RhoA. BRAFV600E regulation of RhoA activity is mediated by MEK-ERK 
pathway. Cross-talk analysis revealed that RhoA may have an antagonistic 
function with Cdc42 in Caco-BR cells. KRASG12V works towards enhancing 
the ability of colon adenocarcinoma cells Caco-K to migrate and invade through 
filopodia formation and PI3K-dependent Cdc42 activation. Interestingly, in 
Caco-K cells Cdc42 mediates expression of Rac1, as shown by siRNA 
approach. HRASG12V induces a well differentiated mesenchymal morphology, 
through the Epithelial to Mesenchymal Transition (EMT) process, associated 
with Rac1 activity. RhoA activity is suppressed in Caco-H cells through 
activation of PI3K pathway. Moreover, BRAF and KRAS oncogenes cooperate 
with TGFβ-1 pathway to provide cells with additional transforming properties.  
This study discriminates oncogene-specific cell migration and invasion 
pathways mediated by Rho GTPases and by their regulatory GAPs , GEFs and 
GDIs in colon cancer cells and reveals potential new oncogene-specific 
characteristics for targeted therapeutics.  
 
 
1. Oikonomou E., Makrodouli E., Evagelidou, M., Joyce T., Probert, L. and Pintzas 
A. (2009). BRAFV600E efficient transformation and induction of MSI versus 
KRASG12V induction of senescence markers in human colon cancer cells. 
Neoplasia 11, 1116-1131  
2. Joyce, T., Cantarella, D., Isella, C., Medico, E. and Pintzas A. (2009). A 
molecular signature for Epithelial to Mesenchymal transition in a human colon 
cancer cell system is revealed by large-scale microarray analysis. Clin Exp 
Metastasis 26, 569–587  
3. Roberts, M., Drosopoulos, K., Vasileiou, G., Stricker, M., Taoufik E., Maercker, 
C., Guialis, A., Alexis, MN. and Pintzas, A. (2006). Microarray analysis of the 
differential transformation mediated by kirsten and harvey ras oncogenes in a human 
colon adenocarcinoma cell line. Int. J. Cancer 118, 616–627.  
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Most data on the therapeutic potential and expression of TRAIL in colorectal 
cancer have shown increased sensitisation of tumour cells as compared to 
premalignant or physiological cells or tissues. Thus, particular oncogenes like 
MYC and RAS can be sensitisers for TRAIL induced apoptosis. We have 
previously shown that RAS oncogenes can sensitise colon cells to TRAIL 
induced apoptosis (1). We have presented evidence in cell models that this 
effect is usually mediated by TRAIL receptor DR4 and DR5 overexpression 
and/or redistribution (2).  
In this study, colorectal cell lines bearing RAS and BRAF mutant oncogenes or 
colorectal clinical samples were either treated with recombinant TRAIL or 
analysed for the presence of RAS and BRAF oncogenic mutations and DR4, 
DR5 expression. We present evidence that BRAF oncogenes can sensitise colon 
cancer cells to TRAIL induced apoptosis via TRAIL receptor DR5. The 
underline mechanisms for this sensitization involve MAPK and PI3K pathways, 
depending on the genetic alteration profile of the individual tumour . We have 
also shown that DR5 is the most frequently upregulated DR in clinical samples 
of colon cancer. Furthermore, the presence of K-RAS and BRAF mutations in 
the tumour may directly or indirectly enhance DR expression (3). Mutations on 
K-RAS and BRAF oncogenes have been shown in many studies to be 
associated with resistance to EGFR targeted therapeutics and combinations. 
TRAIL-based therapeutics, other as mono- or combination therapy could 
provide a promising alternative for K-RAS/BRAF bearing colorectal tumours. 
The implications of these findings on personalized therapeutics will be 
discussed.  
 
(1) Drosopoulos, K. Roberts , M., Cermak, L., Sasazuki , T., Shirasawa, S., Andera 
L. and Pintzas, A. (2005). Oncogenic Ras transformation sensitizes human colon 
cancer cells to TRAIL induced apoptosis by upregulating DR4 and DR5 receptors 
through a MEK dependent pathway . J. Biol. Chem. 280, 22856-22867.  
(2) Psahoulia, F. H., Drosopoulos K. G., Doubravska, L., Andera, L. and Pintzas, A. 
(2007). Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by 
inducing the accumulation of death receptors in lipid rafts. Mol. Cancer. Ther 6, 
2591-2599.  
(3) Oikonomou, E., Kosmidou, V., Katseli, A., Kothonidis, K., Mourtzoukou, D., 
Kontogeorgos, G., Andera, L., Zografos, G., and Pintzas, A. (2009). TRAIL 
Receptor Upregulation Correlates to KRAS/ BRAF Mutations in Human Colon 
Cancer Tumours and Respective Normal Tissue. Int. J. Cancer 125, 2127-2135  
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Targeting the process of tumor vascularization is a key aspect of modern 
anticancer therapy. However, the cellular and molecular mechanisms by 
which tumors enroll vasculature remains relatively undefined. Furthermore, 
the role of host inflammatory cells, and bone marrow derived (BMD) cells 
in this process remains controversial. BMD endothelial progenitor cells 
(EPCs) have been identified by our lab and others as being critical for the 
angiogenic switch1,2. However, because different markers are used to track 
these cells in the bone marrow, blood and tumour-stroma, controversy 
exists as to whether the same cell is truly being followed in vivo. We have 
developed a series of lentiviral based gene reporters which can be used to 
dynamically track EPCs in vivo; and shown that EPCs form a distinct 
lineage which can be tracked from the BM to their incorporation as part of 
tumour vasculature. Follow-up work using transgenic mice has confirmed 
that the Inhibitor of DNA Binding 1 (Id1) is a marker of EPCs; and plays an 
important role in their function2. Finally, these same tools have been used to 
identify the molecular mechanisms which might underlie tumour-EPC 
biology in vivo; including the role and identity of putative EPC-linked and 
endothelial microRNAs.  
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Spy1A is a unique cell cycle activator known to mediate cell cycle 
progression and override the DNA damage response. This work focused on 
determining the role of this protein on postnatal mammary gland 
morphogenesis and neoplasia. We have demonstrated that Spy1A levels are 
tightly regulated during mammary gland development and that ectopic 
expression stimulates precocious development and results in disrupted 
morphology of the gland. Importantly, we demonstrate that overexpression 
of Spy1A accelerates tumorigenesis in vivo and that elevated protein levels 
are implicated in a number of human cancers, including that of the breast. 
We have begun to dissect the molecular mediators regulating Spy1 
expression and Spy1-mediated effects during mammary development and 
tumorigenesis. Collectively our work is the first to determine that the 
Spy1/RINGO family of proteins may play an essential role in regulating 
both normal and abnormal growth processes in the breast. 
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Mouse models of cancer have led to important insights, aided mechanistic 
understanding of tumorigenesis as well as guided therapeutic development. 
To facilitate experimental use of genetically engineered mouse models 
while recapitulating the stochastic nature of human cancer, we developed a 
mouse tumor model strategy involving stepwise genetic manipulation of 
embryonic stem (ES) cells and chimera formation to enable tumor induction 
in tissues containing both normal and engineered cells. An allelic series of 
lung cancer models containing HER2, KRAS, or EGFR oncogenes 
demonstrated that resultant  
adenocarcinomas arising within normal lung tissue exhibited features of 
advanced malignancies.  
 
An experimental therapeutic trial performed on the EGFRL858R and 
KRASG12V chimeric models with an EGFR inhibitor accurately reflected 
clinical observations with the ERBB-driven tumors responding well to 
treatment and the KRAS-driven tumors exhibiting resistance. On the 
molecular level, transcriptome and immunohistochemical analyses revealed 
that these tumors featured differences in downstream pathway activation: 
namely, PI3K pathway activation was unique to ERBB-driven tumors while 
KRAS- driven tumors showed activation of JNK pathways. The latter 
suggests a novel therapeutic point of intervention in this important and 
therapeutically non-responsive tumor category. In addition, we tested the 
response of KRAS- and EGFR-driven lung tumors to tivozanib, a potent, 
selective VEGFR inhibitor, currently in pivotal trials in Kidney cancer and 
in earlier stage studies in NSCLC. Uniform regression of these tumors was 
observed resulting in a significant survival benefit to the tumor bearing 
mice in both models. With these combined findings, we have demonstrated 
that our chimeric models not only provide insight into key pathway 
activation mechanisms of cancer biology, but can also aid in targeted drug 
efficacy studies, potentially leading to improved patient therapies.  
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High throughput chemical screens identify daunting numbers of cytotoxic 
compounds. However, a major bottleneck in drug development is the 
systematic description of how these cytotoxic compounds exert their effects 
in vitro and in vivo. While high throughput microarray and pool-based RNA 
interference-based approaches can be used to examine drug mechanism, 
their scale limits broad dissemination. Specifically, there is an unmet need 
for a measurement system that is capable of examining the function of an 
entire gene family in a broad array of physiologic contexts and drug 
conditions. We present a flexible Luminex based assay with which we 
systematically interrogate how the entire BCL-2 family modulates 
therapeutic response in vitro and in vivo. Using this approach, we perform 
the first in vivo screen for modulators of therapeutic response. Notably, we 
find that the in vivo suppression of components of the extrinsic death 
pathway can promote resistance to front-line genotoxic chemotherapy. 
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Breast cancer is a major cause of cancer-related deaths in American women; 
therefore, the characterization of novel breast-cancer related molecules for 
the discovery of new markers and drug targets remains essential. The 
human DEK gene encodes a chromatin-binding protein with specific roles 
in the regulation of DNA topology. Using classical transformation assays 
and knockout mice, we have recently identified DEK as a bona fide 
oncogene in keratinocytes, but the role of DEK in breast cancer is unknown. 
We demonstrate here that DEK is highly expressed in breast cancer cell 
lines compared to immortalized cells and normal tissue. DEK over-
expression in non-tumorigenic MCF10A mammary epithelial cells resulted 
in increased growth rates and motility with evidence of an epithelial-to-
mesenchymal transition (EMT). Conversely, DEK knockdown in 
tumorigenic MCF7 and MDA-MB-468 breast cancer cells resulted in 
decreased cell proliferation, survival and migration. The use of DEK-
proficient and -deficient breast cancer cells in an orthotopic xenograft 
model further suggested that DEK contributes to tumor formation and 
metastatic growth in vivo. Molecular analyses for proteins commonly 
deregulated in breast cancers revealed that DEK positively regulated ΔNp63 
expression and β-catenin signaling, pathways which also are important for 
the growth of normal and cancer stem cells. To determine whether DEK 
might regulate cancer stem cell formation or maintenance, we subjected 
DEK knockdown and overexpressing breast cancer cells to mammosphere 
assays. The results suggest that DEK increases mammosphere formation. 
Together, our data indicate that DEK expression stimulates the growth, 
motility and stem cell character of breast cancer cells in vitro and in vivo. 
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Inducing cancer cell death with DNA-damaging chemotherapeutic agents is 
the most widely used strategy in cancer therapy. However, DNA-damaging 
drugs kill both normal and cancerous cells, which severely limits current 
treatment regimens. A high-throughput, cell-based screen for small 
molecules that activate transcription of a p53-regulated target gene in cancer 
cells uncovered a remarkable naturally occurring small molecule, 
piperlongumine (PL). PL selectively induces apoptosis in cancer cells and 
tumor explants regardless of p53 status while leaving normal cells and 
tissues unaffected. A quantitative proteomic method for target identification 
and mechanistic studies revealed that PL induces reactive oxygen species 
(ROS) in cancer cells but not normal cells by inhibiting proteins involved in 
ROS metabolism. In addition, PL protected normal cells from chemo-drug-
mediated DNA damage response. In vivo experiments demonstrate potent 
anti-tumor activities of PL at low concentrations with no apparent adverse 
effects on normal organ and tissue function. PL-induced selective killing of 
cancer cells supports the theory that cancers, including their cancer stem 
cells in the case of ROS, have increased dependence on stress-response 
pathways. By targeting ROS, PL constitutes a novel strategy for cancer 
therapy that preferentially eradicates cancer cells. 
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Squamous Cell Carcinoma (SCC) is a common form of human cancer that 
can arise in various epithelial tissues such as the lungs, skin, and head and 
neck region. Morbidity and mortality rates for SCC are high compared to 
many other cancers, and relatively little progress has been made in 
treatment due to a lack of molecular understanding of the disease. The p53-
related protein p63 is essential for the formation of various epithelial 
tissues, such as the skin, and has many reported roles including suppression 
of apoptosis, maintenance of stem cell regenerative potential, regulation of 
differentiation, and maintenance of cellular adhesion. In SCC, p63 is over-
expressed and has found to be the target of genomic amplification 
suggesting an important role in this disease. Previous in vitro studies have 
shown that p63 is required for survival of SCC cells in culture, however, 
cell lines lack the complex microenvironment found in human cancer, and 
thus the in vivo relevance of these results is unclear. To determine the role 
of p63 in vivo, we have generated a murine model of SCC, which faithfully 
recapitulates many of the molecular and pathological features of human 
SCC including invasion and metastasis. To test the role of p63 in tumor 
maintenance we crossed this model to a conditional p63-null allele (p63flox) 
and a tamoxifen-inducible Cre transgene, K14-CreER. We have found that 
genetic excision of both copies of p63 in established SCC tumors results in 
rapid and dramatic regression of tumors. In addition, even loss of a single 
copy of the p63 gene results in a reduced rate of growth, suggesting that 
SCC tumors are exquisitely sensitive to levels of p63 protein. These results 
support the idea that the p63 pathway is critical for the survival of SCC 
tumors in vivo, and targeting this pathway in SCC may result in more 
effective therapy for this highly refractory tumor type. 
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The pro-survival Bcl2 family members Bcl2 and Mcl1 are currently being 
evaluated as drug targets in many types of cancers. Overexpression of either 
Bcl2 or Mcl1 is commonly found in acute myeloid leukemia (AML) and 
mediates resistance to therapeutics. We previously developed mouse models 
of human leukemia and showed that those expressing MLL fusion proteins, 
like their human counterparts, were refractory to conventional 
chemotherapy. In order to determine the effect of Bcl2 and Mcl1 inhibition 
on established MLL/AF9 driven AML, we developed a system for inducible 
in vivo RNAi in mosaic mouse models. Tet-regulatable shRNAs targeting 
Mcl1, Bcl2, or neutral control genes were transduced into TetOn-competent 
MLL/AF9-AML cells, which were subsequently transplanted into recipient 
mice. Following disease onset, mice were treated with doxycycline to turn 
on shRNA expression. RNAi-mediated suppression of either Mcl1 or Bcl2 
led to rapid depletion of leukemic blasts in vivo. Histology indicated 
clearance of leukemia cells from infiltrated tissues, leading to a substantial 
survival benefit, though mice eventually succumbed to the disease. To 
determine whether these effects were leukemia specific, we tested the same 
shRNAs for effects on normal hematopoiesis. Remarkably, suppression of 
Mcl1 completely abolished reconstitution of the hematopoietic 
compartment, while Bcl2 suppression was well tolerated in all lineages. 
Nonetheless, leukemia bearing mice did not respond to the available 
inhibitors of Bcl2 (ABT-737, Obatoclax), indicating either that they are not 
sufficiently potent or that RNAi-mediated inhibition affects distinct 
activities of Bcl2 that are not targeted by these agents. In summary, we 
demonstrate that MLL/AF9 driven AML is sensitive to RNAi-mediated 
inhibition of either Bcl2 or Mcl1. While Mcl1 inhibition is likely toxic in 
normal hematopoietic cells, Bcl2 may be an effective target in MLL 
rearranged AML, although more effective inhibitors are needed. 
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Malignant Melanoma is a highly aggressive and therapy-resistant cancer 
with a high affinity to disseminate cells into the brain. Patients who suffer 
from CNS metastasis are confronted with a poor prognosis and 
conventional therapy brings only little benefit (e.g. surgery, radio- and 
chemotherapy result in <13% 1-year survival rate). It remains yet unclear 
what cellular mechanisms or what cellular identities can be made 
responsible for the remarkable therapy resistance. Recent studies exposed 
tumor cell heterogeneity and the identification of tumor initiating 
subpopulations as crucial elements for the development of new therapeutic 
approaches. It was shown that primary cell cultures maintained under “stem 
cell conditions” could recapitulate cellular heterogeneity in vitro and in 
vivo. These conditions generally imply the use of defined serum-free media 
and a continuous supply of growth factors for the maintenance of cells in 
vitro. It would be reasonable to assume that these methods are ideally suited 
for the application of high throughput drug screening assays. Here, we 
present data acquired from a primary compound screen using the Killer 
Collection® library that encompasses 160 cellular and biochemical toxins. 
Three samples of melanoma brain metastases were investigated in adhesive 
vs. anchorage-independent settings. We found an intriguing dissemination 
of identified hits in our experiments that could not be explained based on 
sample variance alone. Our data rather suggest that the influences of cell-
cell and cell-matrix interactions on the readout of primary drug screening 
assays are currently underestimated. 
 
(Supported by the Lichtenberg Program of the VW Foundation.) 
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Neuroblastoma (NB) is the second most common extracranial pediatric 
tumor and the most common pediatric solid tumor. High-risk NB is a 
molecularly heterogeneous disease with amplification of the MYCN 
oncogene detected in about one third of high-risk cases. Despite intensive 
therapy, survival of patients with high-risk disease is less than 40%. A 
parallel high throughput siRNA screen was performed in high-risk 
neuroblastoma cell lines with and without MYCN amplification to identify 
critical survival pathways and therapeutic targets for high-risk NB. The 
screen included a set of 43 genes previously implicated in neuroblastoma 
pathogenesis and a collection of siRNA targeting the entire human kinome 
(~750 genes). Network pathway analysis was utilized to integrate the gene 
“Hits” from the screen with available microarray data (Oncogenomics 
website link: http://pob.abcc.ncifcrf.gov/cgi-bin/JK). The screen highlighted 
differential sensitivities between MYCN amplified and non-amplified lines 
to inhibition of key players of WNT and NGF signaling, as well as to 
inhibition of mitotic kinases, such as STK6 (Aurora A), NEK2, NEK4 and 
WEE1. However, additional genes, not previously implicated in NB were 
also revealed. A complete list of “hits” will be presented and linked to both 
known and novel NB pathways, which could constitute potential therapeutic 
targets. This study identified druggable genes and pathways required for 
proliferation of high risk NB cells in vitro. In vivo validation of these genes 
through stable RNAi or using available small molecule inhibitors, will 
provide evidence for future therapeutic target development. Furthermore, 
our study indicates the importance of combining functional genomics with 
gene expression data to select within the patient population who could 
benefit the most from specific biologic therapies. 
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Chemotherapy resistance is a major obstacle in the treatment of cancer. 
Investigating the mechanisms of how tumors evade or succumb to 
chemotherapeutics can help researchers design more effective therapies and 
improve customized regimens for patients with specific tumor genotypes. 
One method of identifying genes that modulate chemotherapy response is 
by using loss of function genetic approaches. For example, RNA 
interference (RNAi) screens have been performed in cell culture to identify 
pathways that impact the response of cancer cells to chemotherapeutics. 
While these cell culture (or in vitro) screens can be informative, they fail to 
model important aspects of tumor biology due to the absence of many 
relevant factors found in animals. For this reason, we used an in vivo 
screening approach to identify modulators of response to vincristine (VCR), 
a frontline chemotherapeutic indicated in the treatment of several types of 
cancer. By performing in vivo and in vitro screens in parallel, we were able 
to identify genes that mediate chemotherapeutic response specifically in the 
in vivo setting. 
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A complex interplay between epithelial and stromal compartments of 
mammary tissue is critical in the control of mammary gland development. 
Disruption of the mammary epithelium and stroma communication leads to 
aberrant mammary gland development and can induce mammary 
tumorigenesis. Macrophages are an important stromal component and NF-
κB has been implicated in these processes. Here we show rescuing the 
mammary gland defect by transplanting wild-type bone marrow into 
AEBP1-/- mice that exhibit reduced NF-κB activity, whereas transplanting 
AEBP1TG bone marrow into non-transgenic mice result in alveolar 
hyperplasia with up-regulation of NF-κB activity and increased TNFα 
expression in mammary gland as displayed by AEBP1TG mice that over-
express macrophage AEBP1. We further show that stromal macrophage-
supplied TNFα is critical for promoting survival signal, Akt activation, and 
NF-κB activation in mammary epithelium. Our results presented here show 
that macrophage AEBP1 is a critical stromal factor that mediates stromal-
epithelial crosstalk in signaling physiological apoptosis and proliferation of 
mammary epithelium through its positive regulation of NF-κB in 
macrophages that is constitutively activated in many tumors. 
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Targeted therapeutics are the next wave of chemotherapy drugs. On the 
forefront of designed therapies, the orally available, small molecule tyrosine 
kinase inhibitors (TKIS) such as erlotinib (OSI Pharmaceuticals, Roche) 
have already been FDA approved and have been in use in clinical use for 
years. Unfortunately only a small percentage of patients respond to 
erlotinib, and of those who respond, resistance often arises quickly, 
sometimes on the order of just a few months. While we have begun to 
understand the role of mutations in EGFR, which may underlie 
susceptibility to erlotinib, we still know very little about the downstream 
signaling changes that facilitate differential sensitivity. To further 
investigate downstream signaling and to identify ways in which we can 
increase susceptibility, we performed an shRNA screen in PC9, a non-small 
cell lung cancer cell line, known to harbor an EGFR amplification and an 
EGFR mutation. This cell line is exquisitely sensitive to erlotinib, with an 
IC20 of ~20nM. The shRNA library contained roughly 10,000 shRNAs, 
covering approximately 3,000 genes, or ~10% of the genome. 23 candidates 
were selected for follow up analysis, two of which validate to date. The top 
candidates cause a downward shift in the IC20 of cells stably infected with 
shRNAs. When compared to parental cell lines, shRNA expressing cells are 
at a competitive disadvantage, dropping out of the population when treated 
with erlotinib. Work on identifying downstream alterations affecting 
sensitivity is still ongoing in lab. We are also working to expand these 
findings to multiple cell lines. 
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Schwann cells, the glia of the peripheral nervous system, retain the capacity 
for self-renewal throughout the lifespan of an organism. Following damage 
to peripheral nerves mature, specialised Schwann cells dedifferentiate and 
re-enter the cell cycle giving rise to a pool of progenitor like cells with the 
potential to re-differentiate. This dynamic behaviour is critical to the 
success of peripheral nervous system repair but must be tightly regulated to 
avoid both tissue degeneration and aberrant proliferation. Work from our 
laboratory has demonstrated a role for the Ras/Raf/ERK signaling pathway 
in controlling Schwann cell plasticity. The molecular mechanism 
controlling this switch in cell state is however, unknown. Here we show that 
Raf/ERK signaling drives Schwann cell dedifferentiation via the direct and 
potent repression of myelin gene promoters. This effect is dominant over 
the activity of the pro-differentiative transcription factor, Krox-20 and 
results in the rapid downregulation of myelin-associated genes. The effects 
of Ras signalling on Schwann cell behaviour is of particular interest since 
hyperactive Ras is known to be causal to the formation of Schwann cell-
derived tumours in patients with the cancer predisposition syndrome 
Neurofibromatosis Type I. Identification of the molecular mechanisms 
controlling Schwann cell dedifferentiation could therefore provide 
important insights into the development of neurofibromas and may provide 
novel therapeutic targets for the treatment of this disease. 
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Myc oncoproteins are master transcription factors that coordinate cell 
metabolism, growth and division, and that trigger apoptosis during 
tumorigenesis. Myc binds to target genes harboring preferred E-boxes to 
induce their expression, but this response explains only a fraction of the 
biological responses controlled by Myc. Regulation of mRNA stability 
controls the expression of many genes, and one mechanism involves AU-
binding proteins (AUBPs), which generally bind to AU-rich elements 
(AREs) found within the 3’ untranslated regions (3’ UTRs) of ~10% of all 
mammalian mRNAs. ARE-containing mRNAs have short half-lives and 
contribute to a variety of biological processes including cell growth, the 
immune response, differentiation, and apoptosis. In human Burkitt 
lymphoma (BL) and Eµ-Myc transgenic mice, a model of BL, expression 
profiling revealed that Myc regulates hundreds of ARE-containing genes. 
Notably, the expression of several AUBPs is also altered by Myc, including 
the RNA-destabilizing AUBP Tristetraprolin (TTP), which is directly 
suppressed by Myc. To test the contribution of the Myc-to-TTP pathway in 
lymphomagenesis we generated Eμ-TTP transgenic mice, and crossed these 
to Eμ-Myc transgenics. Strikingly, restoration of TTP expression in Myc-
expressing B cells significantly delays lymphoma development; thus, TTP 
is a novel tumor suppressor. Finally, analyses of these mice revealed that 
the Myc-to-TTP pathway regulates a very select cast of ARE-containing 
genes having known roles in proliferation, apoptosis and transformation. 
These findings support a model whereby Myc targets ARE-containing 
genes that control cell fate and transformation via the agency of AUBPs, 
which are revealed as a new cast of tumor suppressors and oncogenes. 
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Transgenic expression of Cyclin D1 in the mouse pineal gland results in 
pineal hyperplasia, limited by p53-dependent senescence. We set out to 
dissect the contribution of the p53 pathway to the initiation and 
maintenance of senescence in this in-vivo model. 
We found that p53 was activated at 10 days of age in response to Cyclin D1 
in the mouse pineal cells, at which time proliferation was still ongoing. 
Investigation of signaling upstream of p53 showed that p19Arf was 
dispensable. However, the DNA damage response (DDR) was activated at 
10 days of age, temporally correlating with activation of the p53 tumor 
suppressor pathway. At that time, the cells acquired phospho-H2AX foci, 
and showed expression of phosphorylated Chk1 and p53. In the absence of 
p53, the DDR was activated but ineffective, resulting in continued cell 
proliferation and tumor formation.  
Despite activation of the DDR and p53 pathway, apoptosis was only 
slightly increased at 10 days of age; however cellular proliferation slowly 
ceased over the next 2 weeks, and senescence set in over a period of 3-4 
weeks, with chromatin condensation in senescence-associated 
heterochromatin foci (SAHF). Interestingly, the DNA damage foci resolved 
by time of senescence, suggesting either completed damage repair, or 
hiding of damaged genomic sequences within the SAHF.  
To dissect the pathways linking the DDR pathway to senescence in this 
model, we have succeeded in growing primary cultures of murine pineal 
cells explanted at a pre-senescent stage. We found that the senescence 
response to Cyclin D1 in these neuronal cells can be recapitulated in 
culture, and that the DDR is activated in cultured cells as well. This in-vitro 
system will now allow us to investigate mechanistic details of the p53-
dependent senescence response to Cyclin D1 signaling, including the 
specific roles played by members of the DDR pathway. 
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The centrosome maintains euploidy by directing the formation of a bipolar 
mitotic spindle, leading to the equal segregation of sister chromatids during 
mitosis. To maintain a normal content of one or two centrosomes, the 
centrosome duplication cycle must be tightly coordinated with the cell 
cycle. Aberrant centrosome duplication results in centrosome amplification 
(CA), attachments of spindle fibers to misaligned chromosomes (merotelic 
attachments), aneuploidy and chromosome instability (CIN). CA and 
aneuploidy are proposed to contribute to the genesis and progression of 
most cancers, since most human cancers display elevated frequencies of 
those abnormal phenotypes. Nonetheless, the cell cycle molecules directly 
mediating CA in cancers are unknown. Even though biochemical evidence 
showed that Cyclin E/A/Cdk2 coordinates the centrosome duplication cycle 
with the cell cycle, a genetic approach showed that Cyclins E1-/-E2-/- or 
Cdk2-/- mouse embryonic fibroblasts (MEFs) harbored normal centrosomes. 
This finding suggested that another G1 Cdk -perhaps Cdk4- individually or 
cooperatively regulates the centrosome cycle. We showed that while 
ablation of Cdk2 or Cdk4 results in minor defects in entry into S phase, only 
Cdk4-/- MEFs display major defects in the centrosome duplication cycle. On 
the other hand, de-regulated cyclinE/A/Cdk2 or cyclinD/Cdk4 activities 
correlate with CA and CIN. p53 has been postulated to signal centrosome 
amplification through p21CIP1, a regulator of Cdk2 activity. However, this 
was based on correlative, and not genetic evidence. We find that Cdk2 or 
Cdk4 mediate CA and CIN in p53-null cells. Ablated Cdk2 or Cdk4 
prevents centrosome amplification by restricting excessive licensing and 
centriole duplication. Ablated Cdk2 or Cdk4 restricts excessive licensing of 
the centrosome cycle by preventing hyper-phosphorylation of NPM, a 
major negative regulator of the centrosome cycle. Indeed, introduction of an 
NPM mutant lacking Cdk2 and Cdk4 phosphorylation sites also prevents 
CA and CIN in p53-null MEFs. Our findings demonstrate that Cdk2 and 
Cdk4 are unique in their ability to regulate centrosome duplication, but 
redundant in mediating CA and CIN. We propose a model where Cdk2 and 
Cdk4 converge in centrosome regulatory targets to signal CA. 
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Metastatic melanoma is an extremely aggressive disease that is resistant to 
current therapy and has a poor prognosis. The progression of melanoma 
involves changes in gene expression that promote metastasis to distant 
organs. Transcriptional activation often requires epigenetic changes that 
convert repressive chromatin structure to a permissive conformation. 
Understanding the epigenetic mechanisms involved in the deregulation of 
gene expression during metastasis is important for developing an effective 
strategy to treat melanoma. SWI/SNF enzymes are multi-subunit complexes 
that include BRG1 or BRM ATPase subunit and alter chromatin structure 
and regulate gene expression. Several SWI/SNF subunits have been shown 
to be aberrantly expressed in a number of human cancers. We previously 
demonstrated that heterogeneous SWI/SNF complexes containing either 
BRG1 or BRM are epigenetic modulators that regulate important aspects of 
the melanoma phenotype and are required for melanoma tumorigenicity in 
vitro. 
 
Our new studies indicate that stage IV melanoma tumors express 
significantly higher levels of BRG1 compared to normal melanocytes and 
melanoma in less advanced stages. To determine the role of BRG1 in 
melanoma metastasis, we over-expressed BRG1 in an established 
melanoma cell line that lacks BRG1 expression. We found that BRG1 
dramatically altered expression of a number of adhesion proteins and 
extracellular matrix remodeling enzymes. BRG1 altered melanoma 
adhesion to different extracellular matrix components. Expression of BRG1 
in melanoma cells that lack BRG1 increased invasive ability while down-
regulation of BRG1 inhibited invasive ability in vitro. Activation of 
metalloproteinase (MMP) 2 expression greatly contributed to the BRG1 
induced increase in melanoma invasiveness. We found that BRG1 is 
recruited to the MMP2 promoter and directly activates expression of this 
metastasis associated gene. The results suggest that high levels of BRG1 are 
required to promote the epigenetic changes required for melanoma 
metastasis. 
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The normal mammary gland is composed of distinct cell populations that 
can be distinguished by the expression of the cell-surface markers EpCAM 
and CD49f: differentiated luminal cells (EpCAM+/CD49-), luminal 
progenitors (EpCAM+/CD49+), stromal cells (EpCAM-/CD49-) and basal 
myoepithelial/stem cells (EpCAMlow/CD49high). It has been hypothesised 
that breast basal-like tumours, which are characterised by the mixed 
expression of basal and luminal markers, may originate from the 
transformation of mammary stem cells that have undergone a block in their 
differentiation program.  
Here we tested if normal and tumorigenic human basal-like cell lines 
contain cell subpopulations with stem cell features. First, we observed that 
basal-like, but not luminal, cell lines contain distinct subpopulations that 
resemble those observed in the normal mammary gland. After isolation by 
FACS sorting, these subpopulations were subjected to a variety of in vitro 
methods to assess their stem cell potential. We demonstrated that EpCAM+ 
cells and CD49high cells show stem–cell characteristics: high Aldefluor 
activity, formation of acini-like hollow structures in matrigel, generation of 
anchorage-independent mammospheres and the ability to regenerate all cell 
populations within the parental cells. In contrast, EpCAM-/CD49- cells 
show highly fibroblastic phenotype and form invasive cell strands in 
matrigel, suggesting that they have undergone an Epithelial-Mesenchymal-
Transition (EMT). Surprisingly, these cells show very limited repopulation 
ability, low Aldefluor activity and reduced mammosphere formation, 
indicating that they have decreased stem-cell potential.  
Moreover, microarray-based gene expression profiling in the different 
sorted populations identified a number of transcription factors potentially 
involved in maintaining the stem-cell phenotype and inducing fibroblastic 
conversion in basal-like cells.  
 
In conclusion, our data indicates that basal-like cell lines contain a 
heterogeneous mixture of cell subpopulations, some of which show stem 
cell features. We suggest that these cells may be unable to fully differentiate 
into myoepithelial cells in vitro, but instead may have intrinsic proclivity 
for EMT.  
 
Funding: This work has received funding from the European Community’s 
Seventh Framework Programme (FP7/2007-2013) under grant agreement 
PIEF-GA-2008-221083  
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Targeted therapeutics have changed the treatment myeloproliferative 
diseases like CML, but in genetically more complex cancers their clinically 
success has been mixed. Inactivation of tumor suppressors including Arf, 
p53 or Pten have been invoked along with re-setting of signaling pathways 
through feedback mechanisms. Taking the example of lymphoma treatment 
with inhibitors of mTOR, we show that signaling redundancy inherent to 
these tumors significantly hampers the effectiveness of both targeted and 
conventional therapies. For example, the constitutively active Pim kinases 
are abundantly expressed in lymphomas, act through mechanisms that 
parallel the PI3K/Akt pathway, and affect the clinical outcome of 
lymphoma therapy. Using murine lymphoma models and xenografted 
human lymphomas we explore different avenues to overcome resistance 
caused by redundant signaling in lymphoma. These include combinations of 
targeted inhibitors affecting either upstream components of both pathways 
or blockade of key downstream effectors that are shared by overlapping 
signaling cascades. Genetically well-defined murine models provide an 
excellent system to test the combinatorial strategies in genetically complex 
cancers. 
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p53 limits the proliferation of precancerous cells by inducing cell-cycle 
arrest or apoptosis. How the decision between survival and death is made at 
the level of p53 binding to target promoters remains unclear. Using cancer 
cell lines, we show that the cooperative nature of DNA binding extends the 
binding spectrum of p53 to degenerate response elements in proapoptotic 
genes. Mutational inactivation of cooperativity therefore does not 
compromise the cell-cycle arrest response but strongly reduces binding of 
p53 to multiple proapoptotic gene promoters (BAX, PUMA, NOXA, 
CASP1). Vice versa, engineered mutants with increased cooperativity show 
enhanced binding to proapoptotic genes, which shifts the cellular response 
to cell death. Furthermore, the cooperativity of DNA binding determines the 
extent of apoptosis in response to DNA damage. Because mutations, which 
impair cooperativity, are genetically linked to cancer susceptibility in 
patients, DNA binding cooperativity contributes to p53's tumor suppressor 
activity. 
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In vivo RNAi screens in mice have been proven valuable for filtering 
oncogenomic data to identify “driver” mutations relevant to human cancer. 
To identify novel tumor suppressor genes in human lymphoma, an shRNA 
library was designed to cover the mouse orthologues of 329 human genes 
that are recurrently deleted in human Non-Hodgkin lymphoma. The library, 
spanning 1429 shRNAs and sub-divided into 14 pools, was screened for the 
ability to promote lymphomagenesis in an in-vivo myc-driven lymphoma 
model. A candidate tumor suppressor was defined as a gene for which 
multiple shRNAs were found enriched in accelerated tumors and/or a single 
shRNA was found in multiple tumors. We validated the novel tumor 
suppressor genes by individual re-testing of multiple shRNAs for each 
candidate in vivo. Strikingly, some of our new tumor suppressor genes are 
genetically linked at 8p21-23, an area of frequent deletion in human 
lymphoma but also many epithelial tumor types. Examples include the BAR 
domain family factor Bin3 and the complement regulator CSMD1. 
Interestingly, both genes have previously been linked to cancer, as Bin3 +/- 
mice develop lymphoma and Bin1, a paralogue of Bin3 has been identified 
as a Myc interactor with tumor suppressor properties. Moreover, CSMD1 is 
a candidate tumor suppressor in other cancer types, particularly gastric 
carcinoma. We also identified multiple tumor suppressors targeting known 
signaling networks that have not been linked to tumor suppression before. 
Our results therefore provide insight into the organization of the cancer 
genome, and point towards new tumor suppressor networks relevant to 
human lymphoma and perhaps other cancer types. 
 
*authors contributed equally 
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The c-Myc oncoprotein is highly expressed in most human tumors and its 
high expression has been linked to poor outcome. In this study we have 
investigated post-translational mechanisms that regulate both c-Myc 
expression and its oncogenic activity in breast cancer. Using breast cancer 
cell lines and paraffin sections from primary patient tumor samples we 
show that phosphorylation at the conserved Serine 62 (S62) residue is 
enhanced while phosphorylation at Threonine 58 (T58) is reduced in breast 
cancer relative to control, and this is associated with increased c-Myc 
protein stability. The signaling cascade that controls phosphorylation at T58 
and S62 is coordinated by the scaffold protein Axin1. Analysis of Axin1 in 
breast cancer revealed both decreased AXIN1 expression and a shift in the 
ratio of two naturally occurring AXIN1 splice variants. We demonstrate that 
both contribute to increased c-Myc protein stability, altered phosphorylation 
at S62 and T58 and increased colony-forming ability in human breast 
cancer cells. In addition, we have developed unique c-myc knockin mice 
that conditionally express either c-MycWT, or the c-MycT58A or c-
MycS62A phosphorylation mutant, from the constitutively active ROSA26 
locus in response to Cre recombinase to study the role of these 
phosphorylation sites in vivo. Using a mammary specific Cre model, we 
found that expression of c-MycT58A, which has a similar phosphorylation 
ratio to c-Myc in human breast cancer, had increased tumorigenic activity 
compared with deregulated expression of c-MycWT, and this was 
associated with increased genomic instability and suppressed apoptosis. 
Alternatively, c-MycS62A expression reduced mammary gland density 
relative to control glands, and this was associated with increased genomic 
instability and normal apoptotic function. Our work reveals that key 
phosphorylation events on c-Myc regulated by Axin1 control both c-Myc 
expression level and its specific oncogenic activity in the mammary gland. 
These discoveries provide mechanistic insight into the development of 
human breast cancer, which could lead to new therapeutic strategies. 
*authors contributed equally 
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The ability of the p53 transcriptional factor to elicit apoptosis, growth 
arrest, or DNA repair upon diverse stress conditions is the core of its tumor 
suppressor function. p53 acts not as a single polypeptide, but rather as a 
complex protein assembly, that remodels itself in a different way depending 
on a type of stimulus, leading to different biological outcomes. In essence, 
to understand p53 is to understand how its interaction with proteins and thus 
DNA, is controlled. In order to address these thrilling questions of p53 
biology and to identify key p53 modulators and effectors contributing to 
alternative p53-mediated biological responses we integrated genome-wide 
expression profiling data, ChIP-seq and proteomics data. As a model we 
used MCF7 breast carcinoma cells treated with small molecules activating 
p53, RITA and nutin3a. Although both molecules target p53/MDM2 
interaction, nutlin3a induces growth arrest in MCF7 cells, whereas RITA 
triggers apoptosis. Thus, RITA and nutlin3a represent excellent research 
tools to address the mechanisms of differential outcomes upon p53 
activation. Notably, analysis of microarray data followed by functional 
validation suggest that transcriptional repression of crucial pro-proliferative 
and survival genes by p53, including c-Myc, Mcl-1, Bcl-2, survivin, PI3 
kinase, and IGF-1R greatly contribute to the induction og apoptosis by p53. 
Our integrated analysis lead to the identification of a set of 52 key nodes 
and candidate cofactors of p53, as well as a set of novel p53 target genes. 
We analyzed the contribution of the selected 52 factors to the p53 biological 
response using shRNA-mediated depletion. Interestingly, functional 
analysis revealed that more than a half of the factors which can affect p53-
mediated growth suppression are involved in the IGF-1 receptor signalling. 
In order to understand the molecular mechanisms of their impact, we 
analyzed gene expression profiles upon p53 activation in cell lines stably 
expressing shRNA for selected factors. Further characterization and 
functional analysis of factors/genes directing alternative biological 
responses by p53 will help to answer important questions of p53 biology, 
thus opening the way to novel therapeutic approaches. 
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Breast cancer is the most common malignancy in women. To date, 
inheritance of a mutant BRCA1 or BRCA2 gene is the best-established 
indicator of an increased risk of developing breast cancer, the most 
frequently diagnosed cancer in women. For BRCA1/2 mutation carriers the 
lifetime risk of developing breast cancer is up to 80%. Therefore, it is not 
surprising that individuals with a family history of these cancers are now 
opting to know if they have a mutation in one of these genes. One of the 
inherent drawbacks of sequencing-based approaches is the determination of 
the actual risk associated with any variant identified in the gene. This is 
evident by the fact that more than 800 variants of BRCA1 and 1100 variants 
of BRCA2 are listed as variants of unknown clinical significance in the 
breast cancer information core database. We have recently reported a mouse 
embryonic stem cell based assay to test the functional significance of 
variants of unknown clinical significance identified in BRCA1 and BRCA2. 
The assay is based on the ability of human BRCA1/2 to complement the 
loss of endogenous genes in mouse embryonic stem cells. The procedure 
involves generation of a desired mutation in BRCA1 or BRCA2 present in a 
bacterial artificial chromosome (BAC) and introduction of the BAC into ES 
cells engineered for the assay. Using this assay we have now characterized 
R1699Q, a low risk variant of BRCA1. Interestingly this variant affects ES 
cell survival but exhibits no defect in genomic stability or cell cycle 
regulation. We have used this variant to uncover the role of BRCA1 in 
regulation of an oncogenic micro RNA. We show that over expression of 
this micro RNA contributes to tumorigenesis. Our findings show how 
BRCA1 can act as a tumor suppressor by regulating an oncomir. 
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The biology and the signal transduction pathways that lead to the 
development of triple negative breast cancer (TNBC) is not understood. 
There are no established biomarkers for TNBC. In the present study, we 
evaluated the expression of Annexin A2 (AnxA2) and its role in Her-2 
negative breast cancer progression. Immunohistochemical analysis of breast 
cancer tissue specimens demonstrated that AnxA2 staining might be a good 
indicator of cancer progression in Her-2 negative breast cancer (p<0.002). 
However in Her-2 positive breast cancer, AnxA2 expression is inversely 
correlated with Her-2 staining pattern (p<0.008). Our cell line analysis 
revealed that TNBC cells with basal or nil Her-2 levels, express high 
AnxA2 and the cells with Her-2 amplification demonstrate a very low level 
of AnxA2. We found increased membrane localization and secretion of 
AnxA2 in TNBC cells. AnxA2 induction after Her-2 downregulation and 
increased expression with EGFR in TNBC ascertains its role in various 
cancer associated functions. In this study, we validated the role of AnxA2 in 
EGFR downstream signaling in triple negative breast cancer cells. We made 
a novel observation that, presence of AnxA2 is very critical for the 
constitutive activation of the EGFR downstream signaling molecules like 
ERK1/2, AKT and STAT-3 and in further regulation of cancer cell 
metastasis, survival and apoptosis. The specific expression pattern of 
AnxA2 in TNBC cells, increased secretion compared to normal cells and its 
role in the regulation of EGFR downstream signaling makes AnxA2 as a 
potential tissue and serum biomarker and an excellent therapeutic target in 
TNBC. 
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Epidemiological studies show that cigarette smoke (CS) is a major risk 
factor for several life threatening diseases including lung cancer. A large 
body of evidence indicates that in majority of cancer cases transcription 
factor NF-κB is constitutively active in the nucleus. NF-κB is a dimeric 
complex formed from five subunits: RelA (p65), RelB, c-Rel, p50 (NF-
κB1) and p52 (NF-κB2). The combinatorial diversity of subunit 
composition contributes to the regulation of distinct, but overlapping sets of 
genes. In unstimulated cells NF-κB remains in the cytosol in an inactive 
form associated with regulatory proteins called inhibitors of κB (I-κB), such 
as I-κBα, I-κBβ and I-κBξ. NF-κB is activated mainly through the 
phosphorylation of I-κB by the I-κB kinase (IKK) complex, which results in 
proteasome-mediated degradation of I-κB, followed by nuclear 
translocation of NF-κB dimers that turns on expression of target genes. 
Different I-κB molecules have distinct and overlapping specificities and 
they may also differ in their tissue distribution pattern. Thus I-κB molecules 
control the regulation of different genes in various tissues by inhibiting 
specific NF-κB subsets.  
The effect of CS on NF-κB activity has been first reported in 1999. 
However the upstream events leading to this activation is unclear as there 
are conflicting reports regarding the role of I-κBα in this process. As NF-κB 
plays a pivotal role in generation and maintenance of malignancies, we have 
targeted our efforts to understand the detailed mechanism of CS-induced 
NF-κB activation. Our results showed that in alveolar epithelial A549 cells, 
CS-induced NF-κB activation is independent of I-κBα. Instead it involves 
the degradation of I-κBξ, which is highly expressed in lung. Contrary to a 
previously published report showing the involvement of p65 subunit, 
nuclear-cytosolic fractionation, immunofluorescence and si-RNA mediated 
gene silencing experiments demonstrate that CS-induced NF-κB activation 
is mediated predominantly, if not exclusively, by nuclear translocation of c-
Rel. This observation was further bolstered by immunostaining result on 
lung sections obtained from CS-exposed guinea pigs. Further study revealed 
that the treatment of A549 cells with cigarette smoke extract (CSE) causes 
activation of IKK, which is required for I-κBξ phosphorylation and CS-
induced NF-κB activation. Therefore, the current study provides a new axis 
of NF-κB activation in lung epithelial cells wherein I-κBξ and c-Rel play 
the central role. Role of c-Rel has long been implicated in different forms of 
malignancy. Thus the present study provides a possible mechanism of 
cancer growth in smoker’s lung and also identifies c-Rel as a putative target 
of therapeutic interventions as c-Rel knockout mice do not display any 
significant phenotypic defects.  
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Ionizing radiation (IR) and Apo2 ligand/tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) regulate cell death as well as survival 
signaling and have been used widely as therapeutics for prostate cancer 
(PCa). However, cellular resistance that is mostly cell type specific once 
developed hinders the effectiveness of therapy. We found PC3 cells to be 
more sensitive to TRAIL induced cell death compared to LNCaP-derived 
C42 cells. Both apoptotic and non-apoptotic cell death was observed 
indicating that other pathways, such as autophagy can also cause 
cytotoxicity. Following TRAIL and IR treatment of PC3 cells, microtubule 
associated protein-1 light chain LC3, a classical marker for autophagy, was 
recruited into autophagosomes following its cleavage (LC3 I) and lipid 
modification (LC3 II). In contrast, LC3 was not observed to be associated 
with the autophagosomes in C42 cells. Moreover, inhibition of 
autophagolysosome formation with chloroquine resulted in accumulation of 
LC3 II to a larger extent in C42 cells, suggesting that lipid modification of 
LC3 is intact and that LC3 turnover by autophagy might be faster in C42 
cells. We further determined the rate of autophagic flux using the GFP-
mCherry-LC3 fusion protein. Interestingly, C42 cells showed more 
lysosomal LC3 II whereas PC3 had predominantly autophagosomal LC3 II, 
indicating that the rate of autophagic outflux is higher in C42 cells upon 
TRAIL treatment. Electron micrographs also indicated that C42, unlike PC3 
cells have efficient autophagy without accumulation of autophagosomes. 
We next examined the expression and sub-cellular distribution of other 
autophagy-related proteins. Membrane associated ATG5 is decreased in 
PC3 and C42 cells following TRAIL and IR treatment. The SQSTM1/p62 
levels increased in poly-ubiquitinated aggregates in PC3 but not in C42 
cells upon TRAIL treatment, further indicating slower autophagy in PC3 
cells. Moreover, we observed differences in ATG5 and p62-associated 
native protein complexes among PC3 and C42 cells upon TRAIL treatment. 
Characterization of these complexes would provide new insights into 
autophagic signaling and TRAIL response. Our results suggest that in 
TRAIL or IR-sensitive PC3 cells accumulation of autophagosomes triggers 
cell death whereas a more efficient autophagic response in C42 cells might 
be the reason for their resistance against TRAIL or IR. Further defining the 
function of autophagy-regulatory genes will delineate their role in 
mediating cell death or survival outcomes in a cell context dependent 
manner, which may lead to the design of better therapies for PCa. 
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Tumor cells are completely dependent on their local inflammatory and 
angiogenic microenvironment, making the tumor microenvironment a 
potential target for cancer therapy. However, whether the tumor instructs or 
drives changes in the tumor microenvironment or vice versa remains 
unclear. This, plus the abiding degeneracy in extracellular signaling 
pathways, has confounded pharmacological targeting of the tumor 
microenvironment. To address the relationship between tumor and 
microenvironment, we combined the well characterized RIP1-Tag2 mouse 
islet tumor model with a mouse in which endogenous Myc function can be 
reversibly inactivated in vivo. We demonstrated that transient inhibition of 
endogenous Myc, either systemically or only in the β cell compartment, 
triggers rapid collapse of tumor stromal vasculature, disappearance of 
inflammatory cells and hypoxia, precipitating tumor regression. Hence, 
endogenous Myc in tumor cells is causally and non-redundantly required to 
instruct and maintain the tumor microenvironment. Targeting Myc could 
therefore circumvent the robustness inherent in the tumor 
microenvironment. 
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Glioblastoma mutliforme (GBM) is the most common and lethal tumor of 
the central nervous system in the adult. Despite decades of efforts, GBMs 
patients remain refractory to standard therapies and they have a very low 
survival rate. Understanding the mechanisms responsible for this poor 
therapy response is instrumental to develop new treatment modalities. 
Preservation of genomic integrity is essential for embryonic development 
and adult tissue homeostasis. Defects in the DNA-damage response (DDR) 
machinery, a network of protein complexes capable of detecting the DNA 
lesions and signaling to downstream effector pathways (cell cycle 
checkpoints, DNA repair, apoptosis, etc.), are linked to numerous 
pathological states including cancers. The DDR has been suggested to act as 
a barrier against tumor progression, where precancerous lesions need to 
inactivate p53 or other elements of the DDR to proceed to a more 
aggressive status.  
A detailed analysis of the TCGA (The Cancer Genome Atlas) database 
revealed that many genes encoding component of the DDR are frequently 
altered in human glioblastomas, being CHEK2 loss one the most frequent 
events. To investigate the role of this pathway in gliomagenesis we took 
advantage of the RCAS/tv-a system, which allows postnatal gene transfer 
and expression in a cell-type-specific manner. We collected evidences that 
some of the essential molecules of the DDR, such as Chk2, ATM and p53 
exert an important tumor suppressive role in PDGF induced gliomagenesis, 
and loss of any of those genes not only shorten tumor latency but also lead 
to a more aggressive phenotype, increasing the frequency of high-grade 
tumors (GBMs). We further analyzed the role of Chk2 in GBM radiation 
response both in vivo and in vitro and we show that Chk2 null gliomas 
present defects in both apoptotic response and cell-cycle checkpoints. 
Notably we discovered a clear dependence on Chk2 for G1/S checkpoint 
control in glioma tumor neurospheres and normal neuronal stem cells 
(NSCs), a situation that contrasts with what observed in other murine cell 
types. Our data suggest that regulation of both apoptosis and cell-cycle 
checkpoint could contribute to the tumor suppressor activity of the 
ATM/Chk2/p53 cascade in gliomas. 
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Hypoxia is an important feature of solid tumors and contributes extensively 
to the genetic heterogeneity and instability in the aggressive phenotype. 
Active repeat mediated recombination is one of the mechanisms which lead 
to genomic instability in cancer and cell stress. We have previously studied 
the phenomenon of active alu mediated recombination in two such cellular 
stress models. Glial cells treated with sequentially increasing doses of 
cisplatin and cells exposed to long term (6 week) hypoxia, showed 
increased transcription and mobilization of alu repeat sequences. In light of 
these observations, we were interested in developing hypoxia models which 
could identify active recombinogenic fragments which formed a part of 
genome content of cells which were selected for survival in hypoxic stress. 
Hypoxia models of short (24 hours onwards) and long term models (upto 9 
weeks) were propagated and studied for consistent changes in the banding 
patterns using inter-alu PCR. Inter-alu PCR, with primers directed outwards 
from the alu sequence, amplifies fragments that represent regions flanked 
atleast at one end by alu repeats. Changes detected (as compared to 
normoxia controls) represent alu mediated recombination events. Most of 
the changes were random in the different inter-alu PCR profile. However, a 
few alterations appear to be reproducibly consistent under progressive 
durations of hypoxia, indicating selection of certain population of cells 
harboring a particular genome content. We identified one such consistently 
altered fragment :an exonic region of F-Box 27 (FBXO27) flanked by 
inverted alu repeats enhanced during the short term and also in the 
progressively long term hypoxia model. F Box proteins are a large family of 
proteins with at least one F-Box motif and form a part of the Skp, Cullin, F-
box containing complex (or SCF complex) which is a multi-protein E3 
ubiquitin ligase complex. The F Box protein directly interacts with S-phase 
kinase protein (SKP1) through these motifs. An increase in transcript levels 
of both FBXO27 and SKP1 in long term hypoxia suggest that cells with this 
alteration are significantly selected for and populated in chronic hypoxia. 
We are currently investigating the functional significance of our 
observations. Our results suggest that cells exposed to short and long term 
hypoxia are useful for identifying active repeat mediated alterations which 
are specifically selected for survival during stress. 
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(Background) A certain population of tumor cells which exhibits stem cell-
like features should be therapeutic target. To date, a number of molecules 
were reported as markers for cancer stem-like cells in various types of 
tumors. However, most of them are epithelial malignancy referred as 
carcinoma, and for mesenchymal malignancy as sarcoma, none of the 
marker was established as cancer stem-like cells. In this study, we focused 
on the human synovial sarcoma (SS), which generally arises in young 
adults, caused by chimeric gene product SYT-SSX (Nagai, M., et al., 
PNAS, 98, 2001). Precise role for SYT and SSX is unknown, but we have 
reported that SYT is essential for mice embryonal development (Kumura, 
T., et al., Lab. Invest., 89, 2009).  
(Methods and Results) First, we focused on the role of CD133, and found 
that CD133 mRNA was detectable in two human SS cases. CD133 positive 
fraction is isolated by using SS cell lines, SYO-1 and Fuji. The growth of 
CD133 positive cells was slower than CD133 negative cells in vitro and in 
vivo, and the phosphorylation levels of Akt were elevated in CD133 
negative cells. As Akt inhibitor suppressed growth of CD133 negative cells, 
regulation of Akt maybe involved in the growth of these cells. Second, we 
established sphere culture condition of human SS cell lines and analyzed the 
feature of sphere formed cells which express Nanog, Oct3/4, and Sox2, and 
found that sphere cells grow slower than non-sphere cells in vivo. Gene 
expression profile of sphere cells were analyzed by micoarray and several 
transcription factors were up-regulated and tyrosine kinase receptors were 
down-regulated in sphere form of cells. Currently, we are focusing on the 
possibility that these molecules include markers which define and 
contribute to the feature of sarcoma stemness. 
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Membrane-type matrix metalloproteinases MT1- and MT2-MMP promote 
tumor cell invasion through basement membranes and collagen type I-rich 
tissues, whereas the functions of MT3-MMP in tumor invasion have 
remained less clear. Interestingly, MT3-MMP has been reported to be 
overexpressed in human melanoma selectively in the most aggressive 
nodular type tumors. We demonstrate here that MT3-MMP inhibits MT1-
MMP-driven melanoma cell sprouting and single cell invasion in three-
dimensional collagen, thus resulting in restricted, yet MT1-MMP-dependent 
expansion of compact cell colonies. In WM852 cells that have been 
originally isolated from nodular human melanoma, endogenous MT3-MMP 
expression was associated with rapid fibrin invasion and unexpectedly 
limited MT1-MMP-driven collagen invasion, both of which were reversed 
by siRNA-mediated MT3-MMP gene silencing. Consistent with such 
reverse matrix composition-dependent MT3-MMP functions, MT3-MMP 
overexpression reduced collagen invasion in parallel with increased fibrin 
invasion of Bowes cells with superficially spreading melanoma origin. 
Rather than altering MT1-MMP transcription, catalytically active MT3-
MMP interacted with MT1-MMP thus impairing the proinvasive MT1-
MMP activity in collagen. While MT3-MMP, unlike MT1-MMP, is not 
universally overexpressed in primary melanoma, it was significantly 
upregulated in pathologic specimens of human melanoma metastasis to 
lymph nodes. MT1-MMP-MT3-MMP interactions thus seem to provide 
tumors with a novel mechanism to restrict local cell invasion but allow 
nodular tumor cell growth in collagen-rich tissues such as skin, while 
simultaneously promoting invasive spread into distant sites. 
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Lung cancer leads to the death of ~165,000 deaths/year in the USA. 
Mutational activation of KRAS or BRAF is detected in ~25% and 5% of 
lung cancers respectively. Hence, it is likely that the RAS-regulated RAF-
MEK-ERK MAP kinase pathway may be an important target for treatment 
of a subset of lung cancers. Conditional mouse models for both KRASG12D- 
and BRAFV600E-induced lung tumorigenesis have previously been 
described. Intranasal instillation of Ad-Cre into KRasLSL or BRafCA results 
in the expression of KRASG12D or BRAFV600E in the distal lung epithelium. 
Although early stages of KRASG12D- and BRAFV600E-induced lung 
tumorigenesis appear to be almost identical, only mice expressing 
KRASG12D develop malignant adenocarcinoma of the lung where mice 
expressing BRAFV600E develop benign lung tumors. However, when 
BRAFV600E is combined with silencing of either Trp53 or Cdkn2a 
expression malignant lung cancers develop. An important question is the 
role of the RAF-MEK-ERK MAP kinase pathway in the maintenance of 
KRASG12D-induced lung cancers. To address this we employed PD325901, 
a potent, specific and selective inhibitor of MEK1/2, in the KRasLSL model 
in conjunction with in vivo imaging using the LucRep transgene. As 
observed with BRAFV600E-induced lung tumorigenesis, MEK inhibition 
entirely prevented the onset of KRASG12D-induced lung tumors. Moreover, 
MEK inhibition alone promoted dramatic regression of established 
KRASG12D-induced lung tumors as evidenced by in vivo imaging. These 
data indicate that single agent MEK inhibition suffices to promote 
regression of KRASG12D-induced lung tumors in mouse models and that 
such agents may be useful in the clinical management of both KRASG12D- 
and BRAFV600E-induced lung cancers in the clinic. 
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Within all developmental lineages, cells are more or less susceptible to 
transformation and thus have intrinsically different propensities to become a 
cell of origin for cancer. Our understanding of the hematopoietic system, 
particularly B lymphopoiesis, provides a unique opportunity to test the 
vulnerability of developmental cell stages. The study of Myc-driven 
lymphomagenesis in murine models has revealed that a critical constraint to 
transformation is the p53-dependent apoptotic response that sustained Myc 
expression evokes. With the removal of this constraint, aggressive B cell 
lymphomas develop. This type of modeling, however, largely relies on 
expression of an oncogene at an early developmental timepoint (e.g. HSC). 
The stage at which an oncogene or tumor suppressor is creating the 
conditions necessary for transformation is thus unclear. We have devised a 
strategy to model Myc expression with ‘p53 loss’ at specific developmental 
points within the B cell lineage. From these studies we hope to establish if 
tumors arise regardless of the stage at which an oncogenic state is created. 
Additionally, we would like to exploit this system to study how cells 
respond to other putative tumor-initiating events when their expression is 
restricted to a specific developmental stage. 
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Cell proliferation and growth rate is dependent on the regulation of the 
protein synthesis apparatus, the ribosomes. Nol6/Nrap (Nucleolar RNA 
Associated Protein) is a nucleolar protein which is highly conserved across 
eukaryotic organisms, however, its function is poorly characterised. 
Recently, Nol6 was found to have a significant role in ribosomal biogenesis. 
Our work shows that its expression markedly affected the levels of 45S 
rRNAs indicating its functional role in rRNA synthesis. Ribosome 
biogenesis is known to be regulated by nucleophosmin (B23/NPM) and its 
interacting partner, p19ARF which are abnormally expressed in cancer cells. 
Here we show that Nol6, is highly expressed in tumor tissues and it exists in 
a complex with the nucleolar proteins B23 and p19ARF in primary mouse 
embryonic fibroblast cells. Nol6 knock-down using siRNA significantly 
increased B23 protein levels and down-regulated the protein levels of 
p19ARF. In addition, Nol6 has also been found to co-localise with SUMO 
and seems to be sumoylated. B23 and p19ARF have previously been shown 
to regulate the progression of cell cycle. While exogenous Nol6 is rapidly 
degraded in normal cells, loss of Nol6 has been found to lead to cell 
apoptosis and de-stabilises the normal progression of the cell cycle. We 
hypothesise that loss of Nol6 leads to cell apoptosis by triggering the p53 
pathway. In this work, we demonstrate for the very first time, the functional 
role of NOL6 within the nucleolus and the cell cycle and its association 
with B23 and p19ARF and propose Nol6 to be a key regulator in maintaining 
their expressions within a non tumor cell. 
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Epigenetic alterations, including DNA methylation and histone 
modifications, have been recognized as important hallmarks for tumor 
development. One group of complexes involved in regulating one particular 
histone modification is referred to as ASH2-MLL complexes. These have 
attracted considerable interest, both from a mechanistic and a clinical point 
of view. These complexes possess histone methyltransferase activity and 
control gene expression by trimethylating lysine 4 of histone H3, a histone 
mark that is associated with actively transcribed genes. Moreover several 
subunits of these complexes are associated with tumorigenesis, suggesting 
strongly that ASH2-MLL complexes are important regulators of cell 
physiology. Mixed-lineage leukemia (MLL) genes and proteins have been 
found deregulated and/or mutated in many cancers. These proteins are the 
catalytic subunits of ASH2-MLL complexes, i.e. MLL proteins are histone 
methyltransferases. Another subunit associated with at least some ASH2-
MLL complexes is Menin, a tumor suppressor protein. Finally we identified 
human ASH2 as a interactions partner of the oncoprotein MYC. This 
finding, together with the observation that hASH2 interacts with MLL, led 
us to test whether hASH2 itself is involved in transformation. We observed 
that hASH2 cooperates with activated RAS to transform cells. This finding 
suggests that ASH2 functions as an oncoprotein. Although hASH2 
expression at the mRNA level was generally not deregulated, hASH2 
protein expression was increased in most human tumors and tumor cell 
lines. In addition, knockdown of hASH2 inhibited tumor cell proliferation. 
Taken together, these observations define hASH2 as a novel oncoprotein. 
To further validate this model we have generated transgenic mice that 
express ASH2 specifically in the liver. The tumor development in these 
animals also in combination with a MYC transgene will be discussed. 
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Herpesviruses are known to encode micro (mi)RNAs and to use them to 
regulate the expression of both viral and cellular genes. The genome of 
Kaposi’s sarcoma herpesvirus (KSHV) encodes a cluster of twelve 
miRNAs, which are abundantly expressed during both latency and lytic 
infection. Relatively few cellular targets of KSHV miRNAs are known. 
Here, we used a microarray expression profiling approach to analyze the 
transcriptome of both B lymphocytes and endothelial cells stably expressing 
KSHV miRNAs and monitor the changes induced by the presence of these 
miRNAs. We generated a list of potential cellular targets by looking for 
miRNA seed-match-containing transcripts that were significantly down 
regulated upon KHSV miRNAs expression. Interestingly, the overlap of 
putative targets identified in B lymphocytes and endothelial cells was 
minimal, suggesting a tissue-specific target-regulation by viral miRNAs. 
Among the putative targets, we identified caspase 3, a critical factor for the 
control of apoptosis, which we validated using luciferase reporter assays 
and western blotting. In functional assays we obtained further evidence that 
KSHV miRNAs indeed protect cells from apoptosis. Currently we are 
analysing this protective effect in primary effusion lymphoma (PEL) cell 
line, which is naturally carrying KSHV genome, and also in endothelial cell 
line stably expressing KSHV miRNAs.  
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Wnt/β-catenin signaling is important for normal tissue homeostasis and is 
also implicated in the genesis of several different types of carcinomas. 
Earlier, we had shown that high levels of Wnt signaling inhibit multi-
lineage differentiation of human mesenchymal stem cells (hMSCs) in vitro 
and in vivo. Sarcomas are mesenchymal tumors that account for a majority 
of pediatric cancers. Recent studies indicate that at least certain sarcomas 
originate from hMSCs, which we have shown to exhibit low levels of Wnt 
signaling. Current work identifies that a high fraction of human sarcomas 
and sarcoma cell lines of distinct histological subtypes show upregulation of 
canonical Wnt pathway. Multiple molecular mechanisms including 
overexpression of Wnt ligands and LRP5/6 co-receptors and loss of 
different antagonists contribute to autocrine activation in most sarcoma cell 
lines. Importantly, downregulation of Wnt pathway induces growth arrest 
both in vitro and in vivo. Also, our study identifies CDC25A, a novel Wnt 
target gene, to be overexpressed in sarcomas. The high prevalence of Wnt 
pathway activation in human sarcomas described here and the ability to 
identify Wnt pathway activation in primary sarcoma tissues make it 
reasonable to test whether naturally occurring Wnt antagonists such as 
DKK1 or FRP or recently reported small molecule Wnt inhibitors may 
complement standard agents in the treatment of this most common 
childhood malignancy. 
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During Helicobacter pylori infection of the human stomach, the CagA 
effector protein is translocated into host cells where its presence is 
associated with gastric cancer formation. CagA has been shown to interact 
with a number of host cell proteins belonging to several conserved signaling 
pathways, and these interactions are thought to facilitate the initiation of 
carcinogenic events. Using a transgenic Drosophila model, we have shown 
that expression of CagA results in dramatic perturbations of the simple 
model epithelium created by the larval wing imaginal disc. In cultured cells, 
CagA has been shown to disrupt epithelial cell polarity via interaction with 
tight junction proteins. Loss of cell polarity is a potent activator of JNK 
signaling which can lead to apoptotic cell death or cooperate with oncogene 
activation to promote tumorigenesis. Therefore we postulated that CagA 
might activate JNK signaling in epithelial cells to give rise to downstream 
effects associated with H. pylori virulence. Our results demonstrate that 
expression of CagA in the developing wing causes a distinct pattern of 
apoptosis characterized by extrusion of apoptotic cells from the basal 
surface of the epithelium. This cell death phenotype is enhanced by 
coexpression with Basket (Bsk), the Drosophila homolog of JNK, and 
suppressed by coexpression with a dominant-negative form of Bsk. In 
addition, we have shown that CagA expression can enhance the growth and 
invasion of tumors generated by expression of activated Ras in a 
Drosophila model of metastasis. These data provide in vivo evidence that 
CagA causes JNK-dependent apoptosis in a simple polarized epithelium, 
and enhances tumorigenesis caused by oncogene activation. We are 
currently testing whether CagA activates JNK signaling via disruption of 
epithelial cell polarity, and if CagA cooperates with activated Ras to 
enhance tumorigenesis through JNK pathway activation. 
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Cells from organisms with renewable tissues can permanently withdraw 
from the cell cycle in response to a variety of stimuli, including 
dysfunctional telomeres, DNA damage, physiological stress, and activation 
of certain oncogenes. This phenomenon, cellular senescence, is controlled 
by the p53 and RB tumour suppressor proteins, and constitutes a potent 
anti-tumour mechanism.  
The underlying mechanism controlling cellular senescence and the signal 
transduction pathways involved are poorly defined and the critical 
downstream targets of the p53 and RB pathways in this process have not 
been identified. As most breast cancers originate in epithelial cells, we 
developed a conditionally immortalized human mammary epithelial line, 
226 8/13, derived from human mammary luminal epithelial cells, in which 
we carried out a genome wide loss of function RNA interference screen to 
identify these targets. 226 8/13 cells constitutively express hTERT, the 
catalytic component of human telomerase, and a temperature sensitive non-
DNA-binding mutant of Simian Virus 40 large T (LT) antigen. These cells 
grow at the permissive temperature, 34°C, but undergo a rapid irreversible 
arrest at the non-permissive temperature, 38°C, upon inactivation of the 
thermolabile LT antigen allowing activation of the pRB and p53 tumour 
suppressor pathways.  
The Open Biosystems human GIPZ lentiviral shRNAmir library and pSM2 
retroviral shRNAmir library were applied to the conditional system, and 
several genes whose inhibition leads to cells overcoming the conditional 
growth arrest were identified. These genes are now being investigated in the 
context of several breast cancer cell lines. Furthermore, we will test if 
knock-down of these genes can rescue from Ras-induced senescence in the 
context of primary human mammary epithelial cells (HMECs).  
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Background: Human hepatocellular carcinoma (HCC) is associated with 
elevated expression of inducible nitric oxide synthase (iNOS), but the role 
of nitric oxide (NO) in the pathogenesis of HCC remains unknown. 
Deactivation of NO bioactivity and control of protein S-nitrosylation 
critically depends on S-nitrosoglutathione reductase (GSNOR). The human 
GSNOR gene (ADH5) is located at approximately 4q23, a region in which 
chromosomal deletion occurs frequently both in cirrhotic and dysplastic 
hepatocytes and in HCC. 
Objectives: We investigated whether GSNOR deficiency, through 
dysregulated S-nitrosylation, is a critical mechanism of 
hepatocarcinogenesis. 
Methods: The abundance and activity of GSNOR were analyzed in pairs of 
HCC and associated noncancerous liver tissues from 24 HCC patients. Mice 
deficient in GSNOR or deficient in both GSNOR and iNOS were employed 
in the models of both spontaneous and carcinogen-induced HCC. Also 
studied in the HCC models were DNA repair proteins and related repair of 
specific DNA lesions. 
Results: We found that both GSNOR enzymatic activity and amount of 
GSNOR protein were significantly decreased in ~50% of the patients with 
HCC, with GSNOR reduction of 80 to 90% in 20% of the patients. 
GSNOR-deficient mice were very susceptible to spontaneous and 
carcinogen-induced HCC. During inflammatory responses, the livers of 
GSNOR deficient mice exhibited substantial S-nitrosylation and 
proteasomal degradation of the key DNA repair protein O6-alkylguanine-
DNA alkyltransferase. As a result, repair of carcinogenic O6-alkylguanines 
in GSNOR-deficient mice was significantly impaired. Predisposition to 
HCC, S-nitrosylation and depletion of alkylguanine-DNA alkyltransferase, 
and accumulation of O6-alkylguanines were all abolished in mice deficient 
in both GSNOR and iNOS. 
Conclusion: Our data suggest that GSNOR deficiency, through 
dysregulated S-nitrosylation and possibly inactivation of a DNA repair 
system, promotes hepatocellular carcinoma. These findings suggest that 
patients with GSNOR deficiency and concurrent iNOS overexpression in 
the liver may be at an increased risk of HCC, and inhibition of iNOS-
derived S-nitrosylation in these patients may provide a therapeutic strategy 
to prevent liver cancer. 
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The ETS transcription factors (TFs) represent one of the largest families of 
transcriptional regulators in mammalian genomes, playing diverse roles in 
various biological processes. Some ETS-factors such as ERG and ETS1 can act 
as oncogenes in malignant transformation and tumor development. All ETS-
factors share a conserved ETS domain, which binds to a set of similar DNA 
sequence motifs in vitro but contributing to targeting specificities in vivo.  
To systematically decipher the regulatory networks downstream of ETS TFs, 
we set up a novel version of the enhancer-element locator program that allows 
identification of TF cistrome and regulatory SNPs. We globally predicted 
regulatory elements activated by the oncogenic ETS family members, and SNPs 
affecting TF binding sites within these elements based on TF DNA-binding 
specificity. We validated the ETS-regulated elements by ChIP-seq mapping of 
ETS-binding sites and epigenetic signatures in Ewing’s sarcoma, leukemia and 
prostate cancer cells. RNAi followed by expression profiling were further 
applied to correlate ETS family DNA-binding and transcriptional regulation. To 
find causal rSNPs, we combined the rSNP predictions with genome-wide 
association studies, resulting in identification of a SNP in an ETS-regulated 
element upstream of the c-MYC gene that predisposes to prostate cancer (PCa).  
TMPRSS2-ERG fusion is present ~50% of all PCa cases. In addition to 
mapping TMPRSS2-ERG target genes as described above, we also 
systematically analyzed TMPRSS2-ERG-regulated miRNA networks and found 
that miR-25~106b cluster and its host gene MCM7 are potential ERG targets. 
Given evidence indicating that PTEN is a target of the miR-25~106b cluster, 
our results suggest a causal molecular link between the concurrent events of 
TMPRSS2-ERG translocation and decreased PTEN abundance observed in a 
subset of PCa cases.  
 
Refs: Hallikas O, et al., Cell. 2006. 124:47; Han B, et al., Mod Pathol. 2009. 
22:1083; Poliseno L, et al., Sci Signal. 2010. 3:ra29; Wei GH, et al., EMBO J. 
2010 in press.  
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Mammalian cells maintain genomic integrity despite frequent DNA damage 
due in part to the actions of checkpoint signaling pathways headed by the 
kinases Atm and Atr. While mutations in the well-characterized Atm 
pathway lead to increased cancer risk, the role of the Atr pathway in tumor 
suppression is less well understood, as deletion of any component of this 
pathway, including Hus1, results in embryonic lethality. As a member of 
the PCNA-like Rad9-Rad1-Hus1 (9-1-1) complex, Hus1 is recruited to sites 
of DNA damage and acts as a scaffold that promotes checkpoint signaling 
and DNA repair. In order to bypass the severe effects of complete Hus1 
inactivation, we previously developed an allelic series in which mice 
express incrementally reduced levels of wild-type Hus1. Mice with reduced 
Hus1 expression show increased genomic instability and genotoxin 
hypersensitivity but nevertheless appear grossly normal and are not prone to 
spontaneous cancers. To investigate how partial Hus1 inactivation impacts 
tumor development, we assessed skin papilloma formation in Hus1 
impaired and control mice following chemical carcinogenesis. A subset of 
mice with reduced Hus1 expression initially developed papillomas at a 
modestly accelerated rate relative to control animals, suggesting that 
genomic instability and checkpoint failure in initiated cells with reduced 
Hus1 expression can shorten the latency for papilloma development. 
However, at later timepoints mice expressing reduced levels of Hus1 had a 
decreased risk of papilloma development, and they ultimately showed 
significantly reduced papilloma size and number. These effects were not 
associated with acute cell death or decreased proliferation following 
carcinogen exposure, suggesting that the reduced papilloma formation may 
be due to an inability of cells with partial Hus1 impairment to survive the 
stresses of neoplastic proliferation because of insufficient genome 
maintenance. Consistent with this hypothesis, preliminary data suggest that 
cultured mouse embryonic fibroblasts with reduced Hus1 expression are 
partially defective for anchorage-independent growth and other 
characteristics of malignant transformation following expression of 
activated oncogenes. Overall, these studies highlight a fundamental 
requirement for intact Hus1 function during cell transformation and 
tumorigenesis, and suggest that targeting this checkpoint mechanism may 
be an effective strategy for cancer therapy. 
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Follicular lymphoma (FL) is the most common histological type of Non-
Hodgkin’s lymphoma. FLs are characterized by the t(14;18)(q32;q21) and 
increased expression of the anti-apoptotic Bcl2 protein. Lymphomagenesis 
and ultimate transformation towards aggressive lymphoma are driven by 
additional genetic events. In particular, deletions of Chr. 6q occur in ~ 30% 
and are linked to early progression and shortened survival of FL patients. 
To pinpoint genetic suppressors of FL and guided by an array-CGH 
analyses 70 FL specimens, we conducted a deletion-specific short-hairpin 
RNA screen. In addition to FoxO3 and TnfAip3/A20, which are also 
somatically mutated in FL, we identify a truncated variant of the Ephrin 
receptor (EphA7TR). EphA7TR acts as a secreted tumor suppressor in vitro 
and in a murine FL model. In addition to chromosomal deletions, we find 
that EphA7TR is epigenetically silenced in nearly all FL cases we 
examined. Strikingly, re-administration of the purified EphA7TR protein by 
injection suppresses Src and Mapk signaling and produces remissions in 
xenografted human lymphomas in vivo. Hence, the soluble EphA7TR 
tumor suppressor is widely inactivated in follicular lymphoma can be 
administered as a therapeutic agent. 
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p19Arf is an critical tumor suppressor protein with roles regulating cell cycle 
arrest in development and suppressing oncogenesis. Previous studies 
established that p19Arf regulates pericyte-like cells in the hyaloid vascular 
system (HVS) in the primary vitreous of the developing eye. Arf-deficient 
mice have hyperplasic expansion of pericytes in the vitreous, a 
developmental defect driven by excessive Pdgfrβ signaling. We have used 
complementary studies of cultured cells and mouse embryos to further 
explore the functional interactions between p19Arf and Pdgfrβ. First, we 
determined if Pdgfrβ acts as a survival factor or a mitogen to foster the 
accumulation of pericytes in the Arf-/- vitreous using the ArfGfp/Gfp knock-in 
reporter mouse. Quantitative studies of cell proliferation and apoptosis in 
E13.5 ArfGFP/GFP embryos that have or lack Pdgfrβ-/- indicated that cell 
proliferation was increased by threefold in the Arf expressing cells in the 
presence of Pdgfrβ. The presence or absence of Pdgfrβ did not change the 
small number of apoptotic cells in the vitreous of the eye. Second, we used 
a cell culture model in which retroviral expression of p19Arf in 10T1/2 
pericyte-like cells and Arf-/-, Mdm2-/-, and p53-/- “TKO” MEFS cells 
significantly repressed Pdgfrβ protein levels following transduction. 
Interestingly, Pdgfrβ was not repressed when p19Arf was expressed in Arf-/-, 
p53-/- MEFs, suggesting that endogenous Mdm2 may interfere with p19Arf in 
the absence of p53. Conversely, knockdown of p19Arf in wild type MEFs 
using pSIRPP retrovirus vector increased Pdgfrβ protein levels. Mature and 
primary transcript analysis indicates repression of the protein levels occurs 
earlier than repression of the transcript, suggesting p19Arf primarily 
represses Pdgfrβ by a post-transcriptional mechanism. Consistent with this, 
transient co-transfection of p19Arf and the 1.4kb minimal Pdgfrβ promoter-
reporter plasmid failed to show consistent repression. Overall our data show 
that p19Arf controls Pdgfrβ-driven proliferation in the developing eye by 
downregulation of Pdgfrβ protein levels via a post-transcriptional 
mechanism. On-going experiments are elucidating mechanisms underlying 
Pdgfrβ control by p19Arf, and evaluating the importance of the Arf-Pdgfrβ 
pathway in cancer models. 
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Therapeutic resistance afforded over expression of apoptotic pro-survival 
proteins is observed in over 50% of all cancers. This type of resistance is 
observed with the histone deacetylase inhibitor Vorinostat. However 
recently a small molecule inhibitor that neutralizes Bcl-2 pro-survival 
proteins has been developed called ABT-737. We have been able to show 
that pre-treatment with Vorinostat followed by further treatment with ABT-
737 overcomes Bcl-2-mediated chemo-resistance in both haematological 
(Eμ-myc lymphomas) and solid tumours (4T1 breast carcinoma). However 
the molecular mechanisms underpinning the observed synergy were yet to 
be fully delineated. We observed that transcription of the BH3-only gene 
Bmf was induced in response to pre-treatment with Vorinostat and that Bmf 
expression was concomitant with increased acetylation at the Bmf 
promoter. Utilizing RNA-mediated knockdown of Bmf and Bmf knockout 
lymphoma cell lines we found that Bmf was essential for the synergistic 
apoptosis induced by Vorinostat and ABT- 737 in cells expressing high 
levels of Bcl-2. In defining the mechanism of HDACi-mediated priming we 
discovered a requirement for a functional p53 pathway for effective 
synergism. In line with previous studies we confirmed a requirement for the 
induction of p53 target gene (Noxa) expression for synergistic apoptosis 
involving ABT-737. Moreover the combined loss of Bmf and p53 
expression completely ablated the synergistic apoptosis induced by 
Vorinostat and ABT-737. To determine the clinical potential of Vorinostat 
and ABT-737 in combination we undertook preliminary pre-clinical ex vivo 
therapy studies with human chronic lymphocytic leukemia (CLL) cells. 
Specific priming by BMF was not observed in the patient sample and could 
potentially account for the observed marginal resistance to Vorinostat and 
ABT-737 in this sample. Collectively the findings presented in this thesis 
provide new insight into the novel molecular mechanisms that underpin 
apoptosis induced by the combination therapy of Vorinostat and ABT-737. 
Moreover they demonstrate the potential therapeutic application of 
Vorinostat and ABT-737 against malignancies expressing high levels of 
Bcl-2. 
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The incidence of bladder cancer continues to rise and is the fourth most 
common cancer in men and ninth most common in women with over 70,000 
cases diagnosed each year. The genetic profiles of different types of bladder 
cancer are being characterized with the aim of identifying new targets for 
therapy. Two genetic profiles have been characterized for different types of 
proliferative lesions in the bladder. Superficial hyperplastic and papillary 
lesions of low malignant potential (PUNLMP) are associated with 
activating mutations in HRAS and FGFR3 overexpression. Invasive 
carcinomas are associated with changes in p53, Rb, and PTEN pathways. 
Expression of downstream effectors of p53 such as p21 and upstream 
regulators such as MDM2 are also common in bladder cancer. The ataxia 
telangiectasia group D-complementing (ATDC) gene product, also known 
as TRIM29, is a member of the tripartite motif (TRIM) protein family. The 
ATDC gene product has been implicated in a variety of cellular processes 
including cell proliferation. We recently identified ATDC as a gene that is 
highly over-expresed in pancreatic adenocarcinomas. We also found that 
ATDC promoted cancer cell proliferation in vitro and enhanced tumor 
growth and metastasis in vivo via a β-catenin dependent mechanism. ATDC 
also appears to make pancreatic cancer cells resistant to current therapies. In 
order to study the oncogenic function of ATDC in vivo, we generated 
transgenic mice that expressed ATDC under the control of a ubiquitous 
promoter. Among the tissues that expressed high levels of ATDC was the 
urinary bladder, more specifically the urothelium. The ATDC transgenic 
mice developed a number of proliferative and neoplastic lesions but the 
most common was bladder lesions. Nearly 40% of CAG-ATDC tg mice 
developed severe bladder obstruction associated with urothelial hyperplasia 
or bladder cancer. The mice developed the full range of bladder lesions 
from simple to papillary hyperplasia, PUNLMP, carcinoma in situ, 
carcinomas, and muscle invasive carcinomas. 
 232 
ANEUPLOIDY ALTERS THE IMMORTALIZATION PROCESS IN 
PRIMARY MAMMALIAN CELLS 
 
Bret R Williams, Catherine C Clark, Angelika Amon  
 
Massachusetts Institute of Technology, Howard Hughes Medical Institute, 
David H. Koch Institute for Integrative Cancer Research, Cambridge, MA, 
02139 
 
Aneuploidy, an incorrect chromosome number, is a hallmark of cancer. 
While almost all human cancers are aneuploid, the role of aneuploidy in the 
development of cancer is not well understood. To determine the effects of 
aneuploidy on cell physiology and growth, we generated a series of primary 
mouse cell lines that harbor an extra copy of one of four mouse 
chromosomes. In all trisomic lines analyzed, proliferation was impaired and 
metabolic properties were altered. To understand how aneuploidy might 
alter the process of tumorigenesis in vitro, the rate of spontaneous 
immortalization was determined in aneuploid cells and we observed that the 
rate of immortalization was altered; indicating the barrier of reduced 
proliferation caused by aneuploidy can be overcome. Presently, we have 
altered primary aneuploid cells to determine growth potential following 
genetic events inducing immortalization. We show that the growth defect of 
primary aneuploid cells is only partially rescued by reducing the expression 
of p53. Additionally, we observe that the expression of the adenoviral E1a 
protein alters the fitness of primary aneuploid cells compared to euploid 
controls. Our data indicate that aneuploidy can influence the efficiency and 
determine the genetic events required during immortalization primary cells. 
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MicroRNAs (miRNAs) have emerged as novel cancer genes. In particular, 
the miR-17-92 cluster, containing six individual miRNAs, is highly 
expressed in hematopoietic cancers and promotes lymphomagenesis in vivo. 
Clinical use of these findings hinges on isolating the oncogenic activity 
within the 17-92 cluster and defining its relevant target genes. Here we 
show that miR-19 is sufficient to promote leukemogenesis in Notch1-
induced T-cell acute lymphoblastic leukemia (T-ALL) in vivo. In 
concordance with the pathogenic importance of this interaction in T-ALL, 
we report a novel translocation that targets the 17-92 cluster and coincides 
with a second rearrangement that activates Notch1. To identify the miR-19 
targets responsible for its oncogenic action, we conducted a large-scale 
short hairpin RNA screen for genes whose knockdown can phenocopy miR-
19. Strikingly, the results of this screen were enriched for miR-19 target 
genes, and include Bim (Bcl2L11), AMP-activated kinase (Prkaa1) and the 
phosphatases Pten and PP2A (Ppp2r5e). Hence, an unbiased, functional 
genomics approach reveals a coordinate clampdown on several regulators of 
phosphatidylinositol-3-OH kinase-related survival signals by the 
leukemogenic miR-19. 
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The identification of chromosomal alterations in primary tumor cells can 
provide insight into the regulation of the growth of the cancer cell. 
Epigenetic variations can also affect the cancer phenotype. We provide a 
coarse-grained bioinformatic analysis of copy number variation and DNA 
methylation covering the genetic landscape of ovarian cancer tumor cells. 
We individually identified the copy number variation and DNA methylation 
for each gene among 42 ovarian cancer tumor samples from our MOMA-
ROMA technology and separately analyzed the epigenetic data for another 
379 tumor samples presented in The Cancer Genome Atlas. Using the 
ROMA array method we determined copy number variability per 
chromosome for each of the 42 ovarian tumor samples. We also provide 
MOMA derived DNA methylation fold changes from normal to tumor 
sample for 11,975 genes. We have identified 346 genes with significant 
deletions or amplifications among the tumor samples. We also predict 156 
genes with significantly altered copy number and correlated changes in 
expression. We show DNA methylation and gene expression dependence 
for each gene in the entire range of copy number deletion and amplification. 
And we have predicted 416 genes with either epigenetic tumor suppressor 
or oncogenic features as a relation to copy number variation. Finally, we 
apply functional analysis for significantly altered genes and examine 
possible biological mechanisms of tumorigenesis specific to the ovarian 
cancer cells. 
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Rb tumor suppressor plays a critical role in regulating both embryonic 
hematopoiesis and bone marrow-derived hematopoiesis in mice. Since 
previous studies have shown that Rb function can be mediated by various 
E2F activities, we sought to determine whether genetic deletion of 
individual E2fs can modulate the hematopoietic defects induced by the loss 
of Rb. We found that among the activating E2F members, E2f2 plays the 
most important role in mediating Rb function in the control of 
hematopoiesis. Importantly, concomitant deletion of E2f8, one of the two 
newly identified repressor E2F family members, significantly exacerbates 
the hematopoietic defects resulted from the Rb loss. While mice deficient 
for E2f8 or Rb in hematopoietic stem cells (HSC) experience no or mild 
hematopoietic defects, mice with HSC deficient for Rb and E2f8 exhibit 
severe anemia and have substantially enlarged spleens that are almost 
completely filled with immature erythroids. The severe erythropoietic 
defects are accompanied by marked multi-lineage cytopenia in the bone 
marrow and peripheral blood. Furthermore, although both ineffective 
erythropoiesis and excessive red blood cell destruction resulted from 
hemolysis may contribute to the severe anemia observed in mice with HSC 
deficient for Rb and E2f8, hemolysis is only evident in the double knockout 
mice, suggesting a strong synergy between Rb and E2F8 in preventing 
hemolysis. Surprisingly, concomitant deletion of E2f7, which has very 
similar functional domains and biochemical features as E2f8, does not 
significantly impact on the hematopoietic defects resulted from Rb 
deficiency. Consistent with the notion that E2f7 makes little contribution to 
mediating Rb function in the control of hematopoiesis, concomitant deletion 
of E2f7 in mice with HSC deficient for Rb and E2f8 does not significantly 
enhance the hematopoietic defects observed in the double knockout mice. 
Taken together, our data suggest specificity of activating E2F members in 
mediating Rb function in the control of bone marrow-derived 
hematopoiesis, and reveal an intriguing synergistic role of Rb and E2F8 
(but not E2F7) in maintaining normal hematopoiesis and preventing 
hemolysis. 
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During chronic liver damage repetitive waves of hepatocyte cell death and 
compensatory proliferation take place, eventually culminating in chronic 
liver failure and often in the development of hepatocellular carcinoma 
(HCC). A misregulated regenerative response to chronic liver injury may 
represent the base for development of HCC. Therefore, a more detailed 
understanding of signaling pathways involved in proliferation control of 
hepatocytes not only holds the great promise of informing new therapies to 
increase the hepatic regenerative potential but also to deduce new strategies 
for the treatment of HCC. We have established a unique system to perform 
in vivo RNAi screens to genetically dissect cellular signaling networks 
regulating hepatocyte proliferation during chronic liver damage. We show 
that FAH-/- mouse livers can be stably repopulated with complex 
microRNA based shRNA libraries. Quantification of shRNA representation 
in shRNA pools and chimeric mouse livers is accomplished by deep 
sequencing. Assuming that proliferation control during liver regeneration 
and hepatocyte transformation may engage overlapping signaling pathways, 
we performed a first screen using a thematically focused shRNA library 
consisting of 631 constructs targeting 362 genes which were found in focal 
genomic deletions of 98 human HCCs. Mouse livers were stably 
repopulated with the shRNA library and after repopulation, mice were 
subjected to chronic CCl4 treatment to induce liver damage. ShRNA 
representation in the starting library pool, in the liver after repopulation and 
after four weeks of CCl4 treatment was deconvoluted using deep 
sequencing. While the majority of shRNAs did not change representation 
during liver repopulation or CCl4 mediated liver damage, we identified 
some shRNAs which showed strong enrichment during regeneration and 
therefore pinpoint new regulators of liver regeneration. Interestingly, our 
top scoring candidate represents a kinase, which is accessible to 
pharmacological inhibition. Functional in vivo validation studies show that 
stable knockdown of the candidate gene by different shRNAs can 
significantly increase the repopulation efficiency of mouse hepatocytes and 
also increases the regenerative capacity of chronically damaged mouse 
livers. Despite the fact that some human HCCs show focal deletion of the 
candidate gene, a therapeutic window for regenerative therapy exists, as 
mice stably repopulated with shRNAs against the candidate did not develop 
liver tumors even after long term CCl4 challenge. 
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The unlimited proliferation of human cancer cells depends on the 
maintenance of telomere length. This is achieved either by upregulation of 
telomerase (in 85% of human cancers) or by a telomerase-independent 
mechanism referred to as Alternative Lengthening of Telomeres (ALT) (in 
5-10% of human cancers). Although telomere elongation in ALT appears to 
be recombination dependent, details of the mechanism are not clear. Studies 
using the stn1-M1 mutant of the yeast K. lactis, which has many parallels 
with ALT cells, may provide information for understanding the mechanism 
of telomere lengthening of ALT cancers. The similarities between stn1-M1 
cells and ALT cells include very long and heterogeneous telomeres, 
elevated level of telomere recombination and production of telomeric 
circles (t-circles).  
Our work has now provided several new lines of evidence that support that 
recombinational telomere elongation in newly generated stn1-M1 cells 
involves the Roll and Spread mechanism, where a t-circle is used as a 
template to make an initial long telomere with other telomeres becoming 
lengthened by copying its sequence. First, sequences from a transformed 
DNA circle containing telomeric repeats could be copied onto telomeres of 
stn1-M1 cells in a tandem repeating manner. Second, formation of the long 
telomere phenotype in cells with telomeres tipped with composition of 
mutationally-tagged telomeric repeats commonly produced repeating 
patterns of the two repeat types. Third, studies using cells with a single 
telomere composed entirely of mutationally-tagged repeats has shown that 
the sequence from a single elongated telomere could be copied onto other 
telomeres via a Break Induced Replication (BIR) like event. Our findings 
support that the telomere lengthening in stn1-M1 mutant may often occur 
through a Roll and Spread model and may suggest that formation of the 
ALT state could occur through a similar process.  
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Lung cancer represents the most frequent cancer type and the leading cause 
of cancer death (1.3 million worldwide). Non-small cell lung cancer 
(NSCLC) accounts for 80% of all lung cancer cases. NSCLC development 
is associated with frequent mutations in well-defined oncogenes and tumor 
suppressor genes such as Kras (30%) and p53 (50-70%). We recently 
demonstrated that hyper-activated NF-κB pathway in NSCLC is required 
for the initiation and maintenance of lung cancer, indicating this pathway as 
a promising therapeutic target. In this study, we tested therapeutic delivery 
of proteasome inhibitor Bortezomib (Velcade) to inhibit NF-κB pathway in 
NSCLC mouse models. In mouse lung cancer cell lines harboring 
KrasG12D and p53 loss (KP cells), Bortezomib efficiently reduced nuclear 
p65, repressed NF-κB target genes such as Bcl2 and rapidly induced 
apoptosis. The cell lines with high NF-κB activity are especially sensitive to 
Bortezomib. Using autochothonous mouse models and microCT imaging, 
we showed that Bortezomib treatment at a well-tolerated dose leads to lung 
tumor regression in mice and prolonged survival. Our results demonstrated 
using preclinical mouse models to study cancer treatment response and 
supported NF-κB pathway as an effective therapeutic target in lung cancer. 
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Aberrations in epigenetic processes, such as histone methylation, can lead 
to cancer. The JmjC domain protein Retinoblastoma Binding Protein 2 
(RBP2) is capable of demethylating tri- and di-methylated lysine 4 in 
histone H3, which are epigenetic marks for transcriptionally active 
chromatin. Here we show that loss of RBP2 demethylase activity induces 
senescence and inhibits proliferation of mouse embryonic fibroblasts in a 
pRB-dependent manner. Furthermore, loss of RBP2 promotes the 
differentiation of murine myoblasts and embryonic stem cells in vitro. 
Genetic ablation of Rbp2 decreased tumor formation, and prolonged 
survival, in Rb1+/- mice. These studies provide insights into the roles of 
histone demethylase RBP2 in tumorigenesis and nominate RBP2 as a 
potential target for cancer therapy. 
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Netrin-1 is a secreted extracellular matrix protein. It was discovered as an 
important regulator of embryogenic axon guidance. Recently it has been 
observed to act as a survival factor for different forms of cancer such as 
aggressive neuroblastoma, metastatic breast cancer and non small cell lung 
cancer. It also promotes tumorigenesis of colorectal cancer. According to 
microarray data on Oncomine database netrin-1 is upregulated in 
glioblastoma, most severe human brain cancer. So far, no efficient treatment 
has been discovered for glioblastoma. Glioblastoma is very invasive and 
aggressive cancer which invades diffusively among normal brain tissue and 
is therefore impossible to remove surgically. It is also resistant to 
chemotherapy. We analyzed the effects of netrin-1 on glioblastoma cells. 
According to Matrigel invasion assays overexpression of netrin-1 increased 
the invasiveness of human glioblastoma cells whereas partial knock-down 
of netrin-1 by shRNAs reduced the invasiveness. In wound healing assays 
netrin-1 overexpression increased and partial knockdown decreased 
migration of human glioblastoma cells. On the other hand, complete knock-
down of netrin-1 led to apoptotic death of human glioblastoma cells. Our 
results suggest that netrin-1 is an important regulator of glioblastoma 
tumorigenesis and that the inhibition of netrin-1 signaling may prove out to 
be a treatment option for human glioblastoma. 
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Progression of the cell cycle in mammalian cells is regulated by the 
interplay of cyclin-dependent kinases (CDKs) and their respective cyclin 
partners, which act as positive coactivators or as negative regulators in the 
case of the so-called cdk inhibitors. Cyclin A is a rate-limiting component 
required for both the initiation of DNA synthesis and entry into mitosis. Jun 
dimerization protein 2 (JDP2), a member of the AP-1 family, is able to form 
homodimers, and, also, heterodimers with other members of the AP-1 
family, such as c-Jun, JunB, JunD and ATF2, and with a member of the 
C/EBP family, C/EBPγ. JDP2 most likely participates in the repression of 
transcription via multiple mechanisms, which include DNA-binding 
competition and inactivation of formation of heterodimer with other 
members of the AP-1, recruitment of HDAC 3, inhibition of histone 
acetylation and the direct regulation of chromatin assembly (1). However, 
the details of the physiological role of JDP2 in cell fate remain unknown, 
and the mechanisms by which JDP2 acts as a regulator of the proliferation 
or transformation of cells remain to be clarified. We reported that “knock-
out” of Jdp2 affects adipocyte differentiation (2) and resistance to 
replicative senescence (3).  
We report here a novel role for JDP2 as a regulator of the progression of 
normal cells through the cell cycle. The healing of wounded skin of Jdp2 
knockout mice (KO) mice proceeded more rapidly than that of control mice 
and more proliferating cells were found at wound margins. Fibroblasts 
derived from embryos of Jdp2KO mice proliferated more rapidly and 
formed more colonies than wild-type fibroblasts. JDP2 was recruited to the 
promoter of the gene for cyclin A2 (ccna2) at a previously unidentified AP-
1 site. Cells lacking Jdp2 had elevated levels of cyclin A2 mRNA. 
Moreover, reintroduction of JDP2 resulted in repression of transcription of 
ccna2 and of cell cycle progression. Thus, transcription of the gene for 
cyclin A2 appears to be a direct target of JDP2 in the suppression of cell 
proliferation.  
 
Refs; (1) C. Jin et al., Nat. Struc. Mol. Biol. 13, 331-338 (2006), (2) Nakade 
et al., Cell Death & Differ. 14, 1398-1405 (2007), (3) Nakade et al., J. Biol. 
Chem. 284, 10808-10817 (2009).  
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Senescence is a permanent G1 cell-cycle arrest that can be triggered by 
acute stresses such as activated oncogenes and chemotherapeutic agents. In 
company with apoptosis, senescence serves as a barrier to cancer 
development. Senescent cells are metabolically active and exhibit distinct 
chromatin features compared with proliferating cells. Rb-associated nuclear 
complexes were reported to lead to chromatin remodeling in response to 
oncogenic Ras. Recruitment of a histone H3 lysine 9 methyltransferase into 
such complexes promotes the formation of senescence-associated 
heterochromatin foci, in which trimethylated H3K9(H3K9me3) imposes a 
repressive histone mark. Indeed, the enrichment of H3K9me3 on E2F-
responsive growth promoting (mostly “S-phase”) genes explains the firmly 
cell-cycle arrest status of senescent cells. However, senescent cells not only 
exhibit a cell-cycle block, but also display other functional capabilities, for 
example a senescence-associated secretory phenotype(SASP) and features 
of autophagy. Therefore, the senescent state – as controlled by a global 
chromatin remodeling process – reflects a functionally reprogrammed cell 
condition.  
Here, we performed promoter tiling analysis on H3K9me3-
immunoprecipitated lysates(“ChIP-on-chip”) from human diploid 
fibroblasts, upon transduction with oncogenic Ras vs. non-senescent empty 
vector-infected cells. As a result, we identified 193 genes whose H3K9me3 
enrichment level was significantly changed(>2-fold). We also analyzed 
gene expression profiles on Affymetrix transcriptome chips. 50 genes 
exhibited significant changes(>2-fold), out of which 36 transcripts 
presented changes consistent with the ChIP-on-chip data. Gene ontology 
analysis clustered the 36 genes into several functional groups, including 
cell-cycle control, transcription regulation, protein metabolism, signal 
transduction and apoptosis. Notably, several candidates with reported effect 
on crucial signaling pathways such as NF-κB or Jak/Stat potentially serve as 
the pivotal regulators controlling SASP and other novel gain-of-function 
capabilities. We are currently conducting functional studies on these 
candidates and generating additional data by “ChIP-Seq” on drug-induced 
senescent lymphomas with and without H3K9me3 defects. In essence, our 
data indicate that genome-wide changes of senescence-associated 
H3K9me3 are informative regarding a functionally profoundly re-
programmed phenotype of the senescent condition beyond a mere cell-cycle 
arrest. 
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Cellular senescence suppresses tumorigenesis. Paradoxically, senescence 
inducers (such as activated oncogenes and tissue aging) are often known to 
promote cancer. Here we report a novel cell-intrinsic mechanism that 
promotes senescence while predisposes cells to senescence escape by 
allowing for secondary hits. We show that senescence inactivates the 
BRCA1 DNA repair complex by disassociating BRCA1 from chromatin. 
This event precedes senescence-associated cell cycle exit and coincides 
with DNA damage accumulation. Mechanistically, downregulation of 
BRIP1, a physiological partner of BRCA1, triggers BRCA1 chromatin 
disassociation. Conversely, ectopic BRIP1 rescues BRCA1 chromatin 
disassociation and suppresses senescence. Significantly, cells undergoing 
senescence do not exhibit a BRCA1-dependent DNA damage repair 
response when exposed to DNA damage, and DNA damage promotes 
senescence escape. These data place the altered BRCA1 DNA repair 
complex at the heart of senescence regulation, and provide a molecular 
basis whereby senescence inducers select for mutations that overcome 
senescence and ultimately lead to cancer. 
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We recently showed that the pRb-Skp2-p27T187p pathway plays essential 
survival roles in tumorigenesis following loss of pRb in susceptible cells 
(Wang et al 2010, Nature Genetics). In addition to tumor suppression, pRb 
plays essential roles in normal development as Rb1-/- embryos die in 
midgestation. In this meeting, we will report our studies of the pRb-Skp2-
p27T187p pathway in embryogenesis to determine whether the synthetic 
lethal relationships between Rb1 loss and Skp2 loss, and between Rb1 loss 
and p27T187A mutation during tumorigenesis are applicable to 
embryogenesis. We are studying this topic with germ line knockout, 
embryo proper knockout (Meox2-Cre), and tissue-specific knockout 
(Nestin-Cre) to determine the roles of the pRb-Skp2-p27T187p pathway at 
multiple levels. Our results so far demonstrate significant roles of Skp2 in 
Rb1-/- embryos consistent with its role in pituitary tumorigenesis following 
Rb1 loss. Rb1-/-Skp2-/- embryos die two days earlier than Rb1-/-Skp2+/+ 
embryos with massive apoptosis in neuroepithelium, providing the first case 
that inactivating a pRb target worsens Rb1-/- embryogenesis. The massive 
apoptosis in neuroepithelium appears cell autonomous as it is reproduced 
with targeted Rb1 deletion by Nestin-Cre. Downstream of Skp2, the 
pathway diverges from what was seen in pituitary tumorigenesis. 
p27T187A knockin does not shorten Rb1-/- embryo viability, while still 
lead to massive apoptosis in neuroepithelium as well as in other organs such 
as the lung. The massive apoptosis in neuroepithelium however is not 
reproduced with targeted Rb1 deletion by Nestin-Cre. These results 
establish that Skp2 also plays essential survival roles following Rb1 loss in 
susceptible cells during normal development, but how Skp2 functions in 
this capacity diverges. In some cells, Skp2 still functions through the 
SCFSkp2-p27T187p mechanism, in others, Skp2 appears to function via 
other mechanisms. Further genetic and biochemical studies are ongoing to 
delineate and compare the functional roles and mechanisms of the pRb-
Skp2-p27T187p pathway in tumorigenesis and embryogenesis. 
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The p53 tumor suppressor limits proliferation in response to cellular stress 
through several mechanisms. Here, we test whether the recently described 
ability of p53 to limit stem cell self-renewal suppresses tumorigenesis in 
acute myeloid leukemia (AML), an aggressive cancer where p53 mutations 
are associated with drug resistance and adverse outcome. Our approach 
combined mosaic mouse models, Cre-lox technology and in vivo RNAi to 
disable p53 in concert with endogenous KrasG12D – a common AML 
lesion that promotes proliferation but not self-renewal. We show that p53 
inactivation strongly cooperates with oncogenic KrasG12D to induce 
aggressive AML, while both lesions on their own induce T-cell 
malignancies with long latency. This synergy is based on a pivotal role of 
p53 in limiting aberrant self-renewal of myeloid progenitor cells, such that 
loss of p53 counters the deleterious effects of oncogenic Kras on these cells 
and enables them to indefinitely self-renew. Consequently, myeloid 
progenitor cells expressing oncogenic Kras and lacking p53 become 
leukemia-initiating cells, resembling cancer stem cells capable of 
maintaining AML in vivo. Our results establish an efficient new strategy for 
interrogating oncogene cooperation, and provide strong evidence that the 
ability of p53 to limit aberrant self-renewal contributes to its tumor 
suppressor activity. 
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Protein tyrosine kinase 6 (PTK6) is a nonmyristoylated Src-related 
intracellular tyrosine kinase, which is localized to different cellular 
compartments including the nucleus. Although not expressed in the normal 
mammary gland, PTK6 is expressed in a majority of human breast tumors 
examined, and its expression has been correlated with ErbB2 expression in 
human breast cancer. Expression of PTK6 is also upregulated in other types 
of cancer including colon cancer, ovarian cancer, head and neck cancer and 
metastatic melanoma. PTK6 has been linked to ErbB receptor signaling and 
AKT activation in breast cancer cell models, but the exact role of PTK6 in 
regulating AKT activation is not clear. We demonstrate that AKT is a direct 
substrate of PTK6, and that AKT tyrosine residues 315 and 326 are 
phosphorylated by PTK6. Association of PTK6 with AKT occurs through 
the SH3 domain of PTK6, and is enhanced through SH2 domain mediated 
interactions following tyrosine phosphorylation of AKT. Using Src, Yes, 
and Fyn null mouse embryonic fibroblasts (SYF cells), we show that PTK6 
phosphorylates AKT in a Src-family kinase independent manner. 
Introduction of PTK6 into SYF cells sensitized these cells to physiological 
levels of EGF and increased AKT activation. Stable introduction of active 
PTK6 into SYF cells also resulted in increased proliferation. Knockdown of 
PTK6 in BPH-1 human prostate epithelial cell line led to decreased AKT 
activation in response to EGF. Our data indicate that in addition to 
promoting growth factor receptor mediated activation of AKT, PTK6 can 
directly activate AKT to promote oncogenic signaling. These studies 
provide insight about the potential benefits of targeting PTK6 as part of a 
therapeutic regime to treat different types of cancer that have up-regulated 
PTK6 expression and activity. 
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It is only in the last decade that the existence of self-renewing cells in the 
brain has become fully appreciated. As a consequence, classic models of 
tumor development in the nervous system have invoked dedifferentiation as 
a requisite for tumor initiation. New concepts have arisen, however, with 
the continuing study of “adult” neural stem cells in vivo and in vitro. For 
example, preparation of neurosphere cultures from primary glioma tissue 
from human tumors and mouse genetic models permits detailed analysis 
and the hope for a full molecular understanding of these cells and how they 
compare to normal stem cells. A central question remains the identification 
of the cell of tumor origin. Our own work using tumor suppressor models of 
gliomagenesis or neurofibromas leads us to propose that the cell of origin in 
these tumors is an early progenitor cell or possibly the primary stem cell. I 
will discuss the nature of these mouse models, recent advances, how we 
hope to resolve our current working hypothesis, and implications for 
sporadic human cancer. If indeed stem or progenitor cells give rise to 
glioma, it becomes critical to fully understand their properties and 
physiological roles. Importantly, the ability to isolate these stem/progenitor 
cells and expand them in culture gives us a powerful resource for high-
throughput screens that could yield potentially novel therapies for cancer 
treatment. 
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Despite the high prevalence and poor outcome of patients with metastatic 
lung cancer, the mechanisms of tumor progression and metastasis remain 
largely uncharacterized. We modeled human lung adenocarcinoma, which 
frequently harbors activating point mutations in KRAS and inactivation of 
the p53-pathway, using conditional alleles in mice. Lentiviral-mediated 
somatic activation of oncogenic Kras and deletion of p53 in the lung 
epithelial cells of KrasLSLG12D/+;p53flox/flox mice initiates lung 
adenocarcinoma development. Although tumors are instigated 
synchronously by defined genetic alterations only a subset become 
malignant, suggesting that disease progression requires additional 
alterations. We developed a method, based on identification of the lentiviral 
integration sites, to distinguish metastatic from non-metastatic tumors and 
determined the gene expression alterations that distinguish these tumor 
types. Cross-species analysis identified the NK-2 related homeobox 
transcription factor, Nkx2-1 (Ttf-1/Titf1) as a candidate suppressor of 
malignant progression. In our model, downregulation of Nkx2-1 is 
pathognomonic for high-grade poorly differentiated lung adenocarcinoma. 
Gain- and loss-of-function experiments in cells derived from metastatic and 
non-metastatic tumors demonstrate that Nkx2-1 controls tumor 
differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-
1 regulated genes and analysis of tumors at defined developmental stages 
indicates that Nkx2-1 constrains progression in part by repressing the 
embryonically-restricted transcriptional regulator Hmga2. While focal 
amplification of NKX2-1 in a fraction of human lung adenocarcinomas has 
focused attention on its oncogenic function, our data specifically link Nkx2-
1 downregulation to loss of differentiation, gain of stem cell characteristic 
and enhanced metastatic proclivity. Thus, the oncogenic and suppressive 
functions of Nkx2-1 in the same tumor type substantiate its role as a dual 
function lineage factor. 
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The targeted inactivation of oncogenes can elicit sustained tumor 
regression, associated with the phenomenon that has been described as 
oncogene addiction. Utilizing conditional transgenic mouse models, we 
have gleaned some insight into the mechanisms of oncogene addiction 
illustrating that upon oncogene inactivation tumors undergo proliferative 
arrest, apoptosis, differentiation and/or senescence. The specific 
consequences of oncogene addiction appear to depend upon both cellular 
and genetic context and both tumor cell intrinsic and host-dependent 
mechanisms appear to be critical. Recently, we have utilized a conditional 
mouse model of MYC induced T-acute lymphoblastic lymphoma to dissect 
the role of host immune effectors in tumor regression associated with MYC 
inactivation. We have found that defects in host immune effectors cause a 
dramatic reduction in the kinetics, degree and duration of tumor 
elimination. Moreover, we have found that upon MYC inactivation immune 
cells are recruited to the tumor site. Finally, we have identified that discrete 
immune effectors are required for MYC inactivation to induce cellular 
senescence in tumor cells and the shut down of angiogenesis in the host. We 
have found that the adoptive reconstitution of cellular effectors can restore 
the ability of MYC inactivation to induce sustained tumor regression. Our 
results illustrate that oncogene addiction is not cell autonomous and that the 
interaction between the host and tumor microenvironment may play a 
critical role in the mechanism by which oncogene inactivation elicits tumor 
regression. We will describe how specific immune effectors and specific 
secreted cytokines appear to be essential to regulate the tumor 
microenvironment. We speculate that targeted oncogene inactivation leads 
to tumor regression through mechanisms that require a restoration of the 
normal tissue micronenvironment. 
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It is becoming increasingly clear that stromal responses elicited by early-
stage neoplastic lesions can promote tumor progression towards a more 
invasive and potentially metastatic state. However, the molecular 
mechanisms that underlie the early recruitment of stroma, and in particular 
immune cells, to sites of neoplasia remain poorly understood. To address 
this question in the context of pancreatic adenocarcinoma, we make use of 
orthotopic pancreatic grafts of primary murine pancreatic ductal epithelial 
cells (PDEC) harboring oncogenic KRas (KRasG12D). We find that 
engrafted KRasG12D-expressing PDEC can elicit a significant 
inflammatory response. The nature and composition of inflammatory 
infiltrates was assessed using FACS sorting as well as 
immunohistochemical techniques and was directly compared to those 
derived from p48-Cre;LSL-KRasG12D mice. Our observations to date 
indicate that the expression of KRasG12D promotes the recruitment of 
immunosuppressive leukocytes in the absence of a notable increase in the 
cytotoxic T cell population. These results support the hypothesis that 
effective tumor immunity mediated by an adaptive T cell response is 
actively suppressed at the very early stage of pancreatic neoplasia. We are 
currently investigating the molecular mechanisms by which oncogenic 
KRas modulates the intratumoral immune response. 
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While numerous cell-intrinsic processes are known to play decisive roles in 
chemotherapeutic response, relatively little is known about the impact of the 
tumor microenvironment on therapeutic outcome. Here, we use a well-
established mouse model of Burkitt’s lymphoma to show that paracrine 
factors in the tumor microenvironment modulate lymphoma cell survival 
following the administration of the genotoxic chemotherapeutic 
doxorubicin. Specifically, IL-6 and Timp-1 are released in the thymus in 
response to DNA damage, creating a “chemo-resistant niche” that promotes 
the survival of a minimal residual tumor burden and serves as a reservoir for 
eventual tumor relapse. Disruption of this chemo-protective cytokine 
signaling or ablation of the protective microenvironment potentiates the 
action of doxorubicin, as assessed by both lymphoma cell survival and 
disease progression. Notably, IL-6 is released acutely from thymic 
endothelial cells in a p38-dependent manner following genotoxic stress, and 
this acute secretory response precedes the gradual induction of senescence 
in tumor-associated stromal cells. Thus, conventional chemotherapies can 
induce tumor regression while simultaneously eliciting stress responses that 
protect subsets of tumor cells in distinct anatomical locations from drug 
action. 
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Cellular organization into epithelial architecture maintains structural 
integrity and homeostasis by suppressing cell proliferation and apoptosis. 
We have previously shown that differentiated epithelial organization of 
MCF10A 3D acini blocks the ability of c-Myc to re-initiate cell cycle 
progression and induce transformation. This epithelial architecture imposed 
restraint to the oncogenic c-Myc is dismantled upon silencing of LKB1, the 
mammalian homologue of polarity protein PAR4 (Partanen et al., PNAS 
2007). We have further explored the role of LKB1 in formation and 
maintenance of epithelial architecture in vivo using mice, in which Lkb1 
alleles can be conditionally deleted in the luminal epithelial cells of 
mammary gland. We show that loss of Lkb1 induces gross alterations in the 
epithelial architecture of 3D structures and in the mammary gland as 
manifested by loss of cell polarity, defects in the basement membrane 
structure and spontaneous hyperbranching. Loss of Lkb1, when combined 
with mammary specific overexpression of c-Myc, led to dramatic 
acceleration of c-Myc-induced mammary tumorigenesis. These mice exhibit 
increased tumor multiplicity and volume, and in addition the tumors show 
histopathological features distinct from Myc-induced mammary tumors. 
Furthermore, the cooperation of Lkb1 loss and c-Myc activation resulted in 
strikingly transformed 3D acini, which allows studies on molecular 
mechanisms underlying the synergy. In conclusion, our data show evidence 
that LKB1 has a crucial role in formation of epithelial architecture and 
apicobasal polarity and that loss of LKB1 significantly cooperates with 
activated c-Myc oncogene in tumorigenesis. 
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Breast cancer is one of the most common cancers in humans and will on 
average affect up to one in eight women in their life time in the US and 
Europe. The Women's Health Initiative (WHI) and the Million Women 
Study have shown that hormone replacement therapy (HRT) is associated 
with an increased risk of incident and fatal breast cancer. In particular 
synthetic progesterone derivatives (progestins) such as 
medroxyprogesterone acetate (MPA), used in millions of women for HRT 
and contraceptives, markedly increase the risk of developing breast cancer. 
Here we report that in vivo administration of MPA triggers massive 
induction of the key osteoclast differentiation factor Receptor Activator of 
NF-κB Ligand (RANKL) in mammary gland epithelial cells. Genetic 
inactivation of the RANKL receptor RANK in mammary gland epithelial 
cells prevents MPA-induced epithelial proliferation, impairs expansion of 
the CD49fhi stem cell-enriched population, and protects these cells from 
DNA damage induced cell death. Importantly, RANK deletion in the 
mammary epithelium results in a markedly reduced incidence and delayed 
onset of MPA-driven mammary cancer. Mechanistically, RANK/RANKL 
increases the self-renewal capacity of mammary cancer stem cells and 
induces anchorage-independent growth of breast cancer cells. Interestingly, 
whereas RANKL-RANK triggers osteoclastogenesis via both NF-κB and 
NFATc1, MPA-driven mammary cancer was only delayed in mice that 
carry IKKα, but not NFATc1, deletions in the mammary epithelium. These 
data identify the essential osteoclast differentiation factors RANKL/RANK 
as a key pathway that controls the incidence and onset of progestin-driven 
breast cancer. 
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Hyper-activation of the PI 3-Kinase/ AKT pathway is common in many 
cancer types. Tumourigenesis through this pathway is prevented by 
concerted action of multiple tumour suppressor genes. Most notably, PTEN 
reverts PI 3-Kinase activity while excessive pathway activation triggers the 
p53-mediated senescence response, which constitutes a fail-safe mechanism 
against cancer. However, it remains ill defined if & at what stage this 
response acts in human prostate cancer. Here we identify the AKT-
inactivating phosphatase PHLPP as a tumour suppressor & demonstrate that 
the p53-response prevents co-deletion of PTEN & PHLPP to form a barrier 
against progression to aggressive prostate cancer. We show that Phlpp-loss 
causes neoplasia & upon partial Pten-loss, carcinoma in mouse prostate. In 
this setting, Phlpp-deficiency shifts active Akt localisation from cytoplasm 
to the membrane & triggers growth arrest via mTor-dependent translation of 
p53. As a consequence, we find that co-deletion of Pten & Phlpp requires 
inactivation of p53 in prostate, as shown by its spontaneous mutation & loss 
of p21 transcription. Finally, we validate this conditional gene inactivation 
scheme for prostate in a gene-copy number & expression dataset on 218 
patient samples. Surprisingly, we find that co-deletion of the PTEN & 
PHLPP loci is almost exclusively observed in metastatic prostate cancer & 
in complete agreement with our results from mouse, is tightly correlated to 
deletion of TP53.  Our findings demonstrate how combining large-scale 
human prostate cancer genomics with mouse genetics allows for discovery 
of progression principles that will help identify patients at risk for 
developing lethal disease through molecular signatures. Identification of 
PHLPP-loss as a critical determinant of metastatic disease progression 
highlights the potential of drug-based inhibition of the mTORC2 kinase 
complex, which directly reverts PHLPP phosphatase activity on AKT.   
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Type I collagen is the most abundant extracellular matrix protein, providing 
a scaffold for organs. Its expression is dramatically increased in primary 
tumors of metastatic cancer, yet, degradation of the collagen scaffold is 
necessary for epithelial invasion. By targeting both type I collagen and the 
matrix metalloproteinases (MMPs) that cleaves it, we show here that 
stromal cleavage of collagen by MMPs controls ductal epithelial invasion in 
mammary gland development. Epithelial invasion is reduced in the absence 
of stromally expressed MMP14 (MT1-MMP), when collagen is MMP-
resistant, or when collagen is hypersensitive to non-MMP mediated 
proteolysis. Therefore, epithelial ductal invasion is reduced when MMP-
dependent collagen remodeling is reduced. To address the role of collagen 
remodeling for epithelial invasion in cancer, we cross-bred MMTV-PyMT 
mice, which develop metastatic mammary carcinoma, with mice with 
MMP-resistant collagen. Primary tumor size was not affected, but 
metastasis to the lungs was significantly reduced. Thus, MMP-specific 
remodeling of the collagen scaffold regulates epithelial invasion in 
development and cancer. 
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The incidence of malignant melanoma has continued to rise over the past 
several decades. It is the most deadly form of skin cancer primarily due to 
treatment resistant metastases. The progression to melanoma is driven by 
activating mutations in either BRAF (60%) or NRAS (30%) that initiate the 
formation of nevi, some of which convert to full blown melanoma 
accompanied by further genetic and epigenetic changes in gene expression; 
most commonly the loss of tumour suppressors p16INK4A or PTEN, which 
facilitate an escape from senescence and an increase in survival and 
invasion, respectively. There may be a link between the highly migratory 
behavior of neural crest derived melanocyte precursors during development 
and the propensity of melanomas to metastasize early. Rho-family GTPases 
determine the mode of motility that human melanoma-derived cells use to 
migrate through 3D ECM. Rho regulates amoeboid migration, whilst Rac 
regulates mesenchymal migration. The Rac-specific GEF, P-Rex1, though 
not expressed in human melanocytes in tissue culture, is expressed in most 
human melanoma derived cell lines, where it is necessary for the 
mesenchymal mode of 3D migration. P-Rex1 is not detectable by 
immunohistochemical staining of normal skin, but is detected in most nevi, 
primary melanomas and metastases. Mouse models are being used to 
investigate the role of P-Rex1 during melanocyte development and 
melanoma progression. C57/Black P-Rex1-/- mice have a melanocyte 
migration defect evidenced by a white belly stripe resulting from retarded 
melanoblast migration observed by the location of DCT-LacZ melanocyte 
precursor cells in 15.5 day embryos. Mouse melanoma models driven by 
tyrosinase (Tyr)-NRASQ61K, or Tyr-CRE recombinase activated 
BRAFV600E expression have been used in conjunction with P-Rex1-/- 
mice. Cutaneous melanomas develop with equal frequency and similar 
latency in Tyr-NRAS, INK4A-/- mice regardless of the presence or absence 
of P-Rex1, however progression to metastasis is dramatically suppressed in 
P-Rex1-/- mice (P=0.001).  
P-Rex1-/- mice with melanomas had a significant increase in survival 
(P=0.037). We conclude that P-Rex1 plays a significant role in melanoblast 
migration during development and progression from primary melanoma to 
metastasis.  
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Human lung adenocarcinomas harboring activating mutations in the 
epidermal growth factor receptor (EGFR) often regress when treated with 
EGFR tyrosine kinase inhibitors (TKIs) but the clinical benefit of EGFR 
TKIs is variable and transient. We hypothesized that the heterogeneity of 
treatment response may be explained by genetic modifiers of dependence on 
mutant EGFR. Through a pooled RNA interference screen, we identified 36 
genes that, when knocked down, specifically enhance cell death induced by 
the EGFR TKI erlotinib. Curiously, silencing of many of these genes, such 
as the TNF receptor family member CD95/Fas, promoted growth in 
conjunction with mutant EGFR in the absence of erlotinib. FAS-mediated 
activation of NFκB, through the intermediate signaling molecules FLIP, 
IKK and IκB, was necessary and sufficient to confer erlotinib resistance in 
EGFR mutant tumor cells. Furthermore, combined inhibition of NFκB and 
EGFR resulted in enhanced apoptosis in erlotinib-sensitive and erlotinib-
resistant EGFR-mutant lung cancer models. These findings provide novel 
insights into the mechanisms by which tumor cells acquire oncogene 
dependence and subsequently escape from oncogene inhibition. 
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Pancreatic adenocarcinoma (PDAC) represents a significant unmet medical 
need with a high failure rate experienced in clinical trials, underscoring a 
need for predictive preclinical models of therapeutic response in this 
disease. Genetically engineered mouse models (GEMMs) of cancer are 
extensively used to mimic human tumorigenesis but despite their potential, 
there is limited evidence of their utility in preclinical drug development. To 
address this deficiency, we recently examined responses to existing 
standard-of-care chemotherapy with gemcitabine and the targeted EGFR 
inhibitor erlotinib (alone and in combination) in a mutant Kras-driven 
GEMM of pancreatic cancer: KrasLSL-G12D; p16/p19fl/fl; Pdx1-Cre. 
Comparisons of progression-free and overall survival patterns observed in 
corresponding clinical trials indicate that the GEMM appropriately models 
human responses. To evaluate new treatment strategies for pancreatic 
cancer, we then assessed responses in this model to anti-angiogenic therapy 
starting with anti-VEGF alone and in combination with gemcitabine and 
erlotinib. Bevacizumab (Avastin®) in combination with gemcitabine was 
not efficacious in human pancreatic cancer, unlike the positive results 
observed with this combination in human pancreatic xenografts. In the 
PDAC GEMM, the combination of gemcitabine and anti-VEGF resulted in 
partial efficacy (as compared to gemcitabine alone), and therapy with the 
triple combination of erlotinib, gemcitabine, and anti-VEGF resulted in an 
incremental benefit recapitulating recent results seen with the latter regimen 
in the clinic. We then tested the hypothesis that pancreatic tumor 
vasculature may be sustained by additional angiogenic factors along with 
VEGF by treating tumor-bearing GEMMs with a novel inhibitor of tumor 
angiogenesis. When this new agent was combined with anti-VEGF, we 
observed a significant impact on tumor growth and on overall survival. The 
triple combination of gemcitabine, anti-VEGF, and this novel therapy was 
significantly efficacious in comparison to gemcitabine treatment alone, 
implicating a new therapeutic target that is required for pancreatic tumor 
progression and angiogenesis. These results will be presented along with 
analyses of treatment effects on tumor vasculature and metastasis. These 
studies lay the foundation for the use of this model in predicting clinical 
outcomes as well as interrogating mechanisms of therapeutic response and 
resistance. 
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Women with heterozygous germline mutations in BRCA1 have a strongly 
increased lifetime risk of developing breast and/or ovarian cancer. BRCA-
related cancers show a good response to DNA-damaging agents, like 
platinum compounds. But resistance to platinum agents is still a serious 
problem in the treatment of BRCA-related cancers. In the human situation, 
genetic reversion of the Brca1 mutation may serve as an important 
mechanism underlying the induction of platinum resistance. Strikingly, 
mammary tumors arising in the K14Cre;Brca1F/F;p53F/F mouse model 
(which lack Brca1 exons 5-13) never become resistant against platinum 
drugs, suggesting that (partial) BRCA1 function is required for platinum 
resistance. To investigate whether BRCA1 function is causally related to 
acquired platinum resistance, mice carrying various Brca1 mutations were 
bred with K14Cre;Brca1F/F;p53F/F mice. One of these mutations is 
Brca1C61G, which is a pathogenic missense mutation disrupting the 
interaction between BRCA1 and BARD1 and thereby the E3 ubiquitin 
ligase activity of BRCA1. Mammary tumor development was observed in 
the K14Cre;Brca1C61G/F;p53F/F model. Sequencing revealed that these 
mammary tumors still carried the Brca1C61G mutation. Brca1C61G/del;p53del 
mammary tumors displayed similar characteristics as Brca1del;p53del 
tumors, like "triple-negativity" and genomic instability. Spontaneous 
Brca1C61G/del;p53del mammary tumors were transplanted orthotopically into 
immunocompetent mice and intervention studies with platinum compounds 
were performed. In contrast to Brca1del;p53del tumors, resistance to platinum 
agents was observed for various independent Brca1C61G/del;p53del tumors. 
Thus far, we have not observed genetic reversion of the Brca1C61G mutation 
as a mechanism of platinum resistance. We are currently investigating 
which other mechanisms can cause resistance to platinum agents in these 
tumors. Identical experiments are performed for tumors carrying to other 
BRCA1 founder mutations, respectively the Brca1185delAG and Brca15382insC 
mutation. This research could reveal the most important mechanisms of 
platinum resistance in BRCA-related cancers and show possible variation in 
sensitivity to platinum drugs of different BRCA1 mutations. These novel 
mouse models could offer an ideal platform to test new treatment strategies 
for BRCA1 mutation carriers. This insight could lead to various treatment 
strategies for carriers of different BRCA mutations and thereby hopefully to 
a better survival. 
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The mTOR kinase is frequently deregulated in human cancer due to genetic 
alterations in various tumor suppressors and oncogenes including PTEN, 
TSC1/2, LKB, NF1, PI3K and RAS. Consequently, mTOR inhibitors have 
been extensively evaluated as anti-cancer agents in the clinic. While these 
agents exhibit efficacy in a subset of tumor-types, responses are typically 
cytostatic and temporary, suggesting that mTOR inhibitors might be more 
effective when combined with other therapies. We now demonstrate the 
potent therapeutic effects of combining an mTOR inhibitor with agents that 
induce ER stress. Using a genetically engineered mouse cancer model we 
show that ER stress-inducing agents, including the Hsp90 inhibitor IPI-504, 
trigger the rapid regression of highly aggressive NF1-deficient malignancies 
in vivo, but only when combined with rapamycin. Together, these agents 
cause pronounced effects on the ER and the mitochondria in tumor cells in 
vivo, induce excessive levels of autophagy and autophagic-associated cell 
death, and promote tumor regression via a caspase-3 independent 
mechanism. Rapamycin/IPI-504 treatment similarly causes tumor 
regression in a KrasG12D/p53 genetically engineered model of non-small 
cell lung cancer (NSCLC), suggesting that the therapeutic potential of this 
combination therapy may extend to other cancers. Importantly, the 
combined efficacy of these compounds would not have been predicted by in 
vitro studies, highlighting the utility of mouse models in preclinical 
discovery. Collectively, these findings reveal a promising strategy for 
developing mTOR inhibitor-based combination therapies for two Ras-
driven malignancies for which there are currently no effective treatments. 
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In many cases, treatment of solid tumors with standard chemotherapy leads 
only to partial response. These recurrent tumors usually prove to be 
resistant to the chemotherapeutic agents initially used to treat the cancer. 
Thus, tumor recurrence driven by tumor-reinitiating cells (TRICs) is a 
central problem in cancer therapy. Despite the importance of this problem, 
the mechanisms accounting for variable chemotherapy response and tumor 
re-initiation in vivo are poorly understood. For example, it is unclear 
whether tumor-reinitiating cells are intrinsically therapy resistant cells with 
distinct genetic or epigenetic characteristics or whether they acquire genetic 
changes that allow them to become therapy resistant. In addition, 
controversy exists regarding whether tumor re-initiating cells arise 
stochastically from a genetically diverse tumor population or whether 
“cancer stem cells” are present in tumors and represent the primary 
reservoir for intrinsic chemoresistance. Surprisingly, relatively little 
attention has been focused on studying the process of tumor re-initiation in 
vivo. Mouse models of cancer that closely mimic the human disease are 
valuable tools to study the process of tumor re-initiation after 
chemotherapy.  
Using one such mouse model of human lung cancer, we have identified a 
subset of tumor cells that can be isolated by their cell surface characteristics 
and have an increased intrinsic resistance to chemotherapy. Our studies 
were carried out in Kras-driven lung tumor model crossed to a conditional 
fluorescent transgenic reporter (tdRFPLSL) to facilitate isolation of tumor 
cells by FACs. We first noted that cisplatin-treatment of these mice led to a 
dramatic decrease in the number of CD44+;RFP+ cells, suggesting that 
CD44- cells are chemotherapy resistant. Interestingly, chemoresistance in 
this model is associated with a significant increase in tumor re-initiation 
capacity in transplantation experiments in vivo and “pulmosphere” 
formation in vitro. Gene expression analysis comparing FACS-sorted 
“chemoresistor” cells them to the bulk control population has identified a 
large number of differentially expressed genes that are currently being 
validated. Gene expression analysis identified the cell surface marker CD24 
as upregulated in chemoresistant cells. Subsequent analysis demonstrated 
that in vitro sphere-forming ability is greatly enriched in a CD44-/CD24+ 
subpopulation. Thus, we have uncovered a relationship between 
chemoresistance and characteristics of cancer stem cells (transplantation, 
sphere formation) in this model. Further supporting a link between cancer 
“stemness” and chemoresistance, gene expression and functional studies 
suggest a role for the iPS transcription factor Sox2 in chemotherapy 
resistance in vivo.  
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Copper exposure and intake levels have been associated with cancer 
incidence and mortality. Cancer patients exhibit elevated levels of serum 
and tumor copper; agents that reduce systemic copper levels have been 
demonstrated to retard angiogenesis and tumor growth in mice, 
underscoring the importance of copper in tumor development.  
 
We have previously demonstrated in a mouse model of human cervical 
cancer that tumors overexpress the copper transporter Ctr1 and upregulate 
its activity in response to a decrease in plasma copper levels by a copper 
chelator, but not normal tissues. These observations led us to propose that 
tumors are particularly sensitive to changes in copper levels and may have a 
higher demand for copper. 
 
We dissected the role of copper at different stages of tumorigenesis using 
the mouse model of pancreatic islet carcinoma, RIP-Tag2. A copper 
chelator inhibited angiogenesis at the early stage of tumor development, and 
retarded tumor growth at the late stage. Remarkably, when mice were 
chronically exposed to 20 μM copper in drinking water, which is the 
maximal level of copper allowed in our drinking water by the 
Environmental Protection Agency, there was a two-fold increase in tumor 
volume. Analysis of tumors revealed that copper increased the rate of tumor 
cell proliferation, but did not affect apoptosis or vessel density. In vitro, the 
copper chelator arrested tumor cells in G2, reminiscent of ATP deficiency. 
Copper is a co-factor for cytochrome c oxidase, the last enzyme in the 
respiratory chain of oxidative phosphorylation. We found that the copper 
chelator decreased cytochrome c oxidase activity and increased lactate 
production in tumor cells. We propose that tumor cells use oxidative 
phosphorylation for ATP source in the presence of oxygen and copper, but 
depend on glycolysis when copper becomes scarce. This may explain 
aerobic glycolysis of tumors described by Warburg, and suggests a copper 
chelation therapy as a promising cure for cancer.  
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T cell acute lymphoblastic leukemia (T-ALL) is a devastating blood tumor 
that afflicts both children and adults. Several laboratories including ours 
have shown that the main oncogenic trigger in T-ALL is the activation of 
the Notch signaling pathway. In a recent screen for silencers of the Notch 
oncogenic activity we have identified the ubiquitin ligase Fbw7 and a potent 
tumor suppressor that ubiquitinates and degrades oncogenic Notch1. We 
have also shown that Fbw7 is inactivated by mutations that target its 
substrate binding pockets leading to the stabilization and over-expression of 
oncogenic substrates, including Notch1 and c-Myc. Generation of Fbw7 
knock-out and knock-in (carrying the human mutations) mouse mutants 
mimics human disease and provides clues on the molecular mechanism of 
cell transformation. Using these mice as well as knock-in models of Notch1 
activation (carrying the human mutants found in T-ALL) we were able to 
show that Notch1 activation leads to the hyper-activation of the IKK kinase 
complex and the nuclear translocation of NF-kB transcription factors 
leading to aberrant gene expression. Genetic targeting of the IKK complex 
in already established disease showed that T-ALL maintenance depends on 
IKK signaling suggesting that IKK targeting could lead to future therapies. 
Finally, further biochemical screens have identified another member of the 
ubiquitin complex, the deubiquitinase CYLD as the link between Notch 
signaling and IKK hyper-activation. These studies are important for the 
therapeutic targeting of T-ALL and suggest that the ubiquitin complex adds 
a novel level of complexity in the regulation of blood stem and progenitor 
transformation. 
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The γ-secretase protease complex regulates a variety of cell processes 1, 
notably including the Notch pathway, which is critical for the function of 
stem cells and can be oncogenic when constitutively active 2-5. A large 
proportion of human and murine lung adenocarcinomas have the Notch 
pathway hyperactive, and here we examine its role in lung stem cells, 
tumour initiation and cancer maintenance. The bronchioalveolar stem cells 
(BASCs) have been implicated in the initiation of lung tumorigenesis driven 
by oncogenic Kras 6. Interestingly, genetic disruption of the γ-secretase 
complex by combined deletion of its key components presenilins 1 and 2, 
results in impaired BASC expansion upon lung injury and in complete 
protection from KrasG12V-driven lung adenocarcinomas. We show that the 
activity of the Notch pathway increases during tumour progression and, 
based on this, we have tested the role of γ-secretase in cancer maintenance. 
Importantly, mice with endogenous lung adenocarcinomas were treated 
with a small molecule γ-secretase inhibitor 7 and this resulted in complete 
arrest of cancer growth, often accompanied by cancer regression, as 
measured by positron electron tomography (PET). Immunohistochemical 
analyses of treated cancers indicated loss of Hes1 and active Erk, 
accompanied by decreased proliferation and higher apoptosis. Together, 
these results support a critical role for γ-secretase activity in lung cancer 
initiation and maintenance, and provide proof for the therapeutic potential 
of γ -secretase inhibitors against lung adenocarcinoma. 
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We previously performed a RNA interference screen to discover factors that 
selectively kill cells with activating mutations of KRAS, in which we 
observed synthetic lethality of KRAS mutant cancer cells with knockdown 
of the transcription factor GATA2. We explored this synthetic lethality in 
non-small cell lung cancer (NSCLC) cells with mutations in either KRAS or 
EGFR, two of the most common oncogenic mutations in NSCLC. 
Surprisingly, we observed that knockdown of GATA2 reduces the viability 
of NSCLC cell lines with activating mutations in either KRAS or EGFR. 
Notably, GATA2 knockdown inhibited the growth of EGFR mutant cells 
resistant to erlotinib. In contrast, suppression of GATA2 caused little 
change in the viability of NSCLC cells wild type for KRAS and EGFR, 
suggesting that GATA2 silencing is specifically required in these oncogene-
driven NSCLC cells. 
To understand the consequences of GATA2 suppression on gene 
expression, we examined the transcript profiles of KRAS and EGFR mutant 
cells in the presence or absence of GATA2 knockdown. Interestingly, we 
observed a significant down-regulation of multiple factors which exhibit 
synthetic lethality with oncogenic KRAS. Using gene set enrichment 
analysis, we found observed down-regulation of several signalling pathways 
and molecular complexes known to be requisite for KRAS-driven cancers. 
Furthermore, we generated a gene expression signature for GATA2 
knockdown for assessment in NSCLC cells and primary tumor data sets. 
Coordinate with gene expression analysis, we mapped GATA-2 genome 
occupancy via chromatin immunoprecipitation coupled to 'deep' sequencing 
(ChIP-seq). In particular, we performed ChIP-seq of GATA-2 in NSCLC 
cells containing either oncogenic mutations in KRAS or EGFR or wild type 
for both genes. We found substantial GATA-2 binding across the genome, 
with enrichment of specific gene networks. To characterize the role of 
GATA-2 in transcriptional control, we also performed ChIP-seq for RNA 
polymerase II and histone modifications involved in transcription initiation, 
Polycomb-mediated repression, and regulation of enhancer activity. 
Analysis of these occupancies should clarify the role of GATA-2 in the 
broader chromatin state of NSCLC. 
Taken together, these findings suggest that GATA2 is required for the 
survival of NSCLC cells with oncogenic mutations in either KRAS or 
EGFR. Beyond these initial results, we will test candidate transcripts and 
signalling pathways for their functional relevance to GATA2-mediated cell 
viability. In addition, we will determine the role of GATA2 suppression on 
KRAS and EGFR-driven tumorigenesis in vivo. 
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To effectively monitor protein phosphorylation events governing signaling 
cascades, we have developed a mass spectrometry-based methodology 
enabling the simultaneous quantification of tyrosine phosphorylation of 
specific residues on dozens of key proteins at multiple time points under a 
variety of perturbations. We have recently applied this technique to identify 
key signaling nodes regulating EGFR, Insulin Receptor, and T Cell 
Receptor signaling network response to stimulation.  
Here we have performed an in-depth characterization of the network-wide 
effects of single-point mutations on the oncogenic, constitutively active, 
EGFRvIII receptor tyrosine kinase. This study quantifies the adaptive 
capacity of cellular signaling networks and the pleiotropic effects of 
knocking out individual phosphorylation sites with the network. 
Computational analysis of the phosphorylation data relative to phenotypic 
data highlights the role of selected protein phosphorylation sites in 
regulating biological outcome. We demonstrate the utility of a data-driven 
computational model that is capable of fully describing glioblastoma cell 
growth based on just 13 phosphoproteins. Overall, we have now 
demonstrated that the combination of mass spectrometry-based analysis of 
protein phosphorylation with phenotypic measurements and computational 
modeling yields novel insights into the regulation of cellular signaling on a 
network scale 
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Breast cancer is a collection of diseases with distinct clinical behaviors and 
underlying genetic causes. Triple-negative breast cancer (TNBC) is a 
common subtype of breast cancer that confers a particularly poor prognosis 
and is refractory to current targeted therapies. Unfortunately, the molecular 
determinants driving this aggressive malignancy are poorly understood. 
Using an unbiased genetic screen, we have identified a novel tumor 
suppressor network that governs proliferation and transformation of TNBCs 
in vitro and in vivo. We define SECT21 as a core component in this 
network and a commonly inactivated tumor suppressor in TNBC. SECT21 
is a potent suppressor of human mammary epithelial cell proliferation and 
transformation. SECT21 function is frequently compromised in human 
TNBCs by inactivating mutations or loss of protein expression. 
Mechanistically, SECT21 is a tyrosine phosphatase that suppresses cellular 
transformation by interacting with and inhibiting several oncogenic receptor 
tyrosine kinases including HER2 and EGFR. Notably, the tumorigenic and 
metastatic potential of SECT21-deficient TNBCs is severely impaired by 
restoring SECT21 function or by inhibiting kinase targets of SECT21, 
suggesting that TNBCs are dependent on the proto-oncogenic tyrosine 
kinases constrained by SECT21. Collectively, these data identify SECT21 
as a commonly inactivated tumor suppressor and provide a rationale for 
combinatorially targeting tyrosine kinases in TNBC and other cancers based 
on their profile of tyrosine phosphatase activity. 
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Chromosomal translocations involving the MLL gene are associated with 
infant acute lymphoblastic and mixed lineage leukemia. There are a large 
number of translocation partners of MLL that share very little sequence or 
seemingly functional similarities; however, their translocations into MLL 
result in the pathogenesis of leukemia. To define the molecular reason why 
these translocations result in leukemogenesis, we have purified several of 
the commonly occurring MLL chimeras. We have identified many of the 
MLL partners in a super complex with several of the known RNA 
polymerase II elongation factors. We have named this complex, the Super 
Elongation Complex (SEC). SEC includes ELLs, P-TEFb, AFF4, and other 
MLL partners. We have shown that AFF4 is required for SEC stability and 
proper transcription by poised RNA polymerase II in metazoans. 
Knockdown of AFF4 in leukemic cells shows reduction in MLL chimera 
target gene expression, suggesting that AFF4/SEC could be a key regulator 
in the pathogenesis of leukemia through many of the MLL partners. Our 
studies have provided a molecular insight to why translocations of MLL 
into a large number of genes with seemingly little sequence similarities, 
result in leukemogenesis. Our model in this regard will be discussed. 
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Acute myeloid leukemia (AML) exemplifies the genetic heterogeneity and 
complexity of human cancer; however, our growing genetic knowledge has 
not yet translated into effective targeted therapies. Translocations involving 
the MLL gene on 11q23 induce chemotherapy resistance and define one of 
the most adverse prognostic markers. Here we use an approach combining 
mosaic mouse models, conventional Tet-Off oncogene addiction studies and 
novel Tet-On in-vivo RNAi to systematically survey genes that are required 
for maintenance of MLL/AF9-induced AML. Withdrawal of MLL/AF9 
itself triggers a terminal differentiation program resulting in cure of 
leukemic mice. Using transcriptome profiling, we identify a group of 
transcription factors that act as direct MLL/AF9 targets. Besides known 
targets such HoxA9 and Meis1, these include two human oncogenes – Myc 
and Myb. To test a possible role of Myc and Myb in maintenance of 
MLL/AF9-driven AML in vivo, we developed a TetOn-shRNA expression 
system (TRMPV) and show that shRNA-mediated repression of Myc or 
Myb effectively eliminates MLL/AF9 blasts in vivo. To determine if this 
sensitivity was leukemia specific, we tested the impact of Myc and Myb 
shRNAs in normal hematopoiesis: While Myc suppression completely 
abrogates reconstitution of the hematopoietic compartment, suppression of 
Myb does not interfere with myelo- and eythropoiesis, while partially 
suppressing lymphopoiesis. To further characterize Myb as potential drug 
target, we transplanted leukemia cells that were selected for inducible 
shRNAs. Strikingly, induction of Myb shRNAs in leukemic mice triggers a 
terminal differentiation program that precisely phenocopies MLL/AF9 
withdrawal and results in complete remission, which is permanent even 
after discontinuing doxycycline treatment. In summary, our study identifies 
Myb as a direct and essential transcriptional target in MLL/AF9 
leukemogenesis and shows that transient and subtotal repression of Myb – 
e.g. using emerging RNAi therapeutics - is a promising therapeutic strategy 
in high-risk MLL-rearranged AML. More broadly, we provide evidence that 
partial and transient suppression of a single non-essential gene can cure 
aggressive cancers that are resistant to current therapies. 
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Deregulation of epigenetic factors collaborates with genetic alterations in 
carcinogenesis. The PR domain containing proteins (PRDMs) constitute a 
sub-family of the SET domain family of histone methyl transferases, which 
are involved in epigenetic gene regulation by methylation of histones.  
As several SET/PR domain proteins have been associated with 
tumorigenesis either as oncogenes or tumor suppressors, we undertook a 
functional screening approach to identify novel tumor suppressors amongst 
the SET/PRDMs. The screen was performed as an oncogenic collaboration 
screen, in which MYC was co-transduced into primary mouse embryo 
fibroblasts (MEFs) together with a retroviral vector-based shRNA library 
targeting a set of 61 SET and PR domain containing genes. One of the 
putative tumor suppressors identified was Prdm11, a previously 
uncharacterized member of the PRDMs.  
A Prdm11 knockout (KO) mouse model was generated in order to study the 
function of Prdm11 in vivo. These mice are viable, born in Mendelian ratios 
and morphologically normal. In accordance with a tumor-suppressive 
function of PRDM11, we find that over-expression of PRDM11 in MEFs 
reduces cellular growth and induces apoptosis. In agreement with this, 
Prdm11 KO MEFs grow faster than wt littermate controls and exhibit 
significantly higher susceptibility to transformation by MYC.  
To evaluate the tumor suppressor potential of Prdm11 in vivo, we crossed 
the Prdm11 KO strain with the tumor-prone Eμ-Myc mouse strain. The Eμ-
Myc mouse model mimics Burkitt’s lymphoma by selective expression of a 
Myc transgene in the B-cell lineage. These mice develop malignant 
lymphomas with a mean latency of 100-120 days. Importantly, we found 
that loss of Prdm11 potently accelerates lymphomagenesis in the Eμ-Myc 
mouse to a mean latency of 75 days (P=0.00006). To evaluate a role in 
human cancer, PRDM11 expression levels were evaluated in a panel of 
human lymphoma cell lines. Compared to normal B-cells and reactive 
lymph nodes, PRDM11 levels are low in most cell lines suggesting a tumor 
suppressor function also in human B cells malignancies. Tissue microarrays 
are being setup to evaluate the expression of PRDM11 across a panel of 
human tumor types. Current mechanistic insight places PRDM11 in the 
TNFα/NF-κB pathway with direct binding to several central components.  
In conclusion, this study identifies the PR-domain containing gene, 
PRDM11, as a novel tumorsuppressor.  
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The Promyelocytic Leukemia gene (PML) is a tumor suppressor originally 
identified as a component of the PML-RARα oncoprotein of acute 
promyelocytic leukemia (APL). PML critically regulates cellular 
proliferation and apoptosis. In human tumors, PML deficiency is achieved 
through aberrant ubiquitin/proteasomal degradation or by physical 
interaction with PML-RARα. 
It is well known that PML and PML-RARα undergo SUMOylation, 
however the functional relevance of this event has been contentious. It has 
been reported that SUMOylation promotes PML tumor suppressive 
function, while others have indicated that SUMOylation promotes PML 
degradation. SUMOylation of PML-RARα has been linked to the 
therapeutic effect of arsenic trioxide.  
To gain insight into the biological significance of PML SUMOylation, we 
aimed at the identification of the PML SUMO-E3 ligase.  
We discovered that PIAS1, a member of the Protein Inhibitor of Activated 
STAT family, physically interacts and co-localizes with PML in PML 
nuclear bodies. PIAS1 promotes PML SUMOylation in cell free systems. 
Furthermore, PIAS1 dependent PML SUMOylation leads to ubiquitin 
mediated PML degradation in non-small cell lung cancer (NSCLC) cells. 
Moreover, an inverse correlation exists between the levels of PIAS1 and 
PML proteins in NSCLC cells. Finally, RNAi mediated silencing of PIAS1 
leads to PML protein upregulation and PML dependent inhibition of cell 
proliferation.  
We also determined that PIAS1 efficiently mediates SUMOylation of the 
PML moiety of the PML-RARα oncoprotein leading to its degradation in 
APL cells after arsenic trioxide treatment. Thus, PIAS1 is required for the 
therapeutic effect of arsenic trioxide in APL cells. 
We conclude that PIAS1 is a PML SUMO-E3 ligase whose biological 
output depends on cellular context. We propose that PIAS1 has oncogenic 
properties when targeting wild type PML, while it may oppose 
leukemogenesis when expressed in APL cells where PML is a component 
of the PML-RARα oncoprotein. These findings reveal a novel function for 
the SUMOylation machinery in tumorigenesis providing the rationale for 
pharmacologic targeting of PIAS1.  
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The hTERT gene, which encodes the limiting subunit of human telomerase, 
is highly expressed during embryogenesis, but strictly repressed in most 
adult somatic cells. While hTERT reactivation in cancer cells is critical for 
tumorigenesis, telomere attrition in somatic tissues due to hTERT silencing 
contributes to human aging. In contrast, the mTERT gene is widely 
expressed in adult mouse tissues. This species-specific regulation likely 
contributes to the much longer telomeres in mouse cells and some of the 
distinct characteristics of tumor development in mice vs. humans.  
We previously reported that the endogenous hTERT locus was embedded in 
a condensed chromatin domain in many somatic cells, while an equivalent 
chromatin domain did not exist for the less repressed mTERT gene. To 
determine the cis elements required for hTERT repression, we developed a 
novel technical platform, recombinase-mediated BAC targeting (RMBT), 
for integrating single-copy BAC reporters into specified chromosomal sites. 
Using RMBT, we found that chromatinized BAC reporters containing 
corresponding hTERT and mTERT loci recapitulated their respective native 
genes, indicating that cis regulatory elements were responsible for the 
species-dependent hTERT repression. By analyzing human and mouse 
chimera BAC reporters, we discovered that multiple distal elements, but not 
the proximal promoter, were involved in the stringent hTERT regulation in 
somatic cells. In addition, using the chromatinized BAC reporters and RNA 
interference-mediated genetic screenings, we identified several novel 
repressors of the hTERT gene that acted through the distal silencers. These 
repressors were previously reported to participate in multiple epigenetic 
silencing pathways and their knockdown by siRNAs activated both the 
transgenic hTERT reporters and endogenous hTERT mRNA expression. 
Thus, with these new findings, we are beginning to dissect the pathways 
involved in the human-specific epigenetic hTERT silencing in somatic cells 
as well as its activation during tumorigenesis.  
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The majority of tumors arising in BRCA1 mutation carriers exhibit 
inactivation of p53, a key effector of cell death following DNA damage. 
Despite the loss of p53, BRCA1-deficient tumor cells exhibit increased 
sensitivity to cisplatin, and patients with BRCA1-associated ovarian 
carcinomas experience improved outcomes with platinum-based 
chemotherapy compared to sporadic cases. While it is known that 
chemosensitivity in BRCA1-associated cancers is associated with 
unrepaired DNA damage, the specific effector pathway mediating the 
cellular response to platinum-induced damage in these tumors is poorly 
understood. Here we demonstrate that the p53-related gene p73, encoding a 
pro-apoptotic protein which is linked to chemosensitivity in many settings, 
is upregulated through a novel epigenetic mechanism in both human and 
murine models of BRCA1-associated ovarian carcinoma. BRCA1-deficient 
ovarian carcinoma cells exhibit hypermethylation within a p73 regulatory 
region which includes the binding site for the p73 transcriptional repressor 
ZEB1, leading to abrogation of ZEB1 binding and increased expression of 
transactivating p73 isoforms (TAp73). Cisplatin chemotherapy induces 
TAp73 target genes specifically in BRCA1-deficient cells, and knockdown 
of TAp73 in these cells causes chemoresistance while having little or no 
effect on BRCA1-expressing tumor cells. In primary ovarian carcinomas, 
ZEB1 binding site methylation and TAp73 expression correlate with 
BRCA1 status and with clinical response. Together, these findings uncover 
a novel regulatory mechanism that supports the contribution of TAp73 as an 
important mediator of the response to platinum chemotherapy in a subset of 
ovarian carcinomas. TAp73 may represent a response predictor and 
potential therapeutic target for enhancing chemosensitivity in this disease. 
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Identification of synthetic lethal interactions with key oncogenic mutations 
represents a strategy to identify novel targets for tumor therapy. We present 
here the results of an siRNA screen of the human kinome aimed at 
identifying synthetic lethal interactions with deregulated expression of Myc.  
U2OS cells that carry a hormone-inducible allele of Myc (MycER) undergo 
apoptosis in a p53-independent manner upon depletion of growth factors. 
We have now screened an siRNA library of the human kinome for kinases 
that are specifically required for cell survival in the presence of active Myc, 
but not in its absence. The screen identified a small number of kinases: 
prominent among them are Ark5, a kinase related to AMPK that has 
previously been implicated in invasion and metastasis, and AMPK itself. 
Multiple siRNAs and shRNAs targeting Ark5 strongly suppress growth in a 
Myc-dependent manner. The interaction is observed not only in U20S cells, 
but also in immortalized lung fibroblasts and in cells expressing a 
constitutive allele of Myc. FACS analyses demonstrate that suppression of 
Ark5 induces Myc-dependent apoptosis. 
Rescue experiments show that both the kinase activity of Ark5 and its 
activation by LKB1 are required to suppress Myc-induced apoptosis. 
Recent work by others has shown that Ark5 is a negative regulator of 
LATS, a kinase that is a central player in the Hippo signaling pathway. 
Consistent with these observations, depletion of Ark5 leads to a dramatic 
increase in LATS1 levels. Activation of Myc and depletion of Ark5 
synergize to activate expression of the downstream target of the pro-
apoptotic branch of the Hippo pathway, Puma. 
Experiments are currently underway to validate the relevance of this 
pathway in mouse models of Myc-dependent tumorigenesis. 
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The Myc oncoprotein is a transcription factor that targets thousands of 
genomic loci. While its expression is frequently deregulated in cancer cells, 
Myc is tightly controlled by growth-regulatory signals in normal cells, and 
is required for a normal cellular response to mitogenic stimuli. In spite of a 
wealth of information on numerous Myc-target genes, the Myc-dependent 
transcriptional programs involved in mitogenesis and cancer progression, as 
well as their overlap, largely remain to be identified. We have undertaken a 
concerted genome-wide analysis in two different model systems: (i.) serum-
stimulated fibroblasts and (ii.) Eμ-myc transgenic mice. In each system, we 
combined genome-wide Myc-DNA interaction maps generated by ChIP-seq 
(in collaboration with Dr. Chia-Lin Wei, GIS, Singapore) with gene 
expression profiles generated on Affymetrix GeneChip Arrays. (i.) We used 
3T9 fibroblasts homozygous for a conditional KO allele of c-myc (c-
mycf/f): Cre-mediated deletion was induced in quiescent cells, prior to 
serum stimulation. mRNA profiling identified a group of several hundred 
Myc-dependent serum response (MDSR) genes, the majority of which 
where direct Myc targets. (ii.) B-cells were isolated from control non-
transgenic mice, young Eμ-myc mice at the pre-tumoral stage, or 
lymphomas, and directly processed (without any in vitro culture) for either 
ChIP-seq or expression profiling, allowing identification of the genes 
directly induced by Myc at the two different disease stages. Either MDSR 
genes in fibroblasts or Myc-induced genes in B-cells constitute a small 
fraction of all Myc-bound loci. These represent the “core” Myc targets 
likely to be involved in the mitogenic response, on one hand, and tumor 
promotion and/or suppression, on the other. 
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Myc is a pleiotropic transcription factor whose levels are elevated and 
deregulated in most cancers, suggesting a pivotal role for Myc in oncogenic 
signaling. De-activation of Myc function in tumors driven by oncogenically 
activated Myc triggers their rapid regression through a variety of 
intracellular and extracellular mechanisms, including differentiation, 
apoptosis and vascular collapse. However, Myc mutations are relatively rare 
and deregulated Myc in most tumours appears to be a consequence of 
aberrant upstream signals. The extent to which such endogenous Myc, 
acting as a client of upstream oncogenes, is a therapeutic target will depend 
on the degree to which it coordinates functions essential for tumor 
maintenance and what those functions are, neither of which is known. To 
investigate the therapeutic potential of Myc inhibition we have constructed 
switchable genetic mouse models in which endogenous Myc can be 
systemically and reversibly inhibited in normal and tumor tissues in vivo. 
Our data indicate that inhibiting Myc has a remarkably efficacious 
therapeutic impact on multiple cancer types, independent of the tissue or 
driving oncogenic lesion (various examples will be shown). Importantly, 
Myc inhibition triggers widespread tumour cell apoptosis while elicits 
surprisingly mild, reversible and non-cytotoxic side effects in normal 
tissues. The nature of this differential response between tumor and normal 
tissues will be explored.  
The p53 tumor suppressor, or its attendant pathway, is functionally 
inactivated in almost all human cancers. p53 mediates the cellular apoptotic 
and senescence response to DNA damage, and this is thought to be critical 
for tumor suppression. Using a unique mouse model in which the 
endogenous p53 gene is replaced by one encoding a ligand-dependent, 
reversibly switchable variant of p53, we assessed the contribution of this 
tumor suppressor to the therapeutic impact of Myc inhibition.  
Our data show that targeting essential and non redundant pivotal nodes, 
such as Myc, in tumor cells could have enormous therapeutic impact in 
multiple, if not all, types of cancer.  
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MYCN, a proto-oncogene normally expressed in the migrating neural crest, 
is in its amplified state a key factor in the genesis of human neuroblastoma 
(NB). However, the mechanisms underlying MYCN-mediated NB 
progression are poorly understood. We have identified a MYCN-induced 
miRNA signature in human NB involving the activation and transrepression 
of several miRNA genes from paralogous clusters. Several family members 
derived from the miR-17-92 cluster, including miR-18a and miR-19a, were 
among the up-regulated miRNAs. Expression analysis in NB tumors 
confirmed increased levels of these miRNAs in MYCN-amplified samples. 
Specifically, we show that miR-18a and miR-19a target and repress the 
expression of estrogen receptor-α(ESR1). Furthermore, we demonstrated 
ESR1 expression in human fetal sympathetic ganglia, suggesting a role for 
ESR1 during sympathetic nervous system development. Reconstitution of 
ESR1 expression resulted in marked growth arrest and neuronal 
differentiation. Similarly, inhibition of miR-18a in NB cells led to severe 
growth retardation, outgrowth of varicosity-containing neurites, and 
induction of neuronal sympathetic differentiation markers. We propose that 
MYCN amplification may disrupt estrogen-signaling sensitivity in primitive 
sympathetic cells through deregulation of ESR1, thereby preventing the 
normal induction of neuroblast differentiation. Collectively, our findings 
demonstrate the molecular consequences of abnormal miRNA transcription 
in a MYCN-driven tumor and offer unique insights into the pathology 
underlying MYCN-amplified NB. We are presently investigating 
interacting growth factors and downstream targets involved in the 
regulation of differentiation by ESR1 in NB cells.  
In parallel, we have characterized one low molecular weight compound that 
resulted in downregulation of MYCN followed by apoptosis of MYCN 
amplified NB cells. In vivo treatment of MYCN driven tumors in different 
mouse models delayed their growth. Taken together, our data suggest that 
targeting MYCN is an attractive approach for treatment of childhood NB. 
 
 
Lovén, J., Zinin, N., Wahlström, T., Müller, I., Brodin, P., Fredlund, E., 
Ribacke, U., Pivarsci, A., Påhlman, S., and Henriksson, M. MYCN-
regulated microRNAs repress estrogen receptor alpha (ESR1) expression 
and neural differntiation in human neuroblastoma. Proc. Natl. Acad. Sci. 
USA 107, 1553-1558 (2010). 
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Myc is a BHLH transcription factor that plays a critical role in major 
biological processes, such as proliferation, growth, apoptosis, and 
differentiation. Recently, we discovered Myc-nick, a transcriptionally 
inactive form of Myc that is localized in the cytoplasm. Myc-nick is 
generated by a proteolytic cleavage of the full-length Myc that is carried out 
by members of the calpain family of calcium dependant proteases. Myc-
nick lacks the C-terminal region (nuclear localization signal, Max 
dimerization domain, and DNA binding domain) of Myc but contains an 
intact N-terminus. Ectopic expression of Myc-nick in fibroblasts and 
epithelial cells promotes changes in cell morphology marked by the 
induction of cellular protrusions. We found that GCN5 functions as an 
alpha-tubulin acetyl transferase and it can cooperate with Myc-nick to 
promote alpha-tubulin acetylation. Since induction of alpha-tubulin 
acetylation, calpain activation, and decrease in full length Myc all occur 
during terminal differentiation we investigated the role of Myc-nick in cell 
differentiation. We found that Myc-nick is augmented during the 
differentiation of human and mouse primary myoblasts. In addition, we 
found that while full-length Myc levels diminish, Myc-nick levels remain 
elevated in adult mouse differentiated muscles, brain and cerebellum. 
Ectopic expression of Myc-nick accelerates myoblast fusion and the 
expression of myogenic markers in mouse and human myoblasts and in 
Rhaddomyosarcomas. Importantly we found that the expression of Myc-
nick renders myc-null fibroblasts competent to MyoD induced 
transdifferentiation. Based on our results we propose that while full-length 
Myc blocks differentiation at the transcriptional level, Myc-nick is involved 
in promoting differentiation through transcription independent mechanisms. 
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MiR-17~92 has emerged as the prototypical oncogenic microRNA cluster 
in humans and mice. It encodes six distinct miRNAs that can be grouped 
into four “seed families” (miR17/20, miR-18, miR-19a/b and miR-92). We 
have previously reported the generation and characterization of mice 
carrying a targeted deletion of the entire cluster. Homozygous mutant mice 
are significantly smaller than their wild type counterpart, die soon after 
birth and display a complex array of defects involving heart lungs and 
lymphocyte development. One limitation of such an analysis is that these 
results were obtained by deleting the entire miR-17~92 locus. As such, little 
is known with respect to the relative role of each of the six microRNAs 
encoded by miR-17~92. We will discuss the results of two parallel lines of 
investigation that our laboratory is undertaking to address this important 
issue:  
a) We are carrying out a systematic genetic analysis by creating an allelic 
series of knock-in mice, each lacking only one of the four “seed families” 
encoded by miR-17~92. The analysis of these mice is providing key 
information regarding the specific functions of individual components of 
miR-17~92 . 
b) In a parallel line of investigation, we have used a conditional miR-17~92 
knockout allele to determine the role of this cluster in Myc-induced B cell 
lymphomas. By using this approach we show that endogenous miR-17~92 
is required in lymphoma to suppress apoptosis via the concerted action on a 
number of genes and that this effect is largely, if not exclusively attributable 
to the miR-19 seed family. 
 280 
THERAPEUTIC SENESCENCE – INDUCTION OF TUMOR CELL 
SENESCENCE BY TARGETING MTOR TO PREVENT AND TREAT B 
CELL LYMPHOMAS 
 
Ricky Johnstone, Meaghan Wall, Jake Shortt, Ross Hannan, Rick Pearson, 
Grant McArthur  
 
Peter MacCallum Cancer Centre, Research Division, East Melbourne, 3002, 
Australia 
 
The PI3K/mTOR pathway couples signals from oncoproteins such as c-
myc, growth factor receptors and nutrient sensors to cell machinery 
involved in growth, survival and proliferation. PI3K/mTOR activation is a 
feature of many haematological malignancies, and agents targeting this 
pathway have an emerging therapeutic role. Here we used the allosteric 
mTORC1 inhibitor everolimus (RAD001) and BEZ235 a small molecule 
non-allosteric kinase inhibitor that inhibits PI3K, mTORC1, mTORC2 to 
target the PI3K/mTOR pathway in the Eμ-myc mouse model of B cell 
lymphoma. “Compound mutant” Eμ-myc lymphomas with deletions or 
overexpression of important tumor suppressor genes and oncogenes (i.e. 
p53, Bcl-2) were employed to identify the molecular pathways necessary 
for the biological and therapeutic effects of everolimus and BEZ235. 
Chronic dosing of Eμ-myc transgenic mice with everolimus reduced B cell 
expansion in the bone marrow and spleen and restored B cell 
differentiation. Everolimus significantly improved lymphoma-free survival 
relative to placebo (median survival not reached after 200 days for mice 
treated with everolimus versus 73 days for placebo-treated mice, p=0.004). 
The clearance of premalignant cells was associated with induction of 
cellular senescence as assessed by β-gal staining. Treatment of mice bearing 
established Eμ-Myc lymphomas with everolimus or BEZ235 resulted in a 
significant increase in survival of mice compared to placebo treatment. 
Importantly, everolimus treatment caused tumor cell cycle arrest in G1 and 
induction of senescence with subsequent tumor regression concomitant with 
infiltration of host immune cells. In contrast, BEZ235 caused tumor 
regression associated with robust apoptosis and no sign of cellular 
senescence. Both everolimus and BEZ235 required a functional p53 
pathway to mediate their biological and therapeutic effects. Interestingly, 
overexpression of Bcl-2 abrogated the apoptotic and therapeutic effects of 
BEZ235 but had no effect on the ability of everolimus to induce senescence 
or provide a significant survival benefit to treated mice. 
Our data demonstrate that targeting the PI3K/mTOR pathway at different 
points using everolimus and BEZ235 results in therapeutic efficacy 
however this is achieved by inducing differential biological responses. The 
therapeutic benefit of everolimus-induced senescence was as robust as that 
observed following induction of tumor cell apoptosis by BEZ235. Both 
agents required a functional p53 pathway to mediate their biological and 
therapeutic effects however everolimus but not BEZ235 retained its anti-
tumor effects in cells overexpressing Bcl-2. These data demonstrate the 
potential of ‘pro-senescence’ therapy for cancer prevention and treatment. 
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Cyclin D1 deregulation is implicated in the genesis of multiple human 
cancers. Importantly, cyclin D1 nuclear accumulation promotes DNA re-
replication and subsequent genomic instability mediated by cul4 repression 
and Cdt1 stabilization. Recent molecular dissection of these processes 
identified the protein arginine methyltransferase 5 (PRMT5)/MEP50 
complex as a substrate and effector of cyclin D1-dependent neoplasia. 
Specifically, nuclear cyclin D1 retention during S-phase increases PRMT5-
dependent histone methylation at key target promoters, providing a direct 
correlation between aberrant cyclin D1/CDK4 activity, transcriptional 
regulation, and double strand DNA break (DSB) induction; together, these 
molecular events catalyze the genomic instability necessary for cellular 
transformation. Given that replication-associated DNA damage is central to 
cyclin D1-coupled neoplasia, inactivation of critical checkpoint mediators 
should accelerate cyclin D1-dependent tumorigenesis. To interrogate the 
potential synergy between nuclear cyclin D1 and impaired checkpoint 
integrity, ATM deficient mice harboring the Eμ-D1/T286A transgene were 
generated and evaluated for tumor onset. Eμ-D1/T286A/ATM-/- mice 
exhibit accelerated development of thymic and B-cell lymphomas relative 
to Eμ-D1/T286A or ATM-/- cohorts. Lymphomas harbor clonal 
chromosomal alterations distinct from ATM-null mice that typically acquire 
translocations involving the Tcrα/δ locus during V(D)J recombination. 
Collectively, these findings reveal an intricate relationship wherein nuclear 
cyclin D1/CDK4 activity modulates genetic alterations necessary for 
perturbed DNA replication, genomic instability, and ultimately neoplastic 
transformation. 
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DORMANT REPLICATION ORIGINS ARE REQUIRED FOR 
CHROMOSOME STABILITY AND TUMOR SUPPRESSION 
 
Tsuyoshi Kawabata1, Satoru Yamaguchi1, Spencer Luebben1, Ilze Matise2, 
Tavanna Buske1, Naoko Shima1,2  
 
1University of Minnesota, Genetics, Cell Biology and Development, 
Minneapolis, MN, 55455, 2University of Minnesota, Masonic Cancer 
Center, Minneapolis, MN, 55455 
 
Origin licensing is an essential process to prime replication origins for 
genome duplication through loading of the MCM2-7 complex, the 
replicative helicase. Licensed origins exist in a large excess over the number 
that will actually fire during S phase. While the majority of these excess 
origins remain dormant in unperturbed S phase, we show here that a 
fraction of them are required for the recovery of stalled replication forks, 
contributing to tumor suppression. 
 
We previously reported that homozygosity for Mcm4Chaos3, the first viable 
allele of any Mcm gene in vertebrates, causes spontaneous tumors in mice 
with nearly complete penetrance. In this study, we found that primary 
Mcm4Chaos3/Chaos3 embryonic fibroblasts suffer from a ~50% loss of dormant 
origins, accumulating stalled replication forks in S phase. A substantial 
fraction of these stalled forks apparently persist into early M phase, as the 
number of FANCD2 sister foci increases dramatically. The incidence of 
lagging chromosomes is also significantly elevated in anaphase, leading to a 
two-fold increase in micronucleus formation in Mcm4Chaos3/Chaos3 cells.  
 
These data suggest that insufficient origin licensing drives tumorigenesis by 
increasing the occurrence of chromosome missegregation. Furthermore, our 
findings strengthen the current view that deregulated origin licensing is a 
cause of genome instability in cancer. 
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SPINDLE ASSEMBLY CHECKPOINT AND TUMORIGENESIS: MICE 
HETEROZYGOUS FOR ACETYLATION-DEFECTIVE BUBR1 
ALLELE (K243R) DEVELOP SPONTANEOUS TUMORS 
 
Julgi Kang*, Heyrim Choe*, Eunhee Choi*, Hae-Ock Lee, Hyunsook Lee  
 
Seoul National University, Biological Sciences & IMBG, Seoul, 151-742, 
South Korea 
 
The regulation of BubR1 is central to the control of APC/C activity. We 
found that BubR1 forms a complex with PCAF and is acetylated at lysine 
250. With extensive analyses, we showed that BubR1 acetylation is crucial 
in the control of anaphase onset. Based on our collective results, we 
proposed that the acetylation status of BubR1 is a molecular switch that 
changes BubR1 from an inhibitor to a substrate of APC/C, thus providing 
an efficient way to modulate APC/C activity in a signal-dependent and 
timely-controlled manner (EMBO J., 2009. 28: 2077-2090). In order to 
investigate the physiological role of BubR1 acetylation, we generated 
mutant mice where the acetylation site (K243) was substituted to arginine to 
interfere with the acetylation (K243R). Embryos homozygous for K243R 
allele (BubR1K243R/K243R) exhibited early embryonic death. 
Heterozygous mice (BubR1K243R/+) survived to birth; however they 
displayed poor embryonic growth and generated small-sized littermates. 
Paradoxically, various types of tumors developed in BubR1K243R/+ mice 
around 60 weeks after birth. MEFs from BubR1K243R/+ mice displayed 
aneuploidy, premature sister chromatid breakages (PMSCs), and abnormal 
spindle formation, the hallmarks of mitotic infidelity. Indeed, the spindle 
assembly checkpoint (SAC) was compromised and the mitotic timing was 
shortened in MEFs isolated from BubR1K243R/+ mice. Analyses of the 
large B cell lymphomas and liver cancers from BubR1K243R/+ mice 
indicated massive genomic alterations and chromosome instability. Given 
that the acetylation-defective BubR1 results in decreased BubR1 level in 
mitosis, K243R allele was initially thought to be loss-of-function allele. 
However, the high incidence of cancer development in BubR1K243R/+ 
mice suggests otherwise: the results indicate that BubR1K243R/+ allele 
may be a gain-of-function or a dominant negative allele. The as-yet-
unidentified potential roles of BubR1, and its acetylation/deacetylation, in 
the maintenance of genome integrity will be discussed.  
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VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, west wing, lower level 
 PIN#:  Press 64475 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
